University of Groningen
Exploring the mechanisms underlying the phenotype of MCAD deficiency with Systems Medicine Martines, Anne-Claire
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record
Publication date: 2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA): Martines, A-C. (2019). Exploring the mechanisms underlying the phenotype of MCAD deficiency with Systems Medicine: from computational model to mice to man. Rijksuniversiteit Groningen.
Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Download date: 23-09-2021
Exploring the mechanisms underlying the phenotype of MCAD deficiency with Systems Medicine From computational model to mice to man
Anne-Claire M.F. Martines
ǡ ǡ ǡ ǡ Ǥ Ǥ ȋ ȌǤ
ǣ ȋ ȌǤ ȋ Ȍ ȋ Ȍ ȋǤǤȌ ǤǤ ǣ ǣ Ǧ Ǥ ȋΪ Ǧ Ȍǡ ȋ Ȍ ȋ͵ͲͶǦ ȋ ǣ Ͷͳ͵Ȍȋ ǣʹ Ȍǡ ȋ ǣʹͻͺͷͲͺȌȌ ǣǦǤ Ǥ ǣ ȁǤǤ ǣ ͻͺǦͻͶǦͲ͵ͶǦͳͻͻǦͺȋȌ ͻͺǦͻͶǦͲ͵ͶǦͳͻͺǦͳȋȌ ̹ǤǤ ǤǡʹͲͳͻ Ǥ ǡ ǡǡ ǡ Ǥ
Exploring the mechanisms underlying the phenotype of MCAD deficiency with Systems Medicine
From computational model to mice to man
Proefschrift
ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen op gezag van de rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 10 juli 2019 om 16.15 uur
door
Anne-Claire Micheline Francisca Martines
geboren op 10 oktober 1981 te Willemstad, Curaçao
Promotores Prof. dr. B.M. Bakker Prof. dr. D.J. Reijngoud
Beoordelingscommissie Prof. dr. F.J. Bruggeman Prof. dr. A.K. Groen Prof. dr. F.J. van Spronsen
This PhD thesis is dedicated to my lovely parents, Ingrid Martines-Kirindongo and Edwin Martines, and my loving husband, Amart Schoop, who have always supported me through thick and thin
Paranymfen Natasha Tearr-Marcos Aduni Mariana
CONTENTS
Chapter 1 9 Chapter 2 Ǧ ͵ǦǦ Ǧ 39 Ǧ Ǧ Chapter 3 67 ΪǦ Ǧ Chapter 4 Ǧ ǣ 127 Ǧ Ǧ Chapter 5 157 Ǧ Chapter 6 in vitro 205 Ǥ Chapter 7 225 Appendix 241 243 249 255 265 269 273
Chapter 1
General introduction and outline of the thesis
General introduction and outline of the thesis
Introduction 1 Ǥ Ǥ Ǥ Ǥ ǡ ȏͳȂͶȐǤǡ ȏͷȂͳ͵ȐǤ Ǥ ȏ͵ǡͳͶȂͳȐǤ
Common acquired metabolic diseases Ǧ ǡ ȏͳͺȐǤ Ǧ Ǥ ǡ ͳͻͷȏͳͻȐǤ ǡ ͳͻΨȋͳʹǤͷΨ͵ͺΨȌȏʹͲȐǡ ǡ ʹȋʹȌǡ ȋ ȌȏͳȂͶȐǤʹǡ ȏʹͳǡʹʹȐǤ ȋ Ȍ ǡ Ǧ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ȏʹͳǡʹ͵ȂʹͷȐǤ ȋ Ȍ ʹͲΨǡ ȏʹȂʹͻȐǤ ȋȌ ȋi.e. Ȍ ȏ͵ͲȂ͵͵ȐǤ Ǧ ǡȏ͵ͶȂ͵ȐǤȾǦ ǡ ȋȌ Ǥ ǡ ʹȋʹȌǤ Ǧ ȏ͵ȐǤ ȾǦ ȏ͵ȐǤ ȏ͵ͺǡ͵ͻȐǤ ǡǦǦ ȏ͵ȐǤ ȏͶͲȐǤ ǡ ǡ ȏͶͲȐǡ ȏͶͲȐǤ ǡ Ǥ Ǥ ǡ
ͳͳ Chapter 1
ǡ ȏͳͷǡͶͲǡͶͳȐǤ ǡ ȏͳͷȐǤ ǡ ȋ Ȍǡ ʹǡ ȏͶʹȐǤ ǡ ǡ ǡΪǡ Ǥǡ ȋ ȌǤ Metabolites and common acquired metabolic disease Lipid regulators Ǥ ǡ Ǧ Ǥǡ ǡ ǤͳǣͳǦȏͶ͵ǡͶͶȐǤ Ǥ ȏͶ͵ȂͶȐǤ Ǧ Ǥ Ǧ Ǧ ȋ ȌǤ de novo Ǥ ǡ Ǧ ǦǦ Ǧ ȋ Ȍǡ ǡ ǡ ǡ ȏͶȐǤ ǡ ǡ Ǧ͵Ǧ ǡǦ ȏͶͺȂͷͲȐǤ NAD+ Ϊ ǡ ǡ ǡ ǡ ȏͷͳȂͷ͵ȐǤ ǡ Ϊǡ ȏͷʹȂͷͶȐǤ ǡ Ϊ ǤΪ ʹǡΪǦ ͳ ȋ ͳȌ Ǧ ȾǦ Ǥ ͳ ǤΪ ǦǦǦ ȏͶʹȐǤΪ ͳ Ǥ Ϊ ǡ ͳ Ϊ ǦǦǦ ȏͶʹȐǤΪ Ǧ ǤΪ ǡΪǦ ͵ͺǡ Ǥ ΪǦ Ǥ
ͳʹ General introduction and outline of the thesis
SIRT1Ϊ Ǧǡ ǡ ȏͶʹȐǤ 1 Coenzyme A ȏͷͷȂͲȐǤ Ǥ de novoǡ ǡ ǡ Ǥ ǡ ȋ ǡ ȋȂ ȌȌǤ ʹǤ ǡ PANK1 ǡ ǡǦ ȏͷͷȐǤ ob/obʹ ǡ ȋ Ȍǡ ȏͳǡʹȐǤPANK1 ǡ ȾǦ ǡ ǡ Ǥ ǡǡǡ ȏͷͷȐǤ Ǧ ǡ Ǧ ǦǤ ͳǤ ǡ
ǡ ȋ ͷȌǡ Ǥ ǡǤͳ ǡ ȏ͵ȐǤ ʹǡͳ Ǧ in vitroǡ ȋȌǦ ȋȌȏͶȐǤ Amino acids ǡ ȏͷȐǤ ǡ Ǥ ǡ Ǧ ȋȌǡǡ Ǥ ȋȌ ǡ ȋ ȌǤ ǡ Ǧ ȏͶͶǡȐǤ ǡ ȏͶͶȐǤ ʹȏͶͶȐǤ
ͳ͵ Chapter 1
Advances in approaches and methods to study acquired metabolic diseases Bioinformatic approaches Ǧ Ǧ ǡ Ǧ ȋ Ȍǡ ȏȐǤǦ ǡǦ Ǥ ǡǡ Ǥ ȏȐǤ DzǦ dz Ǥ ǡ Ǧ Dz dz Ǧ ǡ Ǧǡ ȋ Ȍ Ȁ ȏͺȐǤ Experimental models Ǥin vitro Ǥ ǡǡ ʹ ȏͳͶǡͻǡͲȐǤ ǡ ǡ Ǥǡ ǡ Ǥ ǡ ȏͳͶǡͻȐǤ ǡ ȏͳȐǤ ǡin vitro ex vivo ǡ ǡ ȏͻǡʹȐǤ ǡ ǡ Ǧ ǡǦ ȋȌǦ ȏͻǡʹȂȐǤ Analytical methods and data analysis ǡ Ǥ DzǦ dz ǡ Ǧ ȏͳͶǡʹͳǡͻǡȂͺͲȐǤ ǡ ȋȌ ǡ Ǧǡ ǡ ȏͷǡǡȂͺ͵ȐǤ ǡ Ǥ ǦǦ ȋ ȌȏͺͶȐǤ ǡ setsǤ ǡ Ǥǡ Ǥ
ͳͶ General introduction and outline of the thesis
ȋȌǡ Ǥ ǡ ǦǦ ȋ Ȍ 1 Ǧ ǡ ǡ Ǥ ǦǤ Ǧ Ǧǡ Ǧ ȏͺͶȂͺȐǤ ǡ Ǥ ȏͺͺȐǡ ȏͺͻȐǡ ȏͻͲȐ ȏͻͳȐǡ Ǧ ǡ Dz dz ȏͻʹȐ Dz dzȋ Ȍȏͻ͵ǡͻͶȐ Ǥ Dz dzǦ Ǧ Ǧ ͵ʹǡ εͻͲΨ Ǧ ȏͻʹȐǤ Ǧ Ǥ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ȏͻͷȂͳͲͲȐǤ Systems biology and computational modeling ǡ ǡ ȏͳͲͳȂͳͲͶȐǤ Ǧ ȏͻͷȂͳͲͲǡͳͲͷȂ ͳͳͲȐǤ Ǧ ǤǦ ǡ Ǧ ǡ ǡǡǡ ȏͳͳͳȐǤ ǡ Ǥ ǤiHepatocytes2322ǡǦ ǡ ȏͻͻȐǤ ʹ ȏͻȐ ȏͳͳʹȐǤ ǡʹͲǡǡ ǡ ǡ ǡǦ Ǧȋ Ȍȏͳͳ͵ȐǤ Ǥ Ǥ ȏͳͳͳǡͳͳͶȐǤ Ǧ ǦǡǦ ȏͳͳͳȐǤ
ͳͷ Chapter 1
ǡ Ǥ ǡǤ ȋȌ ǡ ǡ Ǥ Ǥ ȏͳͳͷȂͳͳͺȐǤ DzǦdz Ǥ ǡ Ǥ Ǥ ȏͳͳͻȐǤ ǡ ǡ Ǥ Ǧ ȏͳʹͲȐǤǡ Ǥ ǡ Ǥ ǡ in silicoǡin vitro or in vivo ȏͳͳͳȐǤ ȏͳʹͳȐǡ ȏͳͲǡͳʹʹȐǡ ǡ ȏͳʹ͵Ȑǡ Ǧ ȾǦ ȏͳʹͶȐǡ ȏͳʹͷȐǡ Ǧ ȏͳͲͺȐǤ ǡ Ǧ Ǥ Inborn errors of metabolism/Inherited metabolic diseases ȋ Ȍ Ǥ ͳȌ ǡ Ǧ ǡ ʹȌǡ Ǧ Ǧ ǡ͵Ȍ ǡ ȏͳʹȐǤ Ǥ ǡ ͳȀʹͶͲͲ ʹͲͲ͵ͳȀͳͺͻͶ ʹͲͳͷȏǡͻǡͳͲǡͳͺǡͳͲʹǡͳʹȐǤ Ǧ ǦȋȌ ȋȌȏͺȂͳͲǡͳͺǡͳͲʹǡͳʹȐǤ ͳȀͺ͵ͲͲ ʹͲͲʹͲͳͷȏͳʹͺȐͳȀͻͲͻ͵ ʹͲͳͷȏȐǤ Ǧ Ǥ Ǥ ǡ ȏͳͲǡͳͲʹǡͳʹȐǤ
ͳ General introduction and outline of the thesis
Common principles underlying IEMs and acquired metabolic diseases 1 ǡǦ Ǥǡ ǡǤ ǡ ǡ ǡ ȏͳͺǡͳͲʹǡͳʹͻȐǤ ǡ ȋ ȏͳ͵ͲȐȌǡ ǡ ȏͳͺȐǤ ǡ ǡ ǡ ǡ ȏͳͺǡͳ͵ͳǡͳ͵ʹȐǤ Ǥ ǡ Ǥ ȏͳͺȐǤ Ǥ Ǥǡ Ǥ Dz ̶ ȋ ̶̶Ȍ Ǥ Ǥ Ǧ ȋȌ ͺǦ ǡȏͳͺǡͳ͵͵ȐǤ ǡ ȋ Ȍ Ǧ Ǥ ǡ ȋ Ȍ Ǥ ǡ Ǧ ȋǦȌǤ ǡ Ǥǡ Ǥ ǡ Ǥǡ Ǥ ǡ Ǧ ǡ ǡ Ǧ Ǥ ʹͲ ȏǡͳͲǡͳͺǡͳ͵ͶȐǤ Ǥ ǡ ǡ ACADM ͳͲΨ ǡ ȏͳ͵ͶȐǤ ACADM ͺǦ ȏͳͺǡͳ͵͵ȐǤ Ǥ Ϊǡ ǡ ǤΪ
ͳ Chapter 1
ȋ Ȍ ȏͳ͵ͷȂͳ͵ȐǤ ǡ ǡ ȏͳ͵ͷȂͳͶʹȐǤ ͵Ǧ Ǧ ǦǦǦ Ǧȋǡ Ȍ ͵Ǧ Ǧ͵Ǧʹȋ ʹȌ ȏͳ͵ͻǡͳͶͲȐǤ ʹ Ǥ ͵ ȏͳͶͲȐǤǡǡ Ǥ Ϊ ȏͳ͵ǡͳͶ͵ǡͳͶͶȐǤ Ǥǡ ǡȋ Ȍ ȋȌȏͷͻǡͲȐǤ Computational modeling and omics in IEMs ǡ Ǥ ǡ ͳǦȏͳͶͷȐǦ ʹΨ͵ ȏͳͶȐǡ ͵ͺ ȏͻͻȐǤ ʹǤʹǡ ͶΨ Ͷͷ Ǧ ȏͳͳʹȐǤ Ǥǡǡ Ǧ Ǧ ȏͳͲͶǡͳͲǡͳͶȐǤ ǡ Ǥ Ǧ ȏͳͶͺȐǤ Mitochondrial fatty-ĂĐŝĚɴ-oxidation (mFAO) and mFAO deficiency Ǧ Ǥ Ǥ Ǧ ǡ Ǧ ȾǦ ȋ Ǧ Ȍ ǦǤ DzȾdz DzȾǦ dz Ƚȋ ȌȾ ȋ Ȍ Ǧ ǡ Ǧ Ǧ Ǥ ǡ Ǥ ǡ Ǥ Ǥ ȋ ͳȌǤ
ͳͺ General introduction and outline of the thesis
Malonyl-CoA Palmitoyl-CoA Acyl-carnitine 1 carnitine CoASH carnitine CPT1 C16 CACT C4-C16 CPT2 Mitochondrion C4-C16 carnitine CoASH carnitine Acyl-carnitine Acyl-CoA
MCKAT Acetyl-CoA SCAD MCAD LCAD VLCAD FAD C4-C6 C4-C12 C8-C16 C12-C16 C4-C16 CoASH FADH2
Ketoacyl-CoA Enoyl-CoA Acetyl-CoA + NADH + H MTP H2O C4-ketoacyl-CoA NADH + H+ MSCHAD C4-ketoacyl-CoA CROT NAD+ C8-C16 C4-C16 NAD+ C4-C16 CoASH Hydroxyacyl-CoA Figure 1. Schematic representation of the rodent mFAO pathway. ǣ Ǣǣ Ǧ ȋi.e.ǦȀ Ǧ ȌǢ ǣ Ǧ Ǧ ȋi.e. ȌǤ Ǥ ȋȌ ͳͳͺ Ǥ Ǥ Ǧ ȋ Ȍ ǦȏͳͶͻǡͳͷͲȐǤ Ǧ ǦǤ Ǧ Ǥ Ǧ Ǥ ȋͳȌǡ Ǧ Ǧ ȋȌǡ ȋʹȌǤ ǡ Ǧ Ǧ ǡ Ǧ Ǥ Ǧ Ǧ Ǥ ǡ Ǧ Ǧ ʹǤ Ǧ Ǧ Ǧ Ǥ Ǧ Ǧȋ Ȍ Ǧ ȋ ͳȌǤ ǡ Ǧ Ǧ ȏͳͷͳȂͳͷ͵ȐǤ Ǥ Ǧ ȏͳͲͺǡͳͷ͵ȐǤ Ǥ ǡ Ǥ Ǥ Ǧ ǣǦǦǡǦǡǦǡǦ Ǧ ǡ ǡ ǡ Ȍ ȋȌ ȋǤǤ ͳǤ͵ǤͻͻǤ͵ ǤǤͳǤ͵ǤͺǤͳȌǤ Ǧ ǡ Ǥ Ǧǡ ȏͺͲȐ ȏͳͷ͵ȐǤ ǡ Ǧ ͳʹǦͳǡͺǦͳǡͶǦͳʹͶǦ
ͳͻ Chapter 1
ǡǡ ǡ ǡ Ǧ Ǧͳǡ ͶǦͳ ͶǦ ǡ ǡ Ǥ Ǧ ǡ Ǥ ǡ Ǥ Ǧ Ǧȋ ͳȌǤǦͺ ͵ ȋȌǤ ǦǦ Ǥ ǡ Ǧ Ǧ ͵ ǣǦ ȋǡǤǤͶǤʹǤͳǤͶǤǤͶǤʹǤͳǤͳͷͲȌǡ ǦȋȀ ǡǤǤͳǤͳǤͳǤʹͳͳǤǤͳǤͳǤͳǤ͵ͷȌǦ ͵ǦǦ ǦȋǡǤǤʹǤ͵ǤͳǤͳȌȌǡ Ǥ Ǧ Ǥ Ǧ ǦȀ Ǧ Ǥ Ȁ Ϊ ǡ Ǥ Ȁ Ǧ ǦΪ Ǥ ȏͳͲͺȐ Ǥ ȋʹǤͳȉͳͲǦͶȌ Ǥ ǡ ǡ Ǧ Ǧ ǦǤ ͳͲ͵ȏͳͷ͵ȐǤ Ǧ Ǥ ǡ ǡ Ȁ ǣ ǡ ǦȋǤǤʹǦǦʹǦǦȌʹǦǦ͵Ǧ Ǧǡ ʹǦ Ǧ Ǧ ǦȏͳͷͶȂͳͷȐǤ Ǥ Ǥ ͳǡǡʹǡ ǡǡ ǡǡǡȀ ǡ ȏͳͷ͵ȐǤ ǡ ǡ Ǧ ȋ Ȍ ȏͳͷͺȐǤ ȏͳͷͺȐǤ ǡ Ȁ ȋ Ͷ Ȍ ȏͳͷͻȐǤ ǡ Ǧ Ǧǡ Ǧ Ǧ Ǧ Ǧ ȏͳͲȐǤ ǡ Ȁ ȋ ȌǡȀ ʹȋ Ȍ ǦǦ ȏͳͳȂͳ͵ȐǤ ǡ Ǧ ͶǦ Ǧ Ǥ ǡ Ǧ ǡ ǦǤ
ʹͲ General introduction and outline of the thesis
mFAO deficiency 1 ȏͳͷ͵ǡͳͶȐǤ ǡ Ǧ ǡ Ǧ Ǧ Ǥ ǡ ǡ ǯ ǡ ȏͳͲͻǡͳͷ͵Ȑǡ Ǥ ǡ ǡ EǦ Ǥǡ ǡ EǦǤ Ǧ ȋȌ ǡ ǡȏͳͷ͵Ȑ ȏͳͷ͵ȐǤ ǡ ȏͳͷ͵ǡͳͷȐǤ ǡ ǡ ǡ Ǥ Ǥ ȏͳͷ͵ǡͳͷǡͳȐǤ ǡ ǡ Ǧ ǡ ȏͳ͵Ͷǡͳͷ͵ǡͳͷǡͳȂͳͳȐǤ Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency ȋ ʹͲͳͶͷͲȌ ǡ ͳ ͲͲ ȏͳͳǡͳ͵ͲȐǤ Ǥ ǡ Ǥ Ǥ ǦǦ Ǥͻͺͷε ACADM ǡ ǡ Ψ ȏͳ͵ͶȐǤ ͵ͲͶȋǤ͵ͲͶȌǤ ǡ ȏͳʹȂͳͷȐǤǦ ȋ Ȍ ȏͳͷ͵ǡͳͶȐǤ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ȏͳ͵Ͳǡͳ͵ͳǡͳͷȐǤ ǡ ǡ Ǧ Ǧ Ǧ ǦͳͲͺͳͲ ȏͳͷǡͳͲǡͳȂͳͺ͵ȐǤ ͳͲΨ ȏͳ͵ͶȐǤ ǡ Ǥ
ʹͳ Chapter 1
Ǥͻͺͷε ȏͳͳǡͳ͵Ͳǡͳ͵ͳǡͳ͵ͶǡͳͳǡͳͺͶȂͳͺȐǤ ǡ Ǧ Ǧ ȏͳͺͺȐ ͳͺǦʹͶ ȏͳ͵ͳǡͳͷ͵ǡͳͺͻǡͳͻͲȐǤ ȋͲǦʹȌ ǡǡ Ǥ ǡ ǡ Ǧǡ ȏͳ͵ͲǡͳͶǡͳͻǡͳͺ͵ǡͳͻͳȐǤ Ǥ Mouse models of mFAO deficiency ǡǡ ǦǡǦǡǦǦ ȏͳͷ͵ȐǤ ǡ Ǧ ǡ ǡ ǡ ǡǦ ȏͳͷ͵ȐǤǦ Ǧ Ǥ ǡ ͳǦͳʹ ͳǦͺǤ ǡ ͳǦǤǦ Ǧ ǡ Ǧ Ǧ Ǧ ȏͳͷ͵ȐǤ ǡ ǤǦ Ǧȏͳͷ͵ǡͳͻʹȂ ͳͻͶȐǤǦȏͳͻͷȐ ȏͳͻȂͳͻͺȐǤ ǡ Ǧ ȏͳͲͻǡͳͻʹǡͳͻͻȐǤ ǡ Ǧ ͷȀ Ƭ ͳʹͻʹȀ ȏͳͻʹȐǤǦ ǡ ǡͺǦ Ǧ ǡǦ ǡ Ǧ Ǧ ȋȌ ǤʹͶ Ǧ Ǥ ǡ ȏͳ͵ͲǡͳͶǡͳͻǡͳͺͻǡͳͻͳȐǤ ǡ Ǧ Ǥ ǡ ȏͳͻʹȐǤ ǡ ǡ Ǧ ȏͺͲǡͳͻʹǡͳͻͻȐǤ Ǧ ͳʹ ȋȌ ǦǤǦ ȏͳͻͻȐǤ ǡ Ǧ ͷȀ Ǧ ǤǡǦ ǦǦ Ǧ ͺǦ Ǧ ͳʹ Ǥ ǡǦ Ǥ Ǧ
ʹʹ General introduction and outline of the thesis
ǡ Ǧ ǡ Ǧ 1 Ǥ ǡ ͷȀ Ǧ ͳʹ ȏͳͲͻȐǤǦ Ǥ ǡ Ǥ ȏͳͻʹȐǤ
MCAD deficiency ŝŶƐŝůŝĐŽ ǡ ǡ Ǥǡ ǡ ȏͳͺȐǤ Ǧ ȏͳͳʹǡʹͲͲȐǤ ǡ ǡ Ǥ ǡ ǡ ȏͳͲͺȐǤ ǡ ǯ Ǥ ͳǦ ȏͳͲͺȐǤ Ǥ Ǥ in vitro Ǥ ǦȋͳǦ ǦȌ ǦǤ ex vivo ͵ͲǦ Ǧ ȏͳͲͺȐǤ ǡȏͳͲͻȐǤ Ǧ ǡ ǡ ȏͳͲͺȐǤ Ǧ ȏͳͲͺȐǤ ȏͳͲͻȐǤ Ǥǡ ȏͳͲͻȐǤ ǡ ǡ Ǧ ǡȏͳͲͻǡͳͲǡͳȂͳͺǡͳͺʹǡͳͺ͵ȐǤ Ǧ Ǧǡ ȏͳͲͻȐǤ Ǧ ǡ ȏͳͲͻȐǤ ǡ
ʹ͵ Chapter 1
Ǥ Chapter 2Ǥ Chapter 4 Ǥ Ǥ Outline of this thesis: a systems medicine approach for MCAD deficiency Ǥ ǡ Ǥ Ǥǡ Ȁ Ǥ ǡ ǡǡ Ǥ Chapters 2 and 5 Chapters 3, 4, and 6Ǥ ǡ Chapter 5 Ǥ Ǥ Chapter 2 ǦǤ ǡ Ǥ ǡ Ǥ Ǥ Ǥ ǡ ȏͳͳͷȂͳͳͺȐ Ǧ Ǥ ǡ ǡǡ Ǥ Ǥ ǡ Ǥ ȋ ȏͳʹͲȐ Ǥ Chapter 3 Ǥ Ǧ ȋͳʹǦʹͶ ȌǤ Ǥ Ǥ ǡ Ǧ ǡ Ǥ Ϊ ǦǤ
ʹͶ General introduction and outline of the thesis
Chapter 4 ǡ Ǧ Ǥǡ 1 Ǧ ȏͳͻʹȐǤ ǡ Ǧ ǡ ǡǤ Ǥ ǡ Ǧ Ǥ ǡ ǡ Ǥ Chapter 5ǡ Ǥ Ǥ Ǥ ǡǤǡ Ǥ Ǥ Ǥ Chapter 6ǡ in vitroǤ ǡ ǦǦ Ǥͻͺͷε Ǧ ǡ ȏȂͳȐǤ Ǥǡ Ǥ ǡ Chapter 7ǡ ǡ Ǥ ǡ in vitroǦ Ǥ ǡ Ǥ ͳǤ ǫȋChapter 2Ȍ ʹǤ Ǧ ǦǦǫȋChapter 3Ȍ ͵Ǥ Ǧǡ Ǧ ǫȋChapter 4Ȍ ͶǤ ǡ ǡ Ǧ ǫ ȋChapter 5Ȍ ͷǤ Ǧ ǫȋChapter 6Ȍ References
ʹͷ Chapter 1
ͳǤ ǡǡ ǡǡǤ ǣ ǡǡ Ǥ ȋȌǤʹͲͳͺǢͳȋ͵ȌǣʹͻͻȂ͵ͳ͵Ǥ ʹǤ ǡ ǡ ± Ǥ ǤǤʹͲͳͺǢȋʹͲͳͺȌǣͷͻͻȂͳͳǤ ͵Ǥ Ǧǡǡ ǡǡ ǡǡǡ ǡ Ǥ Ǥ ǤʹͲͲͺ ǢʹͻȋȌǣȂͺʹʹǤ ͶǤ ǡ Ǥ ǤǤʹͲͳͻʹͳǢͳȋͳȌǣͳͶȂ ͳǤ ͷǤ ǡǡ ǡ ǡǡ ǡ ǡ ǡǡǡ ǡǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ ǣ Ǥ ǤʹͲͳͺǢͶͳȋ͵Ȍǣ͵͵Ȃͷ͵Ǥ Ǥ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡǡǡǡ ǡ ǡ ǡ ǡ Ǥ ǤǤʹͲͳͷǢͳͳȋȌǣͳͷʹͷȂ͵ͷǤ Ǥ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͲ͵Ǣ͵Ͷͺȋʹ͵Ȍǣʹ͵ͲͶȂͳʹǤ ͺǤ ǡ ǡ ǡǡǡ ǡ ǡ ǡǤ Ǧ Ǧ ǣ Ǥ ǤʹͲͲǢ͵ͻȋͻͷͷͷȌǣ͵ȂͶʹǤ ͻǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ ǣǡ ǡ Ǥ ǤʹͲͲͶǢͳͳͳȋȌǣͳ͵ͻͻȂͶͲǤ ͳͲǤ Ǥ ǣ Ǥ ǤʹͲͳͶǢͳͲͳǣͳͶȂͺʹǤ ͳͳǤ ǡǡǡǡ ǡ ǡǦǡ ǡ ǡ ǡǡ ǡ Ǥ Ǧ Ǧ ȋȌ ǣ Ǥ ǤʹͲͲͺǢ͵ͳȋͳȌǣͺͺȂͻǤ ͳʹǤ ǡ ǡ ǡǡ Ǧ ǡ Ǥ Ǧ Ǧ ǣ Ǥ ǤʹͲͳǢͳͺȋͳʹȌǣͳ͵ʹʹȂ͵Ǥ ͳ͵Ǥ ǡ ǡ Ǥ ǣ ǡ ǡ Ǥ ǤʹͲͳǢʹͺȋȌǣͻͶȂͻǤ ͳͶǤ ǡ Ǥ Ǥ ǤʹͲͳͺǢ͵ʹȋ͵ȌǣʹͻͻȂ͵ͳͷǤ ͳͷǤ ǡǤ Ǥ ǤʹͲͳͻ ǢͳȋͶȌǣͷͳȂʹʹǤ ͳǤ Ǧǡǡ ǡò Ǥ Ǥ ǤʹͲͳͺǢ ͳǤ ǡ Ǥ ʹ Ǥ ʹͲͳͺǢʹͶ͵ȂͶǤ ͳͺǤ ǡ ǡ ǡ Ǥ ǤǤʹͲͳǢʹ͵ȋͳȌǣͳ͵ȂʹǤ
ʹ General introduction and outline of the thesis
ͳͻǤ Ǥ ȏ ȐǤ Ǥ ʹͲͳͺ ȏ ʹͲͳͻ ʹͺȐǤ ǣ ǣȀȀǤǤȀǦȀ Ǧ 1 ȀȀǦǦ ʹͲǤ ʹͲͳ ȏ ȐǤ Ǥ ʹͲͳ ȏ ʹͲͳͺ ʹͺȐǤ ǣ ǣȀȀǤ ǤȀȀǦǤ ʹͳǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ ʹ ǣ Ǧ Ǥ ǤʹͲͳͷǢͳͻȋͻȌǣͷ͵Ȃ͵Ǥ ʹʹǤ ǡǤǡǣ ʹǤ ǤʹͲͳͶ ǢͳͳȋͳʹȌǣʹͻͶͲȂͷͲǤ ʹ͵Ǥ ǡ ǡǡ Ǥ ʹ ᩿ǣ ʹǤʹͲͲǢͳͳȋȌǣͳͺͲʹȂͳʹǤ ʹͶǤ ǡǡ ǡǤͳ ʹǣǡǡǤ ǤʹͲͲ͵ǢͷͶȋ͵Ȍǣ͵ͳȂʹͻǤ ʹͷǤ ǡǡ ǡ ǡ Ǥ ʹǣǤǤ ͶǤǤʹͲͲǢͷͷȋȌǣͳͺ͵ʹȂͻǤ ʹǤ ǡǡ± ǤǦ ǤǤ ʹͲͳͺ ʹͶǢȋͳȌǣȂͻǤ ʹǤ ǡ ǡ Ǧ ǡ ǡ Ǥ Ȁ ʹͲͲͻ Ǥ ǤʹͲͳͲǢͷ͵ȋʹȌǣ͵ʹȂͺͶǤ ʹͺǤ ǡǡǤ ǣ Ǧ Ǧ Ǥ ǤʹͲͳͳǢ͵Ͷȋ͵ȌǣʹͶȂͺͷǤ ʹͻǤ ǡ Ǥ Ǥ Ǥ ʹͲͳ͵ǢͳͲȋͳͳȌǣͺȂͻͲǤ ͵ͲǤ ǡ ǡ ǡǡǡ ǡǤ ǣǦ Ǥ Ǥ ʹͲͲͷ ǢͳʹͻȋͳȌǣͳͳ͵ȂʹͳǤ ͵ͳǤ ǡ ǡǡǡ ǡ ǡ ǡ Ǥ ǣ Ǥ ǤʹͲͲͶ ǢͶͲȋȌǣͳ͵ͺȂͻͷǤ ͵ʹǤ ǡ Ǥ ǣ ǡ ǡǤ ǤʹͲͳͳ ǢʹȋͷȌǣͷͷȂǤ ͵͵Ǥ ǡǡǡ ǡǡ ǡǤ ͳͻͺͺʹͲͲͺǤ ǤʹͲͳͳǢͻȋȌǣͷʹͶȂͷ͵ͲǤͳǤ ͵ͶǤ ǡ Ǥ Ǥ ǤʹͲͳ͵ǢͳȋͶȌǣͶ͵ȂͶͺǤ ͵ͷǤ ǡǡ ǡǡǦǡ ǡǡǡǡ ǡ ǡ Ǥ ǦǦ ʹǤǤʹͲͳͺǢʹȋͳȌǣʹͳͲȂʹͳǤ͵Ǥ ͵Ǥ ǡ Ǧ ǡǡ ǡǡ ǡ ǡ ǡ ǡǦǡ Ǧǡǡǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ʹǤǤʹͲͳͷ ͳʹǢͳͲȋͶȌǣͶͷȂͷͺǤ ͵Ǥ ǡ Ǥǡǡ ǡǤʹͲͳͷǢͳ͵ȋͳͲȌǣͶʹ͵Ȃ ͶͶǤ ͵ͺǤ ǡ ǡǡǤ ǣ Ǥ ǤʹͲͳͻ Ǣʹ͵ͶȋȌǣͺͳͷʹȂͳǤ
ʹ Chapter 1
͵ͻǤ ǡǡǤ ǤǤʹͲͲǢͶͶͲȋͲͺȌǣͻͶͶȂͺǤ ͶͲǤ ǡǤ Ǧ Ǥ ǤʹͲͳͷ ʹǢͶͻȋͳʹȌǣͳͶͲͷȂͳͺǤ ͶͳǤ ǡǡǤ Ǥ ǤʹͲͳǢͳͳȋͶȌǣ͵ͳȂͺʹǤ ͶʹǤ ǡǡ ǤΪ ǣ Ǥ ǤʹͲͳǢͳȋȌǣͺͳȂ͵ͷǤ Ͷ͵Ǥ ǡ ǡ ǡ ǡ Ǥ ǡ ǤʹͲͲͺǢͻ͵͵ȂͶͶǤ ͶͶǤ ǡ ǡ Ǥ ǤǤʹͲͳͺǢͳͻȋ ȌǤ ͶͷǤ ǡ ǡ ǡ ǡ ǡ ± ǡ ǡ Ǥ Ǧ Ǧ ȋȌǤ ǤʹͲͳͷ ͵ǢʹͻͲȋʹȌǣͳͻͻȂͺͺǤ ͶǤ ǡǦǡǤ Ǧ ͵ͺ Ǧ Ǥ ǤʹͲͳͶǢ͵ͻ͵ȋͳȂʹȌǣͳʹͻȂͶʹǤ ͶǤ ǡ ǡǦǡǡ ǡ ǡǡ ǡǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ ǤǤʹͲͳͶǢͳͷͻȋʹȌǣ͵ͳͺȂ͵ʹǤ ͶͺǤ ǡ ǡǤ ǡ ǡ ǤǤʹͲͳͶ ǢͳͻȋͳȌǣʹͳȂ͵Ǥ ͶͻǤ Ǧ±ǡ ǡ ±ǡ ǡǡǦǡǡÀǦ ǡ×Ǧǡǡ ǤǦ ɘǦ͵ ǣ Ǥ ǤʹͲͲͻ Ǣʹ͵ȋȌǣͳͻͶȂͷǤ ͷͲǤ ǡ ǡǡ ǡ Ǥ ᩿ǣ ǤʹͲͳͺǢ͵ͻȋͶȌǣ͵ͺȂͶͲͳǤ ͷͳǤ ǡ Ǥ Ϊ ǡ Ǥ Ǥ ʹͲͳǢ͵ȋͳͺȌǣʹͲͳͻͳ͵ͷǤ ͷʹǤ ǡǤΪǣ ǡǤ Ǧ ǤʹͲͳǢͳͺͶȋͳʹȌǣͳͺȂͺͲͲǤ ͷ͵Ǥ ǡǡǤǣ ǡ Ǥ ǤʹͲͳͷǢͷͲȋͶȌǣʹͺͶȂͻǤ ͷͶǤ ǡ ǡ Ǥ Ǧ ǣ Ǥ ǤʹͲͳǢͺȋȌǣͳȂǤ ͷͷǤ ǡǤ ǡ Ǥ ǤʹͲͳͶǢͶʹȋͶȌǣͳͳͳͺȂʹʹǤ ͷǤ ǡ Ǥ ͳ Ǧ Ǥ ʹͲͳͶǢͳͶȂͷǤ ͷǤ ǡ Ǥ ǡ Dzdz Ǥ ǤʹͲͳͶǢͶʹȋͶȌǣͳͲͷȂͻǤ ͷͺǤ ǡ ǡ ǡ Ǥ ǣ Ǥ Ǥ ʹͲͲͷǢͶͶȋʹȂ͵ȌǣͳʹͷȂͷ͵Ǥ ͷͻǤ ǡ ǡǡǡǡ Ǥ Ǧ Ǥ ǤʹͲͲͺǢͻͶȋͳȌǣͶȂͳͷǤ
ʹͺ General introduction and outline of the thesis
ͲǤ ǡǡǡǡ Ǥ Ǥ ǤʹͲͳͻ ʹͺǢͶȋͳȌǣͳͶͻȂͷͷǤ 1 ͳǤ Ǥ ǤʹͲͲͳǢ͵ͺǣ͵͵ȂͺǤ ʹǤ Ú Ǥ Ǧ ȏ Ȁ ȐǤ Ǥ ʹͲͲǢǣȂͺͷǤ ͵Ǥ ǡ ǡ°ǡ Ǥͳ Ǥ ǤʹͲͳͶǢͶʹȋͶȌǣͳͲͻͶȂͳͲͲǤ ͶǤ Ǧ ǡ ǡ ± ǡ ǡ ǡ Ǥ Ǧͳ ͳ Ǥ ǤʹͲͲͺ ͺǢͷͳȋȌǣͳͳͻʹȂʹͲͳǤ ͷǤ ǡǡ Ǥ Ǥ Ǥͳͻͻ ǢʹͺͳȋͳͷȌǣͺͳͳȂǤ Ǥ ǡǤ ǤʹͲͳͺǢͳȂͺǤ Ǥ ǡǡǡǡ ǡǡ ǤͳͲ ǣǡ ǡǤ ǤʹͲͳ ǢͳͲͳȋͳȌǣͷȂʹʹǤ ͺǤ ǡ ǡǡǡ Ǥ ǡ ǡ Ǧ ǤʹͲͳǢͳͺͳǣ͵͵ͷȂͷ͵Ǥ ͻǤ ǡ ǡǡǡǡ ǡǡǤ Ǧ ȋ Ȍ Ǥ ǤʹͲͳͺǢͳ͵ȋʹȌǣͳͻ͵ȂʹͲͷǤ ͲǤ ǡ ǡ Ǥ Ǧ Ǧ ǤǤʹͲͳǢȋȌǣͳȂͳͲǤ ͳǤ ǡ ǡǡ ǡǡǡ Úǡ ǡò ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ƬǢ ƬǢ Ǥ ʹͲͳǢͷͳ͵ȂʹͷǤ ʹǤ ǡ ǡǡǤ Ȁ ǤǤʹͲͳͷǢͶȋͻȌǣͷͻ͵ȂͲͶǤ ͵Ǥ ǡǡ ¡ ǡǡǤ ʹ Ǥ ǦǤʹͲͳǢͳͺͳȋͳȌǣͷͳȂͻǤ ͶǤ ǡǡ ǡǡǡǡǡ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͳͺ͵ǢͺȋͳȌǣͳͳͺͷǤ ͷǤ ǡ ǡǡ ǡ ǡǡ ǡǤ ǡǦǦ ǡ ͳͲͲͲǦ ͳ Ǥ ǤʹͲͳ͵ǢͷͺȋȌǣͳͻͲȂͳǤ Ǥ ǡ ǡǡ Ǥ ǣ ʹ ǤǤʹͲͳǢͷȋʹͶȌǣͳȂͳʹǤ Ǥ ǡ ǡ ǡ ǡ ǡ ǡ Ǧ ǡ ǡ ǤǦǦ ǣǦ Ǥ Ǥ ʹͲͳͺǢͶͳͲȋʹ͵ȌǣͷͺͷͻȂͲǤ
ʹͻ Chapter 1
ͺǤ ǡǡ ǡ ǡǡǡ ǡ ǡ ǡ ǡǤǣ Ǧ Ǥ ǤʹͲͳ͵ǢͻȋǤͳȌǣͶͶȂǤ ͻǤ ǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ Ǧ Ǥ ǤʹͲͲͷǢ͵ͺȋͳȌǣͳͺͷȂͻ͵Ǥ ͺͲǤ ǡ ǡ ǡ Ǧ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳǢͳͷȋͻȌǣ͵ʹͲͶȂͳ͵Ǥ ͺͳǤ ǡ ǡ ǡǡ ǤǦ ǤǤʹͲͳͺǢͷͷȂ͵Ǥ ͺʹǤ ǡǡǡǤ͵ǯ Ǥ ǤʹͲͳͶǢͳͳȋȌǣʹͷǤ ͺ͵Ǥ ǡ Ǥ ǣ Ǧ Ǥ ǤʹͲͳͶǢͳͷȋʹȌǣͳͳʹȂǤ ͺͶǤ ǡǡǤ ᩿ǣ ᩿ǣ Ǧ Ǧ Ǥ ʹͲͲͷǢ ͺͷǤ ǡǡǡ ǡǡ ǡǡ ǤͶǤͲ᩿ǣ Ǥ ǤʹͲͳͺǢͶȋȌǣͳȂ ͻǤ ͺǤ ǡ ǡǡǤ᩿ǣ ǤʹͲͲͻǢ͵ȋȌǣͷʹȂͲǤ ͺǤ ǡ Ǥ ǣ Ǥ ǤʹͲͳͷ ͳǢͶ͵ȋͳȌǣͷǦͲǤ ͺͺǤ ǡ ǡ ǡ ǡ ǡ Ǥ ǡ ǡ ǣ Ǥ Ǥ ʹͲͳͶ ǢͶʹȋͳȌǣͳͻͻȂʹͲͷǤ ͺͻǤ Ǥ Ǥ ǤʹͲͳͷ ʹͺǢͶ͵ȋȌǣǦͳǤ ͻͲǤ ǡǡǡ ǡǡǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡǡǡǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡǡǡǡ ǡǡǡ ǡ Ǥ Ǥ ǤʹͲͲ ʹ͵Ǣ͵ȋȌǣͳ͵ȂʹͳǤ ͻͳǤ Ǥ ǣ Ǥ Ǥ ʹͲͳͷ ʹͺǢͶ͵ȋȌǣʹͲͶǦͳʹǤ ͻʹǤ ±ǡ ǡ Úǡǡǡǡ%ǡ ǡÚǡǡ ǡǡǡǡǡ ǡ ǡ ǡ ǡǡǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ± Ǥ Ǥ Ǧ Ǥ ǤʹͲͳͷ ʹ͵Ǣ͵ͶȋʹʹͲȌǣͳʹͲͶͳͻǤ ͻ͵Ǥ ǡǡǡǡ ǡǡǡ ǡǡǡ ǡǡǡǡ ǡǡǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡǡ ǡ ǡ ǡ ǡ ǡǡǡ ǡǡ ǡǡ
͵Ͳ General introduction and outline of the thesis
ǡ ǡ ǡ Ǥ ǣ Ǥ ǤʹͲͲǢ͵ͷȋǤͳȌǣͷʹͳȂǤ 1 ͻͶǤ ǡ ǡ ǡ ǡǡǦ ǡǡ ǡǡ ǡǡǡǡǡǡǡǡ ǡ ǡǦǡǡǡǡǡǡǡ ǡ Ǥ ͶǤͲǣ ʹͲͳͺǤ Ǥ ʹͲͳͺ ͶǢͶȋͳȌǣͲͺȂͳǤ ͻͷǤ ǡ Ǥ Ǥ ǤʹͲͳͷǢ͵ͶǣͻͳȂǤ ͻǤ ǡǡ ǡ ǡǡ ǡ ǡǡ ǡǡ ǡǡÚǡǡǡǡ ǡǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ°ǡǡǡ ǡ ǡǡ ǡ ǡ ǡǡǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ]Ǥ Ǧ Ǥ ǤʹͲͳ͵Ǣ͵ͳȋͷȌǣͶͳͻȂʹͷǤ ͻǤ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ ǤǤʹͲͳ͵ǢͻȋͳȌǣͶͻǤ ͻͺǤ ǤǤʹͲͳ͵ǤʹͶͷǤ ͻͻǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ ǤǤʹͲͳͶǢͷȋʹͲͳ͵Ȍǣ͵Ͳͺ͵Ǥ ͳͲͲǤ ǡ × ǡ ǡ Ǥ Ǥ ǤʹͲͳͷ ǢʹͺʹȋʹȌǣʹͻȂ͵ͳǤ ͳͲͳǤ Ǥ Ǥ Ǥ ʹͲͳͷǢͳȋ͵ȌǣͳͶȂͷͺǤ ͳͲʹǤ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͳͻǢͳͲȋ ȌǣͳͻǤ ͳͲ͵Ǥ ǡ Ǥ Ǥ ǤʹͲͲͶǢʹͲȋͳͳȌǣͳͻͷȂǤ ͳͲͶǤ Ǧǡ ǡǡ ǡǡ Ǥ ǦǤǤʹͲͲͻǢ͵ǣʹǤ ͳͲͷǤ ǡ ǡ ǡ ǡ Ǥǡ Ǥ ǤǤʹͲͳͺǢͳ͵ȋȌǣͳȂʹͺǤ ͳͲǤ ǡ ǡǡ ǡǡ ǡ ǤǦ ʹ ǤǤ ʹͲͳͶǢͻȋȌǤ ͳͲǤ Ǥ Ǥ Ǧ ǤʹͲͳ͵ǢͳͲͷȂͶʹǤ ͳͲͺǤ ǡ ǡ ǡǡ ǡǡ ǡ ǡǡ ǡǤ Ǧ ȾǦ ǤǤʹͲͳ͵ǢͻȋͺȌǣʹȂͻǤ ͳͲͻǤ ǡǦǡ ǡǡ ǡ ǡǦ ǡ Ǧǡ ǡ ǡ ǡǦ ǡ ǡǤ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳͲǤ ͳͳͲǤ ǡ ǡ ǡ ǡ ǡ ǡÀ×ǡ ǡ ǡ × ǡ ǡ ǡ ï×ǡ ǡǡ
͵ͳ Chapter 1
ǡ ǡ ǡǡǡǡǡǡ ǡ~ǡ ǡǡ ǡǡ ǡ ǡ Ǥ ǣ Ǥ ǤʹͲͳͻ ͺǢͶȋͳȌǣͳͶȂʹͶǤ ͳͳͳǤ ǡ Ǥ Ǥ Ǥ ʹͲͲǢͳͷȋͳȌǣͶͷȂͷͲǤ ͳͳʹǤ ǡ ǡ ǡ ǡ ǡ Ǧ Ǥ Ȃ Ǧ Ǥ ǦǤʹͲͳͻǢͳͺͷȋʹȌǣ͵ͲȂͲǤ ͳͳ͵Ǥ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ǣ ǤǤʹͲͳͺ ͳǢʹͷͷͺͺͷǤ ͳͳͶǤ Ǥǡǡǡ ǡ ǡǡ ǡ ǡǡǫǫ ǡǡǡ ǡ Ǥ ǣ Ǥ ǤʹͲͲͻǢͷͺȋͳȂ ʹȌǣȂ͵ͶǤ ͳͳͷǤ Ǥ Ǥ ǣ ʹ ǤʹͲͲͳǤǤʹͻͳȂ͵ͲͲǤ ͳͳǤ ǡ ǡ Ǥ Ǧ Ǥ ǤͳͻͺǢͳͷͷȋ͵Ȍǣ͵ͳȂͶͳǤ ͳͳǤ Ǥ Ǥ ǤͳͻͺͷǢͳͲȋͳȌǣͳǤ ͳͳͺǤ ǡ Ǥ ǣ Ǥ ǤͳͻͺͷǢͳͶͺǣͷͷͷȂͳǤ ͳͳͻǤ ǡ ǡ Ǥǡ Ǥ Ǥ ǤͳͻͻͶ ͳǢʹʹͷȋͳȌǣͳͻȂͺǤ ͳʹͲǤ ǡ ǡ Ǥ Ǧ ǣ Ǥ Ǥ ʹͲͲͷǢʹʹȋͺȌǣͳͻͷȂͺͷǤ ͳʹͳǤ Ú ǡ ǡ ò Ǧ Ǥ ǣ Ǥ ǤʹͲͳʹǢͺȋȌǣͳͲͲʹͷǤ ͳʹʹǤ ǡ ǡǤ ȾǦ ǣǦ ǤǤʹͲͳǢͳ͵ȋȌǣͳȂʹ͵Ǥ ͳʹ͵Ǥ ǡǡ Ǥ ǣ ǤǤʹͲͳǢͳʹȋͻȌǤ ͳʹͶǤ ǡǡǤ ǣ ȾǦǤ ǤʹͲͳ͵Ǣͺȋ͵ȌǤ ͳʹͷǤ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡǤ ǤǤʹͲͳͺǢͳͶȋȌǣͳȂͳͻǤ ͳʹǤ ǡ ǡ ǡ Ǧǡ Ǧǡ ǦǤ Ǥ Ǥ ʹͲͳʹǢȋͳȌǣʹǤ ͳʹǤ ǡǦǡǤ ǣ Ǥ ǤʹͲͲ ǢȋȌǣͶͶͻȂͲǤ ͳʹͺǤ ǡǡ ǡ ǡǦ ǡ ǡǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ
͵ʹ General introduction and outline of the thesis
ȋȌ Ǥ ǤʹͲͳͻʹ͵Ǣ͵ͳȋͲȌǤ ͳʹͻǤ ǤǦǦǫ ǤʹͲͲͶǢʹȋ͵Ȍǣ͵ͲͷȂͳǤ 1 ͳ͵ͲǤ ǤǡǤ ǣ Ǥ ǤʹͲͳͲǢ͵͵ȋͷȌǣͷͳ͵ȂʹͲǤ ͳ͵ͳǤ ǡ ǡ ǡ ǡǡ ǡ Ǥ Ǧ ǣ Ǥ ǤʹͲͲǢͳͶͺȋͷȌǤ ͳ͵ʹǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǥ Ǧ ǤʹͲͳͶǢͳͺͶʹȋͳͲȌǣʹͲʹͳȂͻǤ ͳ͵͵Ǥ ǡ ǡ ǡǡǡǡǡ ǡǤ ʹͺ Ǥ Ǥ ʹͲͳ͵ǢͳʹȋȌǣͳͲͻȂʹʹǤ ͳ͵ͶǤ ǡ ǡǡ ǡ ǡ ǡ ǡǦ ǡǡǦǡ ǡ ǡǦ ǡ Ǥ Ǧ Ǧ ǣ Ǥ ǤʹͲͳʹǢǣ͵ͲǤ ͳ͵ͷǤ ǡǡ Ǥ ǫ Ǥ ǤʹͲͳǢ͵ͲȋͳʹȌǣǤʹͲͳͲͲͶͳͲǤ ͳ͵Ǥ ǡǡǡ ǡǡǡ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͳǢʹͻͳȋʹͺȌǣͳͶȂͻͶǤ ͳ͵Ǥ ǡ Ǥ Ǥ ǤʹͲͳǢ͵ͻȋͶȌǣͷͷȂʹǤ ͳ͵ͺǤ ǡ ǡ ǡǦǡ ǡǡǡ ǡ ǡ ǡ ǡ Ǥ ͵ ͵ǦǦ͵Ǧ ʹ Ǥ Ǥ ʹͲͳͲǢͳʹȋȌǣͷͶȂͳǤ ͳ͵ͻǤ ǡǡ ǡ ǡ ǡǡ ǡ ǡ ǡ ǡǡǡǡǡ ǡǡ Ǥǡ ǡ ǡ Ǥ ͵ Ǧ ǤǤʹͲͳͲǢͶͶȋʹͺͷȌǣͳʹͳȂͷǤ ͳͶͲǤ ǡǡǡǡǡ ǡ ǡ ǡ ǡ ǡǡ ǡ ǡ Ǥ͵ȋ ͵Ȍ Ǧ Ǧ Ǥ ǤʹͲͳ͵ǢʹͺͺȋͶȌǣ͵͵ͺ͵ȂͶǤ ͳͶͳǤ ǡǡǡǡ ǡ Ǥ ͳͲ͵ǣ Ǥ ǤʹͲͳͷǢʹͻͲȋͶȌǣʹͶȂ Ǥ ͳͶʹǤ ǡǡ ǡǡǡ ǡ Ǥ ͵ ͷ Ǧ Ǧ ǤǤʹͲͳͷǢͳͲȋ͵ȌǣͳȂͳ͵Ǥ ͳͶ͵Ǥ ǡǤ ǤʹͲͳͷǢʹʹȋͳʹȌǤ ͳͶͶǤ ǡǤ ǣ Ǥ ǤʹͲͳǢ͵ȋͳͷȌǣʹͺͳȂͻǤ ͳͶͷǤ ǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ
͵͵ Chapter 1
ǤʹͲͲǢͳͲͶȋȌǣͳȂͺʹǤ ͳͶǤ ǡ Ǥ Ǥ ǤʹͲͳ͵Ǣʹʹȋͳ͵ȌǣʹͲͷȂʹʹǤ ͳͶǤ ǡ ǤǦǤ Ǥ ǤǤͳͻͺ͵ǢͳͳȋͷȌǣ͵ͳȂͺͶǤ ͳͶͺǤ ǡǡǡǤ Ǧ ǣ Ǥ ǤʹͲͳǢͳȋͻȌǤ ͳͶͻǤ ǤǤǤʹͲͳͶ ǢͶȋͳȌǣͳȂͻǤ ͳͷͲǤ Ǥ ǦǤʹͲͲʹǢͶͳǣͳͻȂʹ͵ͻǤ ͳͷͳǤ ǡ Ǥ ȾǦǤ ǤʹͲͳͲǢ͵͵ȋͷȌǣͶͻȂǤ ͳͷʹǤ ǡ ǡ Ǥ ǦǤ Ǥ ͳͻͻǢ͵ʹͲǣ͵ͶͷȂͷǤ ͳͷ͵Ǥ ǡ ǡ Ǥǡ Ǥ ȾǦ Ǥ Ǥ ʹͲͳǢͺȋͳȌǣʹ͵ȂͶͶǤ ͳͷͶǤ ǡ ǡ ǡ ǡ ǡǡ ǡ ǡ ǡ Ǥ ǣ Ǧ Ǥ Ǥ ʹͲͳ͵Ǣͳͺ͵ʹȋȌǣ͵ȂͻǤ ͳͷͷǤ Ǥ ǤʹͲͳǢͳ͵ʹȂͶʹǤ ͳͷǤ ǡ ǡǡÞǤ Ǧǣ ͵Ǧ Ǥ Ǥͳͻͻʹ ͵ͳǢʹͲͷȋͳȂʹȌǣͳʹȂ͵ͷǤ ͳͷǤ ǡǡǡ ǡǡǡ ǡ ǡ ǡ ǡ Ǥ ǣ Ǥ Ǥͳͻͻ ǢʹͶȋȌǣͳ͵ͻͷȂͺǤ ͳͷͺǤ ǡǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳͲǢʹͺͷȋ͵ͻȌǣʹͻͺ͵ͶȂͶͳǤ ͳͷͻǤ ǡ Ǥ Ǧ Ǥ ǤͳͻͺͶ ʹͷǢʹͷͻȋͳͶȌǣͺͶͺȂ ͷʹǤ ͳͲǤ ǡ ǡ Ǥ ᩿ǫǫǦ Ǥ ȋȌȀǤͳͻͻͳǢͳͲͺͳȋʹȌǣͳʹͳȂͺǤ ͳͳǤ ǡ ǡǤ Ǥ Ǥ ͳͻͺͷ ǢʹͲȋͳȌǣͳͺͺȂͻͲǤ ͳʹǤ ǡǤ Ǧ Ǥ ǤͳͻͺͶǢʹͷͻȋʹͶȌǣͳͷͲͶͲȂͷǤ ͳ͵Ǥ ǡǡ ǡǡǡǡǡ ǤǦ ͵Ǧ Ǧ Ǧ ǤǤʹͲͳʹǢȋͶȌǣͳȂͺǤ ͳͶǤ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͲʹǢͶȋͳȌǣͶȂͷͲʹǤ ͳͷǤ ǡǡ ǡ ǡǡ ǡǡ ǡ ǡǡ ǤʹʹͳǦ Ǧ Ǧ ǣ
͵Ͷ General introduction and outline of the thesis
Ǥ ǤʹͲͳǢͳͳͻȋͳȂʹȌǣͷȂͺʹǤ ͳǤ ǡ ǡ ǤǦ Ǧ ǣ 1 Ǥ ǤʹͲͳǢͶͲȋͷȌǣͶͳȂͷͷǤ ͳǤ ǡ ǡ ǡǡ ǡ ǡǡ ǡǡǡ ǡ ǡ Ǧǡ ǡ ǡǡ ǡ ǡǦǡ ǡ ǡ ǡ ǡ Ǥ ǡ Ǥ ǤʹͲͳͻ ͳ͵Ǣ ͳͺǤ ǡ ǡ ǡ ǡ ǡǡǡ ǡ ǡ ǡ Ǥ Ǧ ͷʹ Ǧ Ǥ ǤʹͲͳǢͳͳͺȋͶȌǣʹʹȂͺͳǤ ͳͻǤ ǦǤ ǡǤʹͲͳͶǤ ͳͲǤ Ǥ ᩿ǣ Ǧ ǣȀȀǤǤ ǤȀ ȀͳͷͲͶʹͳͷͲͶǤȏȏǤǤȐǦǦȐǣȏǤǤȐǢʹͲͲǤ ͳͳǤ ǡ ǡǡǡ ǡ ǡ ǡǡ Ǥ Ǧ Ǧ Ǥ ǤͳͻͻͲǢͺȋʹ͵Ȍǣͻʹ͵ȂͶͲǤ ͳʹǤ ǡǡǡǡòǡǡ ǡǡ ǡ ǡ Þ ǡ ǡ ǡ ǡ Ǥ Ǧ ͵ʹͻ ͳ Ǧ Ǧ Ǥ ǤͳͻͻͳǢͳͶȋ͵Ȍǣ͵ͳͶȂǤ ͳ͵Ǥ ǡ ǡǤ Ǧ Ǧ ȋȌǤͳͻͻͶǢʹͻȋȌǣͶͶͲͳȂͺǤ ͳͶǤ ǡǡǡ ǡ ǡǡǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ Ǧ Ǧ Ǥ Ǥ ʹͲͳͶǢͻȋͶȌǤ ͳͷǤ ǡ ǡ ǡǡ ǡǡǡ ǡ ǡǡ ǡ Ǥ Ǧ ȋȌǦ ǡ ǡ ǤǤʹͲǡ ǤͳͻͻͷǤǤͳͲʹͺͶȂͻͲǤ ͳǤ ǤǦǣ ǫ ǤʹͲͲ͵ǢʹȋʹȂ͵ȌǣͳͺͳȂͺǤ ͳǤ Ǥ ǣ ǤǤʹͲͲʹǢȋͳȌǣ͵ȂͶǤ ͳͺǤ Ǧǡǡ ǡǤ Ǥ ǤͳͻͺǢͳͲǣͳͷͻȂʹͲͲǤ ͳͻǤ ǡǡÞǤ ǦͳͲǦ Ǧ ͳͲǦǦͳǦ Ǧ ǣǦǦͳǦǦ ȋǦͳʹȌ ǤǤͳͻͺ͵ǢͳȋͳͲȌǣͺʹͺȂ͵ͶǤ ͳͺͲǤ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ȋǦ Ȍ Ǧ ȋǦ Ȍǣ ʹ͵ Ǥ Ǥͳͻͺ͵Ǣͳ͵ʹȋʹȌǣͳͺͳȂͻͳǤ ͳͺͳǤ ǡǡ ǡ Ǥ ǣ ȏͳǦͳͶȐ Ǧ Ǧ Ǥ Ǥ ͳͻͺ͵ ͳǢʹʹͳȋͶͲͷȌǣ͵ȂͷǤ
͵ͷ Chapter 1
ͳͺʹǤ ǡ Ǥ Ǧ Ǥ Ǥ ͳͻͻʹǢǣͳͶʹȂͷǤ ͳͺ͵Ǥ Ǥ Ǥ Ǥ ʹͲͳͲǢ͵͵ȋͷȌǣͷ͵͵ȂǤ ͳͺͶǤ ǡ ǡǦǡǦǡ ǡǦ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳ͵ǢͺȋͳȌǣͶ͵Ǥ ͳͺͷǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳͲǢ͵͵ȋͷȌǣͷͷͷȂͳǤ ͳͺǤ ǡǡ ǡ ǡ ǡǡǤ Ǧ Ǧ Ǥ Ǥ ͳͻͻǢͻȋ͵Ȍǣ͵ȂͺǤ ͳͺǤ ǡ ǡ ǡ ǦǡǤƮ ǯ Ǧ Ǧ Ǥ ǤͳͻͺǢͺȋȌǣͳͲͷʹȂǤ ͳͺͺǤ ǡ ǡ ǡǡ ǡ Ǥ Ǧ Ǧ Ǧ Ǥ ǤͳͻͻͶǢͳȋͳȌǣͶȂͺͲǤ ͳͺͻǤ ǡ ǡ ǡ ǡǡ Ǥ Ǥ ǤʹͲͲǢͳȋͳȌǣͷȂͳͳǤ ͳͻͲǤ Ǥ ǣ Ǥ ǤʹͲͲͻǢ͵ʹȋʹȌǣʹͳͶȂǤ ͳͻͳǤ Ǥ Ǧ ǣ Ǥ Ǥ ʹͲͳǢʹ͵ȋͳȌǣͷͳȂͷǤ ͳͻʹǤ ǡ ǡǡ ǡ ǡǡǡ ǡǤ Ǧ Ǧ Ǧ Ǥ Ǥ ʹͲͲͷǢͳȋʹȌǣͲʹͲͷȂͳʹǤ ͳͻ͵Ǥ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ͳͻͻͺǢͳͲʹȋͻȌǣͳʹͶȂ͵ͳǤ ͳͻͶǤ ǡǤ ǦǤ ǤʹͲͲʹǢͶ͵ȋʹȌǣͷȂͷǤ ͳͻͷǤ ǡǤ ǣ Ǥ ǤʹͲͳͲǢ͵͵ȋͷȌǣͷ͵ͻȂͶǤ ͳͻǤ ǡ ǡ ǡǡǡ ǡ ǡ ǡǡ ǡ ǡ ǡǡ Ǥ Ǧ Ǥ Ǥ ʹͲͳͶǢ͵Ͳȋ͵Ȍǣ ͵ʹȂ͵ͺǤ ͳͻǤ ǡǡǡǡǡǡ ǡ ǡǤ Ǧ Ǧ Ǧ Ǥ ǤʹͲͲͶǢ͵Ͷȋ͵ȌǣͳͻͳȂǤ ͳͻͺǤ Ǥ Ǧ Ǧ ǦǤ ǤʹͲͲͷǢʹͻͲȋ͵Ȍǣ ͳʹͺͻȂͻǤ ͳͻͻǤ ǡ ǡ ǡǡ ǡ ǡ ǡòǡ ǡ ǡ Ǥ Ǧ Ǧ ȋȌǦ Ǥ ǤʹͲͲͺǢͶȋȌǣͳͺͻͶȂͻͲͶǤ ʹͲͲǤ ǡ ǡ ǡ Ǥ
͵ ǤǤʹͲͳʹǢͺȋͳͲȌǣʹͷͶͷȂͷͺǤ
Chapter 2
The promiscuous enzyme medium-chain 3-keto-acyl-CoA thiolase triggers a vicious cycle in fatty-acid beta-oxidation
Anne-Claire M.F. Martines1,2, Karen van Eunen1,2, Dirk-Jan Reijngoud1,2, and Barbara M. Bakker1,2,*
1 Laboratory of Pediatrics, University of Groningen, University Medical Center Groningen, The Netherlands 2 Systems Biology Centre for Energy Metabolism and Ageing, University of Groningen, University Medical Center Groningen, The Netherlands
PLoS Comput Biol. 2017;13(4):1–22
The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
Abstract Ǧ Ǧȋ Ȍ Ǥ Ǥ 2 Ǥ ǡ ǡ Ǯ ǯȋ ȌǤ ǡ Ǥ ǡ Ǥ Ǥ ǡ Ǧ Ǧ ȋȌǡ Ǥǡ Ǥǡ ǡ Ǥǡǯ Ǧ Ǥ ǡ ȀǦ Ǧ ǡ ǡ ǡ ǦǤ Ǧ Ǥ ǡ Ǥ ǡ ǡ Ǥ ǡ Ǯ ǯǤ Ǥ
Ͷͳ Chapter 2
Introduction Ǧ ȋ Ȍ Ǥ ǡ ǡ Ǧ Ǥ ǡ Ǥ ǡ ȏͳǡʹȐǤ Ǯ ǯǡ Ǧ ȏͳǡʹȐǤ ǡ ǡ Ǥ ǡ ǦǦ Ǧ Ǧ ȋȌ Ǧ ǡ ȏ͵ȂȐǤ ǡ Ǧ Ǧ Ǧ ȏȐǤ ǡ ǡ ǡ Ǥ ǡ ȏͺȐǤ ǦǡǦ ȋͳȌǡ Ǧ Ǥ ǡ Ǧ ȋȌ Ǥ Ǧ ȏͻȐǡ ǡ ȏͻȐǤ ǡ ǡ Ǧ Ǥǡ ǡ ǡ ȏͳͲȐǤ ǡ ǡ ǡ Ǥ ǡ Ǧ ȏʹǡͺȐǤǦ Ǧ ȋ ͳȌǤ ǡ Ǧ Ǧ Ǥ Ǧ ȋǤǤ ͳǤ͵ǤͻͻǤ͵ ǤǤͳǤ͵ǤͺǤͳȌǡǦ ȋǡǤǤͶǤʹǤͳǤͶǤǤͶǤʹǤͳǤͳͷͲȌǡ ǦȋǤǤͳǤͳǤͳǤʹͳͳǤǤͳǤͳǤͳǤ͵ͷȌ Ǧ ȋǤǤ ʹǤ͵ǤͳǤͳȌȌǤ ȋ ǦǦǡ Ǧǡ Ǧǡ Ǧ Ǧ ǡǡǡȌ ǡ Ǧǡ Ǥ
Ͷʹ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
Malonyl-CoA Palmitoyl-CoA Palmitoyl-carnitine carnitine CoASH carnitine 2 CPT1 C16 CACT C4-C16 CPT2 Mitochondrion C4-C16 carnitine CoASHcarnitine Palmitoyl-carnitine Acyl-CoA
MCKAT Acetyl-CoA SCAD MCAD LCAD VLCAD FAD C4-C6 C4-C12 C8-C16 C12-C16 C4-C16 CoASH FADH2
Ketoacyl-CoA Enoyl-CoA Acetyl-CoA + NADH + H MTP C4-ketoacyl-CoA NADH + H+ C8-C16 MSCHAD C4-ketoacyl-CoA CROT NAD+ C4-C16 NAD+ C4-C16 CoASH Hydroxyacyl-CoA Fig 1. Schematic representation of the modelled mFAO pathway in rat. ǡǤ Ǥ ǣ Ǣǣ Ǧ Ǣǣ ǦǦ Ǥ Ǥ ȏͺȐǡ Ǥ ȋȌ ͺ ǡȋͶȌ ǡ ȀǦ Ǧ ȋȀ Ȍǡ Ǧ Ǧ ȋȌǤ ǡ Ǥ ȏͺȐǡ ǡǤǤ Ǥ Ǥ ǡ Ǧ ǡ Km Ǥ ǡ ͳǦ Ǧ ǡǣ
ሾభలషೌషಲሿ ሾಷಲವሿ ሾభలషషಲሿ ሾಷಲವಹమሿ ௦ೇಽಲವǡభలήೌೣǡೇಽಲವήቌ ή ି ή ቍ ಼ೇಽಲವǡభలషೌషಲ ಼ೇಽಲವǡಷಲವ ಼ೇಽಲವǡభలషೌషಲ ಼ ೇಽಲವǡಷಲವήܭ݁ݍǡܸܮܥܣܦ ݒǡଵ ൌ ሾభలషೌషಲሿ ሾభలషషಲሿ ሾషೌషಲሿ ሾషషಲሿ ሾಷಲವሿ ሾಷಲವಹ ሿ ήቆଵା ା మ ቇۊ ଵା ା ା σసభర ାۇ ಼ ಼ సభమ಼ ಼ ಼ ಼ ೇಽಲವǡభలషೌషಲ ᇣᇧᇧೇಽಲವǡభలషషಲᇧᇧᇧᇧᇧᇧᇤᇧᇧᇧᇧᇧᇧᇧᇧᇥ ᇣᇧᇧᇧᇧᇧᇧೇಽಲವǡషೌషಲᇧᇧᇧᇧᇧᇧᇧᇧᇧᇧᇧᇧᇧᇤᇧᇧᇧᇧᇧೇಽಲವǡషషಲᇧᇧᇧᇧᇧᇧᇧᇧᇧᇧᇧᇧᇧᇧᇥ ೇಽಲವǡಷಲವ ೇಽಲವǡಷಲವಹమ ی್್ೝೌೝೠ ್್ೞೠ್ೞೝೌೞೌೝೠೞೝೌೞ ۉ ȋͳȌ ǡ Ǥ in silico ȋǤǤ Ȍǡ Ǥ
Ͷ͵ Chapter 2
ȏͺǡͻȐǤHow ǡǡǤ ǡ Ǥ Ǥ Ǥ ǡ ȋȌ ȋȌ Ǥ ȏͳͳȐǡ ȏͳʹȐǤ Ǥ Ǥ Results Description of the phenotype Ǧ
ȋȏǦȐȌȋ ʹȌǡ ȋ ʹȌǤ AB 2.0 6000 ) -1 free CoA 1.6 5000
M) Intermediate ȝ 4000
.gProtein CoA esters
-1 1.2 3000 C6/C4 CoA esters 0.8 2000 C4-CoA (μmol.min [Metabolite] ( esters 0.4 1000 C6-CoA uptake
J esters 0.0 0 0 50 100 150 200 250 0 50 100 150 200 250
[Palmitoyl-CoA]CYT (ȝM) [Palmitoyl-CoA]CYT (ȝM) CD 8 8 vmtpC8 vmckatC4 ) 7 vmtpC10 ) 7
-1 vmckatC6 -1 6 vmtpC12 6 vmckatC8 vmtpC14 5 5 vmckatC10 vmtpC16 vmckatC12 .gProtein .gProtein -1 4 -1 4 vmckatC14 3 3 vmckatC16 2 2
J (μmol.min 1 1 J (μmol.min 0 0 0 50 100 150 200 250 0 50 100 150 200 250 [Palmitoyl-CoA] ȝ0 [Palmitoyl-CoA]CYT ȝ0 CYT Fig 2. Simulated steady-state fluxes and concentrations in the mFAO model. (A) Ǧ ȋȏǦȐȌ Ǧ Ǥ Ǧ Ǧȋ Ȍȋ ǦǦ
ͶͶ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
ǡǤǤǦ Ȍǡ et al. ʹͲͳ͵ȏͺȐ ǤǦ Ǥ (B) Ǧ ȋ ȏͺȐȌǡ ǡͶǦ ͶǦ 2 ȋ ȌǤ (C-D) Ǧ ȋ Ȍ Ǧ ǡ Ǥ ȋ Ǥ ͳȌ Ǥ
ǡ Ͷ ȋ ʹȌǤ Ǧ ǣ ȋ ͳȌǡ ͺ ǡ Ǧ Ȁ Ǧ ȋ ͳȌǡ ͶͳǤǡͶǦ ǦȀ Ǧ ǡ Ǥ ǡ ͺ Ǧ ȋ ʹȌǤ Ͷ ǡ ǡǦȀ Ǧ ȋ ʹȌǤǡ Ǧ Ǥ Ǧ Ǥ
The flux decline originates at the promiscuous MCKAT enzyme ǡ Ǥǡ Ȃ Ȃ ȋȌǤ Ǧ ǡ ǡ Ǥ ȋVmaxȌ ȋ ȌǤ ȋ ͵ȌǤ ǡ ǡ Ǧ ȋ ͵ȌǤ ǡ ȋ ͳ Ȍǡ ȋ ͵ȌǤǡ exceptǡ ȋ ͵ȌǤȂ Ǧ ͷͲ ρ ǦǤ ǡ Ǧ ʹͷͲρǡ ȋͳ ȌǤ ǡǦ ȋ ͵ȌǤ ǡ ǡ Ǥ
Ͷͷ Chapter 2
AB 2.0 4 ) -1 CPT1 1.6 Published model 2
.gProtein 1.2 No promiscuity at MCAD -1 MCKAT 0 0.8 No promiscuity SCAD except at MCKAT -2 (μmol.min 0.4 No promiscuity MCKAT Flux control coefficient (-) uptake
J 0.0 -4 0 50 100 150 200 250 0 50 100 150 200 250
[Palmitoyl-CoA]CYT ȝ0 [Palmitoyl-CoA]CYT (ȝM)
CDJuptake Juptake E Rp Rp -2.5 0.0 2.5 -2.5 0.0 2.5 3 sfcpt1C16 Keqmschad vmschadC4 Vcpt1 Vmckat
]/[NADH] vmschadC6 CarCYT [NAD+]/[NADH] + 2 vmtpC8 Kmcpt1CarCYT CoACYT uptake [NAD J CoACYT Keqcrot vmtpC10 sfmckatC4 Kmcpt1CoACYT vmtpC12 C16AcylCoACYT sfcpt1C16 1 Kmcpt1C16AcylCoACYT Vcpt1 vmtpC14 Keqcpt1 KmmckatC4ketoacylCoA vmtpC16 Keqcact Kmcpt1CarCYT 0 Vfcact CarCYT sfcactC16 Kmcpt1CoACYT [NAD+]/[NADH] C16AcylCoACYT -1
Vmckat KmmckatC4acylCoA Reaction-partitioned R 5 15 25 53.37 60 250 Keqmschad KmmckatCoAMAT [Palmitoyl-CoA] (μM) CYT Fig 3. The role of the short-chain branch. (A) Ǧ ȏǦȐ ȋ Ȍǡ ȋ ǡ ȏͺȐ Ȍǡ ȋȌǡ ǡȋȌǤ (B) ȏǦȐǤ Ǣ ǡʹ Ǥ(C-D) ͳͷ ʹͷɊȋȌͲɊȋȌȏǦ ȐǤp ǦǤ ͳǦ ǡ Ȁ Ǧ ǡ Ǧ Ǧ (E) Ϊ ୳୮୲ୟ୩ୣ Ǥ ȏ ȐȀȏ ȐȋሾୈశሿȀሾୈୌሿȌ Ϊ Ǧ ͷǦ ܴሾேశሿȀሾேுሿ ൌ σ ௩ . (cf. Eq. 4). ୳୮୲ୟ୩ୣ ܥ ήߝሾேశሿȀሾேுሿ Ȁ ͺǦͳሾୈశሿȀሾୈୌሿ Ǥ MCKAT becomes the most important flux-controlling enzyme when the flux declines Ǧͳǡǡ ͳǡǡʹȋ ͳȌǤ Ǧ ͳ Ǥ ǡ Ǥ ȏͳͳǡͳ͵ȂͳͷȐǡ ܥ iǦJ ǣ ௗȀௗ ܥ ൌ ȋʹȌ డ௩Τడ p viǤ ͳ p ȋǤǤ VmaxȌ ǦǤ
Ͷ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
ǡ Ǧ Ǥ p ǡ Ǧ Ǥ ͵Ǥ Ǧ 2 ͳ ǡ ͳǡ ȋ ͵ ʹȌǤǦ ǡǡ ͳ ǡ Ǥ ȏͳͳǡͳͶȐ ͳǡ ͳ Ǥ ǡ ȋ ͵ ʹȌǤ ǡ ǦǦ Ͷ ȋ ʹ Ȍǡ Ǧ Ǥ ȋʹ ȌǤ The accumulation of intermediates is amplified by the short-chain branch ǡ ǡ ͳǡ ǡ Ǥ ǡ p Ǧ ǣ ȋʹͷɊȌ ȋͲɊȌǤ ܴȏͳͷȐ pǦ ǣ ܴ ൌ ݈݀݊ܬΤ ݈݀݊ ȋ͵Ȍ ͵ ͵ ͳͷ ʹͷɊͲɊǦǡ Ǥ ͳǡ ʹͷρ ͳǡ ȋȌ Ǧ
ȋǡ ǡ ͳ Ȍǡ ȋͳǡͳ ͳȌǡ
ȋǡͳǡǡ ǡͳǡǡ ǡͳǡͳ Ȍ ȋ ͵Ȍǡ Ǥ Ͳ ρǡ ǡ
ȋǤǤͶǡǡͶǡǡ ǡͶǦ Ǧǡǡ ǡͶǦ Ϊ ǦǡǡǡȌǤ ǡȏ ȐȀȏ Ȑ Ȁ ȋ Ȍ ȋ Ȍ Ͷ ȋ ͵ȌǤ Ϊ Ȁ ǡ ȏΪȐȀȏ Ȑ Ǥ Ǥ Ϊ ǡ Ȁ Ǧ Ǥǡ
Ͷ Chapter 2
ȏΪȐȀȏ Ȑ ǡ ȏͳͷȐǣ
௩ ܴሾேశሿȀሾேுሿ ൌσ ܥ ήߝሾேశሿȀሾேுሿ ȋͶȌ
iǡߝேାȀேு ȋǤǤ Ȍ iΪǦ ǡ ǣ ௩ ା ሿሻ ȋͷȌܪܦܣሿΤ ሾܰ ܦܣߝሾேశሿΤ ሾேுሿ ൌ ߲݈݊ݒΤ߲ሺሾܰ ௩ ǤͶ Ǧ ܥ ήߝሾேశሿȀሾேுሿȋ ͵Ȍ ǡͶ Ȁ Ǥ Ǥ ȏΪȐȀȏ Ȑ Ǧ ȋͶȌȀ ǡ Ǥ Ȁ ȋ ǤȀ ͵ ǡ ͵ ȌǤ ȏΪȐȀȏ Ȑ ǡ Ǥ Ȁ ʹǤͳȉͳͲǦͶȋǡ Ǥ ͳȌ Ǥ ͶǦ Ǧǡ ǡ ǦȀ ǡ ȏΪȐȀȏ Ȑ ȋ ͵ ȌǤ ͵Ǥͳ͵ǡ Ǧ ȋ ͵ ȌǤǡȀ ǡ Ǥ
ǡ ͵Ͷ ȋǤǤǡͶǡ
ǡ ǡͶǦ ǦȌǡ ǡ
ͶǦ Ǧ ȋǤǤǡ ǡͶǦ ǦȌǡ Ǥ Ͷ ǡ ȋȌ ͶǦ
ȋͶǡ ǦǦ ȌʹǦǦ
ȋȌ ȋͲǤͶͻ ͳȌ ȋȌ ʹǦ ͶǦ ǦǦ Ǧǡ
ʹǦ Ǧ ȋȌȋͳʹǤͶǤɊȌǤ Internal regulation reveals a vicious cycle around MCKAT ǡ Ǥ ͲǤͳ ρǡ Ǧ ʹͷ Ͳ ρ Ǥ ǡ
Ͷͺ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
Ǧȋ Ͷ ȌǤ ǦȋʹͷρȌ ȋ ͷ ȌǤ Ͳ ρǡ ǡ ǡ Ͷȋ ͶȌǤ 2 AB 1.5 0.01 C16-Ketoacyl-CoA ) ) vMCKATC6 C14-Ketoacyl-CoA í -1 vMCADC4 + C12-Ketoacyl-CoA 1.4 vSCADC4 C10-Ketoacyl-CoA C8-Ketoacyl-CoA vMCKATC4 C6-Ketoacyl-CoA 1.3
.gProtein C4-Ketoacyl-CoA .mgProtein -1
2 0 C16-Acyl-CoA í j C14-Acyl-CoA 1.2 vmckatC4 X
Ĭ C12-Acyl-CoA C10-Acyl-CoA 1.1 C8-Acyl-CoA C6-Acyl-CoA (μmol.min v (μmol.min C4-Acyl-CoA 0.0 -0.01 Free CoA 0 100 200 300 0 100 200 300 time (min) time (min) Fig 4. Time course of key short-chain reaction rates and regulation of the MCKAT-C4 reaction. (A) Ͷ ȋ Ͷǡ Ȍ Ͷ ȋͶ Ϊ ͶȌȏǦȐͲǤͳͲɊǤ(B) ͶȏǦȐ ͲǤͳͲɊǤ ͶǦ Ǧ ͶǦ Ǧ Ǧ Ǥ ǡ ʹͺ ǡ Ǥ Ȁ ǡȋ ȌǤ Ǥ Ǥ ǡ ǡ ǤʹͲͲͷȏͳʹȐǤ v Xj ǡ j ǣ ௗ௩ డ௩ ௗೕ ௩ ሺݐሻ ൌ σ ሺݐሻ ή ሺݐሻ ؠ σ ȣ ሺݐሻ ȋȌ ௗ௧ డೕ ௗ௧ ೕ
௩ డ௩ ௗೕ ǣ ȣ ሺݐሻ ؠ ሺݐሻ ή ሺݐሻ ȋȌ ೕ డೕ ௗ௧
4തതതఫ ଵ ௧ ௗ௩ ଵ ௧ డ௩ ௗೕ Xjǣ ሺ߬ሻ݀߬ ൌ σ ሺ߬ሻ ή ሺ߬ሻ݀߬ ൌ ௧ ௗ௧ ௧ డೕ ௗ௧ ଵ ௧ σ ȣ௩ ሺ߬ሻ݀߬ ൌ σ ȣഥ௩ ௧ ೕ ೕ ȋȌ ǣ
Ͷͻ Chapter 2
ଵ ௧ ȁȣഥȁ௩ ൌ ቚȣ௩ ሺ߬ሻቚ ݀߬ ȋͺȌ ೕ ௧ ೕ ௩ ͶǦ ȣೕሺݐሻ Ͷ Ǧ ͲǤͳͲρ Ǧǡ Ǥ Ǥ ഥ ௩ெ்ିସ j ȁȣȁೕ Ͷ Ǥ ͶǦ ǦǤ Ǧ ǡ Ǥ Ǥ డ௩ ಾ಼ಲషరǡ ǡ డ୪୬ሾሿ Ǥ ͷǦ ǦͲǤͳρ ǦǤ ͶǦ Ǧǡ ȋ ͷȌǤͲǤͳͲ ρǡǦ Ǧ ȋǤǤͶǦ Ǧ ͶǦ Ǧ Ǧ Ǧ Ȍǡ Ǧ ǡ Ǧ ǡ Ǧ Ǥ Ǧ ǡ ȋ ȌǤ Ǧ Ǥ Ǧ Ǥ ǡ Ǧ ͶǤ ǦͶǦ ǦǦ Ǧ ͶǦ Ǥ ǡ ȋ ȌǤǦ Ǧ ǡ Ǧ Ǧ ǦǤǦͶǦ ǦǦ ǡ Ǥ ǯ ͶǦ Ǧ ǦǤ ǡ Ǧǡ ǦǦǤ Ǧ Ǧ Ǥ Ǧ Ǥ Ǥǡ Ǥ Ǧǡ Ǥ ȋ ͶȌ Ǧ Ǧȋ ͶȌǤ Ǧ
ͷͲ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
ǡ Ǧ ȋ ͺ ȌǤ ǡ ͶǦ Ǧ Ǧǡ ǤͶ Ψ Ͳ ρ Ǧȋ ͺ ȌǤ 2 A B vMCKATC6 vMCKATC4 100% Free CoA Free CoA Free CoA C4-Acyl-CoA Free CoA C4-Acyl-CoA C6-Acyl-CoA C6-Acyl-CoA 75% C8-Acyl-CoA C8-Acyl-CoA C10-Acyl-CoA C10-Acyl-CoA C12-Acyl-CoA C12-Acyl-CoA Â
j C14-Acyl-CoA C14-Acyl-CoA j v X
| 50% C16-Acyl-CoA C16-Acyl-CoA v X | ഥ Ĭ
| C4-Ketoacyl-CoA C4-Ketoacyl-CoA ഥ Ĭ j | C6-Ketoacyl-CoA C6-Ketoacyl-CoA σ C6-ketoacyl-CoA C4-ketoacyl-CoA 25% C8-Ketoacyl-CoA C8-Ketoacyl-CoA (substrate) C10-Ketoacyl-CoA (substrate) C10-Ketoacyl-CoA C12-Ketoacyl-CoA C12-Ketoacyl-CoA C14-Ketoacyl-CoA C14-Ketoacyl-CoA 0% C16-Ketoacyl-CoA C16-Ketoacyl-CoA 0 50 100 150 200 250 0 50 100 150 200 250
[Palmitoyl-CoA]CYT ȝ0 [Palmitoyl-CoA]CYT ȝ0 C vMCADC6 D vSCADC4 100% C4-Enoyl-CoA C6-Enoyl-CoA C4-enoyl-CoA 75% C8-Enoyl-CoA C10-Enoyl-CoA Â j C12-Enoyl-CoA C4-Enoyl-CoA j v X
| 50% v X | ഥ Ĭ C4-Acyl-CoA C6-Enoyl-CoA | ഥ Ĭ j |
σ C4-Acyl-CoA C6-acyl-CoA C8-Acyl-CoA C4-acyl-CoA 25% (substrate) C10-Acyl-CoA (substrate) C6-Acyl-CoA C12-Acyl-CoA C6-Acyl-CoA 0% 0 50 100 150 200 250 0 50 100 150 200 250
[Palmitoyl-CoA]CYT ȝ0 [Palmitoyl-CoA]CYT ȝ0
E vMTPC8 F vCPT2C16 100% Free CoA Free CoA C4-Acyl-CoA C4-Ketoacyl-CoA Free CoA C6-Acyl-CoA Free CoA C6-Acyl-CoA 75% C8-Acyl-CoA C8-Acyl-CoA C10-Acyl-CoA
 C10-Acyl-CoA
j C12-Acyl-CoA j v X C12-Acyl-CoA | C14-Acyl-CoA v X | ഥ Ĭ 50% C14-Acyl-CoA | C16-Acyl-CoA ഥ Ĭ j | C16-Acyl-CoA C4-Acyl-carnitine σ C8-Enoyl-CoA C6-Acyl-carnitine 25% C8-enoyl-CoA C10-Enoyl-CoA C16-acyl-carnitine C8-Acyl-carnitine C10-Acyl-carnitine (substrate) C12-Enoyl-CoA (substrate) C14-Enoyl-CoA C12-Acyl-carnitine C16-Enoyl-CoA C14-Acyl-carnitine 0% C16-Acyl-carnitine 0 50 100 150 200 250 0 50 100 150 200 250
[Palmitoyl-CoA]CYT ȝ0 [Palmitoyl-CoA]CYT ȝ0 Fig 5.Regulation of key reactions by their substrates and products. (A-F) ࢜ ȁࢨഥȁࢄ ǡǤǤ ή Ψ,ͲǤͳɊ σ ȁࢨഥȁ࢜ ࢄ Ǧǡ ȋȌǡͶȋȌǡ ȋȌǡͶȋȌǡͺȋȌǡʹͳȋ Ȍ. ǡ Ǧǯ ͵ͲǤͶΨ Ǥǡ Ǧ ͳǤΨǤ ǡ Ǧ Ǥ ǡǡʹ Ǥ ǡ Ǧ ǡ
ͷͳ Chapter 2
ͶǦ ǦǦ ȋ ͷ ȌǤ ǡ ȋ ͵ ȌǤ ͶǦǦ Ǧȋ ͺ ȌǤ Ǧ Ǥʹ ǡ ȋ ͷ ȌǤ Discussion Ǧ Ǥ ǡ ȋ ȌǤ Palmitoyl-CoA
Mitochondrion 5. Acyl-CoA 2. 3. MCKAT Acetyl-CoA SCAD MCAD LCAD FAD 4. C4-C6 C4-C12 VLCAD C4-C16 CoASH FADH2
Ketoacyl-CoA 1. Enoyl-CoA 2.
MSCHAD NADH + H+ CROT Acetyl-CoA C4-ketoacyl-CoA MTP C4-C16 NAD+ C4-C16 CoASH K = 5. eq Hydroxyacyl-CoA 0.0002 2. Fig 6.Elucidating the mechanism of flux decline. 1. Ǧ ǡǯ Ǧ Ǥ2. ǡ ȀǦ Ǧ ǡ ǡ ǡ ǦǤ3. Ǧ Ǥ4. ǡ Ǥ ǡ ǡ Ǥ5Ǥ ȋ Ȍǡ Ǯ ǯ Ǥ ǡ ǡǡ Ǧ Ǥ substrates ȏͺȐǤ ǡ Ǥ ȏͻȐǤ Ǥ ǡǡ ǡǡȋǡ ͳȌȋȌ ȏͳȐǤ ǡ ǦǦ
ͷʹ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
Ǧ ȏͳǡͳͺȐǡ Ǧ Ǥ ǡ Ǧ ǡ ȏͳͻȐǤ 2 Ǧ Ǥ ǡ Ǧ Ǥ de novo Ǥ Ǥ ȋȌ Ǧ ǡ Ǧ Ǣ ȋȌ Ǧ Ȁ ȏΪȐȀȏ Ȑ ǢȋȌ Ǥ Ǥ Ǥ MCKAT – Ǥ Ǧ ǡ ͳ ǡ ȏʹͲǡʹͳȐǤ ǡ ǡ Ǧ Ǥ ȾǦ ǡ ȏʹͳȐ Ǥ ȏʹʹǡʹ͵ȐǤ ȏʹͶȐǤ Ǥ ǡ Ͷ ǡ ȏʹͷȐǤ ǡ in vivoǤ ǡ ȏʹͷȐ SHC1 Ǥǡ ȋ Ȍ Ǧ Ǥ ȋʹȌ SHC1 Ǧ Ǥ M/SCHAD and the mitochondrial redox state – ȏΪȐȀȏ Ȑ ǤȏΪȐȀȏ Ȑ ǦǦ Ȁ Ǥ ǡ ǡ Ǥ
ͷ͵ Chapter 2
A link to CoA metabolism – Ǥ ǡ Ǧ ǡ Ǧ Ȁ Ǥǡ Ǥ ǡ Ǥ ǡ ǡ ʹ Ǥ Ǧ Ǥ Ǧ ȏʹȂʹͺȐ ͶǦ ȋ ǦȌ ǦǤ ǡ Ǧ ǡ ȏʹͳȐǤ Ǧ Ǧ ǡ Ǧ ȋȌȏʹǡʹͻȐǡǦ Ǥ ǦȋȌͻ Ǧ Ǥ ǦǦ ǦȏʹͺȐǡ Ǥ ǡ ͻ ȏʹͺȐǡ Ǧ Ǧ Ǥǡͻǡ ȏʹͺȐǤ Ǧǡ ǡ Ǥ ǡ Ǧ Ǧ Ǥ ǡ ǡ Ǧ ȏ͵ͲȐ Ǥ ǡ Ǧ ȋ Ǧǡ ͳǡ ȏ͵ͳȐȌǡ Ǧȏ͵ʹǡ͵͵Ȑǡ Ǥ ǡ Ǧ Ǥ ȏ͵ͶȐ Ǥ CASǡT R ȋȌ Ǥ Ǧ Ǥ ȏ͵ͷȂ͵Ȑ Ǥ ǡ ȋ Ȍ Ǧ ȋ ͻ ȌǤ ǡ Ǧ Ǥ ǡ Ǥ ǡ Ǥ ǡ ǡ Ǧ
ͷͶ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
ǡ ȏ͵ǡͶȐǤ ȏ͵ͺȂͶͳȐǤǡ Ǥ 2 Ǥ ǡ ȏͶʹȐǤ ȏͶ͵Ȑ Ǧ Ǧ ȏͶͶȐǤǡ Ǧ ͳǦǡǤ Formation of enzyme supercomplexes – ȏͶͷȂͷͳȐǡ Ǥ Ǥ ǡǡ Ǥ Ȁ ȏͷʹǡͷ͵ȐǤ Ǥ Ȁ Ǥ ǡ Ǧ Ǧ ǡ ȏͷͶȐǤ Ǧ Ǥ ǡǡ Ǧ ǯ Ǧ Ǥ ǡȀ Ǧ ǡ ȏͷͷȐǤ Ǧ Ǥ Ǧ Ǥ Concluding remarks – Ǥ ǡ Ǥ ǡ Ǥ ǦǦ Ǥ Methods Computational models ȏͺȐǤ ȋ ǡ Ǥǡǡ ǡȌǡͳͲǤʹǤͲǤͲǤ ȏͺȐǤ ǣȀȀǤǤǤȀȀǤ Ǧ Ǧ Ǧ ȋȏǦ
ȐȌ ͲǤͳ ɊǤ ǡ ǡȏͺȐǤ
ͷͷ Chapter 2
Ǧ ȋ Ȍǡ ǦͳǦ Ǧ Ǥ ഥ ௩ ȁȣȁೕ ͳʹǤ Removal of promiscuity ǡ Ǥ ȏͺȐ Ǥ ǡ ǡ ȋǦǤ ͻȌǤ ǡ ǦǦ D Ǥ D Ǣͳ Ǥ ȏͺȐ D ǡ ʹͷρǦǤ ǤͳǦ Ǧ Ǥ ǣ
ݒǡଵ ൌ
ሾభలషೌషಲሿ ሾಷಲವሿ ሾభలషషಲሿ ሾಷಲವಹమሿ ௦ೇಽಲವǡభలήೌೣǡೇಽಲವήቆ ή ି ή ቇ ಼ೇಽಲವǡభలషೌషಲ ಼ೇಽಲವǡಷಲವ ಼ೇಽಲವǡభలషೌషಲ ಼ೇಽಲವǡಷಲವή಼ೇಽಲವ ሾభలషೌషಲሿ ሾభలషషಲሿ ሾషೌషಲሿ ሾషషಲሿ ሾಷಲವሿ ሾಷಲವಹ ሿ ȋͻȌ ቆଵା ା ାσసభర ା ቇήቆଵା ା మ ቇ ಼ ಼ సభమ಼ ಼ ಼ ಼ ೇಽಲವǡభలషೌషಲ ೇಽಲವǡభలషషಲ ೇಽಲವǡషೌషಲ ೇಽಲವǡషషಲ ೇಽಲವǡಷಲವ ೇಽಲವǡಷಲವಹమ ǣ
ሾభలషೌషಲሿ ሾಷಲವሿ ሾభలషషಲሿ ሾಷಲವಹ ሿ ఈή௦ ή ήቆ ή ି ή మ ቇ ೇಽಲವǡభల ೌೣǡೇಽಲವ ಼ ಼ ಼ ಼ ݒ ൌ ೇಽಲವǡభలషೌషಲ ೇಽಲವǡಷಲವ ೇಽಲವǡభలషೌషಲ ೇಽಲವ ǡଵ ሾభలషೌషಲሿ ሾభలషషಲሿ ሾಷಲವሿ ሾಷಲವಹ ሿ ȋͳͲȌ ቆଵା ା ቇήቆଵା ା మ ቇ ಼ ಼ ಼ ಼ ೇಽಲವǡభలషೌషಲ ೇಽಲವǡభలషషಲ ೇಽಲವǡಷಲವ ೇಽಲವǡಷಲವಹమ Metabolic control analysis ǣ
ήܸ௫ ή݂ሺࢄሻ ȋͳͳȌ݂ݏݒൌ
vǡsfCn Vmax ǡf() Ǥ ǣ
ௗȀௗ ௗ ೌೣǡ ο ೌೣǡ ܥ௭௬ ൌ ൌ ή ൎ ή ȋͳʹȌ డ௩Ȁడ ௗೌೣǡ οೌೣǡ p Ǥ ǡVmaxǡ ȋǤ ͳͳȌǤ 'ΪͲǤͲͲͲͳΨǦͲǤͲͲͲͳΨǡ ͳΨǤ ǦǦ ǣ
ο ௦ ܥ௭௬ǡ ൎ ή ȋͳ͵Ȍ ο௦
οݏ݂ ΪͲǤͲͲͲͳΨǦͲǤͲͲͲͳΨǤ ǦǦ ǡ ͳȏͳͳǡͳͶȐǤ ǣ
ௗ ο ܴ ൌ ൎ ή ȋͳͶȌ ௗ ο
ͷ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
Ǥ ΪͲǤͲͲͲͳΨ ǦͲǤͲͲͲͳΨǤ ȏͳͳǡͳͶȐ ȏΪȐȀȏ Ȑ ȏͳͳǡͳͶȐǤ 2 ǡǤ
Quantification of regulation of enzyme rates by individual variable metabolites ȏͳʹȐǤ ǡ ǣ ௗ௩ ௗ ఋ௩ ሺ௧ሻ ௗ ሺ௧ሻ ଵ ቚ ሺݐሻ ൌߝ௩ ሺݐሻ ή ೕ ൌ൬ ሺݐሻ ή ೕ ൰ή ೕ ή ȋͳͷȌ ௗ௧ ೕ ௗ௧ ఋ ௩ሺ௧ሻ ௗ௧ ሺ௧ሻ ೕ ೕ ೕ
Ǥ Ͷ Ǥ ͷǦ ǡ ȋ DzdzȌȋαͲͶͲͲǡ Ȍ Dz dz ഥ ௩ ͶͲͲǤȋȌ ȋȁȣȁೕȌǤ ǡ Ǥ ǡ ȋ Ȍǡ αͲ Ǥ ͷǦ Ǥ ͷǦ ǡ ǣ
ഥ ೡ ȁȁ ೕ ȋͳȌ σ ȁഥȁೡ ೕ ೕ ǡ ǣ ഥ ೡ ȁȁ σ ೕ = 1 ȋͳȌ σ ȁഥȁೡ ೕ ೕ
Acknowledgements Ǥ References ͳǤ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͲʹǢͶȋͳȌǣͶȂͷͲʹǤ ʹǤ ǡ ǡ Ǥǡ Ǥ ȾǦ Ǥ Ǥ ʹͲͳǢͺȋͳȌǣʹ͵ȂͶͶǤ ͵Ǥ ǡ ǡ ǡ ǡǡ ǡ Ǥ Ǧ ǣ Ǥ ǤʹͲͲǢͳͶͺȋͷȌǤ ͶǤ ǡǡǡǡ ǡ ǡǦǡ ǡ ǡ ǡǡ ǡ Ǥ Ǧ
ͷ Chapter 2
Ǧ ȋȌ ǣ Ǥ ǤʹͲͲͺǢ͵ͳȋͳȌǣͺͺȂͻǤ ͷǤ ǡ ǡǦǡǦǡ ǡǦ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳ͵ǢͺȋͳȌǣͶ͵Ǥ Ǥ ǡ ǡǡ ǡ ǡ ǡ ǡǦ ǡǡǦǡ ǡ ǡǦ ǡ Ǥ Ǧ Ǧ ǣ Ǥ ǤʹͲͳʹǢǣ͵ͲǤ Ǥ ǡ ǡ ǡǡ ǡ Ǥ Ǧ Ǧ Ǧ Ǥ ǤͳͻͻͶǢͳȋͳȌǣͶȂͺͲǤ ͺǤ ǡ ǡ ǡǡ ǡǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ ǤǤʹͲͳ͵ǢͻȋͺȌǣʹȂͻǤ ͻǤ ǡǦǡ ǡǡ ǡ ǡǦ ǡ Ǧ ǡ ǡ ǡ ǡ Ǧ ǡ ǡ Ǥ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳͲǤ ͳͲǤ ǡ ǡǡǡǡ ǡ ǡǡ ǡ ǡ ǡ Ǥ ǤǤʹͲͲͺǢȋͳȌǣͶͷȂͷǤ ͳͳǤ Ǥ Ǥ ǣ ʹ ǤʹͲͲͳǤǤʹͻͳȂ͵ͲͲǤ ͳʹǤ ǡ ǡ Ǥ Ǧ ǣ Ǥ Ǥ ʹͲͲͷǢʹʹȋͺȌǣͳͻͷȂͺͷǤ ͳ͵Ǥ Ǥ Ǥ ǤͳͻͺͷǢͳͲȋͳȌǣͳǤ ͳͶǤ Ǥ ǣ Ǥ ǤͳͻͻʹǢʹͺȋʹǣ͵ͳ͵Ȃ͵ͲǤ ͳͷǤ ǡ ǡ Ǥǡ Ǥ Ǥ ǤͳͻͻͶ ͳǢʹʹͷȋͳȌǣͳͻȂͺǤ ͳǤ ǡ Ǥ ȾǦǤ ǤʹͲͳͲǢ͵͵ȋͷȌǣͶͻȂǤ ͳǤ ǡ ǡǡǡ Ǥ Ǧ Ǥ Ǥ ǦǦ Ǧ Ǥ Ǥͳͻͻʹ ͳͷǢʹȋʹȌǣͳͲʹȂ͵͵Ǥ ͳͺǤ ǡǦǡǤ Ǧ Ǧ ǤǤͳͻͺͷǢ ͳͻǤ Ǥ ǣ Ǥ ǤʹͲͳͶǢͳͷͻȋȌǣͳʹͷ͵ȂʹǤ ʹͲǤ ǡ ǡ ǡ Ǥ ȝǦ Ǥ ǤͳͻͻǢ͵ʹ͵ǣͳͳͻȂʹʹǤ ʹͳǤ Ǥ ǦǤʹͲͲʹǢͶͳǣͳͻȂʹ͵ͻǤ ʹʹǤ ǡ Ǥ ͶǦǦʹǦ ͵Ǧ Ǧ Ǥ ǤͳͻͺͺǢʹȋͳȌǣͷͻͻͷȂͲͲͲǤ ʹ͵Ǥ ǡ ǤͶǦ ǡ Ǥ ǤͳͻͺʹǢȋͳͲȌǣͷͶͲͺȂͳ͵Ǥ
ͷͺ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
ʹͶǤ Ǥ Ǧ Ǧ Ǧ Ǧ ǤǦǤͳͻͺͺǢͻ͵ʹȋȌǣͺȂͳǤ ʹͷǤ ǡǡǡ ǡǡǡ ǡ ǡ ǡ 2 Ǥ Ͷ Ǥ Ǥ ʹͲͳǢʹͻͳȋʹͶȌǣͳʹͷͷȂͺͷǤ ʹǤ ǡǡǡ ǡǡǡ ǡ ǡ ǡ ǡǤ ǦǦʹ Ǥ ǤʹͲͳͶǢͷͷȋͳʹȌǣʹͶͷͺȂͲǤ ʹǤ ǡ Ǥ Ǧ ǤǤʹͲͲʹǢͶͳȋʹȌǣͻͻȂͳ͵ͲǤ ʹͺǤ ǡ Ú ǡ ǡ ǡ ǡ ǡ Ǥ ǦͻȋͻȌ Ǥ ǤʹͲͳͶǢͳȋͷȌǣͻ͵͵ȂͶͺǤ ʹͻǤ ǡ ǡ Ǥ Ǧ Ǧ ǤǤʹͲͳͷǢͳͲȋ͵ȌǣͲͳͳͷͺǤ ͵ͲǤ ǡ ǡǡǤ ȽǤ ǤʹͲͳǢͳȋͳʹȌǣʹͲͻ͵Ǥ ͵ͳǤ ȏ ȐǤ ȏ ʹͲͳ ʹȐǤ ǣ ǣȀȀǤǤȀ ͲͲͲͲͲͲͷʹ͵ͻǦͳȀȀ ͵ʹǤ Ǥ Ǧ Ǥ Ǥ ͳͻ͵Ǣͳ͵ʹȋͶȌǣͳȂ͵ͲǤ ͵͵Ǥ Ǥ Ǧ Ǥ ǤͳͻͶǢͳ͵ͻǣͳͲͻȂʹͳǤ ͵ͶǤ ǡ ǡǡǡǡ Ǥ Ǧ Ǥ ǤʹͲͲͺǢͻͶȋͳȌǣͶȂͳͷǤ ͵ͷǤ ǡ ǡ ǡ ǡ Ǥ ʹͷ ȋʹͷͶʹȌ ͵ ǯǡͷ ǯǦ Ǥ ǤʹͲͲͻǢʹͺͶȋʹȌǣͳͺͳͷʹȂͻǤ ͵Ǥ ǡǡǡǡǡ ǡǡ æǡ ǡ ǡ Ǥ ͶǯǦ ǤǤʹͲͳͷǢͳͳȋȌǣͳȂʹǤ ͵Ǥ ǡǡǡ ǡǡ ǡǡ ǡ Ǥ ʹͷͶʹ Ǥ ǤʹͲͳǢͳ͵ͷȋͳȌǣʹͳȂ͵ͲǤ ͵ͺǤ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ Ǧ ǤǤͳͻͺ͵ǢͳȋͳͳȌǣͺȂͺͶǤ ͵ͻǤ ǡǡǡ ǡ ǡ ǡǤǦ ǣ Ǥ ǤͳͻͺͷǢͳͻǣȂͳǤ ͶͲǤ ǡ ǡ ǡ ǡ Ǥ ǡ ǡ ǣ Ǧ Ǧ Ǥ ǤͳͻͻͳǢͺȋ͵Ȍǣ͵ʹͺȂ͵͵Ǥ ͶͳǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳ͵Ǣ͵ȋȌǣͻ͵ȂͺͳǤ ͶʹǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ
ͷͻ Chapter 2
ʹͲͳͲǢ͵͵ȋͷȌǣͷͷͷȂͳǤ Ͷ͵Ǥ ǡǤ ǣ Ǥ ǤʹͲͳͲǢ͵͵ȋͷȌǣͷ͵ͻȂͶǤ ͶͶǤ ǡ ǡǡǡ Ǥ Ǥ Ǧ ǤʹͲͳͶǢͳͺͶͳȋȌǣͻͺȂͻͶǤ ͶͷǤ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ǣ ȾǦǫ Ǥ ʹͲͲͲ ͳǢʹͺȋʹȌǣͳǦͳͺʹǤ ͶǤ ǡ ǡ ǡ Ǥ ȾǦ ǣ Ǥ Ǧ ȋȌ Ȁ͵Ǧ Ǧ Ȁ͵Ǧ Ǧ Ǥ Ǥ ͳͻͻʹǢʹȋʹȌǣͳͲ͵ͶȂͶͳǤ ͶǤ ǡ ǡǡǡǤ ȾǦ Ǥ ǤʹͲͲͶǢʹ͵ȋͳͶȌǣʹͶͷȂͷͶǤ ͶͺǤ ǡ Ǥ Ǧ Ǥ ǤͳͻͺͶ ʹͷǢʹͷͻȋͳͶȌǣͺͶͺȂ ͷʹǤ ͶͻǤ ǡ ǡ ǡ ǡǤ ȾǦǤǤʹͲǡ ǤͳͻͻͷǤǤͷ͵ͲȂͷǤ ͷͲǤ ǡǡǡ Ǥ Ǥ ǤʹͲͲͳǢʹͻȋʹȌǣʹͻȂͺʹǤ ͷͳǤ ǡ ǡ Ǥ ȾǦǣ Ǥ ǦǤ ͳͻͻͻǢͳͶ͵ȋ͵ȌǣͶͲʹȂͺǤ ͷʹǤ ǡ Ǥǡ ǡ Ǥ Ǥ ǤͳͻͺͻǢʹͶȋʹͺȌǣͳͶͺ͵ȂͺǤ ͷ͵Ǥ ǡǤ Ǧ Ǥ ǤͳͻͺͶǢʹͷͻȋʹͶȌǣͳͷͲͶͲȂͷǤ ͷͶǤ ǡǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳͲǢʹͺͷȋ͵ͻȌǣʹͻͺ͵ͶȂͶͳǤ ͷͷǤ ǡǡ ǡǡǡǡǡ ǤǦ ͵Ǧ Ǧ Ǧ ǤǤʹͲͳʹǢȋͶȌǣͳȂͺǤ
Ͳ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
Supplementary information
AB
2.0 Published model ) 2.0 ) -1 -1 No prom CPT2 2 1.6 No prom VLCAD 1.6 No prom LCAD Published model .gProtein .gProtein
1.2 No prom MCAD -1 1.2 -1 No prom SCAD No prom CROT 0.8 0.8 No promiscuity No prom MSCHAD at MCKAT (μmol.min (μmol.min 0.4 No prom MCKAT 0.4 No prom MTP uptake uptake No promiscuity J J 0.0 0.0 0 50 100 150 200 250 0 100 200 300 400 500 [Palmitoyl-CoA] [Palmitoyl-CoA] CYT ȝ0 CYT ȝ0 S1 Fig. Model versions with full or limited promiscuity. (A)Ǧȋ ǡǤǤ ͳȌ ȏǦȐǡ ͻ Ǥ(B) ȏǦȐ ͲͷͲͲɊǤ
AB 4 CPT1 4.0 CACT 3.5 vmckatC4 2 CPT2 3.0 vmckatC6 VLCAD 2.5 vmckatC8 LCAD 2.0 vmckatC10 0 MCAD 1.5 vmckatC12 SCAD vMCKATC4 vmckatC14 CROT 1.0 -2 MSCHAD 0.5 vmckatC16 vMCKATC6 MCKAT 0.0 Flux control coefficient (-) Flux control coefficient Flux control coefficient (-) Flux control coefficient -4 MTP -0.5 0 50 100 150 200 250 0 50 100 150 200 250 [Palmitoyl-CoA] (ȝM) [Palmitoyl-CoA]CYT ȝ0 CYT
S2 Fig. Flux control coefficients. (A) Ǥ(B) Ǧ Ǧ Ǥ Ǧ ೠೌೖ ܥெ் ǡ Ǥ ABC D [Acyl-CoA@ ȝ0 [Enoyl-CoA@ ȝ0 [Hydroxyacyl-CoA@ ȝ0 [Ketoacyl-CoA@ ȝ0 400 800 2500 8 C16 C14 C12 2000 C10 C16 C16 300 C8 600 6 C16 C14 C14 C14 C6 C12 C4 C12 C12 C10 1500 C10 C10 C8 200 400 C8 4 C8 C6 C6 C6 C4 1000 C4 C4
100 200 2 500
0 0 0 0 0 50 100 150 200 250 0 50 100 150 200 250 0 50 100 150 200 250 0 50 100 150 200 250 [Palmitoyl-CoA] ȝ0 [Palmitoyl-CoA] ȝ0 [Palmitoyl-CoA] ȝ0 [Palmitoyl-CoA] ȝ0 CYT CYT CYT CYT S3 Fig. Steady-state CoA ester concentrations. Ǧ Ǧ (A)ǡǦ(B)ǡ Ǧ(C) Ǧ(D) ȏǦȐǡ Ǥ
ͳ Chapter 2
A 25 ȝM [Acyl-CoA@ ȝ0 [Enoyl-CoA@ ȝ0 [Hydroxyacyl-CoA@ ȝ0 [Ketoacyl-CoA@ ȝ0 400 800 2500 8 C16 C16 C16 C16 C14 C14 C14 C14 C12 C12 2000 C12 C12 300 C10 600 C10 C10 6 C10 C8 C8 C8 C8 C6 C6 1500 C6 C6 200 C4 400 C4 C4 4 C4 1000
100 200 2 500
0 0 0 0 0 100 200 300 400 0 100 200 300 400 0 100 200 300 400 0 100 200 300 400 time (min) time (min) time (min) time (min) B 60 ȝM 400 800 2500 8
C16 C16 C16 C16 C14 C14 2000 C14 C14 300 C12 600 C12 C12 6 C12 C10 C10 C10 C10 C8 C8 1500 C8 C8 C6 C6 C6 C6 200 C4 400 C4 C4 4 C4 1000
100 200 2 500
0 0 0 0 0 100 200 300 400 0 100 200 300 400 0 100 200 300 400 0 100 200 300 400 time (min) time (min) time (min) time (min)
S4 Fig. Time course of mitochondrial CoA ester concentrations. ǦǡǦǡ Ǧ ǦȏǦ ȐͲǤͳʹͷɊ(A) ͲɊ(B)Ǥ
ʹ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
1.5 vCPT2C16 vMTPC16 vMTPC14 + vMCKATC14 )
-1 vVLCAD16 + vLCADC16 vVLCAD14 + vLCADC14 1.4 vVLCAD12 + vLCADC12 + vMTPC16 vMCKATC14 + vMTPC14 vMCADC12 vMTPC12 + vMCKATC12 1.3 2 .gProtein -1
1.2
1.1 v (μmol.min v
1.0 0 100 200 300 0 100 200 300 0 100 200 300 time (min) time (min) time (min)
1.5 vMTPC12 + MCKATC12 vMCKATC10 + vMTPC10 vMCKATC8 + vMTPC8 )
-1 1.4 vLCADC10 + vMCADC10 vLCADC8 + vMCADC8 vMCADC6 + vSCADC6 vMTPC10 + MCKATC10 vMTPC8 + vMCKATC8 vMCKATC6 1.3 .gProtein -1 1.2
1.1 v (μmol.min v
1.0 0 100 200 300 0 100 200 300 0 100 200 300 time (min) time (min) time (min)
1.5 vMCKATC6 )
-1 vMCADC4 + vSCADC4 1.4 vMCKATC4
1.3 .gProtein -1
1.2
1.1 v (μmol.min v
1.0 0 100 200 300 time (min)
S5 Fig. Time course of the rates of Cn-acyl-CoA production, dehydrogenation and Cn-2-acyl-CoA production per chain length (thus per oxidation cycle) after an upshift of [palmitoyl-CoA]CYT 0.1 to ʹͷɊǤ
1.5 ) -1 1.4 vMCKATC8 + vMTPC8 vMCADC6 + vSCADC6 1.3 vMCKATC6 .gProtein -1 1.2
1.1 v (μmol.min v 1.0 0 100 200 300 time (min) S6 Fig. vMTPC8+vMCKATC6, vMCADC4+vSCADC4 and vMCKATC6 after an upshift of [palmitoyl- CoA]CYT ͲǤͳͲɊǤ
͵ Chapter 2
) 0.01 C16-Ketoacyl-CoA í C14-Ketoacyl-CoA C12-Ketoacyl-CoA C10-Ketoacyl-CoA C8-Ketoacyl-CoA C6-Ketoacyl-CoA C4-Ketoacyl-CoA
.mgProtein 0 C16-Acyl-CoA 2 í j C14-Acyl-CoA vmckatC6 X C12-Acyl-CoA Ĭ C10-Acyl-CoA C8-Acyl-CoA C6-Acyl-CoA C4-Acyl-CoA (μmol.min -0.01 Free CoA 0 100 200 300 time (min) S7 Fig. Metabolite contributions to vMCKATC6 after a sudden [palmitoyl-CoA]CYT increase from 0.1 ͲɊǤ
A 1 B 1 Acetyl-CoA C4-Ketoacyl-CoA C4-Enoyl-CoA C4-Acyl-CoA C4-Acyl-CoA C6-Ketoacyl-CoA C6-Enoyl-CoA C4-acyl-CoA C6-Acyl-CoA C8-Ketoacyl-CoA C4-enoyl-CoA C6-Acyl-CoA C8-Acyl-CoA C8-Enoyl-CoA 0.5 C10-Ketoacyl-CoA 0.5 C10-Acyl-CoA C8-Acyl-CoA C6-acyl-CoA C12-Ketoacyl-CoA C10-Enoyl-CoA C12-Acyl-CoA C10-Acyl-CoA C14-Ketoacyl-CoA C6-enoyl-CoA C14-Acyl-CoA C12-Enoyl-CoA C16-Ketoacyl-CoA C12-Acyl-CoA
C16-Acyl-CoA per chain-length occupancy MCAD
MCKAT occupancy per chain-length occupancy MCKAT 0 0 0 50 100 150 200 250 0 50 100 150 200 250
[Palmitoyl-CoA]CYT ȝ0 [Palmitoyl-CoA]CYT ȝ0 C 1
C4-enoyl-CoA C4-Enoyl-CoA C4-Acyl-CoA 0.5 C6-Enoyl-CoA C6-Acyl-CoA
C6-enoyl-CoA
SCAD occupancy per chain-length per occupancy SCAD 0 0 50 100 150 200 250
[Palmitoyl-CoA]CYT ȝ0 S8 Fig. Fraction of the active site occupied by each of the indicated metabolites, calculated for MCKAT (A), MCAD (B), and SCAD (C) as a function of [palmitoyl-CoA]CYT. ȋ Ȍ ȋȌ ǣ ሾೕሿ ಼ ಶǡೕ ܱܿܿாǡ ൌ ȋͳͺȌ ೕ ሾೕሿ ሾ ሿ ൭ଵା ାσ ೖ ൱ ಼ ೖ಼ ಶǡೕ ಶǡೖ Ǥ
Ͷ The promiscuous enzyme MCKAT triggers a vicious cycle in fatty-acid beta-oxidation
) 2.0 -1 0.5x CoAt,m 1x CoAt,m 1.6 2x CoAt,m 3x CoAt,m .gProtein -1 1.2 4x CoAt,m 2 5x CoAt,m 0.8 6x CoAt,m 7x CoAt,m (μmol.min 0.4 8x CoAt,m 9x CoAt,m uptake
J 10x CoAt,m 0.0 0 50 100 150 200 250
[Palmitoyl-CoA]CYT ȝ0
S9 Fig. The effect of varying total mitochondrial CoA concentration (CoAt,m) on flux decline.
S1 Appendix. Model without promiscuity. Confer PLoS Comput Biol. 2017;13(4):1–22 for the corresponding script.
S12 Appendix. Calculation of average absolute regulatory contribution. Confer PLoS Comput Biol. 2017;13(4):1–22 for the corresponding script.
ͷ
Chapter 3
Transcriptomic analysis suggests a compensatory role of cofactors coenzyme A and NAD+ in medium-chain acyl-CoA dehydrogenase knockout mice
Anne-Claire M.F. Martines1, Albert Gerding1,2, Sarah Stolle1, Marcel A. Vieira-Lara1, Justina C. Wolters1, Angelika Jurdzinski1, Laura Bongiovanni3, Alain de Bruin1,3, Pieter van der Vlies4, Gerben van der Vries5,6, Vincent W. Bloks1, Terry G.J. Derks1, Dirk-Jan Reijngoud1, Barbara M. Bakker1,*
1 Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 2 Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, The Netherlands 3 Department of Pathobiology, Faculty of Veterinary Medicine, Dutch Molecular Pathology Center, Utrecht University, The Netherlands 4 HZPC Research B.V., Metslawier, The Netherlands 5Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 6Genomics Coordination Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Under revision at Scientific Reports
Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Abstract ǡ Ǧ ȾǦȋ Ȍ ǤǦǦ Ǧ Ǧ ȋȌ Ǧ Ǥ ǡ Ǥ 3 Ǧ ȋǦȌ ǡ ǦȋȌ ǡǤ Ǥ ǦǦ Ǥǡ ǡ ǡ Ǥ ǦǤ Ǧ Ǧ Ǥ ǡ ǦȋȌȋ ȌǦ Ǥ Ǧ ǦǦ Ǥ
ͻ Chapter 3
Introduction ȋ Ȍ ǡ de novo ǤǦǦ Ǥͻͺͷε ACADMǡ Ǧ ǦȋȌǡ Ǧ ȏͳǡʹȐǤ ǡ ȏ͵ȂͳͳȐǤǡ Ǧ Ǧ ȏͳʹȐ ͳͺǦʹͶ ȏͳǡ͵ǡͳ͵ǡͳͶȐǤ ǡ ǡ ȏʹǡͳͳǡͳͷȂͳȐǤ ͳǤ Ǧ ǦǤ Ǧ Ǥ ǡ Ǧ ǡ ǦȏͳǡͳͺǡͳͻȐǤ ǡ Ǧ ǡ Ǧ Ǥ ǡǦǦǡ ǦǡǦǡǦ ǦȋǡǡǡȌǤ ǡ ȏͳǡʹͲȐǤ ȋΪȌ ȋ Ȍ ȏʹͳȂʹͷȐǤ ȋȌǡǦ ǡ ͷȀ Ƭ ͳʹͻʹȀ ȏʹȐǤ ǡ ǡͺǦ Ǧ ǡǦ ǡǦ Ǧ ȋȌǤ ǡʹͶ ȋȌ Ǧ ǡ ȏʹǡͳͳǡͳͷȂͳȐǤ ǡ Ǧǡ Ǧ ǡ ȏʹȐǤ ȏʹȐǤ ǡ ǦͷȀ Ǧ ȏʹͺȐǤ ǡǦ ǦǦ Ǧ ͺǦ Ǧ ͳʹǤǡ ǡǦ ȏʹǡʹǡʹͻȐǤǡǦ Ǥ ǡǡ ǦǦ MCAD Ǥ ȏ͵ͲȐ Ǥ Ǧ
Ͳ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Ǥ ͷȀ Ǧ Ǧ ǦǦǡͳ ǤǦ Ǧ Ǥ ǡ ǡ ǡ Ǥ ǡ 3 Ǥ ȋȌȋ ȌǦ Ǥ Ǥ Results Biometric and hepatohistological characterization of the pure-background MCAD-KO mice ǦͷȀ ǦǦ ͳǤ ǡǦǡǡ ȋ ͳǦ ʹȌǤǦ Ǧ ȋ ͳȌǡ ͺΨǤ ȏʹǡʹǡʹͻȐǤ AB 50 4 LF fed ‡‡ LF fasted ‡‡ ‡‡ ‡‡ HF fed HF fasted ‡‡ 3 40 LF fasted HF fasted * # 2 30 #
1
Body weight (g) weight Body 20 20 0 0
WT KO decrease (g) weight Body WT KO
C 15 ‡ LF fed HF fed ## LF fasted 10 ## ## ## HF fasted
5 Blood glucose (mM) glucose Blood 0 WT KO
Figure 1. Mouse biometric measures (A-C) under different conditions A: Body weight; B: body weight decrease after fasting; C: Blood glucose levels at termination. ǡ Ǧ ͷΨ ͳǤͷȉǦȋ ȌʹͷΨ ͳǤͷȉ ǤαǦͺǤ ȗǣδͲǤͲͷ ǡ͓͓͓ǣδͲǤͲͷδͲǤͲͳ ǡ ǡșșșǣδͲǤͲͷ δͲǤͲͳ Ǧȋ Ȍǡ Ǥ Ǧ Ǧ ȏʹȐǡ Ǥ ȋ ʹ ͵ǦͶȌǤ ǡ Ǧ
ͳ Chapter 3
Ǧ ȋ ʹ ͳȌǤ ǡǡ Ǧ ȋ ʹȌǤ
10x 40x A B
High-fat fasted MCAD KO
CD
High-fat fasted WT
Figure 2. Similar steatosis grade (A, C) and difference in lobular inflammation (B, D) between MCAD- KO and WT mice in the high-fat fasted condition Ǥ Ǥ Ƭȋ ȌǤ Ǥ ȋͳǦ ȌǤ
MCAD-KO mice show decreased C8-acyl-CoA-dependent state 3 O2 consumption capacity Ǧ
ʹǦ ȋ ͵
ͷȌǤͳǦ Ǧǡ ʹǦ ȋ ͵ǦȌǡ ȏʹͺȐǤǦ
ʹ ͺǦ Ǧ ȋ ͵ȌǤ ǦȋαͲǤͲʹȌ ǦȋαͲǤͲȌȋǦ ʹʹΨǦǦ ȌǤ
ʹ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
A B 150 250 LF fed LF fed HF fed 200 HF fed 100 LF fasted LF fasted HF fasted 150 HF fasted
100 50 50 Pyruvate-induced
consumption rate (St3) rate consumption (St3) rate consumption 3 C16-acyl-CoA-induced 2 0 2 0 (μmol/(min*gmitProtein)) (μmol/(min*gmitProtein)) O O WT KO WT KO
C 150 LF fed HF fed i 100 LF fasted * HF fasted
50 consumption rate (St3) rate consumption C8-acyl-CoA-induced
2 0 (μmol/(min*gmitProtein))
O WT KO Figure 3. Mouse hepatic mitochondrial function in different conditions. Pyruvate- (A), C16-acyl-CoA- (B) and C8-acyl-CoA- (C) induced maximum O2-consumption flux (state 3) in isolated liver mitochondria. State 3 represents the maximum ADP-stimulated oxygen consumption. ǡ Ǧ ͷΨ ͳǤͷȉǦȋ ȌʹͷΨ ͳǤͷȉ ǤαǦͺ ǤȗǣδͲǤͲͷ ǡ͓͓͓ǣδͲǤͲͷδͲǤͲͳ ǡ ǡș șșǣδͲǤͲͷδͲǤͲͳ Ǧȋ Ȍǡ Ǥ
ǡ ͺǦ ǦǦʹǦ ǦȋǦͷΨͶΨ Ǧ Ǧ Ȍǡ ȋαͲǤͳͷͲǤͳ͵ǡ ȌǤ ͺǦ Ǧ
Ǧ ʹǦ Ǧ ǡ ȏʹͻȐǤ ǡ Ǥ Targeted mitochondrial proteomics ǡ Ǥ ǡ Ǧ ȏʹͻȐǤ ȋ ͶǦ ȌǤ ǡ Ǧ Ǥ ǡ ǡ ȋ ͶǡȌ ͺǦ Ǧ Ǥ ǡǡ Ǧ ȋ ȌǤ ǡ Ǥ
͵ Chapter 3
AB SCAD MCAD 150 150 LF fed LF fed HF fed ‡‡ HF fed 100 LF fasted 100 LF fasted g mito prot) g mito HF fasted prot) g mito P
P HF fasted
50 50
**** 0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
CD LCAD VLCAD 150 80 LF fed LF fed HF fed HF fed 60 100 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito P
P HF fasted 40
50 20
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/ Figure 4. Absolute protein levels of the mFAO proteins SCAD (A), MCAD (B), LCAD (C) and VLCAD (D). Ǥ ǡ Ǧ ͷΨ ͳǤͷȉǦȋ ȌʹͷΨ ͳǤͷȉ ǤαǦ ͺ Ǥ ȗǣ δͲǤͲͷ ǡ ͓ ͓͓ǣ δͲǤͲͷ δͲǤͲͳ ǡ ǡșșșǣδͲǤͲͷδͲǤͲͳ Ǧȋ Ȍǡ Ǥ
Differences in hepatic mRNA expression patterns between MCAD-KO and WT mouse Ǧ ǡ Ǥ ȋ ȌǤ ȋ Ȍ ǡ Ǧ Ǥ Ǧ δͲǤͲͳ ͳʹȋ ͺǦȌǤ ǡ ȋ ͷǦ ͺǦ ȌǤ ǡͶ
δͲǤͲͷǢ͵ ͳ ǡ ȋʹȌǤ A B HF Fa LF Fe HF Fa LF Fe
42 47 28 63 110 000 82 44 84 27 00 00
210 200 0 0 0 0 0 0 LF Fa HF Fe LF Fa HF Fe Figure 5. Venn diagrams showing overlap between conditions of upregulated (A) and downregulated (B) genes between WT and KO δͲǤͲͳǤ ʹǤ
Ͷ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
ǡǤ Gene-set enrichment analysis revealed differentially expressed gene sets between WT and KO mice Ǧ ȋ Ȍ 3 Ǧ Ǥ Ǥ Ǧ ȋ Ȍ ȋȌȋ Ȍ ǡ ȋ͵ȌǤ ǦǦ Ǧ ȋ ȌδͲǤʹͷǤ Ǧ ʹ ͳͲ ȋ ͳȌǤ Ǧ ͺ Ǥ Ǧ ǡ Dz dz Dz Ǧ dz ȋ δͲǤͲͷǡ ͳȌǤ δͲǤʹͷ Ǧ ȋͳȌǤǡ ͳʹ ǡ ȋȌȋ Ȍ ǡȋ ͳͶǦͷȌǤ Table 1. Up- and downregulated metabolic gene sets in KO compared to WT based on the GSEA method Upregulated gene sets LFD Fed ͶͷͲ ȗ ȗ Downregulated gene sets LFD Fed HFD Fasted Pyruvate metabolism Metabolism of xenobiotics by cytochrome Fatty acid biosynthesis Drug metabolism - cytochrome p450 Sulfur metabolism Glutathione metabolism ȋȌȋ Ȍ ȗ ȗ Ǧ ȋȌȋ Ȍ ȗ ȗ ȗ ȋ Ȍ ȗ Ǧ ǡ ǡ Ǥ δͲǤʹͷȋȌ δͲǤͲͷȋ ȌǤȗǣ ȋȌȋ Ȍ ǤǦǦǤ ǦͻǤ
ͷ Chapter 3
Ǧ ǡ ͶͷͲǡ Ȃ ͶͷͲǡ ȋ δͲǤͲͷȌǤǡ Ǥ ȋ δͲǤʹͷȌ ȋȌ ǤȋͳȌǤ ͳʹǦǦǦ et al.ȏʹȐǡ Ǥ ͺ ǡ ͲǤͲͷ ͲǤʹͷ ȋȌǤ Ǥͳʹǡ Ͷ ȀȋȌȋ Ȍȋ ȌǡȀȋȌȋ Ȍ ȋͺǡͻȌǤ ǡ Ǥ ǡ ȋȌȋ Ȍ Ǥ Alternative gene set enrichment analysis reveals a role for CoA and NAD(P)(H) metabolism ǡ Ǥ ǡ Ǧ Ǥǡ ȋȌ Ǥ ǡ ȋȌ Ǥ ǡ ǡ ȋ ȌȋͳͲȌǤ ȋȌǤǡ ȋ ʹǡ ͳͳͳʹȌǤͳͲ ʹǤ ȋȌȋ ȌǦ Ǧ Ǥ ǡ ǡǦ Ǥ ȋȌΪ ǡ ǤǦ ȋ ʹȌǤ ͷͲΨ ȋȌȋ Ȍ ȋͳ͵ȌǤǡ Ǧ ȋȌȋ Ȍ Ǧǡ Ǥ
Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Table 2. Up- and downregulated metabolic gene sets in KO compared to WT based on the Alternative GSEA method Upregulated gene sets Downregulated gene sets ȋȌȋ Ȍ ȗǡș NAD(P)(H) main ȗǡș ȋȌȋ Ȍ ȗǡș NAD(P)(H) redox ȗǡș ȗǡș ȗǡș ȗǡș ȗǡș 3 ȗ ȗǡș ȗ Pyruvate metabolism ȗǡș ȗ ȗ ȗ ȗǡș ȗ ǡ ȗ ȗ Fatty acid metabolism ȗǡș ͳͲǦ Dzȋȁʹȋ ȌȁεͲǤͷδͲǤͳȌδͲǤͲͷdz Ǥȗǣ ʹ Ǥșǣ ͳͷ ǤȏʹȐǤǣ δʹͷΨǤ ǣ δͷΨǤ ǦǦǤͳͲǦͳʹǤ The example of Acot expression between MCAD-KO and WT mice Ǧǡ Ǧȋ Ȍ ȏ͵ͳȂ͵ͶȐ ǡ ǤǡͳͷAcotȏ͵ʹǡ͵͵ȐǡǦ Ǧ Ǥ ȋ ͻȌǡ ȏ͵ʹȐǤ Ǧ Ǥǡ Acot ǡAcot2,Ǧ Ǧȋ ͳǤͺδͲǤͲͷǢ Ȍ Ǥ Ǧȋ ʹǤͲαͲǤͲͷǢ ȌǤ AB mRNA expression of Acot2 mRNA expression of Acot2 6 p=0.02 2.5 p=0.05
2.0 4 1.5
1.0 2 0.5 Normalized readcount Normalized expression 0 0.0 WT KO WT KO Figure 6. Acot2 gene expression. Acot2 ȋAȌ ǦȋBȌǤ ȋαͶȌǤǦAcot2 ȋάȌȋαͺȌǤ
Chapter 3
Acot2 ǦǤ
Discussion ǡ ͷȀ Ǧ Ǥ ǡ ǡ Ǥ ͵ͲǦͶͲΨ Ǧ ǦǤ ǡ ǡ Ǧ ȏʹͺȐǤ Ǧ Ǧ Ǥǡ Ǥ ǡ ǡ Ǧ ȏʹͲǡʹǡʹȐǤ Ǧ Ǧ ǡȏʹȐǤ Ǧ Ǧ ȏʹȂʹͺȐǤ Ǧ ȏ͵ͷȂͶͲȐ ȏͶͳȐǡ ȏͶʹǡͶ͵ȐǤ ǡ ǦǤ ǡǡ ͶͶ Ǥ ǡ Ǧ ȏͶͶȐǤ ȋȌȋ Ȍ Ǧ Ǥ ȋȌȋ Ȍ Ǥǡ ǡ ǡ ǡ ȏͶͷȐǤ Ǧ Ǧ ǦȋȌΪǦ ȀǦ Ǧ ȋȀ Ȍ ȏͶȐǤ ȏΪȐǦȏ Ȑ ȏͶȐǤ Ͷ ȏͶȐ Ϊ ȏͶͺȐ Ǥ ǦȋȌȋ ȌǡǤ ȋȌȋ Ȍ Ǥ ǡ ǡ Acot2Ǥʹ ȏ͵ͳǡ͵͵Ȑ ȋǦȌ Ǥ ʹ Ǥ ȋȌȋ ȌǦǤ Materials and Methods
ͺ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Animals, Experimental design and Tissue sampling ǦǦȋȌ ͷȀ ȋ ͳͲ ȌǦȋʹͳιȌǦ ȋͳʹȌ ȋǡ ǡ ȌǤ ʹǦͶ Ǥ Ǥ ǡ ǦǦǦ ȋͳʹͶͷͲͳʹͶͷͳȏͶͻȐǡ 3 ǡ ǡ ǡ Ȍ ǡ ǤǦ ͶͷΨ ǡ ȋͶͲǣͶͲǣʹͲȌǤ ͳȋǮ ǯȌͳ ȋǮ ǯȌǤ ͷǡǤǤͲǦ ʹ Ǥ ̺ȋ ǡǡȌǤ ͳͻͳͳ Ǥ ǡ ǡ Ǧ ǡ ͳͲΨ Ǧ̺Ǥ ǡ ʹͷͲ ͳͲ ȋ ǤͲȌ Ǥ Ǥ Liver histology ǡ ǡ Ǥ Ǧ̺ ǦǦǤ ǤǦ ǡ ȋ Ȍ ȋȌ ǤȏͷͲȐǤ Hepatic triglyceride (TG) concentration Ǧ ͳͷΨȋȀȌȋ ǤͶȌ Ǥ ƬȏͷͳȐǤ ʹΨǦͳͲͲ ȋ ǡǡ Ȍ ǯ Ǥ Oxygen consumption rates in fresh liver mitochondria ǤȏͷʹȐǡ ͺͲͲǡʹͲͲʹͲͲͷͲǡͲͲͲͲͲͲǡ Ǥ Ǧǡ Ǧ ȋͳǦ ǦȌǦ Ǧ ȋͺǦ ǦȌǦ ͵ιǦ Ǧ Ǧʹ ȋǡ ǡ Ȍ Ǧ Ͳͷ ȋǤǤ ͳ Ǥȏͷ͵ȐȌǤǦ ȋ͵ȌǡͶǤͺǦͳǡͳʹǤͷ ͳ Ǥ ȋͶȌǡ ͳǤʹͷɊ Ǥ Targeted quantitative proteomics of mitochondrial proteins
ͻ Chapter 3
εͷͲ ǡ ȋ Ȍǡ Ǧ ȾǦǡ ǡ ȋͳ͵Ǧ Ȍ ȋ Ȍȋ ǡ ǡ Ȍ ǤǤȏʹͻȐǤ RNA isolation, RNASeq analysis and quantitative reverse transcriptase polymerase chain (qRT-PCR) ǡǦ ͳǤ Origin of mixed-background MCAD-KO mice microarray data ȏʹȐ ȋ ͵ͷͶȌ ͷȀ Ƭ ͳʹͻʹȀ Ǧ Ǧ Ǧ Ǥ ǡ ǤǤ ͳʹǤ Pattern recognition on RNAseq and microarray data Gene-set enrichment analysis Ǧ ȋ Ȍ ǤʹͲͲͷȏͷͶȐ ȋʹǤʹǤͶǡ ȌǤǦ ǡ Ǧ ʹǦ ǦǦǦǡ Ǥ Ǧ ǡ Ǧ ǦȏͷͷȐǤ Ǧ ȏͷȐȋͶ͵ͲʹǤ ȌǤ ȋ ȂǤͲȌǡ Ǥ ȋȌ ȋȌǡȋȌ ȋȌΪȋȌ ȋȋȌȋ ȌȌǡȋȌ ȋȌȋ ȌȋȋȌȋ ȌȌǡ ǡ Ǥ ͳͲͲͲǡ Ǥ ǡ ȋ Ȍ δʹͷΨǡ ȋȌȋ Ȍ Ǥ ȋȌ ͓ܥܩ̴ேுȀ͓ܥܩ ̴ܴܴேு ൌ ሺ͓݃݁݊݁ݏ̴ேு െ͓ܥܩ̴ேுሻȀሺ͓݃݁݊݁ݏ െ ͓ܥܩሻ ͳǤ ͓
ǡ͓ ̴
ȋȌȋ Ȍǡ̴͓͓ ȋȌȋ ȌǤ Alternative gene set enrichment analysis ǡǦ ǡ ǣ ȋȁʹȋ ȌȁεͲǤͷδͲǤͳȌδͲǤͲͷǤ ȋ Ȍ ȋ ȌǤ ʹȋ Ȍ
ͺͲ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Ǥ Ǧ ǡ ǡ ǡ Ǧ Ǥ Ǥ Ǥ ǡ ǡ ǡ 3 Ǧ Ǥ
ǦȋȌͳǡ ǣ ͓ܦܧܩ௧ǡ௦௧Ȁ͓ܦܧܩ௧ǡ ܴܴ௦௧ ൌ ௧ǡሻܩܧܦ͓ െ ݏ௧ǡ௦௧ሻȀሺ͓݉݁ݐܾ݈ܽ݅ܿ݃݁݊݁ܩܧܦ௦௧ െ͓ݏሺ͓݃݁݊݁
͓ ǡ ǡ͓ ǡ ǡ
Dz͓dzDz͓ dz ǡ Ǥ Statistical analysis ȋȌǡ ȋ ȌǡȋȌ Ǧ Ǧ Ǥ ǦǤPpiaǦ Acot2 Ǧ ǯǦǤ ʹʹǤͲ ȋ Ǥǡ ǡ ǡ Ǥ δͲǤͲͷǤ
Data Availability Ȁ Ǥ References ͳǤ ǡ ǡ Ǥǡ Ǥ ȾǦ Ǥ Ǥ ʹͲͳǢͺȋͳȌǣʹ͵ȂͶͶǤ ʹǤ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͲʹǢͶȋͳȌǣͶȂͷͲʹǤ ͵Ǥ ǡ ǡ ǡ ǡǡ ǡ Ǥ Ǧ ǣ Ǥ ǤʹͲͲǢͳͶͺȋͷȌǤ ͶǤ ǡǡǡǡ ǡ ǡǦǡ ǡ ǡ ǡǡ ǡ Ǥ Ǧ Ǧ ȋȌ ǣ Ǥ ǤʹͲͲͺǢ͵ͳȋͳȌǣͺͺȂͻǤ ͷǤ ǡ ǡǦǡǦǡ ǡǦ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳ͵ǢͺȋͳȌǣͶ͵Ǥ Ǥ ǡ ǡǡ ǡ ǡ ǡ ǡǦ ǡǡǦǡ ǡ ǡǦ ǡ Ǥ
ͺͳ Chapter 3
Ǧ Ǧ ǣ Ǥ ǤʹͲͳʹǢǣ͵ͲǤ Ǥ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳͲǢ͵͵ȋͷȌǣͷͷͷȂͳǤ ͺǤ ǡǡ ǡ ǡ ǡǡǤ Ǧ Ǧ Ǥ Ǥ ͳͻͻǢͻȋ͵Ȍǣ͵ȂͺǤ ͻǤ ǡ ǡǡǡ ǡ ǡ ǡǡ Ǥ Ǧ Ǧ Ǥ ǤͳͻͻͲǢͺȋʹ͵Ȍǣͻʹ͵ȂͶͲǤ ͳͲǤ ǡ ǡ ǡ ǦǡǤƮ ǯ Ǧ Ǧ Ǥ ǤͳͻͺǢͺȋȌǣͳͲͷʹȂǤ ͳͳǤ ǤǡǤ ǣ Ǥ ǤʹͲͳͲǢ͵͵ȋͷȌǣͷͳ͵ȂʹͲǤ ͳʹǤ ǡ ǡ ǡǡ ǡ Ǥ Ǧ Ǧ Ǧ Ǥ ǤͳͻͻͶǢͳȋͳȌǣͶȂͺͲǤ ͳ͵Ǥ ǡ ǡ ǡ ǡǡ Ǥ Ǥ ǤʹͲͲǢͳȋͳȌǣͷȂͳͳǤ ͳͶǤ Ǥ ǣ Ǥ ǤʹͲͲͻǢ͵ʹȋʹȌǣʹͳͶȂǤ ͳͷǤ Ǥ Ǥ Ǥ ʹͲͳͲǢ͵͵ȋͷȌǣͷ͵͵ȂǤ ͳǤ Ǥ Ǧ ǣ Ǥ Ǥ ʹͲͳǢʹ͵ȋͳȌǣͷͳȂͷǤ ͳǤ ǦǤ ǡǤʹͲͳͶǤ ͳͺǤ ǡ Ǥ ȾǦǤ ǤʹͲͳͲǢ͵͵ȋͷȌǣͶͻȂǤ ͳͻǤ ǡ ǡ Ǥ ǦǤ Ǥ ͳͻͻǢ͵ʹͲǣ͵ͶͷȂͷǤ ʹͲǤ ǡǦǡ ǡǡ ǡ ǡ ǡ Ǧǡ ǡ ǡ ǡ ǡ ǡǤ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳȂͳͷǤ ʹͳǤ ǡ Ǥ Ϊ ǡ Ǥ Ǥ ʹͲͳǢ͵ȋͳͺȌǣʹͲͳͻͳ͵ͷǤ ʹʹǤ ǡǤΪǣ ǡǤ Ǧ ǤʹͲͳǢͳͺͶȋͳʹȌǣͳͺȂͺͲͲǤ ʹ͵Ǥ ǡǡǤǣ ǡ Ǥ ǤʹͲͳͷǢͷͲȋͶȌǣʹͺͶȂͻǤ ʹͶǤ ǡ ǡ Ǥ Ǧ ǣ Ǥ ǤʹͲͳǢͺȋȌǣͳȂǤ ʹͷǤ ǡ ǡǡǡǡ Ǥ Ǧ Ǥ ǤʹͲͲͺǢͻͶȋͳȌǣͶȂͳͷǤ ʹǤ ǡ ǡǡ ǡ ǡǡǡ ǡǤ Ǧ Ǧ Ǧ Ǥ Ǥ ʹͲͲͷǢͳȋʹȌǣͲʹͲͷȂͳʹǤ
ͺʹ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
ʹǤ ǡ ǡ ǡǡ ǡ ǡ ǡǫǫǡ ǡ ǡ Ǥ Ǧ Ǧ ȋȌǦ Ǥ ǤʹͲͲͺǢͶȋȌǣͳͺͻͶȂͻͲͶǤ ʹͺǤ ǡǦǡ ǡǡ ǡ ǡǦ ǡ Ǧǡ ǡ ǡ ǡǦ ǡ ǡǤ ǣ Ǧ 3 ǤǤʹͲͳǢͳͶȋͳȌǣͳͲǤ ʹͻǤ ǡ ǡ ǡ Ǧ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳǢ ͵ͲǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǥ Ǧ ǤʹͲͳͶǢͳͺͶʹȋͳͲȌǣʹͲʹͳȂͻǤ ͵ͳǤ ǡǡǡ ǡǡǡ ǡ ǡ ǡ ǡǤ ǦǦʹ Ǥ ǤʹͲͳͶǢͷͷȋͳʹȌǣʹͶͷͺȂͲǤ ͵ʹǤ ǡ ǡ Ǥ Ǧ Ǧ ǤǤʹͲͳͷǢͳͲȋ͵ȌǣͲͳͳͷͺǤ ͵͵Ǥ ǡ ǡǤ ǣ ǦǦ Ǥ ǤʹͲͳǢʹͺȋȌǣͶ͵ȂͺͶǤ ͵ͶǤ ǡ Ǥ Ǧ ǤǤʹͲͲʹǢͶͳȋʹȌǣͻͻȂͳ͵ͲǤ ͵ͷǤ ǡǡǡǡǡ ǡǡ ǡ Ǥ ǣ Ǥ ǤʹͲͳʹǢ͵ͳȋͳȂʹȌǣ͵ʹͻȂ͵ͷǤ ͵Ǥ ǡ ǡ ǡǡǤ ǦǦ ǡ ǡ Ǧ Ǥ ǦǤʹͲͲͺǢͳȋͳͲȌǣͳʹȂͺʹǤ ͵Ǥ ǡ ǡǡǡǡǡ ƹ ǡ ǡǤ Ǧ Ǧ Ǥ ǤʹͲͲͻǢͳʹͻǣͳͳȂʹǤ ͵ͺǤ ǡ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͳǢͷǣʹ͵ʹͶͲͻͺͳͲͳͶǤ ͵ͻǤ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǥ Ǥ ʹͲͳͶǢ͵ȋͷȌǣͲͻȂͳͶǤ ͶͲǤ Ǥ ǣǤǤʹͲͳǢ͵ǣͳʹͲȂ ͵ͳǤ ͶͳǤ ǡ ǡ ǡ Ǥ Ǧ Ǧ ǦȋȌǦ Ǥ ǤʹͲͳͲǢͳͲͳȋͳȌǣͶͲȂǤ ͶʹǤ ǡ ǡǤ Ǧ Ǥ ǤʹͲͳͳǢʹͺȋʹȌǣͳͺʹȂͻͶǤ Ͷ͵Ǥ ǡ ǡ ǡ Ǥ
ͺ͵ Chapter 3
᩿ǣ ǤǤ ʹͲͳͳǢ͵ȋͳȌǣͶ͵ȂͺǤ ͶͶǤ ǡǡ ǡ ǡǡ ǡ ǡ Ǥǡ ǡ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳͶǢ͵ȋͷȌǣͺ͵ȂͻǤ ͶͷǤ ǡ ǡ ǡǡ ǡǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ ǤǤʹͲͳ͵ǢͻȋͺȌǣʹȂͻǤ ͶǤ Ǧ ǡǡǦ ǡǤ Ǧ ͵ǦǦ Ǧ Ǧ ǦǤ ǤʹͲͳǢͳ͵ȋͶȌǣͳȂʹʹǤ ͶǤ ǡǡǡ ǡǡǡ ǡ ǡ ǡ Ǥ Ͷ Ǥ Ǥ ʹͲͳǢʹͻͳȋʹͶȌǣͳʹͷͷȂͺͷǤ ͶͺǤ ǡǡǡ ǡ ǡǡǤ͵ͺ ȋ ǡ͵ǤʹǤʹǤͷȌ Ǧ Ǥ ǤʹͲͲǢʹͳȋͳ͵Ȍǣ͵ʹͻȂ͵ͻǤ ͶͻǤ ǡ Ǧ ǡ ǡ ǡ ǡ ǡòǡ ǤǦ ͷȀ Ǥ ǤʹͲͲͺǢͳȋͳȌǣͳͶǤ ͷͲǤ ǡǡǡǡ ǡǡ ǡǡ ǡ Ǧ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͲͷǢͶͳȋȌǣͳ͵ͳ͵Ȃ ʹͳǤ ͷͳǤ ǡ Ǥ Ǥ ǤͳͻͷͻǢ͵ȋͺȌǤ ͷʹǤ ǡ ǡǡ Ǥ ʹǡʹǯǡͷǡͷǯǦ Ǥ ǤʹͲͲʹǢͷȋʹȌǣʹʹͲȂǤ ͷ͵Ǥ ǡǡ ǡǡ ǡǡǤ ǤǤʹͲͲͲǢͶ͵ͳȂͶʹǤ ͷͶǤ ǡǡǤ ᩿ǣ ᩿ǣ Ǧ Ǧ Ǥ ʹͲͲͷǢ ͷͷǤ ǡǡǡ Ǥǣ Ǧ Ǥ ǤʹͲͳͶǢͳͷȋʹȌǣͳȂͳǤ ͷǤ ǡ ǡ ǡǡ ǡ ǡǡ ǡǫǫǡ ǡ ǡ ǡ Ǥ Ǧ Ǥ Ǥ ʹͲͳ͵ǢʹʹȋʹͷȌǣͷʹͶͻȂͳǤ Acknowledgements ǣ ȋǣȀȀǤ ǤȀ ȌǢ ǡ ȋȌ ȋǣȀȀǤ ǤȀȀ Ȁ Ȁ Ȁ ȀȀǤǤǡ ǡ ǡ Ǥ Author Contributions
ͺͶ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
ǡ Ǧ Ǥ ǡ Ǥ ǡ ǡǡ ǡ ǡǡǡǡ Ǥ ǡǤ ǡǡ ǡǡǡǡ ǡǦ ǡǤ Ǥ ǡ ǡǡǡǡǡǦ Ǥ 3 Competing interests Ǥ
ͺͷ Chapter 3
^ƵƉƉůĞŵĞŶƚĂƌLJĨŝŐƵƌĞƐ͕ƚĂďůĞƐĂŶĚŵĞƚŚŽĚƐ Acyl-CoA
Mitochondrion Acyl-CoA
MCKAT Acetyl-CoA SCAD MCAD LCAD VLCAD FAD C4-C6 C4-C12 C8-C16 C12-C16 C4-C16 CoASH FADH2
Ketoacyl-CoA Enoyl-CoA
MSCHAD NADH + H+ Acetyl-CoA C4-C16 NAD+ CoASH Hydroxyacyl-CoA Supplementary Figure 1. Schematic representation of the murine mFAO pathway. ǣ ǢǤ ǢǡǡǣǦǦ ǡǦǡǦǡǦ Ǧǡ ǢǣǦ Ǧ Ǣ ǣȀǦ Ǧ
AB 3 8 LF fed LF fed HF fed HF fed ΐ ΐ 6 ΐΐ LF fasted ηη LF fasted 2 ηη HF fasted ηη͕ΐΐ HF fasted ηη͕ΐ 4 ηη ηη 1 2 Liver weight (g) weight Liver
0 0 WT KO Relative liver weight (%) WT KO
C 250 LF fed 200 HF fed LF fasted 150 HF fasted
100 mol/g liver) P ( 50 [Liver triglyceride] [Liver 0 WT KO Supplementary Figure S2. Liver weight (A), relative liver weight (B) and liver triglyceride content (C)Ǥ ǡ Ǧ ͷΨ ͳǤͷȉǦ ȋ Ȍ ʹͷΨ ͳǤͷȉ ǤαǦͺǤȗǣδͲǤͲͷ ǡ͓͓͓ǣδͲǤͲͷ δͲǤͲͳ ǡ ǡ ș șșǣ δͲǤͲͷ δͲǤͲͳ Ǧ ȋ Ȍǡ Ǥ
ͺ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
AWTBKO
3
C WT D
E WT F
G WT H
Supplementary Figure S3. Liver tissue integrity determined by H&E stainingǤǦǣǦǡǦǡ Ǧ ǡ Ǧ ǣ Ǧ ǡ Ǧ ǣ Ǧ Ǥ ǡ ǡ ǡ ǣ Ǥ ǡǡ ǡ ǣ Ǥ ͳ
ͺ Chapter 3
AWTBKO
C WT D
E WT F
G WT H
Supplementary Figure S4. Extent of steatosis determined by Oil Red O staining. ǦǣǦǡǦǡ Ǧ ǡ Ǧ ǣ Ǧ ǡ Ǧ ǣ Ǧ Ǥ ǡ ǡ ǡ ǣ Ǥ ǡǡ ǡ ǣ Ǥ ͳ
ͺͺ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Supplementary table ST1: Histological semi-quantitative scoring of liver health NAFLD Oil Red O Vacuolar Steatosis Lobular Portal Ballooning activity staining changes grade inflammation inflammation score Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM ͲǤ͵ ͲǤ͵ ͳǤͲ ͲǤͲ ͲǤ͵ ͲǤʹ ͲǤͲ ͲǤͲ ͲǤͷ ͲǤ͵ ͲǤ ͲǤͷ ͲǤͺ ͲǤͶ ͵ǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͳǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͶ ͲǤʹ ͲǤ ͲǤ͵ ͳǤͶ ͲǤʹ ʹǤͷ ͲǤ͵ ͳǤͲ ͲǤͲ ʹǤ͵ ͲǤʹ ͲǤͲ ͲǤͲ ͲǤͷ ͲǤʹ ͳǤͲ ͲǤͶ ʹǤͺ ͲǤ͵ 3 ʹǤ͵ ͲǤ͵ ͲǤͲ ͲǤͲ ʹǤ ͲǤʹ ͲǤͳ ͲǤͳ ͲǤͻ ͲǤͳ ͳǤͻ ͲǤͷ ͵Ǥ ͲǤ͵ ͲǤͺ ͲǤ͵ ͳǤͲ ͲǤͲ ͲǤͷ ͲǤʹ ͲǤͲ ͲǤͲ ͲǤͷ ͲǤʹ ͳǤͲ ͲǤͶ ͳǤͲ ͲǤ͵ ʹǤͺ ͲǤ͵ ͲǤͲ ͲǤͲ ͳǤͲ ͲǤʹ ͲǤͲ ͲǤͲ ͲǤͶ ͲǤʹ ͲǤ ͲǤͶ ͳǤͶ ͲǤ͵ ʹǤ͵ ͲǤ͵ ͳǤͲ ͲǤͲ ʹǤʹ ͲǤ͵ ͲǤʹ ͲǤʹ ͲǤͷ ͲǤʹ ͲǤͺ ͲǤͷ ʹǤͺ ͲǤ ʹǤͷ ͲǤ͵ ͲǤͲ ͲǤͲ ʹǤ ͲǤʹ ͲǤ ͲǤͶ ͳǤ͵͓ ͲǤʹ ͵ǤͲ ͲǤͺ ͶǤͶ ͲǤͷ ǡ ͳͲΨ Ǥ ǡ Ǥ ȏͶʹȐǤ͓ǣδͲǤͳǤ
AB10 40 LF fed LF fed HF fed HF fed 8 30 LF fasted LF fasted 6 HF fasted HF fasted 20
RCI (-) 4
10 2 Pyruvate-induced Pyruvate-induced consumption rate (St4) rate consumption
2 0 0 (μmol/(min*gmitProtein))
O WT KO WT KO
CD 10 40 LF fed LF fed HF fed HF fed 8 30 LF fasted LF fasted 6 HF fasted HF fasted 20
RCI (-) 4
10 2 consumption rate (St4) rate consumption C16-acyl-CoA-induced C16-acyl-CoA-induced 2 0 0 (μmol/(min*gmitProtein))
O WT KO WT KO
EF 10 40 LF fed LF fed HF fed HF fed 8 30 LF fasted LF fasted 6 HF fasted HF fasted 20
RCI (-) 4
10 2 consumption rate (St4) rate consumption C8-acyl-CoA-induced C8-acyl-CoA-induced
2 0 0 (μmol/(min*gmitProtein)) O WT KO WT KO Supplementary Figure S5. Pyruvate- (A-B), C16-acyl-CoA – (C-D) and C8-acyl-CoA-induced (E-F) state 4 oxygen consumption flux (A,C,E) and RCI (B, D,F) in liver mitochondria. State 4 is the basal oxygen consumption. RCI is the respiratory control index, calculated as State 3 O2 consumption rate divided by State 4 O2 consumption rate. ǡ Ǧ ͷΨ ͳǤͷȉǦ ȋ Ȍ ʹͷΨ ͳǤͷȉ Ǥα Ǥ ǣ Ǧǡ ǣ Ǧǡ ǣ Ǣ ʹ ͵ ʹ ͶǤ
ͺͻ Chapter 3
AB Atp5b Cox5a 800 150 LF fed LF fed HF fed HF fed 600 LF fasted 100 LF fasted g mito prot) g mito HF fasted prot) g mito HF fasted P P 400
50 200
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
CDCycs Gpx4 80 10 LF fed LF fed HF fed 8 HF fed 60 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito 6
P HF fasted P 40 4 20 2
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
EF Gsr Mtnd5 6 10 LF fed LF fed HF fed 8 HF fed 4 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito 6 P HF fasted P
4 2 2
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
GH Ndufs1 Prdx6/Prdx6b 60 10 LF fed LF fed HF fed 8 HF fed 40 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito 6 HF fasted P P
4 20 2
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
ͻͲ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
IJ Sdha Sdhb 150 100 LF fed LF fed HF fed 80 HF fed 100 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito 60 HF fasted P P
40 50 3 20
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
KL Slc25a3 Slc25a4 200 50 LF fed LF fed HF fed HF fed 150 40 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito 30 P HF fasted 100 P 20 50 10
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
MNSlc25a5 Sod2 600 100 LF fed LF fed HF fed 80 HF fed 400 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito 60 HF fasted P P
40 200 20
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
OP Ucp2 Ucp3 2.5 2.0 LF fed LF fed HF fed HF fed 2.0 1.5 LF fasted LF fasted g mito prot) g mito g mito prot) g mito HF fasted 1.5 HF fasted P P 1.0 1.0 0.5 0.5
0.0 0.0 WT KO
WT KO [Protein] (fmol/ [Protein] (fmol/
ͻͳ Chapter 3
QR Uqcrc2 Aco2 150 150 LF fed LF fed HF fed HF fed LF fasted 100 LF fasted 100 g mito prot) g mito g mito prot) g mito HF fasted HF fasted P P
50 50
0 0 WT KO
WT KO [Protein] (fmol/ [Protein] (fmol/
STCs Dlat 150 60 LF fed LF fed HF fed HF fed 100 LF fasted 40 LF fasted g mito prot) g mito HF fasted prot) g mito HF fasted P P
50 20
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
UVDld Dlst 100 100 LF fed LF fed 80 HF fed 80 HF fed LF fasted LF fasted g mito prot) g mito 60 HF fasted prot) g mito 60 HF fasted P P
40 40
20 20
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
WX Fh (Fh1) ldh2 80 80 LF fed LF fed HF fed HF fed 60 60 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito P HF fasted P 40 40
20 20
0 0 WT KO
[Protein] (fmol/ WT KO [Protein] (fmol/
ͻʹ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
YZ ldh3a Mdh2 40 250 LF fed LF fed HF fed 200 HF fed 30 LF fasted LF fasted
g mito prot) g mito prot) g mito 150
P HF fasted P HF fasted 20 100 3 10 50
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
AAOgdh/Ogdhl AB Pdha1 40 80 LF fed LF fed HF fed HF fed 30 60 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito P
P HF fasted 20 40
10 20
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
AC AD Pdk1 Slc25a1 6 100 LF fed LF fed HF fed 80 HF fed 4 LF fasted LF fasted g mito prot) g mito g mito prot) g mito 60 P HF fasted HF fasted P
40 2 20
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
AESlc25a10 AF Slc25a11 80 60 LF fed LF fed HF fed HF fed 60 LF fasted 40 LF fasted g mito prot) g mito HF fasted prot) g mito P
P HF fasted 40 ΐΐ
20 20
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
ͻ͵ Chapter 3
AG AH Slc25a22 Sucla2 40 80 LF fed LF fed HF fed HF fed 30 60 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito HF fasted P P 20 40
10 20
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
AI AJ Suclg1 Suclg2 200 150 LF fed LF fed HF fed HF fed 150 LF fasted 100 LF fasted g mito prot) g mito g mito prot) g mito HF fasted HF fasted P P 100 η͕ΐΐ η͕ΐ 50 50
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
AKAcaa2 AL Acadl 1000 150 LF fed LF fed 800 HF fed HF fed LF fasted 100 LF fasted g mito prot) g mito 600 HF fasted prot) g mito HF fasted P P
400 50 200
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
AMAcadm AN Acads 150 150 LF fed LF fed HF fed HF fed ΐΐ 100 LF fasted 100 LF fasted g mito prot) g mito HF fasted prot) g mito HF fasted P P
50 50
ΎΎΎΎ 0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
ͻͶ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
AO AP Acadvl Cpt1a 80 60 LF fed LF fed HF fed HF fed 60 LF fasted 40 LF fasted g mito prot) g mito HF fasted prot) g mito P
P HF fasted 40 20 3 20
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
AQ AR Cpt1b Cpt2 4 80 LF fed LF fed HF fed HF fed 3 60 LF fasted LF fasted g mito prot) g mito g mito prot) g mito
P HF fasted HF fasted P 2 40
1 20
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
ASDecr1 AT Echs1 150 200 LF fed LF fed HF fed HF fed 150 LF fasted 100 LF fasted g mito prot) g mito g mito prot) g mito HF fasted P
P HF fasted 100
50 50
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
AU AV Eci1 Etfa 150 400 LF fed LF fed HF fed HF fed 300 100 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito HF fasted P P ΐΐ 200
50 η 100
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
ͻͷ Chapter 3
AW AX Etfb Etfdh 300 100 LF fed LF fed HF fed 80 HF fed LF fasted LF fasted
200 prot) g mito g mito prot) g mito 60 HF fasted HF fasted P P
40 100 20
0 0 WT KO
WT KO [Protein] (fmol/ [Protein] (fmol/
AYHadh AZ Hadha 300 200 LF fed LF fed HF fed HF fed 150 200 LF fasted LF fasted g mito prot) g mito HF fasted prot) g mito HF fasted P P 100 ΐΐ 100 50
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
BAHadhb BB Slc25a29 250 4 LF fed LF fed 200 HF fed HF fed 3 LF fasted LF fasted g mito prot) g mito 150 HF fasted prot) g mito HF fasted P P 2 100
1 50
0 0 WT KO WT KO [Protein] (fmol/ [Protein] (fmol/
BC Slc25a20 15 LF fed HF fed 10 LF fasted g mito prot) g mito HF fasted P
5
0 WT KO [Protein] (fmol/ Supplementary Figure S6. Absolute levels of mitochondrial liver proteins. In the figure, the gene names corresponding to the proteins are given. ǡ Ǧ ͷΨ ͳǤͷȉǦȋ ȌʹͷΨ ͳǤͷȉ Ǥ ǣǦ ǣ ǦǤαǦͺ ǤȗǣδͲǤͲͷ ǡ͓͓͓ǣδͲǤͲͷδͲǤͲͳ ǡ ǡșșșǣ δͲǤͲͷδͲǤͲͳ ǡ Ǥ
ͻ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
10
0
-10 3
PC2 (23%) -20
-30
-40 -20 -10 0 10 20 30 PC1 (39%) Supplementary figure S7. Principal Component Analysis of mRNA expression data. Ǧǣ Ǣ ǦǣǢ ǣǡ ǣǢ ǣǦǢ ǣ ǦǤ α͵ǦͶǤ
Low-fat fasted High-fat fasted A B 100 100 50 50
5 5 4 4 3 3
Fold Change 2 Change Fold 2 1 1 0 0 Low-fat fed High-fat fed C D 100 100 50 50
5 5 4 4 3 3
Fold Change Fold 2 Change Fold 2 1 1 0 0
Voom_up Voom_up DeSeq2_up DeSeq2_up Voom_down Voom_down DeSeq2_down DeSeq2_down Method Method
EFUp Down ,&&Ă >&&Ğ ,&&Ă >&&Ğ
ϮϮ Ϯϵ ϭϴ ϯϬ ϭϬϬ ϭϬϬ ϰϵ Ϯϱ ϳϱ ϭϯ ϬϬ ϬϬ
ϭϬϬ ϭϭϬ Ϭ Ϭ Ϭ Ϭ Ϭ Ϭ >&&Ă ,&&Ğ >&&Ă ,&&Ğ
Supplementary figure S8. KO vs WT fold changes for the differential gene expression analysis methods DeSeq2 and Voom (A-D) and Venn diagrams for the Voom method (E-F) (p<0.01)ǣ αǦ ǡ α Ǧǡ α ǡ α Ǥ α͵ǦͶǤ
ͻ Chapter 3
Supplementary table ST2. Differentially-expressed genes (p<0.01)a Low-fat fasted KO/WT (DeSeq2) High-fat fasted KO/WT (DeSeq2) Upregulated Downregulated Upregulated Downregulated Gene FC padj Gene FC padj Gene FC padj Gene FC padj Star 2.3 0.05 Eif4ebp2 0.5 0.01 ͳ ʹǤ ͲǤ͵ͳ ͵ ͲǤͷ ͲǤ͵Ͷ Akr1b7 2.0 0.05 ͳ ͲǤͶ ͲǤʹͲ ͳǤ ͲǤ͵ͳ ͻ͵ʹ ͲǤͷ ͲǤʹ ͳ ͷ͵ ʹǤʹ ͲǤʹͲ ͲǤ ͲǤ͵ Ͷͳʹ ʹǤͳ ͲǤ͵ͳ ͵ ͲǤͷ ͲǤʹ ʹͳ ʹǤͶ ͲǤͶͷ ͳͳͲ ͲǤͷ ͲǤͶͷ ʹ ʹǤͷ ͲǤͶͲ ͲǤ ͲǤʹ ͵ ʹǤͲ ͲǤͶͷ ͳͶ ͲǤ ͲǤͶͷ ͵ͻ ʹǤͲ ͲǤͲ ͳ ͲǤͷ ͲǤ͵ ʹ ʹǤʹ ͲǤͶͷ ʹͷͳͲͲ͵ͻͳͺ ͲǤ ͲǤͶͺ ͳǤͷ ͲǤʹ ͳ ͲǤ ͲǤͻͶ ͳǤͶ ͲǤͶͺ ͳ ͲǤͶ ͲǤͶͺ ʹǤͲ ͲǤʹ ʹͷͳ ͲǤ ͲǤͻͶ ͳͳͶ ͳǤͻ ͲǤͶͺ ʹͺ ͲǤ ͲǤͶͺ ͳ ͳǤͺ ͲǤ͵ ͵ ͲǤͷ ͳǤͲͲ ͳ ͳǤ ͲǤͶͺ ͳ ͲǤͷ ͲǤͶͺ ͵ ͳǤ ͲǤͷ ͳͶ ͲǤͷ ͳǤͲͲ ͳǤͷ ͲǤͶͺ ͲǤͶ ͲǤͶͺ ͳ ʹǤʹ ͲǤͷ ͳ ͲǤͷ ͳǤͲͲ ͳͻ ͳǤͺ ͲǤͶͺ ͻʹ ͲǤ ͲǤͶͺ ʹ ʹǤͳ ͲǤͻͶ ͲǤ ͳǤͲͲ ͳ ͳǤ ͲǤͶͺ ͳ ͲǤ ͲǤͶͺ ͺ ͳǤͺ ͲǤͻͶ ʹ ͲǤ ͳǤͲͲ ͵ ʹǤͲ ͲǤͶͺ ͲǤ ͲǤͶͺ ͳǤͶ ͳǤͲͲ ͲǤͷ ͳǤͲͲ ͳǤ͵ ͲǤͶͺ ͲǤ ͲǤͶͺ ͳ ͳǤ ͳǤͲͲ ͳ͵ͳͻͻ ͲǤͷ ͳǤͲͲ ʹ ͳǤͻ ͲǤͶͺ ͲǤ ͲǤͶͺ ʹʹ ͳǤͻ ͳǤͲͲ ʹͳ ͲǤͷ ͳǤͲͲ Ͷ ͳǤͻ ͲǤͶͺ ͳ ͲǤͷ ͲǤͶͺ ͳ ͳǤͷ ͳǤͲͲ ͲǤ ͳǤͲͲ ͳͳͳ ͳǤ ͲǤͶͺ ʹ ͲǤͷ ͲǤͶͺ Ͷʹ ͳǤͻ ͳǤͲͲ ʹʹ ͲǤ ͳǤͲͲ ʹͲͲͲ ͳǤ ͲǤͶͺ ͳʹ ͲǤ ͲǤͶͺ ͳͻ ͳǤ ͳǤͲͲ ͲǤ ͳǤͲͲ ͳ͵ ʹǤͳ ͲǤͶͺ ͲǤ ͲǤͶͺ ͵ͳ͵ ͳǤͶ ͳǤͲͲ ͲǤ ͳǤͲͲ ͳͳͷ ͳǤ ͲǤͶͺ ʹ͵ ͲǤ ͲǤͶͺ Ͷ ʹǤͲ ͳǤͲͲ ʹ ͲǤ ͳǤͲͲ ͳǤͻ ͲǤͶͺ ͲǤ ͲǤͶͺ ͳͳ ʹǤͲ ͳǤͲͲ ʹ ͵ͺ ͲǤ ͳǤͲͲ ͳ ͳǤͶ ͲǤͶͺ ʹ ͲǤͷ ͲǤͶͺ ͻ͵ ʹǤͲ ͳǤͲͲ ͵ ͲǤ ͳǤͲͲ ͳͶͲ ʹǤͳ ͲǤͶͺ ͻ͵ ͲǤ ͲǤͶͺ ʹͳ ͳǤ͵ ͳǤͲͲ Ͷ ͲǤ ͳǤͲͲ ͳʹͲ ͳǤͺ ͲǤͶͺ ͳͲ ͲǤ ͲǤͶͺ ͷ ͳǤͷ ͳǤͲͲ ͳ ͲǤ ͳǤͲͲ ͳͶ ͳǤ ͲǤͶͺ ʹ ͲǤͷ ͲǤͶͺ ʹͳ ͳǤ ͳǤͲͲ ͷ ͲǤͷ ͳǤͲͲ ͳʹͳ ͳǤ ͲǤͶͺ ͲǤͷ ͲǤͶͺ ʹ ʹǤͲ ͳǤͲͲ ͳͳͳͲͲͷͳʹͲ ͲǤͷ ͳǤͲͲ ͳ ͳǤͻ ͲǤͶͺ ͲǤ ͲǤͶͺ ͳǤͶ ͳǤͲͲ ͳ ͲǤ ͳǤͲͲ ʹ ͳǤͷ ͲǤͶͻ ͷ ͲǤ ͲǤͶͺ ʹʹʹͺ ͳǤͻ ͳǤͲͲ ͳ ͲǤ ͳǤͲͲ ͳ ʹǤͳ ͲǤͶͻ ͲǤ ͲǤͶͺ ʹͲ ʹǤͲ ͳǤͲͲ ͳǤͶ ͲǤͶͻ ͲǤ ͲǤͶͺ ʹ ͳǤͷ ͳǤͲͲ ͳǤ ͲǤͶͻ ʹ ͲǤͷ ͲǤͶͺ ͳǤ ͳǤͲͲ ͷ ͳǤ ͲǤͶͻ ͶͲ ͲǤͷ ͲǤͶͺ ͷͻͲͲ ͳǤͺ ͳǤͲͲ ʹͳͳ ͳǤ ͲǤͶͻ ͳͷ ͲǤ ͲǤͶͺ ʹ ʹǤͲ ͳǤͲͲ ͳ ʹǤͲ ͲǤͶͻ ͷ ͲǤ ͲǤͶͻ ͺͳ ͳǤͻ ͳǤͲͲ ͳͲ ͳǤͷ ͲǤͶͻ ͳ ͲǤ ͲǤͶͻ Ͷ ͳǤ ͳǤͲͲ ͳ ͳǤ ͲǤͶͻ ͳ ͲǤ ͲǤͶͻ ͳͻ ͳǤͻ ͳǤͲͲ ͵ ͳǤͶ ͲǤͷʹ ʹ ͲǤͷ ͲǤͶͻ ͵ ͳǤͶ ͳǤͲͲ ͷ ʹǤͲ ͲǤͷʹ ͷ ͲǤ ͲǤͶͻ ʹ ͳǤ ͳǤͲͲ ʹǤͲ ͲǤͷʹ ʹ ͲǤͷ ͲǤͷʹ ͺ ͳǤͶ ͳǤͲͲ Ͷͻ ͳǤ ͲǤͷʹ ͲǤ ͲǤͷʹ ʹ ͳǤͺ ͳǤͲͲ ͳǤͶ ͲǤͷʹ ͳ ͲǤ ͲǤͷ͵ ͳͲ ͳǤͷ ͳǤͲͲ ͳͶ ͳǤ͵ ͲǤͷͶ ͳ ͲǤͷ ͲǤͷͶ ͳǤͶ ͳǤͲͲ ʹǤͳ ͲǤͷͶ ͲǤͷ ͲǤͷͶ ʹͳ ͳǤͷ ͳǤͲͲ ͳǤͷ ͲǤͷͶ ͵ ͲǤ ͲǤͷͶ ͳǤͻ ͳǤͲͲ ͳ ͳǤͺ ͲǤͷͶ ʹ ͲǤ ͲǤͷͶ ͵ͺ ͳǤͶ ͲǤͷͶ ͳ ͲǤͷ ͲǤͷͶ ͳ ͳǤͶ ͲǤͷͶ ʹ ͲǤͺ ͲǤͷͶ ͳ ͳǤͻ ͲǤͷͷ ʹͷ ͲǤ ͲǤͷͶ ͳ ͳǤ ͲǤͷͷ ͲǤ ͲǤͷͶ ͳͲͲͲʹ ͳͻ ʹǤͲ ͲǤͷ ͲǤ ͲǤͷͷ ʹͳ ͳǤͷ ͲǤͷ Ͷ ͲǤ ͲǤͷͷ ʹ ͳǤͷ ͲǤͷ ͳͲ ͲǤͷ ͲǤͷ ͵ ʹǤͲ ͲǤͷ ʹ ͲǤ ͲǤͷ ͳͷ ͳǤͷ ͲǤͷ ʹ ͲǤ ͲǤͷ Ͷͷ ͳǤͻ ͲǤͷ ͲǤ ͲǤͷ ͷ ͳǤͷ ͲǤͷͺ ͶͶ ͲǤ ͲǤͷ ͳǤͶ ͲǤͷͺ ͳ ͲǤ ͲǤͷ ͳ ͳǤͺ ͲǤͷͺ ʹ ͲǤͷ ͲǤͷ ͳͶ ͳǤͶ ͲǤͷͺ ʹͻ ͲǤ ͲǤͷ ʹͷ ͳǤͷ ͲǤͷͺ ͳ ͲǤ ͲǤͷ ͵ ͳǤͶ ͲǤͷͻ ͵ ͲǤͺ ͲǤͷ ʹ͵Ͳʹͳͻʹʹ ͳǤ͵ ͲǤͲ ͲǤ ͲǤͷ ͳ ͳǤͺ ͲǤͳ ʹͺͲ ͲǤͷ ͲǤͷ ͳǤͶ ͲǤʹ ͳ ͲǤͺ ͲǤͷͺ ͳ ͳǤ ͲǤ͵ ʹ ͲǤ ͲǤͲ ͳ ͳǤ͵ ͲǤ͵ ͷ ͲǤ ͲǤʹ ͳͲͶ͵ ͳǤͺ ͲǤ͵ ͲǤ ͲǤʹ ͳ ͳǤ͵ ͲǤ͵ ʹ ͲǤ ͲǤ͵ ͳʹ ͳǤͺ ͲǤ͵ ʹʹ ͲǤ ͲǤ͵ ͺ ͳǤ͵ ͲǤ͵ Ͷ ͲǤ ͲǤ͵
ͻͺ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Low-fat fasted KO/WT (DeSeq2)- continued Upregulated Downregulated Gene FC padj Gene FC padj Ͷ ͳǤ ͲǤ͵ ʹʹ ͲǤͷ ͲǤ͵ ͳ ͳǤ ͲǤ͵ ʹ ͲǤͷ ͲǤ͵ ͳʹ ͳǤͶ ͲǤ͵ ͳ ͲǤ ͲǤ͵ ͳͲ ͳǤͶ ͲǤ͵ ʹ ͲǤ ͲǤ͵ ͵ ͳǤͷ ͲǤ͵ ͳͳ ͲǤ ͲǤ͵ ʹ ͳǤͻ ͲǤ͵ ͳ ͲǤ ͲǤ͵ ͵ ͳǤ ͲǤ͵ ͳ ͲǤ ͲǤ͵ 3 ʹǦͳ ͳǤ ͲǤ͵ ͳ ͲǤ ͲǤ͵ ʹ ͳǤͷ ͲǤ͵ ʹ ͲǤ ͲǤ͵ ʹ͵ ʹ ͳǤͻ ͲǤ͵ ͳͳ ͲǤ ͲǤ͵ ͳǤͺ ͲǤ͵ ͳͷͳ ͲǤ ͲǤ͵ ͷͻͷ ͳǤͻ ͲǤ͵ ʹ ͲǤͷ ͲǤ͵ ʹͳ ͳǤ ͲǤ͵ ͵ ͲǤͺ ͲǤ͵ ͷ ͳǤͻ ͲǤ͵ ͺ ͲǤͷ ͲǤ͵ ͵ ͳǤͻ ͲǤ͵ ͳ ͲǤ ͲǤ͵ ͲǤͺ ͲǤ͵ Low-fat fed KO/WT (DeSeq2) High-fat fed KO/WT (DeSeq2) Upregulated Downregulated Upregulated Downregulated Gene FC padj Gene FC padj Gene FC padj Gene FC padj ͺ ͳǤͷ ͲǤͷʹ ͵ͳ ͲǤͶ ͲǤʹͲ ʹǤ ͲǤͳ Acnat2 0.4 0.02 ͳ ͳǤͻ ͲǤͺͶ ʹ ͲǤͶ ͲǤ͵Ͳ ͳ ͳǤͺ ͲǤͻ ͷ ͲǤͶ ͲǤͳ ʹǤͲ ͳǤͲͲ ͵ͳ͵ ͲǤͷ ͲǤ͵͵ ͳ ʹǤͳ ͳǤͲͲ ʹʹʹͻ ͲǤͷ ͲʹͻʹͳͶ ʹǤͳ ͳǤͲͲ ͷ ͲǤͶ ͲǤ͵Ͷ Ͷͳʹ ͳǤͺ ͳǤͲͲ ͳ ͲǤ ͳǤͲͲ ͳ ʹǤͳ ͳǤͲͲ ͲǤͷ ͲǤ͵Ͷ Ͷ ʹǤʹ ͳǤͲͲ ͳ ͲǤͷ ͳǤͲͲ ͳǤͺ ͳǤͲͲ ͵ͺ ͲǤͷ ͲǤͷʹ ͳ ͳǤͺ ͳǤͲͲ ͵ͷ ͲǤ ͳǤͲͲ ͵ ʹǤͲ ͳǤͲͲ ͲǤͷ ͲǤͺͶ ͳ ʹǤͳ ͳǤͲͲ ͲǤ ͳǤͲͲ ͳ ͳǤͻ ͳǤͲͲ ͳͳ ͲǤ ͲǤͻͻ ͳ ͳǤ ͳǤͲͲ ʹͶ ͲǤͷ ͳǤͲͲ ʹͳͺ ͳǤͻ ͳǤͲͲ ͳͳ ͲǤ ͲǤͻͻ ͷ ͳǤͻ ͳǤͲͲ ʹ ͲǤ ͳǤͲͲ ʹͶͺ ͳǤͶ ͳǤͲͲ ͲǤͶ ͳǤͲͲ ͳǤ ͳǤͲͲ ʹͻ ͲǤ ͳǤͲͲ ͳ ͳǤ ͳǤͲͲ ͲǤ ͳǤͲͲ ͳ ʹǤͳ ͳǤͲͲ ͳͳ ͲǤ ͳǤͲͲ ͵ͳ ͳǤͻ ͳǤͲͲ ͷͷ ͲǤͷ ͳǤͲͲ ͳͶ ʹǤͳ ͳǤͲͲ ͳ ͲǤ ͳǤͲͲ ʹ ͳǤ͵ ͳǤͲͲ Ͷʹͳ ͲǤ ͳǤͲͲ ͳǤ ͳǤͲͲ ͷʹ ͲǤ ͳǤͲͲ ͳͳʹ ͳǤ ͳǤͲͲ ʹ ͲǤ ͳǤͲͲ ʹ ʹǤͳ ͳǤͲͲ ͲǤ ͳ ͳǤͻ ͳǤͲͲ Ͷ ͲǤ ͳǤͲͲ ʹǤͳ ͳǤͲͲ ͳ ͲǤͷ ͳǤͲͲ ʹ ʹǤͲ ͳǤͲͲ ʹ ͲǤ ͳǤͲͲ ͳ ͳǤͻ ͳǤͲͲ ͳʹͳ ͲǤ ͳǤͲͲ Ͷ ͳǤͺ ͳǤͲͲ Ͷʹ ͲǤ ͳǤͲͲ ͺ ͳǤͷ ͳǤͲͲ ͳʹ ͲǤ ͳǤͲͲ ͳ ͳǤͶ ͳǤͲͲ ʹʹ ͲǤͷ ͳǤͲͲ ͷͷ ͳǤ ͳǤͲͲ ͲǤ ͳǤͲͲ ͳͳ ͳǤͷ ͳǤͲͲ ͵ ͲǤͷ ͳǤͲͲ ͺͻ ͳǤͻ ͳǤͲͲ ͲǤ ͳǤͲͲ ͶͶ ͳǤͻ ͳǤͲͲ ͲǤ ͳǤͲͲ ͺ ͳǤ ͳǤͲͲ ʹ ͲǤͷ ͳǤͲͲ ͳǤͻ ͳǤͲͲ ʹ ͲǤͷ ͳǤͲͲ ʹͳͲͲʹͳͲͳ ʹǤͲ ͳǤͲͲ ͳ ͲǤͷ ͳǤͲͲ ͳ ʹǤͲ ͳǤͲͲ ͲǤͷ ͳǤͲͲ ʹͷ ͳǤͷ ͳǤͲͲ ͳͲ ͲǤ ͳǤͲͲ ͳͺ ʹǤͲ ͳǤͲͲ Ͷ ͲǤͷ ͳǤͲͲ ͳͻ ʹǤͲ ͳǤͲͲ ͳͶͻ ͲǤ ͳǤͲͲ ͳǤͶ ͳǤͲͲ ͲǤ ͳǤͲͲ ͳǤ ͵ͳ ͲǤͷ ͳǤͲͲ ͳǤͻ ͳǤͲͲ ʹ͵ ͲǤͷ ͳǤͲͲ Ͷ ʹǤͲ ͳǤͲͲ ͳ ͲǤ ͳǤͲͲ ͳ ͳǤͻ ͳǤͲͲ ͳ͵ ͲǤ ͳǤͲͲ ͺʹ ͳǤͻ ͳǤͲͲ ͻ ͲǤ ͳǤͲͲ ͵ ͳǤ ͳǤͲͲ ʹͲͻ ͲǤͷ ͳǤͲͲ ͵ ͳǤͷ ͳǤͲͲ ʹʹ ͲǤ ͳǤͲͲ ͳ ͳǤ ͳǤͲͲ ͻͲ ͲǤͷ ͳǤͲͲ ͵ ͳǤͻ ͳǤͲͲ ͳ ͳǤ ͳǤͲͲ ʹͻ ͲǤ ͳǤͲͲ ͳǤͷ ͳǤͲͲ ͳǤͷ ͳǤͲͲ ʹ ͲǤͷ ͳǤͲͲ ͵ͻ ͳǤ ͳǤͲͲ ͳǤͻ ͳǤͲͲ Ǧͷ ͲǤͺ ͳǤͲͲ ͳ ͳǤͷ ͳǤͲͲ ʹ ʹǤͲ ͳǤͲͲ ͵ͻ ͲǤ ͳǤͲͲ Ͷ ʹǤͲ ͳǤͲͲ ʹ ͳǤͷ ͳǤͲͲ ͵ ͲǤͷ ͳǤͲͲ ͳ ʹǤͲ ͳǤͲͲ ʹǤͲ ͳǤͲͲ ͲǤ ͳǤͲͲ ͳͲ ͳǤ ͳǤͲͲ ͳǤͺ ͳǤͲͲ ͲǤ ͳǤͲͲ ͳ ͳǤͶ ͳǤͲͲ ʹ ͳǤͻ ͳǤͲͲ ͷ ͲǤ ͳǤͲͲ ͵͵ ͳǤͺ ͳǤͲͲ ʹ ͳǤ ͳǤͲͲ ͳͺ ͲǤ ͳǤͲͲ ͳ ͳǤͺ ͳͲ ͳǤͷ ͳǤͲͲ ʹ ͲǤ ͳǤͲͲ Ͷ ͳǤͻ ͳǤͲͲ ͵ ͳǤͺ ͳǤͲͲ ͲǤ ͳǤͲͲ ͳǤͶ ͳǤͲͲ ͳ ͳǤ͵ ͳǤͲͲ ͲǤ ͳǤͲͲ ͺͳͲ ͳǤͺ ͳǤͲͲ ͳ ͳǤͷ ͳǤͲͲ ͺͷ ͲǤͷ ͳǤͲͲ ͻ ͳǤ ͳǤͲͲ ʹ ͳǤͷ ͳǤͲͲ ͵ ͲǤ ͳǤͲͲ ͳ ͳǤ ͳǤͲͲ Ͳͻ ͳǤͻ ͳǤͲͲ ͲǤ ͳǤͲͲ ͳͺ ͳǤͺ ͳ ͳǤ ͳǤͲͲ ͳʹ ͲǤ ͳǤͲͲ ʹ ͳǤͻ ͳǤͲͲ ͳǤ ͳǤͲͲ Ͷ ͲǤͷ ͳǤͲͲ ʹͷ ͳǤ ͳǤͲͲ ͳ ͳǤͶ ͳǤͲͲ ͵ ͲǤͷ ͳǤͲͲ ͳǤͻ ͳǤͲͲ ͳǤ ͳǤͲͲ ͳʹ ͲǤ ͳǤͲͲ Ͷ ͳǤ ͳǤͲͲ ͶͶͷ ͲǤͷ ͳǤͲͲ ͳǤͷ ͳǤͲͲ Ͷ ͲǤͷ ͳǤͲͲ ʹͳͲ ͳǤͻ ͳǤͲͲ ͳʹ ͲǤͷ ͳǤͲͲ
ͻͻ Chapter 3
Low-fat fed KO/WT (DeSeq2)- continued Downregulated Gene FC padj ͺ ͲǤͷ ͳǤͲͲ ͳ ͲǤͷ ͳǤͲͲ ʹ ͲǤ ͳǤͲͲ ͷ ͲǤ ͳǤͲͲ ͺ ͲǤ ͳǤͲͲ ͲǤ ͳǤͲͲ ʹ ͲǤͷ ͳǤͲͲ Ͷ ͲǤͷ ͳǤͲͲ ͻ ͲǤͷ ͳǤͲͲ ͳ ͲǤ ͳǤͲͲ ͲǤͷ ͳǤͲͲ ʹǦͶ ͲǤ ͳǤͲͲ ͺ ͲǤ ͳǤͲͲ ͳ ͲǤ ͳǤͲͲ Low-fat fasted KO/WT (Voom) High-fat fasted KO/WT (Voom) Upregulated Downregulated Upregulated Downregulated Gene FC padj Gene FC padj Gene FC padj Gene FC padj ͳȁ ʹͲͶ ͳǤͻ ͲǤͶ Ͷʹ ͳǤͻ ͲǤͳ͵ ͳ ͳǤͻ ͳǤͲͲ ͻ͵ʹ ͳǤͻ ͳǤͲͲ ʹ ͳǤͶ ͲǤͷͻ ͳǤͺ ͲǤͷͻ ͵ͻ ʹǤʹ ͳǤͲͲ ͵ ͳǤͷ ͳǤͲͲ ͳʹ ͳǤͺ ͲǤͷͻ ͳ ͳǤͶ ͲǤͷͻ ͳ ͳǤͷ ͳǤͲͲ ʹͷͳ ͳǤͶ ͳǤͲͲ ͳǤͷ ͲǤͷͻ ͷ ͳǤ ͲǤͷͻ ͳǤͷ ͳǤͲͲ ʹ ͳǤͷ ͳǤͲͲ ͳǤ ͲǤͷͻ ͵͵ͲͲͻͳ ͷǤ ͲǤͷͻ ͳǤͺ ͳǤͲͲ ͻͲ͵ͲͳͻͲͺ ʹǤ͵ ͳǤͲͲ ͳʹͲ ʹǤͲ ͲǤͷͻ ͳͳͲ ʹǤͳ ͲǤͷͻ ͳ ͳǤͻ ͳǤͲͲ ͳ ͳǤͻ ͳǤͲͲ ͳ ͷ͵ ʹǤͲ ͲǤͷͻ ͳǤͷ ͲǤͷͻ ͳ ͳǤͺ ͳǤͲͲ ͳ ͳǤ ͳǤͲͲ ͳǤͶ ͲǤͷͻ ͻʹ ͳǤͷ ͲǤͷͻ ͳǤͷ ͳǤͲͲ ͳ ͳǤ ͳǤͲͲ ͳǤ ͲǤͷͻ ͳǤ ͲǤͷͻ ͺ ͳǤ ͳǤͲͲ ͳ ͳǤͶ ͳǤͲͲ Ͳ ͳǤͻ ͲǤͷͻ ͳͶ ͳǤ ͲǤͷͻ ͳͳͲͶ ͳǤͶ ͳǤͲͲ ͳǤ͵ ͳǤͲͲ ͳͲ ͳǤͶ ͲǤͷͻ ͳͲ ͳǤͷ ͲǤͷͻ ͳͲͲͻ ͵Ǥͺ ͳǤͲͲ ͷ ͳǤ͵ ͳǤͲͲ ͳ ʹ ͶǤͲ ͲǤͷͻ ͳǤ ͲǤͷͻ ͳǤͶ ͳǤͲͲ Ͷ͵Ͳͷ͵ ͳͳ ͳǤͺ ͳǤͲͲ ͳͳͶ ͳǤͺ ͲǤͷͻ ͳǤͶ ͲǤͷͻ ͳ ʹǤ ͳǤͲͲ ͳǤͶ ͳǤͲͲ ͳ ʹǤʹ ͲǤͷͻ ͳǤ ͲǤͷͻ ʹͳ ͳǤ͵ ͳǤͲͲ ͳ ͳǤͶ ͳǤͲͲ ͵ʹͷͶ ʹǤ ͲǤͷͻ ͵ ͳǤͻ ͲǤͷͻ ͳ ͳǤͻ ͳǤͲͲ ͳͶ ʹǤͳ ͳǤͲͲ ͳǤͶ ͲǤͷͻ ͳʹ ͳǤͷ ͲǤͷͻ ͳǤ ͳǤͲͲ ͵ ͳǤ ͳǤͲͲ ͳͻ ͳǤ͵ ͲǤͷͻ ͶͲ ʹǤ ͲǤͷͻ ʹ ͳǤͺ ͳǤͲͲ ͳ ͳǤͻ ͳǤͲͲ ͳǤ͵ ͲǤͷͻ ͳǤ ͲǤͷͻ ʹǤͳ ͳǤͲͲ ͳͺͶ ͳǤ ͳǤͲͲ ͳǤ͵ ͲǤͷͻ ͳǤ ͲǤͷͻ ͳǤͶ ͳǤͲͲ ͳ ʹǤʹ ͳǤͲͲ Ͷ ͳǤ͵ ͲǤͷͻ ͳ͵ ͳǤͶ ͲǤͷͻ ʹͳ ͳǤͶ ͳǤͲͲ ʹ ͵ͺ ͳǤͺ ͳǤͲͲ ͺͳ ͳǤ ͲǤͷͻ ͳ ͳǤͺ ͲǤͷͻ ʹ ʹǤ ͳǤͲͲ ʹͲ ͳǤͶ ͲǤͷͻ ͵ ʹǤͶ ͲǤͷͻ ͵ ͳǤ ͳǤͲͲ ʹʹͲͲͲͲʹͲͳ ʹǤͲ ͲǤͷͻ ͳ ʹǤ ͲǤͷͻ Ͷͳʹ ʹǤͲ ͳǤͲͲ ʹǤͳ ͲǤͷͻ ͳ ʹǤ͵ ͲǤͷͻ ͵ͳ͵ ͳǤͷ ͳǤͲͲ ʹͳ ͳǤ ͲǤͷͻ ͳ ͳǤͷ ͲǤͷͻ Ͷ ͳǤ ͳǤͲͲ ͳͳͳ ͳǤ ͲǤͷͻ ʹ͵ ͳǤ ͲǤͷͻ ʹ ͳǤ ͲǤͷͻ ͳ ͳǤ ͲǤͷͻ ʹͳͶ ͳǤ ͲǤͷͻ ͳͳ ͳǤ ͲǤͷͻ ͳͷ ͳǤ͵ ͲǤͷͻ ʹ ʹǤͷ ͲǤͷͻ Ͷ ͳǤͻ ͲǤͷͻ ͳ ʹǤͳ ͲǤͷͻ ʹͲͺ ͳǤͶ ͲǤͷͻ ͳǤͶ ͲǤͷͻ ͺ ͳǤͶ ͲǤͷͻ ͶͶ ͳǤͶ ͲǤͷͻ ͳͺ ͳǤ ͲǤͷͻ ͳ ͳǤͺ ͲǤͷͻ ͳͶ ͳǤͶ ͲǤͷͻ ʹͷ ͳǤͷ ͲǤͷͻ ͳ ͳǤͷ ͲǤͷͻ ʹͺ ͳǤ ͲǤͷͻ ͳ ͳǤͷ ͲǤͷͻ ͳͺͶ ͳǤ ͲǤͷͻ ͳ ͳǤͶ ͲǤͷͻ ͵ ͳǤͷ ͲǤͷͻ ʹ ͳǤͷ ͲǤͷͻ Ͷ ͳǤͻ ͲǤͷͻ ʹ ͳǤ ͲǤͷͻ ͳǤͶ ͲǤͷͻ ͳͳ ͶǤͶ ͲǤͷͻ ʹ ʹǤʹ ͲǤͷͻ ͳͻ͵ ʹǤͲ ͲǤͷͻ Ͷͷ ͷǤͳ ͲǤͷͻ ʹͳ ͳǤͶ ͲǤͷͻ ͻ ͳǤͶ ͲǤͷͻ ͳ ͳǤ ͲǤͷͻ ͳ ͳǤͺ ͲǤͷͻ ͳǤͷ ͲǤͷͻ ͷ ͳǤ ͲǤͷͻ ͳǤͶ ͲǤͷͻ ͳǤ͵ ͲǤͷͻ Ͷ ͵Ǥ ͲǤͷͻ ͳ ͳǤ ͲǤͷͻ ʹͲ ͳǤͶ ͲǤͷͻ ͷ͵ ͳǤ ͲǤͷͻ ʹ ͳǤͶ ͲǤͷͻ ʹʹ ͳǤͺ ͲǤͷͻ ͳǤͶ ͲǤͷͻ ͳǤͷ ͲǤͷͻ ͳǤͶ ͲǤͷͻ ʹ ͳǤͷ ͲǤͷͻ ͳͲ ͳǤ ͲǤͷͻ ͳ ͳǤ ͲǤͷͻ ʹǤͲ ͲǤͷͻ
ͳͲͲ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Low-fat fasted KO/WT (Voom)- continued Upregulated Downregulated Gene FC padj ͶͶ ͳǤͷ ͲǤͷͻ ͳǤͶ ͲǤͷͻ Ͷ͵ ʹǤͲ ͲǤͷͻ ͵ ͳǤͻ ͲǤͷͻ ͳ ͳǤͷ ͲǤͷͻ ʹ ʹǤͷ ͲǤͷͻ ͲͳͶ͵ ͳǤ ͲǤͷͻ 3 ͳǤ ͲǤͷͻ Ͷ ʹǤͳ ͲǤͷͻ ͷ ͳǤͺ ͲǤͷͻ ʹ ͳǤ͵ ͲǤͷͻ ͵ͲͲ͵ͻͲ͵ ͵Ǥʹ ͲǤͷͻ Ͷ ʹǤ͵ ͲǤͷͻ ͳ ͳǤͶ ͲǤͷͻ ͳ ͳ͵ ͳǤ͵ ͲǤͷͻ ʹͳ ͳǤͷ ͲǤͷͻ ͷͳ ʹǤͷ ͲǤͷͻ Ͷ ͳǤ͵ ͲǤͷͻ ͳǤ ͲǤͷͻ ͳ ͳǤͺ ͲǤͷͻ ͳ ͳǤͶ ͲǤͷͻ ʹ ͳǤ ͲǤͷͻ ͲͺͲ ͳǤͶ ͲǤͷͻ ͳ ʹǤͲ ͲǤͷͻ Low-fat fed KO/WT (Voom) High-fat fed KO/WT (Voom) Upregulated Downregulated Upregulated Downregulated Gene FC padj Gene FC padj Gene FC padj Gene FC padj ͺ ͳǤͷ ͳǤͲͲ ͵ͳ ͶǤͲ ͲǤͻ ʹͳͶ ͳǤ ͳǤͲͲ ʹ ͵Ǥͳ ͲǤʹ Ͷ ͳǤͻ ͳǤͲͲ Ͷ ͳǤͺ ͲǤͻʹ ͳ ͳǤ ͳǤͲͲ ͵ͷ ͳǤͶ ͳǤͲͲ ʹǤͲ ͳǤͲͲ ʹǤʹ ͳǤͲͲ ʹͷ ʹǤͲ ͳǤͲͲ ͷͻ͵ͲͶ͵ͲͲͳ ͳǤ ͳǤͲͲ ȁͳ ͳ ͳǤ ͳǤͲͲ ʹ ͵ǤͲ ͳǤͲͲ ͳͳ ͳǤ ͳǤͲͲ ͳʹͳ ͳǤͷ ͳǤͲͲ Ͷ ʹǤͳ ͳǤͲͲ Ͷʹͳ ͳǤͷ ͳǤͲͲ ͳǤͷ ͳǤͲͲ ͳͳ ͳǤ͵ ͳǤͲͲ ʹͶͺ ͳǤͷ ͳǤͲͲ ͳͺͳͲͲʹͳʹʹ ʹǤͳ ͳǤͲͲ Ͷ ͳǤͻ ͳǤͲͲ ʹǤͲ ͳǤͲͲ ʹ ͳǤͷ ͳǤͲͲ ͳʹ ͳǤ ͳǤͲͲ ͷ ͳǤ ͳǤͲͲ ͻȁ ͷͶͷͳ ͳǤͺ ͳǤͲͲ ͳͷ ͳǤ͵ ͳǤͲͲ ͵ ͵Ǥͳ ͳǤͲͲ ͳ ͳǤ ͳǤͲͲ ͳͶͻ ͳǤͷ ͳǤͲͲ ͳͳ ͳǤͷ ͳǤͲͲ ʹ ͳǤ ͳǤͲͲ ͳ ͳǤ ͳǤͲͲ ͵ͳ ʹǤ͵ ͳǤͲͲ ͳǤͶ ͳǤͲͲ ʹͻ ͳǤͻ ͳǤͲͲ ͲͳͲͲͶͲ Ͳͳ ͳǤͶ ͳǤͲͲ ʹ ͵ͺ ͳǤͺ ͳǤͲͲ ͵ ͳǤͺ ͳǤͲͲ ͳǤͻ ͳǤͲͲ ͳ ͳǤͻ ͳǤͲͲ ͳʹ ʹǤͳ ͳǤͲͲ ͳ ʹǤͲ ͳǤͲͲ ͳͳ ͳǤ ͳǤͲͲ ʹ ͳǤͶ ͳǤͲͲ ʹͷ ͳǤͷ ͳǤͲͲ ʹͳͻ ͳǤͶ ͳǤͲͲ ͳǤ ͳǤͲͲ ͳ ʹǤ͵ ͳǤͲͲ ͵ ͳǤͷ ͳǤͲͲ ͳ ʹǤͶ ͳǤͲͲ ͵ͻ ʹǤͲ ͳǤͲͲ ͳǤͷ ͳǤͲͲ ͳǤͷ ͳǤͲͲ ͵ ͳǤ ͳǤͲͲ ʹ ͳǤͻ ͳǤͲͲ Ͷͳʹ ͳǤͻ ͳǤͲͲ ͷ ͳǤͻ ͳǤͲͲ ͵Ǥ͵ ͳǤͲͲ ͳͶ ͳǤͷ ͳǤͲͲ ʹ ͳǤ ͳǤͲͲ ͳ͵ ͳǤͷ ͳǤͲͲ ͵͵ͲͶͳ ͳ͵ ͳǤ ͳǤͲͲ ͵ ͳǤͶ ͳǤͲͲ ʹͷ ʹǤʹ ͳǤͲͲ Ͷ ʹǤ ͳǤͲͲ ͳ ͳǤͺ ͳǤͲͲ Ͷ ͳǤ ͳǤͲͲ ͳǤͶ ͳǤͲͲ ͳǤͺ ͳǤͲͲ ͷ ͳǤ͵ ͳǤͲͲ ʹͷ ʹǤͲ ͳǤͲͲ Ͷͷ ͳǤ ͳǤͲͲ ͵ ʹ ʹǤͶ ͳǤͲͲ ͳͳ ͳǤ͵ ͳǤͲͲ ʹ ͳǤ͵ ͳǤͲͲ ͳǤͺ ͳǤͲͲ ͺ ͳǤͷ ͳǤͲͲ ͳ ͳǤ͵ ͳǤͲͲ Ͷ ͶǤ͵ ͳǤͲͲ ʹǤ ͳǤͲͲ ͳ ͳǤͺ ͳǤͲͲ ʹͶͳͲͲͳͲ ͳǤ ͳǤͲͲ ͳǤͶ ͳǤͲͲ ͳ͵ ͳǤͷ ͳǤͲͲ ͳǤͺ ͳǤͲͲ ͳͷ ͳǤͷ ͳǤͲͲ ͳǤ͵ ͳǤͲͲ ͳ ͳǤ ͳǤͲͲ ͳ ͻͺǤͻ ͳǤͲͲ ͷ ͳǤ͵ ͳǤͲͲ ͵ͳ͵ ͳǤͷ ͳǤͲͲ ʹ ͳǤ͵ ͳǤͲͲ ͲʹͷͶͶ ͳǤ ͳǤͲͲ ͳ ͳǤͺ ͳǤͲͲ ͳ ͳǤͶ ͳǤͲͲ ͳ ͳǤ ͳǤͲͲ ͷͷ ͳǤͺ ͳǤͲͲ ͵ ͳǤͶ ͳǤͲͲ ʹ ͳǤ ͳǤͲͲ ǣǦ Ǥ Ǥ ǤǤͲͳ̷ Ǥ Ǥ
ͳͲͳ Chapter 3
Supplementary table ST3. CoA and NAD(P)(H) gene sets CoA gene set NAD(P)(H) main gene set NAD(P)(H) redox gene set ͳ ʹͷ ʹ ͵ͺ ʹ ʹͳͲ ͳ ʹ ͵ͻ ͳͻ ͳ ʹͳͻ ʹ ͳ ʹ ͶͲ ͳ Ͷ ʹͻ ͵ Ͷ ʹ ͷͲ ͳ ͷ ʹ ͺ ͷ ʹ ʹͻ Ͷ ͷ ʹ ͷͶ ͳͲͺͳ ͳ ʹ ʹ ͵ ͷ ʹ ͷͷ ͶͶͷͲ ͳ ʹ ͵ͺ ʹ ͷ ʹ ʹ ͵ͻ ʹ ʹ ͳ ͳ ͳͳ ʹ ͶͲ ͳͳ ʹ Ͳ ͳ ʹ ͳ ʹ ͳͳͲ ʹ ͷͲ ͳͳͲ ʹͳͲ ͳ ʹ ͳ͵ ʹ ͷͶ ͳ͵ ʹͳͳ ͳ ͵ ͳ ʹ ͷͷ ͳ ͳ ʹʹʹ ʹ Ͷ ͳ ͳͺ ʹ ͷ ͳͲͺͳ ͳͺ ʹʹ ʹǦ ͳ ͷ ʹ ͳͳ ʹ ͶͶͷͲ ͳͳ ʹͻ ͳͲ ͳ ͳͳ ʹ Ͳ ͳͳ ʹͳ ͳͳ ʹ ͷ ʹͳͲ ʹ ͷ ʹͷ ͳʹ ͵ ʹ ͳͺͳ ʹͳͳ ͳ ͳͺͳ ʹ ͳ͵ ͵ͲͲ ʹͷͳ ͳͳ ʹʹʹ ͳ ͳͳ ʹͳ ʹ ͳ ʹʹ ͳʹ ʹʹ ͳʹ ʹͳ ͵ ʹ ʹͷ ͳ͵ ʹͻ ͳ͵ ʹͳ Ͷ ͵͵ͳ ͳ ʹͳ ʹǦ ͳ ͵ͻͳ ͳͳͳ ͳ ͳͳ ʹͷ ͳͳ ͵ͳͳ ͳͳʹ ʹ ͳͳ ʹ ͳͳ ͵ͳ͵ ͳͳ ͺ ͳ ͳʹ ʹͳ ͳʹ ͵ͳ ͳͳͲ ͻ ͳ ʹ ʹ ʹͳ ʹ ͵ʹͷ ͳͳͳ ͳ ͵ ͵ͳ ʹͳ ͵ͳ ͵Ͷͳ ͳͳʹ ʹ ʹ ʹ ͵ʹ ͵ͻͳ ͵ʹ ͵Ͷͳ ͳͳͶ ʹ Ͷ ͳ ͵ͳ ͵ͳͳ ͵ͳ Ͷͳ ͳʹ ͵ ͵ Ͷ ʹ ͵ʹ ͵ͳ͵ ͳͳͳ ͵ʹ ͶͳͲ ͳ͵ ͳ Ͷ ͵͵ ͵ͳ ͳͳʹ ͵͵ Ͷͳʹ ͳͶ ͵ ͳ ͷ Ͷͳ ͵ʹͷ ͳͳ Ͷͳ ͶͳͶ ͳ Ͷ ͷͳ ͵Ͷͳ ͳͳͲ ͷͳ Ͷ͵ʹ ͳ ͷ ͳ ͳ ͵Ͷͳ ͳͳͳ ͳ Ͷͳ ͵ͳ ͳͳ ͳ Ͷͳ ͳͳʹ ͳ ͶͳͶ ͵ʹ ͳ ͳʹ ͺͳ ͶͳͲ ͳͳͶ ͺͳ Ͷͳͺ ͵͵ ʹ ͳ ͳ͵ ͻͳ Ͷͳʹ ͳʹ ͻͳ Ͷ͵ ͵Ͷ ͵ ʹ ͳͶ ͳ ͶͳͶ ͳ͵ Ͷͳ ͵ͷ Ͷ ʹ ͳͷ ͵ Ͷ͵ʹ ͳͶ ͷͳ ͵ ͷ ʹ ͳ Ͷ Ͷͳ ͳ ͳ ͵ ͳ ͷ ͳ ͷ ͶͳͶ ͳ ͳ ͳ ͳ ʹ ͳͺ Ͷͳͺ ͵ͳ ʹ ͺͳ ʹ ͵ ͳͻ Ͷ͵ ͵ʹ ͵ ͳ ʹ Ͷͳ ͵͵ ͳ ͵ ʹ ͺ ʹͲ ͳ ͷͳ ͵Ͷ ͳ ʹ ͵ ͵ ͳ ʹͳ ʹ ͳ ͵ͷ ͵ ʹͶ ͳ Ͷ ͳ ʹʹ ͳ ͵ ʹ ͷ ʹ ʹ͵ ͺͳ ͵ ͳ ͵ ʹͶ ͳ ͳ ʹ ͻ Ͷ ͵ ͳ ͳ ʹ ͷͳ ͳ ͳ Ͷ ͵ ʹ ͵ ͷʹ ͵ ʹ ͳ ͷ ͵ͺ ʹͶ ͵ ͷ͵ Ͷ ͳ ʹ ͵ ͷͶ ͻ ͳ ͳ ͳ ͷ ͳ ͺ ʹ ͳͳ ʹ ͷ ͻ ͷͳ ͳͻͳ ͳ ͳ ͷʹ ͵ ʹ ͳͳ ͳ ʹ ʹ ͷ͵ Ͷ ͳʹ ʹ ͳ ͳ ͳͲ ͷͶ ͻ ͳͳ ʹ ʹ ͳͳ ͷ ʹͳͳ ͳ ͵ ͵ ͳͷ ͳͳ ʹͶͳ ʹ Ͷ ʹͲ ͳͻͳ ʹͳ ͳ ͳ ͷ ͵Ͳ ͳͳ ͳ ʹ ͳ ʹ ʹ ͶͲ ͳʹ ʹ ͳ ʹͳ ͵ Ͳ ͳͳ ʹ ʹͳ ͳ ͳ ʹͳͳ ͳ ͳ ʹͳʹ ͳ ͳ ʹͶͳ ʹ ʹ ʹͶ ͳ ʹ ͳ ʹ ʹͳ ͳ ͵ ʹͷ ʹ ʹ ͳ ʹ ͳ ͵ ʹͳͲ ͵ ͳ ͺ ʹͳ ͳ ͳ ʹͳͻ Ͷ Ǧͳ ʹ ͺ ʹͳ ʹ ʹ ʹͻ ͷ Ǧʹ ͳ ʹͳʹ ͵ ʹ ʹͻ Ǧ͵ ͵ ʹͶ ͳ ͳ ʹ ͵ ǦͶ
ͳͲʹ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
CoA gene set NAD(P)(H) main gene set -continued NAD(P)(H) redox gene set - continued ͳ ͵ ǦͶ ͳ ͳ ʹ Ͷ Ǧͷ ʹ ʹ ͷ ͳ Ǧ ͵ ͳͲ ͳ ͳͳ ͳ ʹ ͺ ͳʹ ͳ ͳ ͳ ͳ͵ ͳ ʹ ʹ ʹ ͳͶ ͳͲ Ǧͳ ͵ ͳ ͳͳ 3 Ǧʹ ͳ ͳʹ ͳʹ Ǧ͵ ʹ ͳͻ ͳ͵ ǦͶ ͵ ͷ ʹ ǦͶ ͵ Ǧͷ ͳ ͺ Ͷ Ǧ ʹ ͻ Ͷʹ ͳ ͵ ͷ ͷ ʹ ͳ ͳ ʹ ͳ ͳ ͷ ʹ ͳ ͳ ͺ ͳ ͳʹ ʹ ͻ ͳ ͵ ͳ ͳ ͳͲ Ͷ ͳͲ ͳͲ ͳͳ ͷ ͳͳ ͳͳ ͳʹ ͳ ʹ ͳʹ ͳ͵ ͳͲ ͵ ͳ͵ ʹ ͳͳ Ͷ ͳͶ ͵ ͳʹ ͷ ͳ Ͷ ͳͶ ͳʹ Ͷʹ ͳ ͷͳ ͳͻ ͷ ʹ ͷʹ ͺ ͷ ͵ ͷ͵ ͻ Ͷ ͳ ͳ ͺ ͺ ʹ ʹ ͻ ͻ ͺ ͵ ͳ ͷ ͳ ͻ Ͷ ʹ ͳͲ ͳ ͵ ͳ ͷ ͳͳ ʹ Ͷ ʹ ʹ ͷ ͵ Ͷ ʹ ͷͳ ͷ ͳ ͺ ͷʹ ͵ ͳ ͷ͵ ͳ ͳ ʹ ͳ ͺ ʹ ͵ ʹ ͻ ͵ ͵ ͳ ͳ ͳ Ͷ ʹ ʹ ʹ ͳ ͳ ͵ ʹ ʹ ʹ ʹ ͳ ͵
Supplementary table ST4: Contributing genes in upregulated metabolic gene sets in the low-fat fed condition TAURINE AND HYPOTAURINE METABOLISM FDR = 0.13 αλ ʹǦ Ǧǣ Ǧ
METABOLISM OF XENOBIOTICS BY CYTOCHROME P450 FDR = 0.25 RR = 1.03 Ͷ Ͷȋ Ȍǡ ͷ Ǧ ǡͷȋ Ȍ ͳ ͳ ʹ ʹ ͶͷͲǡʹǡǡʹ ͳ ͳǡ Ͷ ǦǡͶ ͳ Ǧǡͳ ͷ Ǧǡͷ ͳ Ǧͳ ʹͷ ʹǡͷ εͳǣǡȋȌȋ Ȍ Ǥ
ͳͲ͵ Chapter 3
Supplementary table ST5: Contributing genes in downregulated metabolic gene sets in the low-fat fed condition PYRUVATE METABOLISM FDR = 0.003 RR = 0.90 ǡ ͳ ͳǡ ȋ Ȍ ʹ Ǧ ʹ ʹ ʹǡȋ Ȍ Ǧ ͳͳ ͳǡͳ ʹ ʹǡ Ǧ ȋʹ Ȍ ͳ ͳǡȋΪȌǦǡ Ǧ ͳ ͳͳ FATTY ACID BIOSYNTHESIS FDR = 0.04 RR = 1.00 ͳ ǦǦ ͳ ͷ ǦǦ ͷ Ǧ Ͷ ǦǦ Ͷ Ǧ SULFUR METABOLISM FDR = 0.04 RR = n.a. ʹ ͵̵Ǧͷ̵Ǧʹ ͳ ͳ ͳ ͳ ǡ ǡ HISTIDINE METABOLISM FDR = 0.09 RR = 0.79 Ǧ ͳͳ ͳǡͳ ʹ ʹǡ OTHER TYPES OF O-GLYCAN BIOSYNTHESIS FDR = 0.18 RR = n.a. ͵ ǦǡʹǦͷǦ͵ Ǧ ǦǦ ȋ Ȍ Ǧ ͵ǦǦǦ Ͷ ͳ Ǧ ǣ ͳǡͶǦ ǡͳ ǦǦ ȋ ȌȋǦǦ ǣǦǦ Ȍ ʹ Ǧ ʹ ͳ ǦǦͳ SYNTHESIS AND DEGRADATION OF KETONE BODIES FDR = 0.18 RR = 2.40 ʹ ͵ǦǦ͵ǦǦʹ ͳ ͵Ǧǡͳ ͳ ͵ǦǦ͵ǦǦͳ ʹ Ǧ ʹ ͳ ͵Ǧ ͳ BIOSYNTHESIS OF UNSATURATED FATTY ACIDS FDR = 0.18 RR = 1.88 ͳ Ǧ ͳ ͳ Ǧ ͳ ͳ Ǧͳ ͵ Ǧ͵ Ͷ ǦͶ Ǧ ͳ Ǧͳǡ ͵ Ǧ͵ǡ ʹ ȋ ͳȀʹǡͶȀ͵ǡȌǦʹ ͷ ͷǡ ȋȌ ǡ ȋȌ ͳ ͳ ʹ ʹ ͳͳʹ
ͳͲͶ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
BIOSYNTHESIS OF UNSATURATED FATTY ACIDS - continued ͳ Ǧͳ ʹ Ǧʹ
FATTY ACID METABOLISM FDR = 0.20 RR = 1.08 ͳ Ǧ ͳ ͳ ͳ ͳ ǦǦ ͳ 3 ʹ Ǧ ʹ ͳͳʹ ȋͳǦȌͳʹ ͷ ǦǦ ͷ ǦǡǦ ͳ Ǧͳ ʹ ȋ ͳȀʹǡͶȀ͵ǡȌǦʹ ʹ Ǧʹ Ͷ ǦǦ Ͷ ǡ ȋȌ
GLYCOSPHINGOLIPID BIOSYNTHESIS - LACTO AND NEOLACTO SERIES FDR = 0.21 RR = n.a. ͵ ͵ ǦǦ ǦǦͳǡͶǦ Ǧʹǡ͵Ǧ ʹ Ǧ ǦͳǡǦǦ Ǧ Ͷ ͳ ǦͳǡͶǦ ͳ ͵ ʹ Ǧʹǡ͵Ǧ ͵ ͳ Ǧͳǡ͵Ǧ ͳ TCA FDR = 0.24 RR = 1.08 ʹ ʹǡȋ Ȍ Ǧǡ Ǧ Ǧ ȋʹ Ȍ ͳ ͳͳ εͳǣǡȋȌȋ Ȍ ǤǤǤǣ ǡ ȋȌȋ ȌǤ
Supplementary table ST6: Contributing genes in metabolic gene sets in the high-fat fasted condition METABOLISM OF XENOBIOTICS BY CYTOCHROME P450 FDR = 0.000 RR = 0.97 ͳʹ ͶͷͲǡͳǡǡʹ ʹ Ǧǡʹ ʹ Ǧǡʹȋ ʹȌ ͳ ͳ ʹͷ ʹǡͷ ͵ Ǧǡ͵ ʹ͵ ʹǡ͵ Ͷ Ͷȋ Ȍǡ ʹͳ ͶͷͲǡʹǡǡͳ ͵ Ǧǡ͵ ͳ Ǧǡͳ Ͷ ǦǡͶ ͳ ͳǡ ͵ Ǧ͵ Ǧǡ ͵ Ǧǡ͵ ͳͳͳ ͳͳǦͳ ʹ͵ͷ ʹǡ͵ͷ ͳ Ǧͳ ͷ Ǧ ǡͷȋ Ȍ ͳ Ǧǡͳ DRUG METABOLISM - CYTOCHROME P450 FDR = 0.001 RR = 0.91 ͳʹ ͶͷͲǡͳǡǡʹ ʹ Ǧǡʹ ʹ Ǧǡʹȋ ʹȌ ʹͷ ʹǡͷ ͵ Ǧǡ͵ ʹ͵ ʹǡ͵ ͳ ͳ Ͷ Ͷȋ Ȍǡ Ͷ Ͷ ʹͳ ͶͷͲǡʹǡǡͳ ͵ Ǧǡ͵
ͳͲͷ Chapter 3
DRUG METABOLISM - CYTOCHROME P450 - continued ͳ Ǧǡͳ Ͷ ǦǡͶ ͳ ͳ ͵ Ǧ͵ Ǧǡ ͵ Ǧǡ͵ ʹ͵ͷ ʹǡ͵ͷ ͳ Ǧͳ ͳ Ǧǡͳ GLUTATHIONE METABOLISM FDR = 0.028 RR = 0.50 ͳ Ǧͳ ͳ ǡ ͳ Ǧ ǡ ͳ ͳ Ͷ Ͷ ʹ Ǧǡʹ ʹ Ǧǡʹȋ ʹȌ ͳʹ ͳʹȋ Ȍ ͵ Ǧǡ͵ ʹ ʹȋΪȌǡ Ǧ ͵ Ǧǡ͵ ͳ Ǧǡͳ Ͷ ǦǡͶ ͵ Ǧ͵ Ǧǡ ͵ Ǧǡ͵ ͳ Ǧͳ ͳ Ǧǡͳ OXIDATIVE PHOSPHORYLATION FDR = 0.08 RR = 1.44 ͷͳ ǡ Ϊǡ ͳ ǡͳ ͷ ǡ Ϊ ͳ ǡ ͷ ǡ Ϊǡ ͳ ǡ ͷ ǡ Ϊǡ ͳ ǡ ͷ ͳ ǡ Ϊǡ Ͳ ǡͳ ͷ ͳ ǡ Ϊǡ Ͳ ǡͳȋͻȌ ͷ ǡ Ϊǡ Ͳ ǡ ͷ ǡ Ϊǡ Ͳ ǡ ͷ ʹ ǡ Ϊǡ Ͳ ǡ ʹ ͷ ǡ Ϊǡ Ͳ ǡ Ͳͳ ǡ ΪǡͲͳ Ͳ ǡ ΪǡͲ ͳ ǡ Ϊǡͳ ͳͳ ǡ Ϊǡͳͳ ͳ ǡ Ϊǡͳ ͳͳ ǡ Ϊǡͳͳ ͳ ͳ ǡ Ϊǡͳ ͳ ʹ ʹ ͵ ͵ Ͷ ͳ ͳ ͷ ͳ ͳ ͳ ǡ ͳ ʹ ʹ ͺ ͳ Ǧͳ ͳ Ǧ ͳ ͳ ȋȌͳ ǡͳ ͳͳ ȋȌͳ ͳͳ ͳʹ ȋȌͳ ǡͳʹ ͵ ȋȌͳ ǡ͵ ȋȌͳ ǡȋͳͶȌ ȋȌͳ ǡȋͳͶǤͷȌ ͳͲ ȋȌͳ ǡͳͲ ͳͳ ȋȌͳ ǡͳͳ ȋȌͳ ǡ ͻ ȋȌͳ ǡͻ
ͳͲ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
OXIDATIVE PHOSPHORYLATION - continued ʹ ȋȌͳǡ ǡʹ ͳ ȋȌ Ǧͳ ʹ ȋȌ Ǧʹ ȋȌ Ǧ ȋȌ Ǧ ͺ ȋȌ Ǧͺ ͳ ȋȌͳ ʹ ȋȌʹ ͵ ȋȌ͵ 3 ʹ ȋ Ȍʹ ǡǡȋ Ȍ ͳ ǡͳǡǡ ΪǡͲ͵ ͳͲ Ǧ ǡ ͳͳ Ǧ ǡ Ǧ Ǧ ǡ NADPH_MAIN FDR = 0.08 RR = 1 Ͷ Ͷȋ Ȍǡ ͳͳ Ǧ ͳǡͳȋ Ȍ ͳͳ Ǧ ͳǡͳ ͷ Ǧ ǡͷȋ Ȍ ͳͳ ͳǡͳ ͳͳ ͳǡͳ ͵ʹ ͵ǡʹ Ͷͳ Ͷǡͳ ͳ ǡͳ ͳ ǡͳ ͳǡ ȋ ȋ ȌȌ ͳ ͳ ͳ ǡͳ ǡ ͷ͵ ͷ ͵ ͳͳ ͶͷͲǡͳǡǡͳ ͳʹ ͶͷͲǡͳǡǡʹ ʹʹͻ ͶͷͲǡʹǡ ǡʹͻ ʹ͵ ͶͷͲǡʹǤ ǡ͵ ʹ͵ͺ ͶͷͲǡʹǡ ǡ͵ͺ ʹͷͲ ͶͷͲǡʹǡ ǡͷͲ ʹͷͶ ͶͷͲǡʹǡ ǡͷͶ ʹͳͲ ͶͷͲǡʹǡǡͳͲ ʹʹʹ ͶͷͲǡʹǡǡʹʹ ʹʹ ͶͷͲǡʹǡǡʹ ʹͳ ͶͷͲǡʹǡǡͳ ʹͳ ͶͷͲǡʹǡǡͳ ʹͳ ͶͷͲǡʹǡǡͳ ͵ͻͳ ͶͷͲǡ͵ͻǡǡͳ ͵ͳͳ ͶͷͲǡ͵ǡǡͳͳ ͵ʹͷ ͶͷͲǡ͵ǡǡʹͷ Ͷͳ ͶͷͲǡͶǡǡͳ Ͷ ͳͶ ͶͷͲǡͶǡǡͳͶ Ǧ ͵ Ȁ ȋȌ͵ Ǧ ȋʹ Ȍ ʹ ǦǦ ʹ ͳ Ȁͳ ͵ Ȁ͵ ͳ ͳ Ͷ Ͷ ͳͷȋȌ ͳͳͳ ͳͳǦͳ ͳͶ ȋͳǦȌͶ ͵ͷ ǦǦͷǦǡ͵ǦǦͷ ͵ ǦǦͷǦǡ͵ǦǦ ͳ ͳȋΪȌǡ ʹ ʹȋΪȌǡ ͵ ͵ȋΪȌ ͵ ͵ȋΪȌǡ ͳ ͳǡȋΪȌǦǡ
ͳͲ Chapter 3
NADPH_MAIN - continued ͵ ǡ ͵ ȋΪȌǡ ͳ ǡ ʹ ʹǡ ͳ ͳ ͳͳ ȋȌͳ ͳͳ ͳʹ ȋȌͳ ǡͳʹ ͵ ȋȌͳ ǡ͵ ȋȌͳ ǡȋͳͶȌ ȋȌͳ ǡȋͳͶǤͷȌ ͳͲ ȋȌͳ ǡͳͲ ͳͳ ȋȌͳ ǡͳͳ ȋȌͳ ǡ ͻ ȋȌͳ ǡͻ ʹ ȋȌͳǡ ǡʹ ͳ ȋȌ Ǧͳ ʹ ȋȌ Ǧʹ ȋȌ Ǧ ȋȌ Ǧ ͳ ȋȌͳ ʹ ȋȌʹ ͵ ȋȌ͵ ͳ ͳ ͳ ȋȌ ǡͳ ͳ ȋǦȌǡͳ ͳͲ ȋǦȌǡͳͲ ͳʹ ȋǦȌǡͳʹ Ͷ ȋǦȌǡͶ ͳ ͳͳ ȋȌ ǦʹǦǦ ͳ ͳ ͳ ͳ ʹ ʹ ͵ ͵ ͷͳ ͷǦ ͳ ͷ͵ ͷǦ ͵ ʹ ʹ Ǧʹǡ͵ǦǦ ʹ ʹ ͵ ͵ͷ ͵ ͵ STEROID HORMONE BIOSYNTHESIS FDR = 0.09 RR = 1.5 ͳͳ Ǧ ͳǡͳ ͳͳ ͶͷͲǡͳǡǡͳ ͳʹ ͶͷͲǡͳǡǡʹ ʹʹͻ ͶͷͲǡʹǡ ǡʹͻ ʹ͵ ͶͷͲǡʹǤ ǡ͵ ʹ͵ͺ ͶͷͲǡʹǡ ǡ͵ͺ ʹͷͲ ͶͷͲǡʹǡ ǡͷͲ ʹͷͶ ͶͷͲǡʹǡ ǡͷͶ ʹͺ ͶͷͲǡʹǡ ǡͺ ʹͲ ͶͷͲǡʹǡ ǡͲ ʹͳͲ ͶͷͲǡʹǡǡͳͲ ʹʹʹ ͶͷͲǡʹǡǡʹʹ ʹʹ ͶͷͲǡʹǡǡʹ ʹͳ ͶͷͲǡʹǡǡͳ ͵ͳͳ ͶͷͲǡ͵ǡǡͳͳ ͵ʹͷ ͶͷͲǡ͵ǡǡʹͷ ͳ ͶͷͲǡǡǡͳ ͳͳͳ ͳͳǦͳ ͵ͷ ǦǦͷǦǡ͵ǦǦͷ ͷͳ ͷǦ ͳ ͷ͵ ͷǦ ͵ ʹ͵Ͷ ʹǡ͵Ͷ ʹ͵ͷ ʹǡ͵ͷ ʹ͵ ʹǡ͵ ʹͷ ʹǡͷ
ͳͲͺ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
NADPH_REDOX FDR = 0.09 RR = 1 Ͷ Ͷȋ Ȍǡ ͳͳ Ǧ ͳǡͳȋ Ȍ ͳͳ Ǧ ͳǡͳ ͷ Ǧ ǡͷȋ Ȍ ͳͳ ͳǡͳ ͳͳ ͳǡͳ ͵ʹ ͵ǡʹ 3 Ͷͳ Ͷǡͳ ͳ ǡͳ ͳ ǡͳ ͳǡ ȋ ȋ ȌȌ ͳ ͳ ͳ ǡͳ ǡ ͷ͵ ͷ ͵ ͳͳ ͶͷͲǡͳǡǡͳ ͳʹ ͶͷͲǡͳǡǡʹ ʹͷ ͶͷͲǡʹǡǡͷ ʹʹͻ ͶͷͲǡʹǡ ǡʹͻ ʹ͵ ͶͷͲǡʹǤ ǡ͵ ʹ͵ͺ ͶͷͲǡʹǡ ǡ͵ͺ ʹͷͲ ͶͷͲǡʹǡ ǡͷͲ ʹͷͶ ͶͷͲǡʹǡ ǡͷͶ ʹͲ ͶͷͲǡʹǡ ǡͲ ʹͳͲ ͶͷͲǡʹǡǡͳͲ ʹʹʹ ͶͷͲǡʹǡǡʹʹ ʹʹ ͶͷͲǡʹǡǡʹ ʹͳ ͶͷͲǡʹǡǡͳ ʹͳ ͶͷͲǡʹǡǡͳ ʹͳ ͶͷͲǡʹǡǡͳ ͵ͻͳ ͶͷͲǡ͵ͻǡǡͳ ͵ͳͳ ͶͷͲǡ͵ǡǡͳͳ ͵ʹͷ ͶͷͲǡ͵ǡǡʹͷ Ͷͳ ͶͷͲǡͶǡǡͳ Ͷ ͳͶ ͶͷͲǡͶǡǡͳͶ ͳ ͶͷͲǡǡǡͳ Ǧ Ǧ ͵ Ȁ ȋȌ͵ Ǧ ȋʹ Ȍ ʹ ǦǦ ʹ ͳ ͳ Ͷ Ͷ ͳͷȋȌ ͳͳͳ ͳͳǦͳ ͳͶ ȋͳǦȌͶ ͵ͷ ǦǦͷǦǡ͵ǦǦͷ ͵ ǦǦͷǦǡ͵ǦǦ ͳ ͳȋΪȌǡ ʹ ʹȋΪȌǡ ͵ ͵ȋΪȌ ͵ ͵ȋΪȌǡ ͳ ͳǡȋΪȌǦǡ ͵ ǡ ͵ ȋΪȌǡ ǡ ͳ ͳ ͳ ͳ ȋȌͳ ǡͳ ͳͳ ȋȌͳ ͳͳ ͳʹ ȋȌͳ ǡͳʹ ͵ ȋȌͳ ǡ͵ ȋȌͳ ǡȋͳͶȌ ȋȌͳ ǡȋͳͶǤͷȌ ͳͲ ȋȌͳ ǡͳͲ ͳͳ ȋȌͳ ǡͳͳ ȋȌͳ ǡ ͻ ȋȌͳ ǡͻ ʹ ȋȌͳǡ ǡʹ ͳ ȋȌ Ǧͳ
ͳͲͻ Chapter 3
ʹ ȋȌ Ǧʹ ȋȌ Ǧ ȋȌ Ǧ ͳ ȋȌͳ ʹ ȋȌʹ ͵ ȋȌ͵ ͳ ȋȌ ǡͳ ͳ ͳͳ ȋȌ ǦʹǦǦ ͳ ͳ ͷͳ ͷǦ ͳ ͷ͵ ͷǦ ͵ ʹ ʹ Ǧʹǡ͵ǦǦ ʹ ʹ ͵ ͵ͷ ͵ ͵ Ǧ TAURINE AND HYPOTAURINE METABOLISM FDR = 0.23 RR = 0 ʹǦȋ Ȍȏ ǣ Ǣ ǣ ǣʹͺͷͲͺ͵Ȑ Ǧȏ ǣ Ǣ ǣ ǣͳͻͳͺʹȐ ȏ ǣ Ǣ ǣ ǣʹͳͺͲͲͻͺȐ εͳǣǡȋȌȋ Ȍ Ǥ
Supplementary Table ST7. Gene-set enrichment analysis (GSEA) results for metabolic gene sets for mixed- background MCAD-KO vs WT mice Upregulated gene sets Downregulated gene sets ǡ Pyruvate metabolism ǡ Glycophingolipid biosynthesis – lacto and neolacto series ȋ Ȍ δͲǤʹͷȋȌǤ δͲǤͲͷ Ǥ et al.ȏͳȐǤ Supplementary table ST8: Contributing genes in the upregulated metabolic gene sets in the Chow fasted condition GLYCOSAMINOGLYCAN DEGRADATION FDR = 0.19 RR = λ ͳ ǡͳ ǡ ȋǦ ȌǦǦ ǦǦ Ǧ ǦǦ ȋ Ȍ ʹǦ
PHENYLALANINE, TYROSINE AND TRYPTOPHAN BIOSYNTHESIS FDR = 0.22 RR = n.a. ͳ Ǧ ͳǡ VALINE, LEUCINE AND ISOLEUCINE BIOSYNTHESIS FDR = 0.24 RR = n.a. Ǧ ʹ ʹǡ εͳǣǡȋȌȋ Ȍ ǤǤǤǣ ǡ ȋȌȋ ȌǤ
ͳͳͲ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Supplementary table ST9: Contributing genes in the downregulated metabolic gene sets in the Chow fasted condition PYRUVATE METABOLISM FDR = 0.04 RR = 0.67 ʹ ǦǦ ʹ ͳ Ǧ ͳ Ǧ 3 ͳ ͳǡ ȋ Ȍ ͳ ͳͳ Ǧ Ǧ ͳ ͳǡȋΪȌǦǡ ͳ ͳ ȋȌ GLYCOSPHINGOLIPID BIOSYNTHESIS - LACTO AND NEOLACTO SERIES FDR = 0.04 RR = n.a. ʹ ȋǦ Ȍʹǡ Ǧ ͵ Ͷ Ǧ ǣ Ǧͳǡ͵ǦǦ Ͷ Ͷ ͳ Ǧ ǣ ͳǡͶǦ ǡͳ ͵ Ͷ ͵Ǧ Ǧʹǡ͵ǦͶ ͵ ͵Ǧ Ǧʹǡ͵Ǧ ͵ ͳ Ǧ ǣ ͳǡ͵Ǧ ǡͳ COA_GENE_SET FDR = 0.06 RR = Ǧ ȋʹ ʹǦǦ Ȍ ͳͳ ǡ ͳͳ ͵ ͵ ͵Ͷ ǡͶ ͷ ǡ ͷ ͳͷ ȋȌǦ ͳͷǡ ʹ ȋȌ ʹ ǦǦ ͵ Ǧ͵ ͳͻ ǡ ͳͻ ͵ǦǦ ʹ ʹ ͵ǦǦ͵ǦǦ ͳ ͳ ͳͷ ǡ ͳͷ Ͷ ǦͶ ǦǦ ͳ ͳǦ Ǧ͵ǦǦ ͳȋ ǡȌ ͺ Ǧͺ ʹ ǡ ʹ ʹ ǦǦ ʹ ͳ Ǧ ͳ Ǧǣ Ǧ ǣ ȋ Ȍ ͵ Ǧ͵ ʹ Ǧǡ Ǧǡ ʹ Ǧ ʹȋǦ Ȍ ʹ Ǧ ʹ ͳ ȋ ͳȀʹǡͶȀ͵ǡȌǦͳ ʹͳ ǡ ʹͳ ȋ ȌǦ ͳ ͳͳ ͳ͵ ǡ ͳ͵ ͳ ͳ ʹͷ ʹȋ Ȍǡͷ ͷ ͷǡ ȋȌ ͳ ǡ ͳ ͵Ǧ Ǧǡ ʹ ǡ ʹ ǡ ȋȌ ͳ Ǧ ͳ ͵ ǦǦ ͵ Ǧ
ͳͳͳ Chapter 3
COA_GENE_SET - continued ͻ ͳǦ Ǧ͵ǦǦ ͻ ͳͳ Ǧͳͳ ʹ Ǧ Ǧ ʹ ȋȌ FATTY ACID BIOSYNTHESIS FDR = 0.06 RR = 0.75 ǦǦ ǣ ȋ Ȍ Ǧ Ǧ ͵Ǧ Ǧǡ ͳͲͲͲͳ ͳͻ ͳͲͲͲͳ ͳͻ ͵ ǦǦ ͵ FATTY ACID METABOLISM FDR = 0.09 RR = 1.61 Ǧ ǦǦ ͳ Ǧ ͳ ǣ ȋ Ȍ ͳͳʹ ȋͳǦȌͳʹ ǦʹǦǦ Ǧ ͷ ͷǡ ȋȌ ͵Ǧ Ǧǡ ͳͲͲͲͳ ͳͻ ͳͲͲͲͳ ͳͻ ǡ ȋȌ ͵ ǦǦ ͵ PROPANOATE METABOLISM FDR = 0.16 RR = 0.67 ǡ ʹ Ǧ ʹ Ǧ Ǧ ͳ ͳ ͵ǦǦ ʹ ǦǦ ʹ ͳ Ǧ ͳ ʹ Ǧǡ Ǧǡ Ǧ Ǧ Ǧ CITRATE CYCLE (TCA CYCLE) FDR = 0.23 RR = 0.95 ǡǡȋ Ȍ ͳ ͳ ǡǡȋ Ȍ ͳ ͳȋΪȌǡ ʹ Ǧǡ Ǧǡ Ͷͻ͵͵ͶͲͷʹͲ Ͷͻ͵͵ͶͲͷʹͲ ͳ ͳͳ ȋȌ RETINOL METABOLISM FDR = 0.24 RR = 1.39 ʹͲ ͶͷͲǡʹǡ ǡͲ Ͷͳʹ ͶͷͲǡͶǡǡͳʹ ͳ ͳ ʹͷͷ ͶͷͲǡʹǡ ǡͷͷ ͷ ͷ ͳͷ Ȁ ͳǡͷ ʹͷͲ ͶͷͲǡʹǡ ǡͷͲ ͵ͳͳ ͶͷͲǡ͵ǡǡͳͳ Ͷ Ͷȋ Ȍǡ ͳͳ ͳͳ
ͳͳʹ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
RETINOL METABOLISM - continued ʹ͵ ͶͷͲǡʹǤ ǡ͵ ȋͳ͵ǡͳͶ Ȍ ͳ ͳǡ ͵ Ȁ ȋȌ͵ ʹ͵ͻ ͶͷͲǡʹǡ ǡ͵ͻ ͳͳ ͳǡͳ ʹ͵ ʹǡ͵ ʹͻ ͶͷͲǡʹǡǡͻ ͵ͶͶ ͶͷͲǡ͵ǡǡͶͶ 3 ʹ͵ͺ ͶͷͲǡʹǡ ǡ͵ͺ ʹ͵ͷ ʹǡ͵ͷ ͳͲ ͳͲȋǦȌ ʹͳͲ ͶͷͲǡʹǡǡͳͲ STEROID BIOSYNTHESIS FDR = 0.24 RR = 1.20 ʹͶ ʹͶǦ ʹ ʹ Ǧ ͳ ȋͳǦȌ ȋȌǦ ʹ Ǧ ʹ ͷͳ ͶͷͲǡͷͳ ͺǤ
ͳͳ͵ Chapter 3
Supplementary table ST10: Differentially-expressed metabolic genes LFD Fed KO/WT (metabolic genes) Upregulated Downregulated DeSeq FC Voom FC DeSeq FC Voom FC ͳǤͺ ͳ ʹǤͳ B3galt1 ʹǤ Pde4d ͶǤ͵ ͳǤͺ Zdhhc7 ʹǤͲ Colgalt2 ʹǤͲ ͵ ͶǤʹ Zdhhc7 ͳǤͺ ͳǤͺ Pik3cd ͳǤͺ B3galt1 ͶǤͲ ͳǤ ͳ ͳǤͺ ͵ ʹ ͳǤͺ Pik3c2g ʹǤͶ Soat2 ͳǤ ͳǤ Hlcs ͳǤͺ ͳ ʹǤʹ Nme6 ͳǤ Pld3 ͳǤ Extl1 ͳǤͺ ͳǤͻ ͳǤ Ͷ ͳǤ ͻͳ͵ͲͶͲͻ ʹ͵ ͳǤͺ ͳǤͻ ͳͶ ͳǤ ͳǤ Ͷͳ ͳǤ Ͷ ͳǤͺ ͳǤ ͳǤ ͳ ͳǤ Ͷ ͳǤͺ Ͷ ͳǤ ͳǤ ͳǤ ͳ ͳǤͺ ͳ ͳǤ ʹ ͳǤͷ ͳ ͳǤ ͳǤͺ Ͷ ͳǤͷ ͳ ͳǤͷ ͳǤ ͳǤ ͳǤͷ ʹ ͳǤͷ ͵ ͳǤ ʹ ͳǤ ͳǤͷ ͳǤͷ ͷ ͳǤ ͵ ͳǤ ͳ ͳǤͷ ʹ ͳǤͷ ͵ ͳǤ ʹ ͳǤ Ampd2 ͳǤͷ ͳ ͳǤͷ ͳǤ ͳ ͳǤ Dcxr ͳǤͷ ʹ ͵ ͳǤͷ ͳ ͳǤ ͳǤ ͳǤͷ ͳ ͳǤͶ Ͷ ͳǤ ͵ ͳǤ ͳǤͷ ͳǤͶ ͳǤ ͳͳ ͳǤ ͳǤͶ ʹ ͳǤͶ Ͳʹ ͳǤ ͳǤͷ ʹ ͳǤͶ ͳ ͳǤͶ ͳǤ ͳǤͷ ͳ ͳǤͶ ͳǤͶ ʹ͵ ͳǤ ͳǤͷ ͳ ͳǤͶ ͳǤ͵ ʹͶ ͳǤͷ ͳǤͷ ʹ ͳǤͶ ͳǤ͵ ͳǤͷ ͵ ͳǤͷ ʹ ͵ ͳǤͶ ͳ ͳǤ͵ ͵ ͳǤͷ ʹͶ ͳǤͶ ͳǤͶ Fnta ͳǤ͵ ͳ ͳǤͷ ʹ ͳǤͶ ͳ ͳǤͶ ͳ ͳǤ͵ ͳ ͳǤͷ Ͷ ͳǤͶ ͳǤͶ Rpn2 ͳǤ͵ ͵ ͳǤͷ ͳ ͳǤͶ ͳǤͶ ͳǤ͵ ʹʹ ͳǤͷ ʹ ͳǤͶ Sgpl1 ͳǤͶ ʹ ͶͶ ͳǤ͵ ͳ ͳǤͷ ND5 ͳǤ͵ Rpn2 ͳǤ͵ ͳ ͳǤʹ ʹ ͳǤͷ ͳͳ ͳǤ͵ ͳǤ͵ ͳͻ ͳǤʹ ͳǤͷ ʹ ͳǤ͵ Vkorc1 ͳǤ͵ ͳǤʹ ͳǤͷ ͳ ͳǤʹ ʹ ͳǤ͵ ͳǤʹ ʹ ͳǤͷ ͳ ͳǤʹ ʹʹ ͳǤ͵ ͳ ͳǤʹ ͳǤͷ ʹ ͶͶ ͳǤ͵ Ͷ ͳǤͷ ͳǤ͵ ͵ͷ ͳǤͶ ͳͳ ͳǤ͵ ʹ ͳǤͶ ͳ ͳǤ͵ ͳͳ ͳǤͶ ͳͻ ͳǤ͵ Ǧʹ ͳǤ͵ ͳ ͳǤʹ ʹ ͳǤ͵ ͳͳ ͳǤ͵ mt-Nd5 ͳǤ͵
HFD Fed KO/WT (metabolic genes) Upregulated Downregulated DeSeq FC Voom FC DeSeq FC Voom FC ʹ͵ͺ ͳǤͻ ʹ͵ͺ ͶǤͲ Acnat2 ʹǤͶ ͶͳͶ ͵Ǥ Cyp4a12b ͳǤͺ Cyp4a12b ͳǤͻ ͳ ͳǤͺ ʹ ͵Ǥͳ Ͷ ͳǤͺ ͵ ͳǤͻ ͺ ͳǤ Cyp2c38 ͳǤͺ ͳǤ ͳ ͳǤͺ Cyp2b9 ͳǤ ͵ͷ ͳǤ ͳǤ ͵ͷ ͳǤͺ ͵ͻͳ ͳǤ ͳͷ ͳǤ ͳͳͲ ͳǤ ͳǤ ͳ ͳǤ ͵ ͳǤ ͵ ͳǤ ͺ ͳǤ ͳǤͷ ͳ ͳǤͷ ʹ ͳǤ ͵ ͳǤ ͳͷ ͳǤͷ ͳ ͳǤͷ ͳ ͳǤ ʹ ͳǤ ͳ ͳǤͷ Acox3 ͳǤͷ ͵ ͳǤ Ͷ ͳǤͷ ͵ ͳǤͷ ʹ ͳǤͶ ͳ ͳǤ ͵ ͳǤͷ Nnt ͳǤͷ ͳǤͶ Ͷ ͳǤͷ ͳǤͷ ͳǤͷ ͳ ͳǤͶ Rev3l ͳǤͷ ͳǤͷ ʹ ͵ͺ ͳǤͷ ͳǤ͵ ͵ʹ ͳǤͷ ͳǤͶ ͳǤͶ ͷͳ ͳǤʹ ͵ͷ ͳǤͷ ͳ ͳǤͶ ͳ ͳǤͶ ʹ ͳǤʹ ʹ ͳǤͷ Gba ͳǤͶ ͵Ͷ ͳǤͶ ͳǤͷ ͳǤ͵ ͳǤͶ ͳǤͷ ͳͳ ͳǤʹ ͵ ͳǤͶ Dctpp1 ͳǤͷ ͳ ͳǤ͵ ͳ ͳǤͷ ͷͳ ͳǤʹ
ͳͳͶ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
HFD Fed KO/WT (metabolic genes) - continued Upregulated DeSeq FC ͳ ͳǤͷ ʹ ͳǤͷ ͳ ͳǤͷ ͳ ͳǤͶ ͳǤͶ ͻ ͳǤͶ ͳǤ͵ 3 ͷ ͳǤ͵ ͳǤ͵ ͳǤʹ
Low-fat fasted KO/WT Upregulated Downregulated DeSeq FC Voom FC DeSeq FC Voom FC Akr1b7 ʹǤͲ ͵ʹ ʹǤʹ Naa40 ʹǤͲ Naa40 ʹǤ Cerk ʹǤͲ ʹǤʹ Ocrl ͳǤͺ Zdhhc17 ʹǤ Entpd2 ͳǤͻ ͷ ʹǤͲ Zdhhc17 ͳǤͺ ʹǤͳ Npr1 ͳǤͻ ʹ ʹǤͲ ͳǤͺ ʹǤͳ ͳǤͺ ͵ͳ ͳǤͺ ͺ ͳǤͺ ͳ͵ ʹǤͳ Acaa1b ͳǤͺ ͳ ͳǤ Cdyl ͳǤͺ ʹǤͲ ʹ ͳǤͺ ͳǤ Pde4b ͳǤ Cdyl ʹǤͲ Chsy1 ͳǤ Ͷ ͳǤ ͳ͵ ͳǤ ʹǤͲ Csad ͳǤ ͷ ͳǤ Pnpt1 ͳǤ Pde4b ͳǤͻ ͳǤ ͳ ͳǤ ͳǤ ͵͵ͳ ͳǤͻ ͳ ͳǤ ʹ ͳǤ ʹ ͳǤ ͳǤͻ ͵ ͳǤ ͳ ͳǤ ͷ ͳǤ ʹ ͳǤͺ ͵ ͳǤ Hsd17b11 ͳǤ ͳ ͳǤ ͳǤͺ ͷ ͳǤ ͳ ͳǤ ʹ ͳǤ Acyp1 ͳǤͺ Cyp21a1 ͳǤ ͳǤ Ͷ ͳǤ ͳǤͺ ͳͺ ͳǤ ʹ ͳǤͷ ͳǤ Pnpt1 ͳǤͺ Hsd17b11 ͳǤ ͳǤͷ ͳ ͳ ͳǤͷ Nt5m ͳǤͺ ͵ ͳǤ ͳǤͷ ͳ ͳǤͷ ͷ ͳǤͺ Ndufab1 ͳǤ ͳǤͷ ͳ ͳǤͷ ͳǤ ͳͳͲ ͳǤ Gda ͳǤͶ ʹ ͳǤͷ ʹ ͳǤ ͳͳ ͳǤͷ Urod ͳǤͶ ͵ ͳǤͷ ͳǤ ͳ ͳǤͷ ͵ ͳǤͶ ʹ ͳǤͷ ʹ ͳǤ ͳǤͷ ͳ ͳǤͶ ͳ ͳǤͷ ͳǤ ͳͳ ͳǤͷ ͳ ͳǤͶ ʹ ͳǤͷ ͺ ͳǤ Ndufa5 ͳǤͷ Crebbp ͳǤ͵ ͳǤͷ ͳ ͳǤ ͳǤͷ ʹ ͳǤ͵ Ͷ ͳǤͷ ͳ ͳǤ ͳǤͷ ͳ ͳǤ͵ ͳ ͳǤͷ Aldh1b1 ͳǤ ͵ ͳǤͶ ͳǤ͵ Aldh1b1 ͳǤͷ ͳǤ ͳ ͳǤͶ ͵ ͳǤ͵ ͷ ͳǤͶ ͳǤ ʹ ͳǤͶ ͳʹ ͳǤʹ ͳǤͶ ͳ ͳǤ ͳǤͶ ͳǤʹ ͳ ͳǤͶ Zdhhc5 ͳǤ ͳǤͶ ͳǤʹ ͵ ͳǤͶ Ͷ ͳǤ ͳǤͶ ͳǤʹ ͳ ͳǤͶ ʹ ͳǤ Crebbp ͳǤͶ ʹ ͳǤʹ ͳǤͶ ͳ ͳǤ ͳ ͳǤͶ ͳǤͶ Ͷͳ ͳǤͷ ͳǤͶ ͳ ͳǤͶ ͵͵ͳ ͳǤͷ Ndufv3 ͳǤͶ Ͷ ͳǤͶ ͳǤͷ ͵ ͳǤͶ ͶͳͶ ͳǤͶ ͳ ͳǤͷ ͳǤͶ ͳ ͳǤͶ ͳ ͳǤͷ ͳ ͳǤ͵ Ͷʹ ͳǤ͵ ͳǤͷ ͳǤ͵ ͳ ͳǤ͵ Ͷ ͳǤͷ ͳǤ͵ ͳǤ͵ Dnmt3a ͳǤͷ ʹ ͳǤ͵ Hsd3b7 ͳǤ͵ ͳǤͷ ͳǤ͵ ͳǤʹ ʹ ͳǤͷ ͵ ͳǤ͵ ͳ ͳǤʹ ʹ ͳǤͷ Ͳ ͳǤ͵ ͷ ͳǤͶ ͷ ͳǤ͵ ͳ ͳǤͶ ͳͳ ͳǤ͵ ʹ ͳǤͶ ʹ ͳǤ͵ ͳǤͶ ͳǤ͵ ͳ ͳǤ͵ ͳ ͳǤ͵ ͳǤ͵ ͳͳ ͳǤʹ ͵ͳ ͳǤ͵ ͳ͵ ͳǤʹ ͳ ͳǤ͵ ǦͶ ͳǤʹ ͳ ͳǤ͵
ͳͳͷ Chapter 3
Low-fat fasted KO/WT - continued Upregulated Downregulated DeSeq FC Voom FC DeSeq FC Voom FC ͳǤʹ ͵ ͳǤ͵ ʹ ͳǤʹ ͳ ͳǤʹ ʹ ͳǤʹ
High-fat fasted KO/WT Upregulated Downregulated DeSeq FC Voom FC DeSeq FC Voom FC Pip4k2a ͳǤͻ Ͷʹ ͳǤͻ Npr1 ʹǤͲ Rce1 ʹǤʹ Hexdc ͳǤͻ ʹ ͳǤͺ ͳ ͳǤͺ Cyp2c38 ͳǤͺ Ͷ ͳǤ Ͷͳʹ ͳǤͺ Cyp2c38 ͳǤ ͳ ͳǤ Steap4 ͳǤ ͵ͳ ͳǤͺ Cndp2 ͳǤ Gstm1 ͳǤ Acer2 ͳǤ Ͷͳʹ ͳǤͺ ʹ ͵ͻ ͳǤ ͳ ͳǤͷ Ͷ͵ͳ ͳǤ Ͷ ͳǤ ʹͳ ͳǤ ͳ ͳǤͷ Ͷͳʹ ͳǤ Ahcy ͳǤ ͳͶ ͳǤ ͳǤͷ ͵ ͳǤ ʹ ͳǤ ʹͶ ͳǤ ʹ ͳǤͷ Ͷ ͳǤ ʹ ͳǤͷ Gstm1 ͳǤ ʹ ͳǤͷ ͵ͳ ͳǤ ͳ ͳǤͷ ͳǤ ͵ ͳǤͷ ͳǤͷ ͵ ͳǤͶ ʹ ͳǤͷ ʹ ͳǤͶ ͳǤͷ ͵ͳ͵ ͳǤͶ ͳ ͳǤͷ ͳǤͶ ͳǤͷ ͳǤ͵ Ͷ ͳǤͷ Adi1 ͳǤͶ ʹ ͳǤͷ ͳǤ͵ ͵ ͳǤͷ ʹ ͳǤͶ Ͷͳʹ ͳǤͷ ʹͳʹ ͳǤ͵ ʹ ͳǤͷ ʹ ͳǤͶ ͵ͷ ͳǤͷ ͵ ʹ ͳǤ͵ ͳǤͷ ʹ ͳǤͶ ͳǤͶ ͳǤʹ ʹ ͺ ͳǤͷ ͵ ͳǤͶ ͷ ͳǤͶ ͶͶ ͳǤͷ Akr7a5 ͳǤ͵ ͳǤͶ ͳǤͶ ͳǤ͵ Cyp3a13 ͳǤͶ ʹͳͷ ͳǤͶ ͳǤ͵ ͵Ͷ ͳǤͶ ͳ ͳǤͶ ʹ͵ͷ ͳǤ͵ ͵ ͳǤͶ ʹ ͳǤͶ ͳ ͳǤ͵ ʹʹ ͳǤ͵ ʹ ͳǤͶ ʹ ͳǤ͵ ͷ ͳ ͳǤ͵ Adi1 ͳǤͶ ʹ ͳǤ͵ ʹͳʹ ͳǤ͵ ͳǤͶ ͵ ͳǤʹ ʹ ͳǤ͵ ʹͳͲ ͳǤʹ ͷ ͳǤ͵ ͳ ͳǤʹ ͳ ͳǤ͵ ʹͳͲ ͳǤ͵ ʹ ͳǤ͵ ʹ ͳǤ͵ ͳ ͳǤʹ ͵ ͳǤʹ ǣǢǣȋȌȋ Ȍȋ ȌǢ ǣ ǢǣǦǢǣδͲǤͲͳǤ Ǥ
ͳͳ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Supplementary table ST11: Metabolic gene sets ranked according to the percentage of genes they contain that fit the “(abs(log2(fold change))>0.5 AND p<0.1) OR p<0.05”criteria Gene set with upregulated genes LF Fa HF Fa LF Fe HF Fe ȋȌȋ Ȍ ͳ ͳ ʹ ͳ ȋȌȋ Ȍ ʹ ͳ ʹ ʹ Ͷ ͻͲ ͳ ʹ ͵ Ͷ ͵ ʹ ͻͲ ͳ ͳͲ ͷ ʹʹ ͳͲ ͷ 3 ͳͲ ͻͲ ͷ ͻ ͳͲ ͳͲ ͷ ͻ ͳͲ ͻͲ ͷ ͳͶ ͻͲ ͷ Ȁ ͳͶ ͳͲ ͳͻ ͷ ͳͶ ͳͲ ͻͲ ͻ Ͷ ͻͲ ͳ ͻͲ ͳͲ ͳ ͷ ͳͲ ͳͻ ͳ ͻͲ Ͷ ͳͲ ͳ ʹʹ ͳͲ ͳͲ ͳ ʹʹ ͳͲ ͳͻ ͷ ʹʹ ͳͲ ͳͻ ͷ ͳͶ ͳͻ ͻͲ ͻͲ ͳͲ ͳͻ ͳ ʹʹ ͻͲ ͵ ͳ Ǧ ʹʹ ͻͲ ͳͻ ͳ ͻͲ ͳͲ ͳͲ ͻͲ ͳͶ ͻͲ ͻͲ ͳ ͻͲ ͻͲ ͳ ͻͲ ͳͲ ͻͲ ͳ ͻ ͻͲ ͻͲ ͳ ͻͲ ͳͲ ͻͲ ͳ Ǧ ͻͲ ͳͲ ͻͲ ͳ ͳͶ ͻͲ ͻͲ ͳ ͻ ͻͲ ͻͲ ͳ ͻͲ ͻͲ ͳͻ ͳ Ǧ ͻͲ ͳͲ ͳͻ ͻͲ Ǧ ͻͲ ͻͲ ͳͻ ͷ ͻͲ ͻͲ ͳͻ ͳ ǡ ʹʹ ͻͲ ͳͻ ͻͲ ʹʹ ͻͲ ͳͻ ͻͲ ʹʹ ͻͲ ͻͲ ͳ ʹʹ ͻͲ ͻͲ Ǧ Ȁ ʹʹ ͻͲ ͳͻ ͻͲ ȋ ȌǦ ʹʹ ͻͲ ͳͻ ͻͲ ʹʹ ͻͲ ͻͲ ͳ ͶͷͲ ʹʹ ͻͲ ͳͲ ͻͲ Ǧ ͶͷͲ ʹʹ ͻͲ ͳͻ ͻͲ ȋ Ȍ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͳͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͳͻ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ Ǧ ͻͲ ͻͲ ͳͻ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ǡ ͻͲ ͻͲ ͳͲ ͻͲ ǡ ͳͶ ͻͲ ͻͲ ͻͲ ǡ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͳͶ ͻͲ ͻͲ ͻͲ ͻͲ ͳͲ ͻͲ ͻͲ ǡ ͻͲ ͻͲ ͻͲ ͻͲ Ǧ Ǧ ͻͲ ͻͲ ͻͲ ͻͲ ǦǦ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͷ Ǧ ͻͲ ͻͲ ͳͻ ͻͲ ͻͲ ͻͲ ͻͲ ͳ ͻͲ ͳͲ ͻͲ ͻͲ Ǧ ͻͲ ͻͲ ͻͲ ͳ ǦȀ ͻͲ ͻͲ ͻͲ ͻͲ Ǧ ʹʹ ͻͲ ͻͲ ͻͲ Ǧ ͻͲ ͻͲ ͻͲ
ͳͳ Chapter 3
Gene set with upregulated genes - continued LF Fa HF Fa LF Fe HF Fe Ǧ ͻͲ ͻͲ ͻͲ ͳ ʹʹ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͳ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ʹʹ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͳ Ǧ ͻͲ ͻͲ ͻͲ ͻͲ ʹǦ ͻͲ ͻͲ ͻͲ ͻͲ
Gene set with downregulated genes LFD Fa HFD Fa LFD Fe HFD Fe ȋȌȋ Ȍ ͵ ͳ ͳ ͳ ȋȌȋ Ȍ ͷ ͳ ʹ ͳ ʹ Ͷ ͵ ͳͲ ͵ Ͷ ͳ ͳͳ Ͷ ͳͺ Ͷ ͵ ͻͲ ͵ ͳʹ ͳͲ ͻͲ ǡ ͳͲ ͻͲ ͳͳ Ͷ ͻͲ ͳͺ Ͷ Ͷ Ȁ ͳͲ ͳͷ ͳͳ ͳʹ ͻͲ ͵ ͳͳ ͳʹ ͳ ͳͳ ͳʹ Ǧ ͻͲ ͳͷ ͳͳ ͳʹ ͳ ͻͲ ͳͳ Ͷ Ǧ ͶͷͲ ͳ ͳͳ ͻͲ ͻͲ ͳͺ ͳͳ ͳʹ ǡ ͳ ͳͺ ͳͳ ͻͲ ͳ ͳͺ ͳͳ ͻͲ ͳ ͳͺ ͻͲ ͳ ͳͺ ͳͳ ͻͲ ͳ ͳͺ ͳͳ ͻͲ Ǧ ͳ ͳͺ ͵ ͳʹ ͻͲ ͵ ͵ Ͷ ͻͲ ͵ Ͷ ͳ ͳͷ ͵ ͻͲ ͳ ͻͲ ͵ ͳʹ ͶͷͲ ͳ ͵ ͵ ͻͲ ͻͲ ͳͺ ͵ ͳʹ Ǧ ͳ ͳͺ ͵ ͻͲ ͻͲ ͻͲ ͷ ͻͲ ͻͲ ͳͲ ͻͲ ͳͳ ͻͲ ͻͲ ͻͲ ͳͳ ͳʹ ͻͲ ͻͲ ͳͳ ͳʹ ͳ ͻͲ ͳͳ ͻͲ ͳ ͻͲ ͳͳ ͻͲ ͳ ͻͲ ͳͳ ͻͲ ͳ ͻͲ ͳͳ ͻͲ ͳ ͻͲ ͳͳ ͻͲ ͻͲ ͳͺ ͻͲ ͳʹ Ǧ ͻͲ ͳͺ ͳͳ ͻͲ ͻͲ ͳͺ ͳͳ ͻͲ ͻͲ ͳͺ ͻͲ ͳʹ ͻͲ ͵ ͻͲ ͻͲ ͳͺ ͵ ͻͲ ͻͲ ͻͲ ͵ ͳʹ ǡ ͻͲ ͳͺ ͵ ͻͲ Ǧ ͳͲ ͻͲ ͵ ͻͲ ͳ ͻͲ ͵ ͻͲ ͻͲ ͻͲ ͵ ͳʹ ͻͲ ͻͲ ͵ ͳʹ
ͳͳͺ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Gene set with downregulated genes - continued LFD Fa HFD Fa LFD Fe HFD Fe ͻͲ ͳͺ ͵ ͻͲ ȋ Ȍ ͻͲ ͻͲ ͻͲ ͳʹ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͵ ͻͲ ͻͲ ͳͺ ͻͲ ͻͲ Ǧ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͳʹ ǡ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ 3 ͻͲ ͻͲ ͵ ͻͲ ͻͲ ͻͲ ͵ ͻͲ ǡ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͳͺ ͻͲ ͻͲ Ǧ Ǧ ͻͲ ͻͲ ͻͲ ͻͲ ǦǦ ͻͲ ͻͲ ͻͲ ͻͲ Ǧ ͳͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͳͳ ͻͲ Ǧ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͵ ͻͲ Ǧ Ȁ ͻͲ ͳͺ ͻͲ ͻͲ Ǧ ͻͲ ͳͺ ͻͲ ͻͲ ǦȀ ͻͲ ͻͲ ͵ ͻͲ ȋ ȌǦ ͻͲ ͻͲ ͻͲ ͳʹ Ǧ ͻͲ ͻͲ ͻͲ ͻͲ Ǧ ͻͲ ͻͲ ͳͳ ͻͲ ͻͲ ͳͺ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͳͺ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ʹǦ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ ͻͲ Ǥ ǣ Ǥ αǦǡ α Ǧǡ α ǡ α
Supplementary table ST12: Risk ratios of the ranked metabolic gene sets in ST11 Gene set with upregulated genes LF Fa HF Fa LF Fe HF Fe ȋȌȋ Ȍ ͳǤ ͳǤͲ ͲǤ ͳǤͲ ȋȌȋ Ȍ ͳǤͺ ͳǤʹ ͲǤͺ ͲǤ ͳǤ ͲǤͲ ͳǤͺ ͳǤͲ ͳǤ ͳǤͳ ͲǤͻ ͲǤͻ ͲǤͲ ͶǤͶ ͳǤͲ ͳǤͶ ͲǤͶ ͲǤͻ ͳǤ ͳǤͶ ʹǤͶ ͳǤ͵ ͲǤͲ ʹǤʹ ͵ǤͲ ʹǤʹ ʹǤ ͵Ǥ ͵Ǥ͵ ʹǤͶ ͲǤͲ ͶǤͳ ͲǤ ͲǤͲ ͳǤ͵ ͳǤʹ Ȁ ͳǤͲ ͳǤͳ ͲǤ ͳǤͻ ͳǤͶ ͵Ǥʹ ͳǤͻ ͲǤͲ ʹǤʹ ͶǤͻ ͲǤͲ ͳǤ͵ ͷǤʹ ͲǤͲ ʹǤ ͳǤͺ ʹǤͳ ͲǤ ͲǤ͵ ͲǤͷ ͲǤͲ ʹǤ ͳǤͲ ͲǤ ͲǤͶ ͳǤͲ ͳǤʹ ͲǤͺ ͲǤ͵ ͲǤͺ ͲǤͷ ͳǤ͵ ͲǤ͵ ͲǤ ͲǤͶ ͳǤͳ ͳǤͲ ʹǤʹ ͲǤ ͲǤͲ ͲǤͲ ͳǤͷ ͲǤͻ ͳǤ͵ ͲǤ ͲǤͲ ͶǤͲ ͳǤ͵ Ǧ ͳǤͲ ͲǤͲ ͳǤͶ ʹǤͲ ͲǤͲ ͳǤͷ ͳǤͻ ͲǤͲ ʹǤ ͲǤͲ ͲǤͲ ʹǤͶ ͲǤͲ ͲǤͲ ͵ǤͲ ͳǤ͵ ͲǤͲ ͵Ǥͳ ͲǤͲ ʹǤ
ͳͳͻ Chapter 3
Gene set with upregulated genes - continued LF Fa HF Fa LF Fe HF Fe ͶǤͻ ͲǤͲ ͲǤͲ ʹǤͺ ͲǤͲ ͶǤ͵ ͲǤͲ ͵Ǥ Ǧ ͲǤͲ ͷǤ͵ ͲǤͲ ͶǤͶ ʹǤͷ ͲǤͲ ͲǤͲ ʹǤ͵ ʹǤͲ ͲǤͲ ͲǤͲ ͳǤʹ ͲǤͲ ͲǤͲ ͲǤͻ ͳǤʹ Ǧ ͲǤͲ ͳǤͷ ͲǤͻ ͲǤͲ Ǧ ͲǤͲ ͲǤͲ ͳǤ ͶǤ ͲǤͲ ͲǤͲ ͳǤͲ ͳǤͶ ǡ ͲǤͺ ͲǤͲ ͳǤͳ ͲǤͲ ͵Ǥʹ ͲǤͲ ͶǤͷ ͲǤͲ ʹǤͲ ͲǤͲ ͲǤͲ ͵Ǥͺ ͲǤ ͲǤͲ ʹǤͷ ͲǤͲ Ǧ Ȁ ͳǤ ͲǤͲ ʹǤ͵ ͲǤͲ ȋ ȌǦ ͳǤ͵ ͲǤͲ ͳǤͻ ͲǤͲ ͳǤͲ ͲǤͲ ͲǤͲ ͳǤͺ ͶͷͲ ͲǤͷ ͲǤͲ ͳǤͶ ͲǤͲ Ǧ ͶͷͲ ͲǤͷ ͲǤͲ ͲǤ ͲǤͲ ȋ Ȍ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ʹǤͶ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ʹǤͷ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ Ǧ ͲǤͲ ͲǤͲ ͶǤͷ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ǡ ͲǤͲ ͲǤͲ ʹǤͷ ͲǤͲ ǡ ͳǤʹ ͲǤͲ ͲǤͲ ͲǤͲ ǡ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͳǤͺ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͳǤ ͲǤͲ ͲǤͲ ǡ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ Ǧ Ǧ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ǦǦ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ʹǤͶ Ǧ ͲǤͲ ͲǤͲ ͳǤͷ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͳͷǤ͵ ͲǤͲ ͵Ǥ ͲǤͲ ͲǤͲ Ǧ ͲǤͲ ͲǤͲ ͲǤͲ ͶǤͶ ǦȀ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ Ǧ ͳǤ͵ ͲǤͲ ͲǤͲ ͲǤͲ Ǧ ͲǤͲ Ǥͳ ͲǤͲ ͲǤͲ Ǧ ͲǤͲ ͲǤͲ ͲǤͲ ͶǤͶ ͲǤͻ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ʹǤͶ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ʹǤ ͲǤͲ ͲǤͲ ͲǤͲ ͵Ǥͷ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ Ǥͳ Ǧ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ʹǦ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ
Gene set with downregulated genes LF Fa HF Fa LF Fe HF Fe ȋȌȋ Ȍ ͲǤ ͳǤͳ ͳǤͲ ͳǤ ȋȌȋ Ȍ ͲǤͷ ͳǤʹ ͲǤͺ ͳǤͺ ͳǤͻ ͲǤͻ ͲǤͻ ͳǤͶ ͲǤͻ ʹǤ ͳǤͷ ʹǤͳ
ͳʹͲ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
Gene set with downregulated genes LF Fa HF Fa LF Fe HF Fe ʹǤͶ ͲǤͻ ͲǤͷ ͳǤͲ ͵Ǥͷ ͳǤͷ ͵Ǥ ͷǤͳ ͵Ǥͳ ͲǤͲ ͵Ǥ͵ ͳǤ͵ ͲǤͻ ͳǤͺ ͳǤͶ ͲǤͲ ǡ ʹǤ͵ ͲǤͲ ʹǤͶ ͷǤ͵ ͲǤͲ ͳǤͳ ͵Ǥ ͵Ǥͺ Ȁ ͳǤ͵ ͳǤ ͳǤ͵ ͳǤͶ ͲǤͲ ͶǤͺ ͳǤͺ ͳǤͻ 3 ͲǤ͵ ͳǤͷ ͲǤ ͲǤͺ Ǧ ͲǤͲ ͶǤ ͵Ǥͷ ͵Ǥ ͲǤͻ ͲǤͲ ͳǤͺ ͶǤͲ Ǧ ͶͷͲ ͲǤ ʹǤ ͳǤ͵ ͲǤͲ ͲǤͲ ͳǤʹ ͳǤͺ ʹǤͲ ǡ ͲǤͺ ͳǤͲ ͳǤ ͲǤͲ ͲǤͺ ͳǤͳ ͳǤͺ ͲǤͲ ͳǤ ʹǤ͵ ͷǤͺ ͲǤͲ ͲǤͺ ͳǤͲ ͳǤ ͲǤͲ ͲǤͻ ͳǤ͵ ʹǤͲ ͲǤͲ Ǧ ͲǤͺ ͳǤͳ ͲǤͺ ͳǤͺ ͲǤͲ ʹǤ ͲǤͷ ʹǤʹ ͲǤͲ ͳǤͻ ͲǤͷ ʹǤͳ ͲǤ ʹǤͲ ͲǤͺ ͲǤͲ ͳǤͲ ͲǤͲ ͳǤͳ ʹǤ͵ ͶͷͲ ͲǤ ͵Ǥ ͲǤ ͲǤͲ ͲǤͲ ͲǤͶ ͲǤ͵ ͲǤ Ǧ ͳǤ͵ ͳǤͺ ͳǤͶ ͲǤͲ ʹǤͶ ͲǤͲ ʹǤͷ ͲǤͲ ͳǤ ͳǤ ͲǤͲ ͲǤͲ ͳǤ ͲǤͲ ͳǤͺ ͲǤͲ ͲǤͲ ͲǤͲ Ǥͳ Ǥͳ ͲǤͲ ͲǤͲ ͵Ǥ͵ ͵ǤͶ ͳǤʹ ͲǤͲ ʹǤͷ ͲǤͲ ͳǤ͵ ͲǤͲ ʹǤͺ ͲǤͲ ͳǤ ͲǤͲ ͵ǤͶ ͲǤͲ ͲǤͻ ͲǤͲ ͳǤͻ ͲǤͲ ͲǤ ͲǤͲ ͳǤͷ ͲǤͲ ͲǤͲ ͳǤʹ ͲǤͲ ʹǤͲ Ǧ ͲǤͲ ʹǤ͵ ͵Ǥ ͲǤͲ ͲǤͲ ͳǤͻ ͵ǤͲ ͲǤͲ ͲǤͲ ͵Ǥͳ ͲǤͲ ͷǤͳ ͵Ǥͺ ͲǤͲ ͳǤʹ ͲǤͲ ͲǤͲ ʹǤͳ ͳǤ ͲǤͲ ͲǤͲ ͲǤͲ ʹǤͺ Ǥʹ ǡ ͲǤͲ ͳǤͶ ͳǤͳ ͲǤͲ Ǧ ʹǤͺ ͲǤͲ ͳǤͶ ͲǤͲ ͳͲǤͳ ͲǤͲ ͳͲǤ ͲǤͲ ͲǤͲ ͲǤͲ ͳǤ ͵Ǥ ͲǤͲ ͲǤͲ ͳǤʹ ʹǤ ͲǤͲ ʹǤͷ ͳǤͻ ͲǤͲ ȋ Ȍ ͲǤͲ ͲǤͲ ͲǤͲ ͵ǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͶǤʹ ͲǤͲ ͲǤͲ ͵Ǥͳ ͲǤͲ ͲǤͲ Ǧ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͳͺǤͷ ǡ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͳǤͳ ͲǤͲ ͲǤͲ ͲǤͲ ͳǤͻ ͲǤͲ ǡ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͵Ǥͷ ͲǤͲ ͲǤͲ Ǧ Ǧ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ǦǦ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ Ǧ ͳǤ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͷǤ͵ ͲǤͲ Ǧ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ʹǤͳ ͲǤͲ Ǧ Ȁ ͲǤͲ ʹǤͻ ͲǤͲ ͲǤͲ
ͳʹͳ Chapter 3
Gene set with downregulated genes - continued LF Fa HF Fa LF Fe HF Fe Ǧ ͲǤͲ ͶǤͲ ͲǤͲ ͲǤͲ ǦȀ ͲǤͲ ͲǤͲ ͳǤͺ ͲǤͲ ȋ ȌǦ ͲǤͲ ͲǤͲ ͲǤͲ ͵Ǥͻ Ǧ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ Ǧ ͲǤͲ ͲǤͲ Ǥͷ ͲǤͲ ͲǤͲ ʹǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͶǤ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ʹǦ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ͲǤͲ ʹǤʹ ͲǤͲ ͲǤͲ Ǥ αǦǡ α Ǧǡ α ǡ α Supplementary table ST13: (Differentially-expressed) metabolic gene sets ranked by their CoA/NAD(P)(H) gene content CoA/NAD(P)(H) gene HF Fa LF Fa Top 10 gene Gene set content (%) FDR<0.25 FDR<0.25 sets ̴ ̴ ͳͲͲ ̴ ͳͲͲ ̴ ͳͲͲ ͺͳ ͻ ͺ ͳ ͻ ͵ ȋ Ȍ ͵ ͳ Ͳ ͷͻ ͷͷ ͷͶ ͷͲ ͷͲ ǡ Ͷ Ǧ Ͷ ͶͶ Ȁ Ͷʹ Ͷʹ ͶͲ ͵ ʹǦ ͵ ͵ ͵ ͵Ͷ ͵͵ Ǧ Ǧ ͵͵ ͵ʹ ͵ʹ ͶͷͲ ʹͻ ʹͻ ʹͺ ʹͺ ʹͺ ʹ ʹ ʹ Ǧ ͶͷͲ ʹͷ ʹ͵ ʹ͵ ʹʹ
ͳʹʹ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
CoA/NAD(P)(H) gene HF Fa LF Fa Top 10 gene Gene set content (%) FDR<0.25 FDR<0.25 sets ʹʹ ʹͳ ǡ ʹͲ Ǧ ͳͺ ͳͺ ͳͺ ͳ ͳ 3 ͳ͵ ͳ͵ Ǧ ͳʹ ǡ ͳͳ ͳͲ ͻ ͻ ͻ Ǧ ͺ Ǧ ͷ ȋ ȌǦ Ͷ Ͷ Ͷ Ͳ ǦǦ Ͳ Ǧ Ȁ Ͳ ǦȀ Ͳ Ǧ Ͳ Ǧ Ͳ Ǧ Ͳ Ͳ Ǧ Ͳ Ǧ Ͳ Ͳ Ǧ Ͳ ǡ Ͳ Ͳ Ͳ ǡ Ͳ Ͳ ͻ ͻ Ǧ ͺ Ǧ ͷ ȋ ȌǦ Ͷ Ͷ Ͷ Ͳ ǦǦ Ͳ Ǧ Ȁ Ͳ ǦȀ Ͳ Ǧ Ͳ Ǧ Ͳ Ǧ Ͳ Ͳ Ǧ Ͳ Ǧ Ͳ Ͳ
ͳʹ͵ Chapter 3
CoA/NAD(P)(H) gene HF Fa LF Fa Top 10 gene Gene set content (%) FDR<0.25 FDR<0.25 sets Ǧ Ͳ ǡ Ͳ Ͳ Ͳ ǡ Ͳ Ͳ ͳ͵Ǥ
A mRNA expression of thioesterases 1600 WT LF fed WT LF fasted 400 KO LF fed 400 Ύ KO LF fasted 300
200
100 Normalized readcount 0
Acot1 Acot2 Acot3 Acot4 Acot5 Acot6 Acot7 Acot8 Acot9 Acot10 Acot11 Acot12 Acot13 Them4 Them5
B mRNA expression of thioesterases 700 WT HF fed 600 WT HF fasted KO HF fed 500 KO HF fasted 400 300 200 100 Normalized readcount 0
Acot1 Acot2 Acot3 Acot4 Acot5 Acot6 Acot7 Acot8 Acot9 Acot10 Acot11 Acot12 Acot13 Them4 Them5 Supplementary figure S9. Acyl-CoA thioesterases gene expression in LFD fed and LFD fasted (A) and in HFD fed and HFD fasted (B) conditions. α͵ Ͷ Ǧ ȋ ȌǦ Ǧ ȋ Ȍ ǡ Ǥǡ Ǧ ͷΨ ͳǤͷȉǦ ȋ ȌʹͷΨ ͳǤͷȉ ǤαǦͺǤȗǣδͲǤͲͷ ǡ͓ ͓͓ǣδͲǤͲͷδͲǤͲͳ ǡ ǡșșșǣδͲǤͲͷδͲǤͲͳ Ǧ ȋ Ȍǡ Ǥ
Supplementary Text 1. RNA isolation, RNASeq analysis and quantitative reverse transcriptase polymerase chain (qRT-PCR) Ǧ ȋ ǡǡǡ ȌǤ ǦͳͲͲͲȋ ǡǡȌǤǡ ȋǡǡǡȌǤ ǡͷǡ ͳͺʹͺ Ǥ ͵ǯȋȌǤ ʹͷͲͲ ȋͳͷͲȌ Ǥ ȋȌ̴ ͵ͺͺʹ ȀͲǤͳǤͷǦǦǦͳǤǤʹͲȏʹȐ Ǥ ǡ ȀͳǤʹǦ ǦͳǤǤʹͲ ȏ͵ȐǤ Ǧ ȀͲǤǤͳͳ Ȃ αȏͶȐǤ ȋ Ȍ ȏͷȐ ʹ ȋͳǤͳͲǤͳȌȋ͵ǤʹǤͷȌǡ Ǥ ȋȌ ȏȐ ʹ
ͳʹͶ Transcriptomic analysis suggests a compensatory role of CoA and NAD+ in MCAD-KO mice
ȋͳǤͳͲǤͳȌȋ͵ǤʹǤͷȌǤ Acot2Ǧǡ ȋ ȌǤ ȋ Ȍ Ǧ ȋ Ǧ ǡ Ȍ ȋȌ ȋȌ ȋ ȌȏȐǤ Acot2 ǦǦ Ǧ ȋPpiaȌ ȋȌ ȋȌ 3 ȋ ȌǤ ͳǤʹȋȌ Ǥ Ppiaȋ Ǧ Ǧ ǡ Ȍ ZĞĨĞƌĞŶĐĞƐ ͳǤ ǡ ǡ ǡǡ ǡ ǡ ǡǫǫǡ ǡ ǡ Ǥ Ǧ Ǧ ȋȌǦ Ǥ ǤʹͲͲͺǢͶȋȌǣͳͺͻͶȂͻͲͶǤ ʹǤ ǡǡ ǡ ǡǡ ǡǡǡ Ǥ ǣǦǤ ǤʹͲͳ͵ǢʹͻȋͳȌǣͳͷȂʹͳǤ ͵Ǥ ǡ ǡǡ ǡ ǡ ǡ ǡ ǡǤ ȀǤ ǤʹͲͲͻǢʹͷȋͳȌǣʹͲͺȂͻǤ ͶǤ ǡ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳͷǢ͵ͳȋʹȌǣͳȂͻǤ ͷǤ ǡǡǡ Ǥǣ Ǧ Ǥ ǤʹͲͳͶǢͳͷȋʹȌǣͳȂͳǤ Ǥ ǡ ǡǤ Ǧ ʹǤ ǤʹͲͳͶǢͳͷȋͳʹȌǣͳȂʹͳǤ Ǥ ǡ ǡ Ǥ Ǧ Ǧ ǤǤʹͲͳͷǢͳͲȋ͵ȌǣͲͳͳͷͺǤ
ͳʹͷ
Chapter 4
The role of hepatic fatty-acid oxidation during cold stress: remodeling of hepatic metabolism in a mouse with medium-chain acyl-CoA dehydrogenase deficiency
A.M.F. Martines1,#, Wenxuan Zhang1,2,#, Albert Gerding1,3, Maaike Goris4, Marcel de Vries1, Mirjam H. Koster1,4, Laura Bongiovanni5, Alain de Bruin1,5, Rob H. Henning4, Terry G. J. Derks1,6, Rainer Bischoff2, Dirk-Jan Reijngoud1,2, Barbara M. Bakker1,*
#Authors contributed equally to this work.
1 Laboratory of Pediatrics, Center of Liver, Digestive and Metabolic Diseases, University of Groningen, Groningen, University Medical Center Groningen, Groningen, The Netherlands, 2 Department of Analytical Biochemistry, University of Groningen, Groningen, The Netherlands 3 Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, The Netherlands 4 Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 5 Department of Pathobiology, Faculty of Veterinary Medicine, Dutch Molecular Pathology Center, Utrecht University, The Netherlands 6 Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center of Groningen, University of Groningen.
Journal publication in preparation
Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
Abstract Ǧ ȾǦ ȋ Ȍ Ǧ ǦȋȌǦ Ǥ ǡ Ǧ ȋǦȌǦȋȌ ǤǦ ǡ ǡ Ǧ Ǧ Ǥ Ǧ Ǧ 4 Ǥ ǤǦ ǡ ǡǡ Ǧ Ǧ Ǥ
ͳʹͻ Chapter 4
Introduction Ǧ Ǧȋ Ȍ Ǥ de novo ȏͳȂ ͵ȐǤǡ ȋ Ȍ ȏͳȂ͵ȐǤ Ǧ Ǧ ȋȌǤ Ǧ ȋȌ ȏͶǡͷȐǡ ǡ ȋ Ȍǡ ǡ ǦȏͳǡȂͻȐǤ ǡǦ ȋǦȌ ȏͳͲǡͳͳȐǤǦ Ǧ Ǧ ǡ ȏͳͲȐǤ ǡǦ ʹͶȏͳͲǡͳʹȐǤ ǡ ȋͶι Ȍ ǡȋȌ ȏͳͲȐǤ ǦǡǦǡǦǦ ǦȋǡȌ ȋȏͳ͵ȐȌǤ ǡ ȋȌ ǡ Ǧ ǡǦ ǦȏͳͶȂͳȐǤ Ǧ ȏͳȐǤ ǡ ȏͳͺȐ Ǧ ȏͳͻǡʹͲȐǤ ǡ Ǧ ȏʹͳȂʹ͵ȐǤ Ǧ ǡ Ǥde novo Ǥ ǡ Ǧ ȏʹͶȂʹȐǤǡ Ǧ ǡ ȏͳͲǡʹȐǤǡ Ǧ Ǥ ǡ Ǧ ͳͶ ʹͳ ι ͶǦͶιǤ ȋͺȌ ȋͳǦʹͲȌǤ ǡ Ǧ ǡǦ Ǥ Ǧ Ǧ ǡ Ǥ Ǧ Ǧ ȋͳͲǣͳȌ ǡ Ǥ Ǧ ȋ Ȍ ǦͳͶ ǡ Ǧ ȋȌ ȀǤ Ǧ Ǥ
ͳ͵Ͳ Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
Ǥ Results Young MCAD-KO mice are more vulnerable to cold exposure than adult MCAD-KO mice. ȋͳǦʹͲȌǦ ǡ ͳͶͶιǡ Ǥ ͶǦ Ͷͺ 4 ǡ ȋ ͳȌǤ
ABC 40 i 40 15
C) i WT q KO 35 30 10 16-20 w.o. 30
5 20 WT 25 20 KO (g) Body weight Blood glucose (mM) glucose Blood
Body temperature ( Body temperature 0 20 0 BF AF AFC BF AF AFC BF AF AFC
DEF 6 1.6 6 * *
1.2 5 4 16-20 w.o. 0.8 4 2 0.4
Liver weight (g) weight Liver 3 3 Ketone bodies (mM) bodies Ketone 0 0.0 0 BF AF AFC WT KO Relative liver weight (%) WT KO
GHI J 40 40 30 40 C) C) C)
q WT q q WT KO 35 KO 25 30 30 30 r=0.84 p<0.0001 8 w.o. 25 20 20 WT 20 20 20 20 20 KO (g) Body weight Body temperature ( Body temperature
0 ( temperature Rectal 0 15 ( temperature Rectal 0 BF AF AFC WT KO BF AF AFC 0 10 20 Body weight AF (g) KL MN 15 4 1.6 6 ** * 3 1.2 5 10 * i 2 0.8 8 w.o. 4 5 1 0.4
Liver weight (g) weight Liver 3 3 Blood glucose (mM) glucose Blood (mM) bodies Ketone 0 0 0.0 0 BF AF AFC BF AF AFC WT KO Relative liver weight (%) WT KO
Figure 1. Biometric results of 8- and 16-20-weeks-old mice. ǦȋA,GȌǡȋB,IȌǡ ȋC,KȌȋD,LȌ ȋ ȌǡͳͶǡ ȋ Ȍ ȋ ȌǡȋE,MȌȋΨȌȋF,NȌͳǦʹͲǦ ȋA-FȌ ͺ Ǧ ȋG,I,K-NȌ ȋHȌǡ ͳͶ ȋJȌͺǦ Ǧ Ǥ αǦͺ Ǥ ǡ Ǧ ͷΨ ͳǤͷȉǦȋ ȌʹͷΨ ͳǤͷȉ Ǥ ǡiǣδͲǤͳǡȗǣδͲǤͲͷǡȗȗǣδͲǤͲͳǡȗȗȗǣδͲǤͲͲͳȗȗȗȗǣδͲǤͲͲͲͳ Ǥ Ǥ
ͳ͵ͳ Chapter 4
Ǧ ǡ ȋͳȌǤ ǡǦ ȋ ͳȌǤ ǡ Ǧ ȋ ͳǦȌǤǡ ǡ Ǧ ȋ ͳǡ ȌǤ ǡ ͺǦǡǡ ǦǦ ȏͳͲȐǤ ͺ ǡǡ ȋͳȌǤǡ͵͵Ǥ͵ΨȋʹȀȌͳΨ ȋͷȀȌ ǡ ǡ ȋ ͳ ǡ ǢͳȌǤ ȋ ͳ ǡ ȌǤ ǡ ǡǦ ȋ ͳ ȌǤ ȋ ͳ ͳȌǤ ǡ Ǧ Ǧ ȋ ͳȌǡ ȋ ͳȌǤǡ ǡǤǤ Ǥ ǡ ȋ ͲǦʹ Ȍǡ Ǥ ȋ ͳǡȌǡ Ǥǡ ǡ Ǧ Ǥ Higher plasma acyl-carnitines and NEFAs in fasted, cold-exposed MCAD-KO mice ǡ Ǧ ǡ ǡ ȏʹͺȐǤ ͺ Ǧ ǡ ȽǦ ǡ Ǧȋ ʹʹȌǤǦ Ǧ ȏʹͻȂ͵͵ȐǤ ǡ Ǧ ͳͲǦ Ǧ Ǧ ǡ ȋ ʹǦʹǦȌǤ Ǧ ȏͳͲǡʹͺǡ͵ͶȐǡ ͳͲǣͳǤ ǡ ͺǦ Ǧ ȏʹͻȂ͵͵ȐǤ Ǧ ǡ ȋ ʹǦǡ ʹǦ ͳȌǤ ǡ Ǧ ȋ ʹȌǤ ȏ͵ͷȐǤ
ͳ͵ʹ Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
A 1500 M) P
1000
500
[Blood amino acid] ( 0
Serine Valine Alanine Cystine Glycine Lysine Proline Arginine Histidine Leucine Tyrosine GlutamateGlutamine Isoleucine Threonine Asparagine Methionine Tryptophan Phenylalanine 4
BDC before fasting 14-hr fasted after cold exposure 0.4
M) 0.4 0.4
P *** *** 0.3 0.3 *** 0.3 * **** *** 0.2 0.2 i 0.2 ** ** ** ** * -acyl-carnitine ( -acyl-carnitine n 0.1 0.1 * 0.1
0.0 0.0 0.0 Blood C C6 C8 C10:1 C10 C12:1 C12 C6 C8 C10:1 C10 C12:1 C12 C6 C8 C10:1 C10 C12:1 C12 E 1500 ** M) P 1000
500 Serum NEFA ( NEFA Serum 0 16-20 w.o. 8 w.o. Figure 2. Blood metabolite concentrations. ȋAȌǡ Ǧ ȋB-DȌ ͺǦǦ ǡ ȋEȌǤ ǡ ǡ Ǥ Altered amino-acid and lipid handling in the liver of cold-exposed MCAD-KO mice ǡ ǡ Ǧ Ǥ Ǧ Ǥ ǡ Ǧ Ǧ Ǧ ȋ ͵ǡ ͵ ͳȌǤ Ǥ ǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǧ ȋiǡδͲǤͳȌǡ ǡȽǦ Ǥ ǡ ǡ ȋ͵ǡȌǤ Ǧ ȋ ͵ǡ ͳȌǤ ǡ Ǧ Ǧ Ǧ ǡ ȏ͵ͶȐǤ
ͳ͵͵ Chapter 4
A 8 i ** 6 ** * *** ** i 4 **
2 i *
[Liver amino acid] (nmol/g)0
Serine Valine Alanine Glycine Lysine Proline Arginine Cysteine Histidine Leucine Tyrosine Glutamine Isoleucine Threonine Asparagine Methionine Aspartic acid Glutamic acid Phenylalanine BC 1.0 100 * **
0.8 80
0.6 60
0.4 mol/g liver) 40 P -acyl-carnitine (nmol/g)
n 0.2 20 TG ( TG
0.0 0
Liver C C6 C8 C10:1 C10 C12:1 C12 16-20 w.o. 8 w.o. Figure 3. Hepatic metabolite profiles.Ǧ ȋAȌǦͳʹ Ǧ ͺǦ ȋBȌǡ ȋ Ȍ ͳǦʹͲǦͺǦǦ ȋCȌǤ ǡ ǦǦ ǡ Ǧ Ǥ ǡ ȋ Ȍ Ǧ ǡȋ ͵Ȍǡ Ǥ Rerouting of medium-chain acyl-CoAs into chain-elongation and triglyceride synthesis Ǧ Ǧ Ǥǡ Ǥ ͲͲ ǡ ȋ Ͷ ʹȌǤ ȋȌ Ǧ ȋ ͶȌǤ Ǥ ȋδͲǤͲͷ εʹǢ Ͷ Ȍ ͵ͻ ǡͳ ǡͳȋ ʹȌǤ Ǧ ǡʹͶǦǡ ͶͲǦͶͺȋ ͶǦ ȌǤ ͳǤǡ Ǧ ͵ͳͶʹ Ǧ ȋ ǡ ͶǤ sn- Ǥͳ͵Ͳ ͳ ȋ͵ȌǤͻͷΨ Ǧ ͳͶǤʹΨ ͳͶ Ǧ ȋ Ͷ ȌǤ ǦtͳǤ ǦͳͲǤ
ͳ͵Ͷ Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
A B C 10 6 TG (240) WT n.s. PC (124) KO TG DG (80) 5 PE (49) 4 Other SP (48) PS (18) 0 CE (18) MG (13) 2 PC2 (25.5%) PG (12) -5 (p-value) -log PI (11) CL (11) -10 0 Total=624 -10 -5 0 5 10 -5 0 5 PC1 (35%) log2(fold change) 4 D E F GH TG(48:8) TG(44:2) TG(42:4) TG(42:2) DG(28:2)
1.5 100 1.8 12 1.5 )
6 **** **** *** **** ****
10 80 1.0 1.2 1.0 60 6 40 0.5 0.6 0.5 20 Liver TG (n.s.i. TG Liver 0.0 0 0.0 0 0.0 WT KO WT KO WT KO WT KO WT KO I TG composition
C6 C8 100 C9 C10 C12 50 C14 C15
Number ofNumber isomers C16 0 >C16 a b c Figure 4. Hepatic lipidomics profile of 8-weeks old mice. ȋAȌǡ ǡ ǡ ȋBȌǡ ȋCȌǤ δͲǤͲͷ Ǥ ǡ ͷȋ ȋD-HȌǡ Ǧ ȋIȌǤI ȋǣȌǡ ǡ ǡ ȏ͵ȐǤ ǡ Ǥǣ ǡȗȗȗδͲǤͲͲͳǡȗȗȗȗδͲǤͲͲͲͳǤαͺǤǤǤǤ Ǥ ͳ Ǥ ʹ Ǥ Ǧ Ǧ ǡ ǡ Ǥ Zooming into an MCAD-KO mouse with a severe liver phenotype ǡ ǡ Ǥ ȋ ȏ͵ȐȌ Ǥ ǡ ȋͳͲȌȋi.e.
ͳ͵ͷ Chapter 4
Ȍȋ ͷͶȌ Ǧ Ǥ ͳͲǡ ȋ ͶȌ ȋͶȌ ǦǤͳͲ ȋͳͺǤͶȌ ȋʹͳǤ͵ιȌǤǦ Ǧ ȋ ǤȌ ͳͲ Ǧ ȋ ͷȌǤ ǡ ǡ Ǥ Ǥ ǡ ǡ Ǧ ǡ Ǥ ǡ Ǧ Ǥ ǡ ΪǤ Ϊ Ǥ Discussion ǡ Ǧ ǡ ǤǡǦ Ǥ Ǧ ȏǤScientific Reportsǡ Ȑǡ ǦǦ ȋǡ ǡȌ Ǥ Ȃ Ȃ Ǧ Ǥ ȏͳͲȐǡ ǡ Ǥ ǡ ǡǦ Ǧ ǡ ǡ ǦͳͶ Ǥ Ǥ Ǥ ǡ Ǥ ǡ ǦȏͳͶȂͳǡʹͲȐǤ ǡǡ ȏ͵ͺȐȏ͵ͻȐǦǤ ǡ ȏͳͻǡʹͲȐǤ ǤȏͳͻǡʹͲȐ Ǥ
ͳ͵ Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
A H&E ORO
KO typical
KO severe (KO10) 4 B
Ń Severe (KO10) Figure 5. KO individual with extreme phenotype. ȋͳͲȌȋAȌ ͺǦǦ ȋBȌǤ ȋȌȋȌǤ
ͳ͵ Chapter 4
ǡ Ǧ Ǥ Ǧ ȏͳͻǡʹͲȐǤ ǡMcad Ǧ Ǥ ǡ Mcad ǤǦ Mcad- ǡ ǡ Acadvl, Acadl and AcadmǡǦǦ ǦȏʹʹȐǤ Ȃ ȋͳǦȌȂ Ǧ Ǥ ȋ ͳ ȌǤ ǡ Ǧ Ǥ Ǥ ǡ ǡ Ǥ ǡ Ǥ ȋ Ȍ Ǧ Ǥ ǡ ǡ ǡǦ ǡ ȋ ͵͵ȌǤǦ Ǧ ǡ Ǥ Ǧ ǡ Ǧ Ǥ Ǧ Ǧ ȏͳͻǡʹͲȐ Ǧ Ǥ Ǧ ǦǤ ȏͶͲȂͶʹȐǤ ǡ Ǧ ǡ Ǥ ǡ Ǧ Ǧ Ǥ Ǧ ǦǤ Ǧ Ǧ Ǥ ǡ Ǧ ȋ ʹǦȌǤ Ǧ ȏͳͻǡʹͲȐ Ǧ Ǧ Ǥ ǡ Ǧ ǡ ǡ Ǧ ȏͶ͵Ȑǡ Ǧ Ǧ Ǥǡ ǡ ǦͳͶ ȋ ͶǦ ȌǤ Ǧ ǤǦͳͲ Ǧ
ͳ͵ͺ Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
Ǥ ͳʹǦͳͶ ǦͳͲ Ǥ ǡ Ǥ Ǧ Ǧ ǡ Ǥǡ 4 ǡ ȏͶͶȐǤ ȏͳǡȂͻȐǤǡǡ Ǥ ȏͺǡ͵ͲǡͶͷȐǡ Ǥ ǡ ǦͳͲȋͳͲȌǤ Ǥ ȋ ȌǤͳͲ Ǥ ǡ ȏͶȐǤǡ Ǧ Ǧ ǡ ͳͲǡ Ǥ ǡͳͲ Ǥ ǡ Ǥ ǡǡ Ǧ Ǥ Ǧ Ǧ Ǥ Ǧ ȏͳͻǡʹͲȐǤ Ȁ ǡ ǡ Ǧ ȏͶͲȂͶʹȐǤ
Materials and Methods Animals, Experimental design and Tissue sampling ǦǦȋȌ ͷȀ ȋ ͳͲ ȏͶȐȌǦȋʹͳιȌǦ Ǥ ͳǦʹͲ ȋ Ȍͺȋ ȌǤ Ǥ ǡ ǦǦ ȋͳʹͶͷͲǡ ǡǡȌͶǦǡ Ǥ ǡ ͳͶ ͷι ͶǦǤ Ǥ ǡ ȋ ǡ
ͳ͵ͻ Chapter 4
ǡ Ȍ Ȁ ȋʹ ȀȌǤ ǡ ȋ ǡǡ ǡȌǤ ǡ ̺ȋ ǡǡȌ ȋ Ȍǡ Ǥ ǡǡ Ǧ Ǣ ͳͲΨ Ǧ̺ǤǡͳͶ ȋǤǤ Ȍȋ ȌǤ Metabolite analysis ǡ Ǧ Ǥ ʹͲΨȋȀȌȋ ǤͶȌǤ ȏͶͺȐǡʹΨǦͳͲͲ ȋ ǡ ǡ Ȍ ǯ ǤǦ et al.ȏͶͻȐǤ Ǧ et al. ȏͷͲȐǤ ȋ ǡ ȌǤ Liver lipid extraction ͲǤͻΨʹͲΨȋȀȌǤ ȋ ǡ ǡ Ȍ Ǥ Ͷ ȋͳͶǣͲȌǡ ȋͳͶǣͲȌǡȋͳǣͳȌǡ ȋͳǣͲȀͳǣͲȌǡ ȋʹ͵ǣͲȀʹ͵ǣͲȌǡ ȋͳͶǣͲȀͳͶǣͲȌǡ
ȋͳǣͲȀͳǣͲȌǡ ȋͳǣͲȀͳǣͲȌǡ ȋͳǣͲȀͳǣͲȌǡ ȋͳͶǣͲȌͶǡ ȋͳͻǣʹȀͳͻǣʹȀͳͻǣʹȌǡ ȋͳǣͲȌǡ
ȋͳͶǣͲȌͺ ȋͳͶǣͲȌǤ ʹͲͲɊ ͵ǣ ȋͳǣͳǡȀȌ Ǧ Ͷͷι ǤȋͷͲɊ γͳͲȌ ǦǤ ȏͷͳȐ Ǥ ǡ ͵ͲͲ Ɋ ͷͲ Ɋ Ǧ ͷ Ǥ ǡͳͲͲͲɊ ͻͲͲ ʹͲǤ ͵ͲͲͲͳͲ ǤȋͻͲͲɊȌǤǦ
ͲͲɊȀ Ȁ ʹȋͳͲǣ͵ǣʹǤͷǡȀȀȌǤ ͳͶͲͲɊ
ͶͷιǤ ͵Ȁ ȋͳǣͳǡȀȌ ǦǤ LC-MS measurement ͵ͲͲͲ ȋ Ȍ Ǧ ȋȌ ȋ ǡ ǡȌǤ ȏͷʹȐǤ Ȁ ȀͷͲΫͳͷͲǤ ͳͲȀ ̱ͳǤʹǤ ͲǡͲͲͲ ͳǡͷͲͲ ǡ Ǥ ǣ ͳͷͲ ιǡǣ͵Ǥͷǡ ǣ͵ͲͲιǤ
ͳͶͲ Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
Lipidomic data analysis ̺ ȋ ͵ǤʹǤ͵ ȋ ǡ ǡ Ȍ Ǥ ̺ ȋ ǡ ǡ Ȍ ǡ ǦǤ ʹͲͲǡͲͲͲ Ǥ ȋ ǡ ǡ Ȍ ȋδͷȌǡ ǡ ǡȀ ǦǤǦ ʹȏͷ͵Ȑ 4 ȋ ͷȌǤ Ǥ ǡ Ǥ ȋȌ ȏͷͶȐǤ Histology Ǧ ǡǤ ǡǦ̺ ǦǦǤ ȋ Ȍ ǤȏͷͷȐǤ Statistical analysis ǡ ǡ ȋǯǦ Ȍ ȋȌǤ ǡǦǤ Ǧ ǯǦ Ǥ δͲǤͲͷ Ǥ ȋʹʹȌ ȋ Ǥǡ ͷǤͲͲǡʹͲͲȌȏͷͶȐǤ Author contributions ǡǡ ǡ ǡ Ǥ ǡ Ǥ ǡǡ ǡ ǡǡǡǡǡ Ǥ ǡ Ǥ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ǡ ǡ ǡ Ǥ Ǥ Acknowledgements Ǥ ǡ ǡ ǡ Ǥ Ǥ Ǥ Declaration of Interests Ǥ References ͳǤ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͲʹǢͶȋͳȌǣͶȂͷͲʹǤ
ͳͶͳ Chapter 4
ʹǤ ǡ ǡ Ǥǡ Ǥ ȾǦ Ǥ Ǥ ʹͲͳǢͺȋͳȌǣʹ͵ȂͶͶǤ ͵Ǥ ǡ ǡò ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ ǤʹͲͳͺǢ ͶǤ ǡ ǡ ǡ ǡǡ Ǥ Ǥ ǤʹͲͲǢͳȋͳȌǣͷȂͳͳǤ ͷǤ Ǥ ǣ Ǥ ǤʹͲͲͻǢ͵ʹȋʹȌǣʹͳͶȂǤ Ǥ Ǥ Ǥ Ǥ ʹͲͳͲǢ͵͵ȋͷȌǣͷ͵͵ȂǤ Ǥ Ǥ Ǧ ǣ Ǥ Ǥ ʹͲͳǢʹ͵ȋͳȌǣͷͳȂͷǤ ͺǤ ǤǡǤ ǣ Ǥ ǤʹͲͳͲǢ͵͵ȋͷȌǣͷͳ͵ȂʹͲǤ ͻǤ ǦǤ ǡǤʹͲͳͶǤ ͳͲǤ ǡ ǡǡ ǡ ǡǡǡ ǡǤ Ǧ Ǧ Ǧ Ǥ Ǥ ʹͲͲͷǢͳȋʹȌǣͲʹͲͷȂͳʹǤ ͳͳǤ ǡǦǡ ǡǡ ǡ ǡǦ ǡ Ǧǡ ǡ ǡ ǡǦ ǡ ǡǤ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳͲǤ ͳʹǤ ǡ ǡ ǡǡ ǡ ǡ ǡǫǫǡ ǡ ǡ Ǥ Ǧ Ǧ ȋȌǦ Ǥ ǤʹͲͲͺǢͶȋȌǣͳͺͻͶȂͻͲͶǤ ͳ͵Ǥ ǡǤ ǣ Ǥ ǤʹͲͳͲǢ͵͵ȋͷȌǣͷ͵ͻȂͶǤ ͳͶǤ ǡ± ǡǡ Ǥ Ǥ ǤͳͻͺͻǢʹͷȋͳʹȌǣͻȂͳͲͳǤ ͳͷǤ ×Ǧ ǡ Ǧ× ǡǡ ǡ ǡǤ Ǥ Ǧ Ǥ ǤͳͻͺͺǢʹͷʹȋ͵ȌǣͺͶ͵ȂͻǤ ͳǤ ǡǡǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡǡǡ ǡ ǡǡ Ǥ Ǧ ǤǤʹͲͳͺǢʹȋȌǣͳ͵ͶͺǦͳ͵ͷͷǤͶǤ ͳǤ ǡǡǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ò ǡ ǡ ǡ ǡ ǡ ǡǡ Ǥ Ǥ ǤʹͲͳͳǢͳȋʹȌǣʹͲͲȂǤ ͳͺǤ ǡǡǤ ǦǤ ǤʹͲͳǢʹͶͻȋ͵ȌǣʹͺͳȂǤ ͳͻǤ ǡ ǡ ǡǡǡǡǡ ǡ ǡ ǡ ǡǡǡ ǡ ǡ ǡ ǡ Ǥ Ǧ ǤǤʹͲͳǢʹȋ͵ȌǣͷͲͻǦͷʹʹǤǤ
ͳͶʹ Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
ʹͲǤ Ǥ ǤǤʹͲͳǢʹȋ͵ȌǣͶͷͶȂͷǤ ʹͳǤ ǡ ǡǡ ǡ ǡǡ ǡ ǡ ǡǡ Ǥ Ǥ ǤʹͲͳͺǢʹ͵ͺȋʹȌǣͻͳȂͳͲǤ ʹʹǤ ǡǡǤ Ǧ ǦȽ ǦǦ Ǥ ǤʹͲͲͷǢͺͶȋͳȌǣ͵ͻȂͶǤ ʹ͵Ǥ ǡǡǡ ǡ ǡǤǦ ǡǤǡǤ 4 ǤʹͲͳ͵ ʹʹǢͺȋȌǣͺͻ͵͵Ǥ ʹͶǤ ǡ ǡ ǡǡǡ ǡ ǡ ǡǡ ǡ ǡ ǡǡ Ǥ Ǧ Ǥ Ǥ ʹͲͳͶǢ͵Ͳȋ͵Ȍǣ ͵ʹȂ͵ͺǤ ʹͷǤ ǡǡǡǡǡǡ ǡ ǡǤ Ǧ Ǧ Ǧ Ǥ ǤʹͲͲͶǢ͵Ͷȋ͵ȌǣͳͻͳȂǤ ʹǤ Ǥ Ǧ Ǧ ǦǤ ǤʹͲͲͷǢʹͻͲȋ͵Ȍǣ ͳʹͺͻȂͻǤ ʹǤ ǡ ǡ ǡ Ǧ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳǢͳͷȋͻȌǣ͵ʹͲͶȂͳ͵Ǥ ʹͺǤ ǡ ǡ ǡǡ ǡ ǡ ǡòǡ ǡ ǡ Ǥ Ǧ Ǧ ȋȌǦ Ǥ ǤʹͲͲͺǢͶȋȌǣͳͺͻͶȂͻͲͶǤ ʹͻǤ Ǧǡǡ ǡǤ Ǥ ǤͳͻͺǢͳͲǣͳͷͻȂʹͲͲǤ ͵ͲǤ ǡǡ ǡ ǡǡ ǡǡ ǡ ǡ Ǥ ʹʹͳ Ǧ Ǧ Ǧ ǣ Ǥ ǤʹͲͳǢͳͳͻȋͳȂʹȌǣͷȂͺʹǤ ͵ͳǤ ǤǦǣ ǫ ǤʹͲͲ͵ǢʹȋʹȂ͵ȌǣͳͺͳȂͺǤ ͵ʹǤ Ǥ ǣ ǤǤʹͲͲʹǢȋͳȌǣ͵ȂͶǤ ͵͵Ǥ Ǥ ᩿ǣ Ǧ ǣȀȀǤǤ ǤȀ ȀͳͷͲͶʹͳͷͲͶǤȏȏǤǤȐǦǦȐǣȏǤǤȐǢʹͲͲǤ ͵ͶǤ ǡǦǡ ǡǡ ǡ ǡǦ ǡ Ǧǡ ǡ ǡ ǡǦ ǡ ǡǤ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳͲǤ ͵ͷǤ ǡǡǡ ǡ ǡ 2Ǥ Ǥ ȋȌǤʹͲͳͺǢͻȋ ȌǣͳȂʹͳǤ ͵Ǥ ǡǡǡǡ ǡǡ ǡ ǡ ǡǤ Ǥ ǤʹͲͲͻǢͷͲȋȌǣͻȂͳͶǤ ͵Ǥ ǡǤ ǣ
ͳͶ͵ Chapter 4
Ǥ ǤʹͲͳͲǢ͵͵ȋͷȌǣͷͳ͵ȂʹͲǤ ͵ͺǤ ǡ Ǥ Ǥ ǤʹͲͳͳǢ͵ͲͳȋʹȌǣʹͺͷȂ ͻǤ ͵ͻǤ Ǥ Ǧ Ǥ Ǥ ͳͻ͵ Ǣʹ͵ʹȋʹȌǣʹͺͷȂͻǤ ͶͲǤ ǡǡ ǡǤ Ǧ ͵ǦǦ Ǧ Ǧ ǦǤ ǤʹͲͳǢͳ͵ȋͶȌǣͳȂʹʹǤ ͶͳǤ ǡ ǡǡǡǡ Ǥ Ǧ Ǥ ǤʹͲͲͺǢͻͶȋͳȌǣͶȂͳͷǤ ͶʹǤ ǡǡǡǡ Ǥ Ǥ ǤʹͲͳͻ ʹͺǢͶȋͳȌǣͳͶͻȂͷͷǤ Ͷ͵Ǥ ǡǦǡ ǡǡ ǡ ǡǦ ǡ Ǧǡ ǡ ǡ ǡǦ ǡ ǡǤ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳͲǤ ͶͶǤ Ǥ ǣ ǤǤǤǢʹͲͲǤͳ͵Ǥ ͶͷǤ ǡ ǡǡ ǡǡǤ Ǧ ǤͳͻͻͷǢʹͲͻȂͳͶǤ ͶǤ ǡǡ ǡ ǡǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳͶǢ͵ȋͷȌǣͺ͵ȂͻǤ ͶǤ ǡǦǡ ǡǡ ǡ ǡ ǡ Ǧǡ ǡ ǡ ǡ ǡ ǡǤ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳȂͳͷǤ ͶͺǤ ǡ Ǥ Ǥ ǤͳͻͷͻǢ͵ȋͺȌǤ ͶͻǤ ǡ ǡ Ǥ Ǥ ǤǤͳͻͷͺ Ǣ͵ͲȋȌǣͳͳͺͷȂͻͲǤ ͷͲǤ ǡǡǡǡ ǡ ǡǦǡ ǡ ǡ ǡǡ ǡ Ǥ Ǧ Ǧ ȋȌ ǣ Ǥ ǤʹͲͲͺǢ͵ͳȋͳȌǣͺͺȂͻǤ ͷͳǤ ǡ ǡ Ǥǡ ǡ Ǥ Ǧ tertǦǦ Ǥ ǤʹͲͲͺǢͶͻȋͷȌǣͳͳ͵ȂͶǤ ͷʹǤ ǡ ǡ ǡ ǡ ǡ ǡ Ǧ ǡ ǡ ǤǦǦ ǣǦ Ǥ Ǥ ʹͲͳͺǢͶͳͲȋʹ͵ȌǣͷͺͷͻȂͲǤ ͷ͵Ǥ ǡ ǡ ǡ Ǥ Ǧ Ǧ ǤʹͲͳǢ ͷͶǤ ǡǡǡ ǡǡ ǡǡ ǤͶǤͲ᩿ǣ Ǥ ǤʹͲͳͺǢͶȋȌǣͳȂ ͻǤ ͷͷǤ ǡǡǡǡ ǡǡ ǡǡ ǡ Ǧ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͲͷǢͶͳȋȌǣͳ͵ͳ͵Ȃ
ͳͶͶ Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
ʹͳǤ
4
ͳͶͷ Chapter 4
Supplementary figures and tables
A B C 40 16-20 w.o. 40 8 w.o. 40 WT WT WT young
C) KO C) C) MCAD KO young
q q KO q WT old 30 30 30 r=0.64 MCAD KO old p<0.001
20 20 20 Temperature ( Temperature 20 ( Temperature 20 ( Temperature 20 0 0 0 0 2 4 6 0 2 4 6 0 8 16 24 32 Time (h) Time (h) Body weight before cold exposure (g)
Suppl. Fig. S1. Rectal and body temperatures. Ǧ ͳǦʹͲȋAȌͺǤ ȋBȌǡ ȋCȌǤ
ͳͶ Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
A 8 w.o. 10000 WT M) P KO 1000
* 100 ** [Blood amino acid] ( 10
Total Taurine Citrulline Ornithine
Aminoadipic acid -Aminobutyric acid D BCDbefore fasting 14-hr fasted after cold exposure 50
M) 50 50
P WT 4 40 40 40 KO 30 30 i 30 20 20 20 ** * 10 10 10 16-20 w.o. -acyl-carnitine ( -acyl-carnitine n 1 1 * 1 **
0 0 0 Blood C Blood Ctotal C0 C2 C3 C4 C5:1 C5 Ctotal C0 C2 C3 C4 C5:1 C5 Ctotal C0 C2 C3 C4 C5:1 C5 EF G
M) 50 50 50 P 40 40 40 30 30 30 20 20 20 10 10 10 8 w.o. -acyl-carnitine ( -acyl-carnitine n 1 1 1 i 0 0 0 Blood C Blood Ctotal C0 C2 C3 C4 C5:1 C5 Ctotal C0 C2 C3 C4 C5:1 C5 Ctotal C0 C2 C3 C4 C5:1 C5 HI J
M) 2.5 2.5 2.5 P
2.0 2.0 2.0
1.5 1.5 1.5 16-20 w.o. 1.0 1.0 1.0 -acyl-carnitine ( -acyl-carnitine n 0.5 0.5 i 0.5
0.0 0.0 0.0 Blood C Blood C14:1 C14 C16:1 C16 C18:2 C18:1 C18 C14:1 C14 C16:1 C16 C18:2 C18:1 C18 C14:1 C14 C16:1 C16 C18:2 C18:1 C18 K L M 2.5 2.5
M) 2.5 P 2.0 2.0 2.0 * 1.5 1.5 1.5 8 w.o. 1.0 1.0 1.0 -acyl-carnitine ( i n 0.5 0.5 0.5
0.0 0.0 0.0 Blood C C14:1 C14 C16:1 C16 C18:2 C18:1 C18 C14:1 C14 C16:1 C16 C18:2 C18:1 C18 C14:1 C14 C16:1 C16 C18:2 C18:1 C18 NPO
M) 0.5 0.5 0.5 P
0.4 0.4 0.4
0.3 0.3 0.3 16-20 w.o. 0.2 0.2 0.2
-acyl-carnitine ( i n 0.1 0.1 0.1 * 0.0 0.0 0.0 Blood C
C5DC C5DC C5DC C12-OHC14-OHC16-OH C18-OH C12-OHC14-OHC16-OH C18-OH C12-OHC14-OHC16-OH C18-OH C18:1-OH C18:1-OH C18:1-OH C4OH+C3DCC5OH+C4DC C4OH+C3DCC5OH+C4DC C4OH+C3DCC5OH+C4DC QR S 0.5 0.5
M) 0.5 P
0.4 0.4 0.4 8 w.o. 0.3 0.3 0.3 i 0.2 0.2 0.2 -acyl-carnitine ( n 0.1 i 0.1 0.1 *
0.0 0.0 0.0 Blood C
C5DC C5DC C5DC C12-OHC14-OHC16-OH C18-OH C12-OHC14-OHC16-OH C18-OH C12-OHC14-OHC16-OH C18-OH C18:1-OH C18:1-OH C18:1-OH C4OH+C3DCC5OH+C4DC C4OH+C3DCC5OH+C4DC C4OH+C3DCC5OH+C4DC Suppl. Fig. S2. Blood non-proteomic amino acids and acyl-carnitine concentration.
ͳͶ Chapter 4
ͺǤǡ ȋAȌǡ Ǧ ȋB,E,H,K,N,QȌǡ ͳͶǡ ȋC,F,I,L,O,RȌǡ ȋǡ ǡ ǡǡǡȌ ͳǦʹͲǦǦȋB-D, H-J, N-PȌͺǦǦ ȋB-D, H-J, N-PȌǤ A 8 w.o. 100 **
10 i
i 1
0.1 *
[Liver amino acid] (nmol/g) 0.01
Total Taurine Citrulline Ornithine Sarcosine saccharopine l-cystathionine Aminoadipic acid -Aminobutyric acid D B C 16-20 w.o. 16-20 w.o. 8 100 *
mol/g) 10 mol/g) P
P 6 1 4 0.1 i i i i 2 i i 0.01
[Liver amino acid] ( 0.001 [Liver amino acid] ( 0
Total Serine Valine Alanine Glycine Lysine Proline Taurine Arginine Cysteine Histidine Leucine Tyrosine Citrulline Ornithine GlutamateGlutamine Threonine Sarcosine AsparagineAsparagine Iso-leucine Methionine Saccharopine Phenylalanine l-cystathionine Aminoadipic acid -Aminobutyric acid D Suppl. Fig. S3. Non-proteomic liver amino acid levels of 8-weeks-old mice (A) and proteomic (B) and non-proteomic liver amino acid levels 16-20-weeks-old mice (C). A B H&E ORO 3 C) q WT 2 1
0
KO BG change by cold ( -1 n Severe (KO10) Suppl. Fig S4. Histological representation of representative WT and KO livers of 8-weeks-old mice (A) and blood glucose change during cold exposure in 8-weeks-old mice (B). ȋȌȋȌǤ Supplementary Table ST1. Biometric results and non-lipidomic metabolite concentrations of the WT and KO mice 16-20 weeks-old 8 weeks-old WT KO WT KO Tissue ʹͻǤͳͲ ά ͲǤͷͻ ʹͻǤͶͺ ά ͲǤͻͷ ʹʹǤͷͳ ά ͲǤ ʹʹǤͺͷ ά ͲǤͷͳ ʹǤͳͻ ά ͲǤ͵ ʹǤ͵Ͳ ά ͲǤͻͶ ͳͻǤͷͻ ά ͲǤͻ ʹͲǤ͵Ͳ ά ͲǤͷͶ ʹͷǤʹͺ ά ͲǤͳ ʹͷǤͻ ά ͲǤͻͻ ͳͺǤͺ͵ ά ͲǤͺ ͳͻǤͷͲ ά ͲǤͷͲ ͺǤ ά ͲǤʹ Ǥͺͺ ά ͲǤͶͻ ͻǤͺ ά ͲǤ͵ͻ ͻǤͲ ά ͲǤ͵ ͷǤͷͷ ά ͲǤ͵Ͳ ͶǤͺͶ ά ͲǤͶʹ ͷǤͻ ά ͲǤͷͺ ͶǤͷͺ ά ͲǤʹͳ i ǤͶ ά ͲǤͲ Ǥͷ͵ ά ͲǤͶͲ Ǥ͵ͻ ά ͲǤͷʹ ͷǤ͵ ά ͲǤ͵ͷ ȗ ͲǤ͵ͳ ά ͲǤͲͶ ͲǤ͵ͺ ά ͲǤͲ͵ ͲǤͶͷ ά ͲǤͲ͵ ͲǤͷ͵ ά ͲǤͲ ͳǤͻ ά ͲǤʹ ͳǤͶͺ ά ͲǤͳ͵ ʹǤʹͶ ά ͲǤͳͻ ͳǤͺͺ ά ͲǤͳͻ ͵ǤͳͶ ά ͲǤ͵ ʹǤͲ ά ͲǤ͵ͻ ʹǤͶ ά ͲǤͳͶ ʹǤ͵ͷ ά ͲǤʹͳ ̴ ͵Ǥͺ ά ͲǤ͵ͳ ͵Ǥͺ ά ͲǤʹͻ ͵ǤͶ ά ͲǤʹͷ ͵Ǥͻ͵ ά ͲǤʹͻ ̴ ͵Ǥʹ ά ͲǤʹͺ ͵ǤͳͲ ά ͲǤʹͷ i ͵ͷǤͶ͵ ά ͲǤͷͻ ͵ͷǤͲ ά ͲǤʹͻ ̴ ͵͵Ǥ͵Ͳ ά ͲǤͺ ʹͺǤͲ ά ʹǤʹͳ ʹͷǤͲͻ ά ʹǤͺͶ ʹͺǤͳͺ ά ʹǤʹͶ
ͳͶͺ Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
16-20 weeks-old 8 weeks-old WT KO WT WT Tissue ͵ͳǤʹͲ ά ǤǤ ʹͺǤʹͲ ά ǤǤ ʹͳǤͶͻ ά ʹǤ͵ ʹͷǤ͵ͻ ά ͳǤͷͻ ͳǤͲ ά ͲǤͲͶ ͳǤʹ͵ ά ͲǤͲͷ ȗ ͲǤͺͻ ά ͲǤͲͶ ͳǤͲͶ ά ͲǤͲ͵ ȗ ͶǤʹͲ ά ͲǤͳͶ ͶǤͻ ά ͲǤͳͷ ȗ ͶǤͳ ά ͲǤͳʹ ͷǤ͵Ͳ ά ͲǤͳͶ ȗȗ ͷǤͷ ά ͶǤ ͳǤʹͷ ά ͶǤͷ ȗ ͲǤ͵ ά ͵Ǥͷͺ Ǥ͵ͺ ά ͵ǤͲͷ ȗȗ ͺͷͷ ά ͻͳ ͻͷͲ ά ͷʹ ͺͳͺ ά ʹͻ ͳͲ͵ ά ʹ ȗȗ Ǧ ʹͷǤʹͲ ά ͳǤʹ ʹͳǤͲͲ ά ʹǤͷͳ ͵ͲǤͺͺ ά ʹǤͷ ʹͻǤͳͶ ά ͳǤʹͺ Ͳ ͳͷǤͲͲ ά ͳǤͳͶ ͳʹǤͲͲ ά ͳǤʹ ͳͷǤͺͺ ά ͳǤʹ ͳͷǤͲͲ ά ͲǤʹ ʹ ǤͶ ά ͲǤͶ Ǥʹͺ ά ͳǤͳʹ ͳͳǤ͵͵ ά ͲǤͻ ͳͲǤͶ ά ͲǤͷ 4 ͵ ͲǤ͵ͷ ά ͲǤͲʹ ͲǤ͵ͺ ά ͲǤͲ ͲǤͷ͵ ά ͲǤͲ ͲǤͷ ά ͲǤͲ Ͷ ͲǤʹͷ ά ͲǤͲ ͲǤʹ ά ͲǤͲͷ ͲǤʹͷ ά ͲǤͲ ͲǤʹͷ ά ͲǤͲͶ ͷǣͳ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͷ ͲǤͲͻ ά ͲǤͲʹ ͲǤͲͻ ά ͲǤͲͳ ͲǤͳͶ ά ͲǤͲʹ ͲǤͳͳ ά ͲǤͲͳ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͲ ά ͲǤͲʹ ȗ ͲǤͲ͵ ά ͲǤͲͳ ͲǤͳͲ ά ͲǤͲʹ ȗ ͺ ͲǤͲͶ ά ͲǤͲͲ ͲǤͲ ά ͲǤͲͳ ȗ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ ȗȗ ͳͲǣͳ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲͷ ά ͲǤͲʹ ȗȗ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲͺ ά ͲǤͲͳ ȗȗ ͳͲ ͲǤͲ͵ ά ͲǤͲͳ ͲǤͲͶ ά ͲǤͲͳ ͲǤͲ͵ ά ͲǤͲͳ ͲǤͲͳ ά ͲǤͲͳ ͳʹǣͳ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͳʹ ͲǤͲ ά ͲǤͲͲ ͲǤͲ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲͳ ͲǤͲ ά ͲǤͲͲ ͳͶǣͳ ͲǤͲͻ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲʹ ͲǤͳͳ ά ͲǤͲͳ ͲǤͳͳ ά ͲǤͲͳ ͳͶ ͲǤʹ͵ ά ͲǤͲ͵ ͲǤʹͲ ά ͲǤͲʹ ͲǤʹ͵ ά ͲǤͲʹ ͲǤʹͶ ά ͲǤͲʹ ͳǣͳ ͲǤͳͲ ά ͲǤͲʹ ͲǤͲͺ ά ͲǤͲʹ ͲǤͳʹ ά ͲǤͲʹ ͲǤͳʹ ά ͲǤͲͳ ͳ ͲǤͺͲ ά ͲǤͲͺ ͲǤͻ ά ͲǤͲͺ ͲǤͻͷ ά ͲǤͲͷ ͲǤͻͲ ά ͲǤͲͶ ͳͺǣʹ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲͶ ά ͲǤͲͳ ͲǤͲ ά ͲǤͲͲ ͲǤͲ ά ͲǤͲͲ ͳͺǣͳ ͲǤ͵Ͷ ά ͲǤͲͶ ͲǤ͵ͳ ά ͲǤͲͺ ͲǤͶͷ ά ͲǤͲͶ ͲǤͶʹ ά ͲǤͲͶ ͳͺ ͲǤͳͻ ά ͲǤͲʹ ͲǤͳͺ ά ͲǤͲʹ ͲǤʹͶ ά ͲǤͲͳ ͲǤʹʹ ά ͲǤͲͳ Ͷ Ϊ͵ ͲǤͲ͵ ά ͲǤͲͳ ͲǤͲʹ ά ͲǤͲͳ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲͶ ά ͲǤͲͲ i ͷ ΪͶ ͲǤͳͳ ά ͲǤͲͳ ͲǤͲ ά ͲǤͲʹ ͲǤͳͶ ά ͲǤͲͳ ͲǤͳ͵ ά ͲǤͲͳ ͷ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͳʹ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͳͶ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͳ ͲǤͲ͵ ά ͲǤͲͳ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͳͺǣͳ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͳͺ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͲȀ ͲǤͷͻ ά ͲǤͲʹ ͲǤͷͺ ά ͲǤͲʹ ͲǤͷʹ ά ͲǤͲʹ ͲǤͷͲ ά ͲǤͲͳ Ǧ ͷͺ ʹͳǤͺ ά ͳǤͻ ͳͺǤͳ͵ ά ͲǤͻ i ʹ͵Ǥͷ ά ʹǤͲʹ ʹͶǤʹͷ ά ͳǤʹ Ͳ ͺǤͲͻ ά ͲǤͷͶ ͷǤͷ ά ͲǤʹͷ ȗȗ ǤͲͲ ά ͲǤ͵͵ ǤͲͲ ά ͲǤͷ͵ ʹ ͳͲǤ͵ͳ ά ͳǤͳͶ ͺǤ͵ͳ ά ͲǤͳ ͳʹǤʹ͵ ά ͳǤͷͲ ͳʹǤͲ͵ ά ͲǤͻͲ ͵ ͲǤͶ ά ͲǤͲͷ ͲǤʹ ά ͲǤͲͶ ȗȗ ͲǤͺ ά ͲǤͳ ͲǤͷͳ ά ͲǤͲͶ Ͷ ͲǤͲͷ ά ͲǤͲͲ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲͶ ά ͲǤͲͳ ͷǣͳ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͷ ͲǤͲͷ ά ͲǤͲͲ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ ͲǤͲ ά ͲǤͲͳ i ͲǤͲʹ ά ͲǤͲͲ ͲǤͳ͵ ά ͲǤͲͳ ȗȗȗȗ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͳʹ ά ͲǤͲ͵ ȗȗȗ ͺ ͲǤͲͶ ά ͲǤͲͳ ͲǤͳͳ ά ͲǤͲͳ ȗȗȗ ͲǤͲ ά ͲǤͲͲ ͲǤͳͷ ά ͲǤͲͳ ȗȗȗȗ ͳͲǣͳ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͳͻ ά ͲǤͲʹ ȗȗȗȗ ͲǤͲʹ ά ͲǤͲͲ ͲǤʹʹ ά ͲǤͲʹ ȗȗȗ ͳͲ ͲǤͲͶ ά ͲǤͲͲ ͲǤͲ ά ͲǤͲͲ ȗȗȗ ͲǤͲ͵ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲͳ ȗȗ ͳʹǣͳ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͲͷ ά ͲǤͲͳ ȗ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͲͷ ά ͲǤͲͳ ȗ ͳʹ ͲǤͲ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ i ͲǤͲͺ ά ͲǤͲͳ ͲǤͳͳ ά ͲǤͲͳ i ͳͶǣͳ ͲǤͳ ά ͲǤͲʹ ͲǤʹ͵ ά ͲǤͲʹ i ͲǤʹͳ ά ͲǤͲ͵ ͲǤʹͷ ά ͲǤͲʹ ͳͶ ͲǤʹ ά ͲǤͲͶ ͲǤ͵͵ ά ͲǤͲ͵ ͲǤ͵ͳ ά ͲǤͲͶ ͲǤͶͳ ά ͲǤͲʹ i ͳǣͳ ͲǤͳͻ ά ͲǤͲʹ ͲǤʹʹ ά ͲǤͲ͵ ͲǤʹͶ ά ͲǤͲ͵ ͲǤ͵Ͳ ά ͲǤͲʹ ͳ ͲǤͺ ά ͲǤͲͻ ͲǤͻͷ ά ͲǤͲͷ ͳǤͲͻ ά ͲǤͳ͵ ͳǤͶͲ ά ͲǤͲ ȗ ͳͺǣʹ ͲǤͲͻ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ ͲǤͳͳ ά ͲǤͲʹ ͲǤͳʹ ά ͲǤͲͳ ͳͺǣͳ ͲǤͲ ά ͲǤͲͻ ͲǤͷ ά ͲǤͲ ͲǤ ά ͲǤͳͲ ͲǤͺͻ ά ͲǤͲͷ ͳͺ ͲǤͳ ά ͲǤͲʹ ͲǤͳͺ ά ͲǤͲͳ ͲǤʹ͵ ά ͲǤͲ͵ ͲǤʹ ά ͲǤͲͳ Ͷ Ϊ͵ ͲǤͳ͵ ά ͲǤͲ͵ ͲǤͲ ά ͲǤͲͳ i ͲǤͳ ά ͲǤͲʹ ͲǤͳͲ ά ͲǤͲʹ i ͷ ΪͶ ͲǤͲ ά ͲǤͲͳ ͲǤͲ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ ͲǤͳͲ ά ͲǤͲͳ ͷ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͳʹ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ
ͳͶͻ Chapter 4
16-20 weeks-old 8 weeks-old WT KO WT WT Tissue ͳͶ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͳ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͲͶ ά ͲǤͲͳ ͲǤͲͶ ά ͲǤͲͲ ͳͺǣͳ ͲǤͲ͵ ά ͲǤͲͳ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲͶ ά ͲǤͲͲ ͳͺ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͲȀ ͲǤ͵ͺ ά ͲǤͲʹ ͲǤ͵͵ ά ͲǤͲʹ ͲǤ͵ʹ ά ͲǤͲͷ ͲǤʹͻ ά ͲǤͲͳ Ǧ ʹʹǤͲ ά ʹǤʹͲ ͳͺǤ͵ ά ͳǤͶͲ ʹǤ͵ ά ʹǤͳ ʹͶǤͷͲ ά ʹǤͳ Ͳ Ǥ ά ͲǤͷ͵ ͷǤͲͲ ά ͲǤͷ͵ ȗ ͷǤͺͺ ά ͲǤͶͶ ͷǤͷ ά ͲǤͷ ʹ ͳͳǤͷ ά ͳǤͶͺ ͺǤ ά ͲǤ ͳ͵ǤͻͲ ά ͳǤͲ͵ ͳʹǤͳ͵ ά ͳǤ͵ͳ ͵ ͲǤͶͺ ά ͲǤͲͶ ͲǤ͵ͳ ά ͲǤͲͷ ȗ ͲǤͶ ά ͲǤͳͲ ͲǤͶ ά ͲǤͲ Ͷ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲʹ ͲǤͲͷ ά ͲǤͲͳ ͷǣͳ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͷ ͲǤͲ͵ ά ͲǤͲͳ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲ ά ͲǤͲͳ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲͺ ά ͲǤͲͳ ͲǤͲʹ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲʹ ȗȗ ͺ ͲǤͲͶ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ ͲǤͲͷ ά ͲǤͲͳ ͲǤͳͶ ά ͲǤͲͳ ȗȗȗ ͳͲǣͳ ͲǤͲʹ ά ͲǤͲͲ ͲǤͳͺ ά ͲǤͲʹ ͲǤͲʹ ά ͲǤͲͲ ͲǤʹ͵ ά ͲǤͲʹ ȗȗȗ ͳͲ ͲǤͲͶ ά ͲǤͲͲ ͲǤͲ ά ͲǤͲͳ ͲǤͲͶ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲͳ ȗ ͳʹǣͳ ͲǤͲ͵ ά ͲǤͲͲ ͲǤͲͶ ά ͲǤͲͲ ͲǤͲͶ ά ͲǤͲͲ ͲǤͲͷ ά ͲǤͲͳ ͳʹ ͲǤͲ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ ͲǤͳͳ ά ͲǤͲͳ ͲǤͳʹ ά ͲǤͲͳ ͳͶǣͳ ͲǤʹʹ ά ͲǤͲʹ ͲǤʹ ά ͲǤͲ͵ ͲǤ͵ͺ ά ͲǤͲͷ ͲǤ͵ ά ͲǤͲ͵ ͳͶ ͲǤ͵ͻ ά ͲǤͲͷ ͲǤͶ ά ͲǤͲ ͲǤͳ ά ͲǤͲ ͲǤ ά ͲǤͲͶ ͳǣͳ ͲǤʹ ά ͲǤͲ͵ ͲǤ͵ͳ ά ͲǤͲͷ ͲǤͶ ά ͲǤͲͷ ͲǤͶ ά ͲǤͲͶ ͳ ͳǤͳʹ ά ͲǤͳͳ ͳǤʹ ά ͲǤͳ͵ ͳǤͲ ά ͲǤͳ ͳǤͺ ά ͲǤͲ ͳͺǣʹ ͲǤͳͶ ά ͲǤͲͳ ͲǤͳͶ ά ͲǤͲʹ ͲǤʹ͵ ά ͲǤͲ͵ ͲǤͳͺ ά ͲǤͲͳ ͳͺǣͳ ͲǤͺ ά ͲǤͲͺ ͳǤͲʹ ά ͲǤͳ͵ ͳǤͶ ά ͲǤͳͻ ͳǤ͵ͺ ά ͲǤͲͷ ͳͺ ͲǤʹʹ ά ͲǤͲʹ ͲǤʹͶ ά ͲǤͲ͵ ȗ ͲǤ͵ ά ͲǤͲͶ ͲǤ͵ ά ͲǤͲʹ Ͷ Ϊ͵ ͲǤͳͷ ά ͲǤͲͶ ͲǤͲͷ ά ͲǤͲʹ ͲǤʹʹ ά ͲǤͲͶ ͲǤͳͷ ά ͲǤͲͳ ͷ ΪͶ ͲǤͲ ά ͲǤͲͳ ͲǤͲ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲͳ ͷ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͶ ά ͲǤͲͶ ͲǤͲͲ ά ͲǤͲͲ ͳʹ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͳͶ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲͶ ά ͲǤͲͳ ͲǤͲ͵ ά ͲǤͲͲ ͳ ͲǤͲͶ ά ͲǤͲͲ ͲǤͲͶ ά ͲǤͲͳ ͲǤͲ ά ͲǤͲͳ ͲǤͲͷ ά ͲǤͲͲ ͳͺǣͳ ͲǤͲͷ ά ͲǤͲͲ ͲǤͲͷ ά ͲǤͲͳ ͲǤͳͲ ά ͲǤͲʹ ͲǤͲ ά ͲǤͲͲ ͳͺ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲͳ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͲǤͲʹ ά ͲǤͲͲ ͲȀ ͲǤ͵Ͳ ά ͲǤͲͳ ͲǤʹ ά ͲǤͲʹ ͲǤʹ͵ ά ͲǤͲͳ ͲǤʹ͵ ά ͲǤͲͲ Ǧ ȋ Ȍ ͵ͲͲ ά ͳͳ ʹͺͶ ά ʹͳ ͵͵ ά ͳ ͵ʹͶ ά ͳʹ Ͳ ʹͺͶ ά ͻ ʹͳ ά ʹͳ ͵ͳͳ ά ͳͺ ͵Ͳ͵ ά ͳ͵ ʹ ͶǤͺͶ ά ͳǤʹ ʹǤ͵ ά ͳǤ͵ͷ ͻǤʹ ά ʹǤʹͳ ͷǤͷͳ ά ͳǤʹ ͵ ͳǤͻ͵ ά ͲǤ͵ͺ ͳǤͺͻ ά ͲǤ͵ ͵ǤͶͺ ά ͲǤͷͺ ͵Ǥʹ ά ͲǤ͵ͷ Ͷ ͲǤʹͶ ά ͲǤͲͷ ͲǤͳͲ ά ͲǤͲʹ ͲǤ͵Ͳ ά ͲǤͲͷ ͲǤʹͻ ά ͲǤͲ ͷǣͳ ͲǤͲͺ ά ͲǤͲͳ ͲǤͲͶ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ ͲǤͲ ά ͲǤͲͳ ͷ ͲǤʹͳ ά ͲǤͳͳ ͲǤͲͺ ά ͲǤͲͳ ͲǤͳ ά ͲǤͲ͵ ͲǤͳʹ ά ͲǤͲͳ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͺ ͲǤͲͺ ά ͲǤͲͳ ͲǤͲͷ ά ͲǤͲͳ i ͲǤͲͺ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ ͳͲǣͳ ͲǤʹͶ ά ͲǤͲͷ ͲǤʹͲ ά ͲǤͲʹ ͲǤ͵Ͷ ά ͲǤͳͲ ͲǤʹʹ ά ͲǤͲʹ ͳͲ ͲǤͳͳ ά ͲǤͲͳ ͲǤͳͳ ά ͲǤͲʹ ͲǤͳ͵ ά ͲǤͲͳ ͲǤͳͶ ά ͲǤͲͳ ͳʹǣͳ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲ͵ ά ͲǤͲͳ ͲǤͲͷ ά ͲǤͲͳ ͲǤͲͶ ά ͲǤͲͳ ͳʹ ͲǤͲ ά ͲǤͲͳ ͲǤͲ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲͳ ͳͶǣͳ ͲǤͲͻ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲͳ ͳͶ ͲǤͲͶ ά ͲǤͲͳ ͲǤͲ͵ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲͳ ͲǤͲͷ ά ͲǤͲͲ ͳǣͳ ͲǤͲ ά ͲǤͲʹ ͲǤͲͷ ά ͲǤͲʹ ͲǤͲͺ ά ͲǤͲͳ ͲǤͲ ά ͲǤͲͳ ͳ ͲǤͳ ά ͲǤͲʹ ͲǤͳ͵ ά ͲǤͲ͵ ͲǤʹ ά ͲǤͲͶ ͲǤͳͻ ά ͲǤͲ͵ ͳͺǣʹ ͲǤͲͻ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲͳ ͲǤͲͻ ά ͲǤͲͳ ͲǤͳͲ ά ͲǤͲͳ ͳͺǣͳ ͲǤʹͳ ά ͲǤͲ͵ ͲǤͳ ά ͲǤͲͶ ͲǤʹͶ ά ͲǤͲ͵ ͲǤʹʹ ά ͲǤͲ͵ ͳͺ ͲǤͲ ά ͲǤͲͳ ͲǤͲ ά ͲǤͲͳ ͲǤͳʹ ά ͲǤͲͳ ͲǤͲͺ ά ͲǤͲͳ ȗ Ͷ Ϊ͵ ͵Ǥͳ ά ͲǤ͵ʹ ͳǤͺ ά ͲǤͳ͵ ͵Ǥͻͺ ά ͲǤʹͷ ʹǤʹͷ ά ͲǤͲͺ ȗȗȗ ͷ ΪͶ ͲǤ ά ͲǤͲ ͲǤͷͺ ά ͲǤͲͶ ͲǤͺͻ ά ͲǤͲͷ ͲǤͲ ά ͲǤͲͶ ȗ ͷ ʹǤͻʹ ά ͲǤ͵͵ ͶǤ ά ͲǤͻ ͶǤͻ ά ͲǤ͵Ͷ ǤͲ ά ͲǤ ȗȗ ͳʹ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ
ͳͷͲ Effect of fasting and cold stress on hepatic metabolism in MCAD-KO mice
16-20 weeks-old 8 weeks-old WT KO WT WT Tissue ͳͶ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͳ ͲǤͲͶ ά ͲǤͲͳ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲ ά ͲǤͲͳ ͲǤͲͶ ά ͲǤͲͳ ͳͺǣͳ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͳͺ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲǤͲͲ ά ͲǤͲͲ ͲȀ ͲǤͻͷ ά ͲǤͲͳ ͲǤͻͷ ά ͲǤͲͳ ͲǤͻʹ ά ͲǤͲͳ ͲǤͻ͵ ά ͲǤͲͳ ȋ Ȍ ͷͻͳͶ ά ͷͲͺ ͶͶ ά ʹͲ ͷͶ͵ ά ͵ͻͻ ͶͲ ά ʹͷʹ i ǤǤ ά ǤǤ ǤǤ ά ǤǤ ͵ ά ʹͳ ͳͺ ά ͵ ͳ͵ ά ͳʹʹ ͳͳ͵ʹ ά ͳʹͲͲ ά ͳ͵ͳ ͻͶ ά Ͷʹ 4 ͳͲͶ ά ͵ ͻͶͳ ά Ͷ ͳʹͺͻ ά ͳ ͳͳͳ ά Ͷ ʹ͵Ǥ ά ͳͲǤͶ ͶͳǤͲ ά ʹͲǤʹ ͵ͳǤͷ ά ͻǤͻ ͳʹǤ͵ ά ͷǤʹ ʹͷʹ ά ͶͶ ͳͻͳͺ ά ʹͷʹ ͷͲͳʹ ά ʹͶͺ ͵Ͳ ά ʹͳͶ ȗȗ ͵ʹͷ ά ͵ ͵͵Ͷ͵ ά ʹ͵ ʹͷ ά ʹ ʹͲͻͷ ά ͳ͵ i ͷͺͲͷ ά ʹ Ͷͻͻ ά ͳ ȗȗ ͷͷͲ ά ͳͻͳ ͶͲͷ ά ͳʹͶ ȗȗ ͳʹͲͲ ά ͻͲͲ ά ͳ͵͵ ȗ ͳͳͻͻ ά ͻ͵ ͳͲ ά ͶͶ ͳʹͷ ά ͺͺ ͳ͵ͳͷ ά ͳͺ ͳ͵ͺ ά ͳͳʹ ͳͳͶͻ ά Ͳ ͵Ͳͷͻ ά ʹͳʹ ʹͻͳ ά ͳͻ ͵͵ͻͷ ά ʹ͵͵ ʹͺͲ ά ͳͳ͵ ȗȗ ͵ͻͶͶ ά ʹͷͷ ͵ʹͻ ά ͶͶͳ ͷͶͻͲ ά ʹͻ Ͷ͵͵ͺ ά ʹͷ ȗ ͺ ά Ͷ Ͷͷ ά ͻͷ i ͻͳͶ ά ͺͶ ͷͳ ά Ͷͳ i ͳ͵ͺͷ ά ͻ ͳͶͲ ά ʹͺ ͳͶʹ ά ͳ͵ ͳͳͺͳ ά ͷ ͳ͵ʹͻ ά ͳͷʹ ͻͺͲ ά ͷ ȗ ͳͳͺ͵ ά ͳͻ ͳͲͲ ά Ͷʹ ͵ʹͲ ά ͳͻͺ ͵͵Ͳ ά ͳͻͻ Ͷ͵Ͷ ά ͳͻͶ ͵Ͷ ά ͳͳ͵ ȗȗȗ ʹͶͳͷ ά ͳͶͺ ʹͳͻͶ ά ͳͶ ʹͺͶͲ ά ͳͶͳ ʹʹʹ ά ͺͳ ȗȗ ͳʹͲ͵ ά Ͳ ͳͲ͵Ͳ ά Ͷ i ͳʹʹ ά ͳͲʹ ͳͲ͵Ͷ ά ͵ʹ ȗ ʹͳͺ ά ͳͺʹ ʹͳͲͲ ά ͵Ͷͷ ͵Ͳͻ ά ͳͻ ʹͶ ά ͳͷͷ ͷͷͳ ά ͳͶͶͺ ͷͶ͵ ά ͳͷ͵ ͳͲͶ͵ ά ͳ͵ͻͲ ͻͲͷ ά ͻͻ ȽǦ ͵͵Ͷ ά Ͷ ͷͳʹ ά ͵Ͳͷ ά ͳʹͶ Ͷ͵ͺ ά i ʹͶ ά ʹͷ ʹͻ ά Ͷ Ͷʹ ά ͷͶ ͵͵ͻ ά ͺ Ǧ ͳͻ ά ͻ ͳʹ ά ͳͲ ά ͳͷ ͵Ͷ ά ȗ ʹͻ͵ͻ ά ͳͻ ʹͻʹ ά ʹͻʹ ͵ͷͻ ά ͳ ͵ʹͷ ά ͳͻͲ i Ͷ ά ͳ͵ ͳʹͻ ά ͷ ͳͷʹ ά ʹ ͳͲͺ ά ͳͺ ͵Ͳͷ ά ͷ͵ͷ ʹͺ ά ͵ͷʹ ʹͳʹͲ ά ͵ͳ ʹͷͲ ά ʹͷͻ ͳͳͲ ά ͳͷ͵ ͺ͵ ά ͳͶ ͷͻͳ ά ʹͲͻ ͷ ά ͳͷͺ i ͵Ͳͷ ά ʹͻͲ ͷͷͻͺ ά ͵ʹͷ ʹʹͻ ά ʹͶͻ ͳͷ ά ͳͺͷ ȗȗ ȋ Ȍ ͵͵͵ ά ʹ ʹͺ͵ ά ͷͲ ͺ ά ͳͷ ͷ ά ͺ ͷͺ ά ͳͲ ͷͳ ά ͺ ά ͷ ά ʹ ʹͷǤͷ ά Ǥ͵ ʹ͵ǤͶ ά ʹǤ͵ ͵ͻ ά ͵ ͳͳ ά Ͷͻ ʹʹʹ ά Ͷͳ ͳͻͳ ά ͵ ͻͶ ά ʹͷ ͳͲ͵ ά ʹͲ ͳͺ͵ ά ͳ ͳͷ ά Ͷͻͺ ά ͺͻ ͶͲʹ ά Ͷͺ ͷͻͻ ά ͳʹͳ Ͷ͵ ά ͻ ͷʹ ά ͻ ͵ͺ ά Ͷ ͳ͵ͷ ά ͵͵ ͳ͵ͺ ά ʹͶ ͺͺ ά ͳͻ Ͷ ά ͳͲ ͳͶ ά ͵Ͳ ͳʹ ά ʹ͵ ʹ ά ͶͲ ʹͲͲ ά ͳͺ Ͷͳ ά ͺ Ͷʹ ά Ͷ ͳͺͺ ά ͷ ͳ͵Ͳ ά ͵Ͷ ͷͻͳ ά ͻʹ ͷʹͶ ά ͷ ͻͶ ά ͳͺ ͺͳ ά ͳͲ ȽǦ ͶͲ ά ʹͲ ά ʹ ȗ ͷͻ ά ά ͺ ͳ͵ͺ ά ͵Ͷ ͳ͵Ͳ ά ʹͷ ͺͳ͵ ά ͷʹ ͻͻ ά ʹ ͷ͵ͻ ά ͺ͵ͷ Ͷʹ ά Ͷͻͷ
ͳͷͳ Chapter 4
ǣǡ ǣͳͶǡ ǣ ǡǣǡ ǣ ǡǣǡǣδͲǤͳǡȗǣδͲǤͲͷǡȗȗǣδͲǤͲͳǡȗȗȗǣδͲǤͲͲͳǡȗȗȗȗǣδͲǤͲͲͲͳ ǤάǤαͷǦͺǤ Supplementary Table ST2. Lipidomic profile results in livers of 8-week-old mice. Ǧ Ǧ Ǧ ʹͲ ȋͶǣȌ ʹǤʹΪͲ ͶǤͳΪͲͷ ͵ǤʹǦͲͺ ǤǦͲ ͷǤʹͺ ͳ ȋͶǣ͵Ȍ ͳǤͳΪͲ ͳǤͳΪͲͷ ʹǤͷǦͲͺ ǤǦͲ ͳͲǤ Ͷ͵ ȋͶͶǣʹȌ ǤʹΪͲ ͶǤ͵ΪͲ ʹǤʹǦͲͺ ǤǦͲ ͳͶǤͶ ʹͷ ȋͶͺǣȌ ͻǤʹΪͲ ͻǤʹΪͲͷ ͷǤͳǦͲͺ ͺǤͲǦͲ ͳͲǤͲͳ ͳ͵ ȋͶͲǣʹȌ ͵ǤʹΪͲ ͵ǤΪͲͷ ͳǤǦͲ ͳǤͺǦͲͷ ͺǤͷ ͳ ȋͶǣȌ ʹǤΪͲ ͵ǤͲΪͲͷ ͳǤͻǦͲ ͳǤͺǦͲͷ ͻǤͳ ͳͷ ȋͶʹǣ͵Ȍ ͺǤΪͲ ͺǤͺΪͲͷ ʹǤͲǦͲ ͳǤͺǦͲͷ ͻǤͺͺ ʹ ȋͶͲǣͲȌ ͶǤͲΪͲͷ ͳǤͲΪͲͷ ʹǤǦͲ ʹǤͲǦͲͷ ͵Ǥͻ ʹͺ ȋͶͶǣ͵Ȍ ǤΪͲ ǤʹΪͲ ͵ǤʹǦͲ ʹǤͲǦͲͷ ͳͲǤͶͻ ͳͻ ȋͶͶǣͶȌ ͳǤͻΪͲ ͳǤΪͲ ͵ǤͲǦͲ ʹǤͲǦͲͷ ͳͳǤͻ ʹͶ ȋͶʹǣʹȌ ǤΪͲ ͶǤͳΪͲͷ ͶǤͶǦͲ ʹǤͷǦͲͷ ͳͺǤͻͷ ͳͶ ȋͶͶǣͷȌ ͵ǤͳΪͲ ʹǤ͵ΪͲͷ ͷǤͳǦͲ ʹǤǦͲͷ ͳ͵ǤͲ͵ ʹ͵ ȋͶǣͷȌ ͳǤ͵ΪͲ ʹǤͲΪͲ ǤͶǦͲ ͵ǤͳǦͲͷ Ǥ͵ Ͷͷ ȋͶ͵ǣͳȌ ͵ǤΪͲͷ ͺǤΪͲͶ ͺǤʹǦͲ ͵ǤǦͲͷ ͶǤ͵ͷ ͳͺ ȋͶͲǣͳȌ ͶǤʹΪͲ ͷǤͲΪͲͷ ͳǤͲǦͲ ͶǤͳǦͲͷ ͺǤͷͲ ʹʹ ȋͶʹǣʹȌ ͳǤΪͲ ʹǤΪͲ ͳǤʹǦͲ ͶǤͷǦͲͷ ǤͲͷ ͳ ȋͶͺǣͺȌ ǤͻΪͲͷ ʹǤͻΪͲͶ ͳǤ͵ǦͲ ͶǤͻǦͲͷ ʹͶǤͲ ͵ ȋʹͺǣʹȌ ǤͺΪͲͷ ͶǤΪͲͶ ʹǤͻǦͲ ͳǤͲǦͲͶ ͳǤͷ͵ ͵Ͳ ȋͶǣͶȌ ͷǤͳΪͲ ͳǤʹΪͲ ͵ǤʹǦͲ ͳǤͲǦͲͶ ͶǤ͵ͻ ͵ʹ ȋͶʹǣͳȌ ʹǤͲΪͲ ͶǤͲΪͲ ͶǤʹǦͲ ͳǤ͵ǦͲͶ ͷǤͳͳ ͵ͳ ȋͶͺǣȌ ǤͻΪͲ ʹǤͳΪͲ ͷǤͺǦͲ ͳǤǦͲͶ ͵Ǥ͵ͳ ͷͷ ȋͶʹǣͲȌ ͳǤ͵ΪͲ ͷǤΪͲͷ ǤʹǦͲ ͳǤǦͲͶ ʹǤ͵ ͵ͷ ȋͶͶǣʹȌ ͶǤͷΪͲ ͳǤͶΪͲ ǤͶǦͲ ʹǤͲǦͲͶ ͵Ǥͳͺ ʹ ȋͷͲǣͺȌ ʹǤͻΪͲ ͻǤͻΪͲͷ ͳǤͷǦͲͷ ͵ǤͻǦͲͶ ʹǤͻ ͳʹ ȋͶʹǣͶȌ ͳǤͳΪͲ ǤΪͲͶ ͳǤǦͲͷ ͵ǤͻǦͲͶ ͳͷǤͻͷ ͶͶ ȋͶǣ͵Ȍ ͳǤͻΪͲ ǤͺΪͲ ʹǤͳǦͲͷ ͷǤͲǦͲͶ ʹǤͺͲ ͵͵ ȋͶͺǣȌ ͵ǤͶΪͲ ͳǤ͵ΪͲ ʹǤͻǦͲͷ ǤǦͲͶ ʹǤͷʹ ͷ͵ ȋͶǣ͵Ȍ ͵ǤͺΪͲ ͳǤ͵ΪͲ ͵ǤͳǦͲͷ ǤͺǦͲͶ ʹǤͻͲ ͳ ȋͶͶǣͳȌ ͶǤΪͲ ͳǤΪͲ ͶǤǦͲͷ ͻǤͺǦͲͶ ʹǤͷ ʹͳ ȋͶͺǣȌ ͵ǤͲΪͲ ͺǤ͵ΪͲͷ ͶǤǦͲͷ ͻǤͺǦͲͶ ͵Ǥͷ ͷʹ ȋͶǣȌ ʹǤΪͲͷ ͺǤͺΪͲͶ ͷǤʹǦͲͷ ͳǤͲǦͲ͵ ʹǤͻͶ ͷͶ ȋͶͷǣʹȌ ʹǤͶΪͲ ͳǤͳΪͲ ǤǦͲͷ ͳǤͷǦͲ͵ ʹǤʹͲ ͵Ͷ ȋͶͷǣ͵Ȍ ͷǤͲΪͲͷ ͻǤΪͲͶ ͺǤͻǦͲͷ ͳǤǦͲ͵ ͷǤͳ ȋͶͶǣͲȌ ͵ǤʹΪͲͷ ʹǤͷΪͲͷ ͵ǤʹǦͲͶ ͷǤͺǦͲ͵ ͳǤʹ ͵ ȋͶǣͷȌ ʹǤͻΪͲ ǤͷΪͲͷ ͶǤͻǦͲͶ ͺǤͺǦͲ͵ ͶǤͶͺ ȋͶǣʹȌ ʹǤͲΪͲͺ ͳǤͲΪͲͺ ͷǤͶǦͲͶ ͻǤ͵ǦͲ͵ ʹǤͲͳ ͺ ȋǦ͵ͺǣͳȌ ͺǤ͵ΪͲͶ ͳǤΪͲͷ ǤͳǦͲͶ ͳǤͲǦͲʹ ͲǤͶͺ ȋ͵ʹǣʹȌ ǤͶΪͲ ͶǤͶΪͲ ǤǦͲͶ ͳǤͳǦͲʹ ͳǤͲ ͵ ȋͶͺǣͷȌ ͵Ǥ͵ΪͲ ͳǤͺΪͲ ǤͺǦͲͶ ͳǤͳǦͲʹ ͳǤͺ ͶͲ ȋͷͲǣȌ ͶǤͶΪͲ ʹǤͳΪͲ ǤǦͲͶ ͳǤͳǦͲʹ ʹǤͲ ʹ ȋ͵ͲǣͳȌ ǤͻΪͲͷ ͵ǤͺΪͲͷ ǤͻǦͲͶ ͳǤʹǦͲʹ ͳǤͺͳ ͷͳ ȋͷͲǣȌ ͳǤΪͲ ǤͺΪͲ ͺǤǦͲͶ ͳǤ͵ǦͲʹ ʹǤͲͻ ͵ ȋͶͷǣͳȌ ʹǤͳΪͲ ͳǤͲΪͲ ͻǤͲǦͲͶ ͳǤ͵ǦͲʹ ʹǤͲ ͷͻ ȋͶͺǣͶȌ ǤͲΪͲ ͵ǤͷΪͲ ͳǤ͵ǦͲ͵ ͳǤͺǦͲʹ ʹǤͲͳ ͺ ȋ͵ʹǣ͵Ȍ ʹǤʹΪͲͷ ͳǤͶΪͲͷ ͳǤͶǦͲ͵ ͳǤͻǦͲʹ ͳǤͲ ͺͺ ȋͶǣͳȌ ͳǤͻΪͲͺ ͻǤΪͲ ͳǤͷǦͲ͵ ʹǤͲǦͲʹ ͳǤͻͳ ͻ ȋͲǣͷȌ ʹǤͲΪͲ ͳǤ͵ΪͲ ͳǤǦͲ͵ ʹǤ͵ǦͲʹ ͳǤͷͺ ͳͺ ȋ͵ͶǣͶȌ ʹǤΪͲ ͳǤͺΪͲ ʹǤʹǦͲ͵ ʹǤͺǦͲʹ ͳǤͷͷ ͺͶ ȋͶͶǣͲȌ ͷǤΪͲ ͵Ǥ͵ΪͲ ʹǤͶǦͲ͵ ͵ǤͲǦͲʹ ͳǤͶ ͵ͻ ȋͷͲǣȌ ͺǤͶΪͲ ͷǤͲΪͲ ʹǤͷǦͲ͵ ͵ǤͳǦͲʹ ͳǤ Ͷ ȋͶͺǣ͵Ȍ ͳǤΪͲͺ ͳǤͲΪͲͺ ʹǤͻǦͲ͵ ͵ǤͷǦͲʹ ͳǤͷͷ ͺʹ ȋͶǣʹȌ ͳǤͳΪͲ ǤΪͲ ͵ǤͶǦͲ͵ ͶǤͲǦͲʹ ͳǤ͵ ͻ ȋͶͺǣʹȌ ͳǤͳΪͲͻ ǤʹΪͲͺ ͵Ǥ͵ǦͲ͵ ͶǤͲǦͲʹ ͳǤͶ ͷ ȋͶǣ͵Ȍ ͵ǤʹΪͲ ͳǤΪͲ ͵ǤͶǦͲ͵ ͶǤͲǦͲʹ ͳǤͻʹ ʹ ȋͷͲǣȌ ͺǤͳΪͲ ͶǤΪͲ ͵ǤͺǦͲ͵ ͶǤ͵ǦͲʹ ͳǤͷ ȋͷʹǣȌ ͵Ǥ͵ΪͲͺ ʹǤͲΪͲͺ ͶǤͲǦͲ͵ ͶǤͶǦͲʹ ͳǤ͵ Ͳ ȋͶͺǣͶȌ ǤͻΪͲ ͶǤͷΪͲ ͶǤʹǦͲ͵ ͶǤͷǦͲʹ ͳǤͷ͵ Ͷ ȋͷʹǣȌ ͷǤͲΪͲ ʹǤͻΪͲ ͶǤ͵ǦͲ͵ ͶǤͷǦͲʹ ͳǤͳ Ͷʹ ȋͶǣͶȌ ǤʹΪͲͷ ʹǤͷΪͲͷ ͶǤ͵ǦͲ͵ ͶǤͷǦͲʹ ʹǤͶ ͳͻ ȋ͵ͶǣͶȌ ͳǤͻΪͲ ͳǤ͵ΪͲ ͶǤͶǦͲ͵ ͶǤǦͲʹ ͳǤͶ͵ ͳͳͷ ȋͶǣͲȌ ʹǤͳΪͲ ͳǤ͵ΪͲ ͶǤǦͲ͵ ͶǤǦͲʹ ͳǤͳ ͷ ȋͶͻǣͷȌ ͶǤͳΪͲ ʹǤͳΪͲ ͶǤͷǦͲ͵ ͶǤǦͲʹ ͳǤͻʹ ͷ ȋǦ͵ǣͳȌ ͳǤͺΪͲͷ ͵ǤͳΪͲͷ ͶǤͻǦͲ͵ ͶǤͺǦͲʹ ͲǤͷͺ ǡδͲǤͲͷ ǡδͲǤͲͷ ǡδͲǤͲͷǡ εʹ ǡδͲǤͲͷǡ δͲǤͷ
ͳͷʹ ͳͷ͵ in MCAD-KO mice mice in MCAD-KO Ǥ 4 ̴ͺǣͲȌ ̴ͳͺǣ͵Ȍ ȋͳǣʹ̴ͳǣʹ̴ͳͺǣʹȌ ̴ͳͺǣͳȌ ȋͳͶǣͳ̴ͳͶǣͳ̴ͳͺǣʹȌ ̴ͳͺǣͳȌ ȋͳǣͲ̴ͳǣʹ̴ͳǣʹȌ ȋͳǣͳ̴ͳǣͳ̴ͳǣʹȌ ̴ͳͺǣͳȌ ȋͳͶǣͳ̴ͳǣͲ̴ͳǣʹȌ ȋͳͶǣͳ̴ͳǣͳ̴ͳǣͳȌ ̴ͳǣͳȌ ȋͳͶǣͳ̴ͳͶǣͳ̴ͳͺǣͲȌ ȋͳͶǣͳ̴ͳǣͲ̴ͳǣͳȌ ̴ͳǣͳȌ ȋͳͶǣͲ̴ͳͶǣͳ̴ͳǣͲȌ ̴ͳǣͳȌ ȋͳͶǣͳ̴ͳͶǣͳ̴ͳǣͲȌ ȋͳͺǣͳ̴ͳͺǣͳ̴ͺǣͲȌ hepatic metabolism hepatic metabolism Ǥαͺ ǡ Ǧ Effect of fasting and cold stress on stress cold and Effect of fasting ͳͺǣͳ̴ǣͲȌ ͳǣͳ̴ͺǣͲȌ ȋͳǣͲ̴ͳͺǣʹ̴ǣͲȌ ȋͳǣͳ̴ͳͺǣͳ̴ǣͲȌ ̴ͳͺǣͳ̴ͺǣͲȌ ȋͳͺǣͳ̴ͳͺǣʹ̴ǣͲȌ Ͳ̴ͳǣͲ̴ͺǣͲȌ Ͳ̴ͳͺǣͳ̴ͺǣͲȌ Ͳ̴ͳͺǣʹ̴ͺǣͲȌ ȋͳǣͳ̴ͳͺǣͳ̴ͺǣͲȌ Ͳ̴ͳͺǣ͵̴ͳͺǣ͵Ȍ ȋͳͶǣͳ̴ͳǣͳ̴ʹͲǣͶȌ ȋͳͶǣͳ̴ͳͺǣʹ̴ͳͺǣ͵Ȍ ȋͳǣͳ̴ͳǣʹ ͳ̴ͳǣͳ̴ͳǣʹȌ ȋͳͺǣͳ̴ͳͺǣ͵̴ͺǣͲȌ ȋͳͺǣʹ̴ͳͺǣʹ̴ͺǣͲȌ ͳ̴ͳͺǣ͵̴ͳͺǣ͵Ȍ ȋͳǣʹ̴ͳǣʹ̴ͳͺǣ͵Ȍ ʹ̴ͳǣʹ̴ͳǣʹȌ Ͳ̴ͳǣʹ̴ͳͺǣʹȌ ȋͳʹǣͳ̴ͳǣͲ̴ͳͺǣ͵Ȍ ȋͳʹǣͳ̴ͳǣͳ̴ͳͺǣʹȌͳ̴ͳǣʹ̴ͳͺǣʹȌ ȋͳʹǣͳ̴ͳǣʹ ȋͳǣͲ̴ʹʹǣͷ̴ͺǣͲȌ ȋͳͺǣͳ̴ʹͲǣͶ̴ͺǣͲȌ Ͳ̴ͳǣʹ̴ͳͺǣʹȌ ȋͳͶǣͳ̴ͳǣͲ̴ͳͺǣ͵Ȍ ȋͳͶǣͳ̴ͳǣͳ̴ͳͺǣʹȌ ȋͳͶǣͳ̴ͳǣʹ ͳ̴ͳǣͲ̴ͳͺǣʹȌ ȋͳʹǣͳ̴ͳǣͳ̴ͳͺǣͳȌ ȋͳͶǣͲ̴ͳͶǣͳ̴ͳͺǣʹȌ ȋͳͶǣͳ̴ͳͶǣͳ ͳ̴ͳǣͲ̴ͳͺǣͳȌ ȋͳʹǣͳ̴ͳǣͳ̴ͳͺǣͲȌ ȋͳͶǣͲ̴ͳͶǣͳ̴ͳͺǣͳȌ ȋͳͶǣͲ̴ͳǣͳ ͳ̴ͳͶǣͲ̴ͳͺǣʹȌ ȋͳʹǣͳ̴ͳͶǣͳ̴ͳͺǣͳȌ ȋͳʹǣͳ̴ͳǣͳ̴ͳǣͳȌ ȋͳͺǣͳ̴ͳͺǣʹ Ͳ̴ͳǣͲ̴ͳǣͳȌ ȋͳʹǣͳ̴ͳͶǣͲ̴ͳͺǣͲȌ ȋͳʹǣͳ̴ͳǣͲ̴ͳǣͲȌͲ̴ͳͶǣͳ̴ͳͺǣͳȌ ȋͳͶǣͲ̴ͳͶǣͲ ȋͳʹǣͲ̴ͳǣͳ̴ͳǣͳȌ ȋͳʹǣͳ̴ͳͶǣͲ̴ͳͺǣͳȌ ȋͳʹǣͳ̴ͳǣͲ
ͳ Ǥ ʹ Ȁ Ȁ Ȁ Ȁ ȋͷͶǣͷ̸ͷ;ǣͷȌ ȋͳǣͲ̴ͳǣͳ̴ͺǣͲȌ ȋͳͶǣͲ̴ͳͺǣͳ̴ͺǣͲȌ ȋͳͲǣͲ̴ͳͶǣͲ̴ͳǣͳȌ ȋͳǣͲ̴ ȋͳǣͲ̴ʹʹǣ̴ͺǣͲȌ ȋͳͺǣʹ̴ͳͺǣ͵̴ͺǣͲȌ ȋͳǣͳ̴ʹͲǣͶ̴ͺǣͲȌ ȋͿǣͶ̸ͷͼǣͶ̸ͷ;ǣͷȌ ȋͷͶǣͶ̸ͷͻǣͶ̸ͷ;ǣͷȌ ȋͳͲǣͲ̴ͳͺǣͳ̴ʹʹǣȌ ȋͳʹǣͲ̴ͳǣͳ̴ʹʹǣȌ ȋͳʹǣͳ̴ͳǣͲ̴ʹʹǣȌ ȋͳͶǣ ȋͳͲǣͲ̴ͳͶǣͳ̴ͳǣͳȌ ȋͳͶǣͲ̴ͳͺǣʹ̴ͺǣͲȌ ȋͳͶǣͳ̴ͳͺǣͳ̴ͺǣͲȌ ȋͳǣͳ̴ ȋͳͲǣͲ̴ͳͶǣͲ̴ͳǣͲȌ ȋͳʹǣͲ̴ͳʹǣͲ̴ͳǣͲȌ ȋͳʹǣͲ̴ͳͶǣͲ̴ͳͶǣͲȌ ȋͳǣ ȋͳͲǣͲ̴ͳͶǣͲ̴ͳͺǣͳȌ ȋͳͲǣͲ̴ͳǣͲ̴ͳǣͳȌ ȋͳʹǣͳ̴ͳͶǣͲ̴ͳǣͲȌ ȋͳǣ ȋͳͲǣͲ̴ͳǣͲ̴ͳǣͲȌ ȋͳʹǣͲ̴ͳͶǣͲ̴ͳǣͲȌ ȋͳͶǣͲ̴ͳͶǣͲ̴ͳͶǣͲȌ ȋͳͲǣͲ̴ͳͶǣͲ̴ͳͺǣʹȌ ȋͳͲǣͲ̴ͳǣͳ̴ͳǣͳȌ ȋͳʹǣͳ̴ͳͶǣͳ̴ͳǣͲȌ ȋͳǣ ȋͳʹǣͲ̴ͳǣͲ̴ʹʹǣȌ ȋͳʹǣͳ̴ͳͺǣͳ̴ʹͲǣͶȌ ȋͳͶǣͲ̴ͳͶǣͲ̴ʹʹǣȌ ȋͳͶǣ ȋͳͲǣͲ̴ͳǣͳ̴ʹʹǣȌ ȋͳͲǣͲ̴ͳǣͲ̴ʹʹǣȌ ȋͳͲǣͲ̴ͳͺǣʹ̴ʹͲǣͶȌ ȋͳͶǣͳ̴ͳͶǣͳ̴ʹͲǣͶȌ ȋͳǣ ȋͳͲǣͲ̴ͳͺǣʹ̴ͳͺǣ͵Ȍ ȋͳʹǣͲ̴ͳǣʹ̴ͳͺǣ͵Ȍ ȋͳʹǣͳ̴ͳǣͳ̴ͳͺǣ͵Ȍ ȋͳʹǣ ȋͳʹǣͲ̴ͳͺǣʹ̴ͳͺǣʹȌ ȋͳʹǣͳ̴ͳͺǣͳ̴ͳͺǣʹȌ ȋͳͶǣͲ̴ͳǣͳ̴ͳͺǣ͵Ȍ ȋͳͶǣ ȋͳͲǣͲ̴ͳǣͲ̴ʹͲǣͶȌ ȋͳͲǣͲ̴ͳͺǣͳ̴ͳͺǣ͵Ȍ ȋͳʹǣͲ̴ͳǣͳ̴ͳͺǣ͵Ȍ ȋͳʹǣ ȋͳͲǣͲ̴ͳͺǣͳ̴ͳͺǣʹȌ ȋͳʹǣͲ̴ͳǣͳ̴ͳͺǣʹȌ ȋͳʹǣͲ̴ͳǣʹ̴ͳͺǣͳȌ ȋͳʹǣ ȋͳʹǣͲ̴ͳͷǣͲ̴ͳͺǣͳȌ ȋͳͶǣͲ̴ͳͷǣͲ̴ͳǣͳȌ ȋͳͶǣͳ̴ͳͷǣͲ̴ͳǣͲȌ ȋͳʹǣͲ̴ͳͷǣͲ̴ͳͺǣʹȌ ȋͳͲǣͳ̴ͳǣͲ̴ͳͺǣʹȌ ȋͳͲǣͲ̴ͳͺǣͳ̴ͳͺǣͳȌ ȋͳʹǣͲ̴ͳǣͲ̴ͳͺǣʹȌ ȋͳʹǣͲ̴ͳǣͳ̴ͳͺǣͳȌ ȋͳʹǣ ȋͳͲǣͲ̴ͳǣͳ̴ͳͺǣ͵Ȍ ȋͳͲǣͲ̴ͳǣʹ̴ͳͺǣʹȌ ȋͳʹǣͳ̴ͳͶǣͳ̴ͳͺǣʹȌ ȋͳʹǣ ȋͳͲǣͲ̴ͳǣͲ̴ͳͺǣ͵Ȍ ȋͳͲǣͲ̴ͳǣͳ̴ͳͺǣʹȌ ȋͳͲǣͲ̴ͳǣʹ̴ͳͺǣͳȌ ȋͳʹǣ ȋͳͲǣͲ̴ͳǣͲ̴ͳͺǣʹȌ ȋͳͲǣͲ̴ͳǣͳ̴ͳͺǣͳȌ ȋͳʹǣͲ̴ͳͶǣͲ̴ͳͺǣʹȌ ȋͳʹǣ ȋͳͲǣͲ̴ͳǣͲ̴ͳͺǣͳȌ ȋͳʹǣͲ̴ͳͶǣͲ̴ͳͺǣͳȌ ȋͳʹǣͲ̴ͳͶǣͳ̴ͳͺǣͲȌ ȋͳʹǣ ȋͳͲǣͲ̴ͳͶǣͲ̴ͳͺǣ͵Ȍ ȋͳͶǣͳ̴ͳͶǣͳ̴ͳͶǣͳȌ ȋͳǣͳ̴ͳͺǣʹ̴ͺǣͲȌ ȋͳǣʹ Name Isomer1 Isomer2 Isomer3 Isomer4Isomer5 Isomer6 Isomer7 Isomer8 Isomer9 Name TG(50:7) TG(50:7) TG(60:5) TG(60:5) TG(50:8) TG(50:8) TG(40:2) TG(40:2) TG(40:0) TG(40:0) TG(40:1) TG(42:1) TG(42:1) TG(42:0) TG(42:0) TG(42:2) TG(48:8) TG(48:8) TG(50:6) TG(48:7) TG(48:7) TG(48:6) TG(48:6) TG(46:5) TG(46:5) TG(47:4) TG(47:4) TG(47:5) TG(47:6) TG(48:4) TG(46:4) TG(46:4) TG(46:6) TG(46:3) TG(46:3) TG(45:1) TG(45:1) TG(45:2) TG(45:3) TG(45:3) TG(46:2) TG(44:5) TG(44:5) TG(44:4) TG(44:4) TG(44:3) TG(44:3) TG(44:2) TG(44:2) TG(44:1) TG(44:1) TG(42:3) TG(42:3) TG(43:1) TG(43:1) DG(28:2) DG(28:2) ǣ Ǥ mice 8-week-old of livers from isomers DG and TG Annotated ST3. Table Supplementary ǤǤǤͲͳ̷ Ǥ Chapter 4
Supplementary Table ST4. Histological examination scores for 16-20-week old and 8-week-old mice 16-20 weeks-old 8 weeks-old WT KO WT KO ͲǤͻ ά ͲǤͲ ͲǤͺ ά ͲǤͳ ȗ ͲǤͻ ά ͲǤͲ ͲǤͺ ά ͲǤͳ ͵ǤͲ ά ͲǤͲ ʹǤͻ ά ͲǤͳ ͵ǤͲ ά ͲǤͲ ʹǤͺ ά ͲǤʹ ͳǤͶ ά ͲǤʹ ͳǤ ά ͲǤͳ ʹǤͲ ά ͲǤͳ ͳǤͺ ά ͲǤʹ ͲǤ͵ ά ͲǤʹ ͲǤ͵ ά ͲǤ͵ ͲǤͳ ά ͲǤͳ ͲǤ ά ͲǤ͵ ʹǤͺ ά ͲǤʹ ͳǤ ά ͲǤ͵ ȗ ͳǤͻ ά ͲǤ͵ ʹǤͲ ά ͲǤ͵ ʹǤͺ ά ͲǤʹ ʹǤͳ ά ͲǤͳ ȗ ʹǤͳ ά ͲǤͳ ʹǤͲ ά ͲǤͲ ͳǤͲ ά ͲǤͲ ͳǤͲ ά ͲǤͲ ͳǤͲ ά ͲǤͲ ͲǤͻ ά ͲǤͳ ͲǤͳ ά ͲǤͳ ͲǤͲ ά ͲǤͲ ͲǤͲ ά ͲǤͲ ͲǤͲ ά ͲǤͲ ͳǤͳ ά ͲǤ͵ ͳǤͳ ά ͲǤʹ ͲǤͺ ά ͲǤ͵ ͳǤͲ ά ͲǤ͵ ͲǤͳ ά ͲǤͳ ͲǤ͵ ά ͲǤʹ ͲǤͳ ά ͲǤͳ ͲǤͷ ά ͲǤʹ ͲǤͷ ά ͲǤʹ ͲǤͳ ά ͲǤͳ ͲǤͲ ά ͲǤͲ ͲǤͲ ά ͲǤͲ ͶǤͲ ά ͲǤͷ ʹǤͺ ά ͲǤͶ i ʹǤ ά ͲǤͶ ͵ǤͲ ά ͲǤͷ Ǥ ͳǤͶ ά ͲǤͶ ͲǤͷ ά ͲǤͷ i ͲǤͻ ά ͲǤͷ ͳǤͲ ά ͲǤ ǡ ͵Ǥ Supplementary Table ST5. Table of possible lipid fragments Fatty acid fa1 fa2 fa3 PL TG DG FA6:0 FA8:0 FA9:0 FA10:0 FA12:0 FA12:1 FA14:0 FA14:1 FA15:0 FA15:1 FA16:0 FA16:1 FA16:2 FA17:0 FA18:0 FA18:1 FA18:2 FA18:3 FA19:0 FA20:3 FA20:4 FA20:5 FA21:0 FA22:3 FA22:4 FA22:5 FA22:6 O-16:0 O-18:0 O-20:0 P-16:0 P-18:0 P-20:0 Type Weight Group FA1_[FA-H2O+H]+ ͳǤ ͳ FA2_[FA-H2O+H]+ ͳǤ ͳ FA3_[FA-H2O+H]+ ͳǤ ͳ [MG(FA1)-H2O+H]+ ͳǤ ʹ [MG(FA2)-H2O+H]+ ͳǤ ʹ [MG(FA3)-H2O+H]+ ͳǤ ʹ [M-(FA1)+H]+ ͵Ͳ ʹ [M-(FA2)+H]+ ͵Ͳ ʹ [M-(FA3)+H]+ ͵Ͳ ʹ
ͳͷͶ
Chapter 5
Simulating the impact of genetic and environmental modifiers on MCAD deficiency in an extended computational model of human liver fatty-acid catabolism
ۥAnne-Claire M.F. Martines1,#, Dirk-Jan Reijngoud1,2, Barbara M. Bakkerƌϭ͕
1 Laboratory of Pediatrics, Center of Liver, Digestive and Metabolic Diseases, University of Groningen, Groningen, University Medical Center Groningen, Groningen, The Netherlands, 2 Department of Analytical Biochemistry, University of Groningen, Groningen, The Netherlands.
Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
Abstract Ǧ Ǧ ȋ Ȍ Ǧ Ǥ ͵ Ͷ Ǥ ǡ Ǥ ǡ Ǥ ǡ ǡ Ǥ ǡ 5 ǡ Ǧ Ǥ ͳǡ ǡ Ǥ Ǥ
ͳͷͻ Chapter 5
Introduction Ǧȋ Ȍ Ǥ ǡ Ǧ Ǧ ȋȌȋ ǦȌ Ǥ Ǧ Ǧǡ Ǥ ǡ Ǧ ǡ ǡ Ǥ Ǧ Ǧ Ǧ Ǧ Ǧ ȋFigure 1ǡ ȌǤ ǡ Ǧ ȋȌͳǡ Ǧ Ǧ ȋȌǡ Ǧ ʹǤ ǦǦ ǡ Ǧ ȏͳȂ͵Ȑ Ǥ ǡ Ǧ ǡ Ǧ Ǥ ǡǦǦǡǦǡ Ǧ ǦȋǡǡȌȏ͵ǡͶȐǤ ǡ Ǧ ǡǦǡ Ǧ
ʹǤ ȋ Ȍ ȋi.e. Ȍ Ǧ
ʹ Ǥ ǡ Ǧǡǡ Ϊ ǡ Ǥ Ǧ Ǧǡ ȋ ǡ ȌǤ ǡ Ǧǡ ǦǦǦ
ʹǡ ȋȌ ȋ ȌǤ ǡ Ǥ ȏ͵ǡͷȐǤ Ǧ ǡ ǡ Ǧ Ǥ ǡǡ ȏ͵ǡͶȐǡ ǯ Ǥ Ǧ ȋȌ ȏȐǤ ȏ͵ȐǤ ǡ Ǧ ȋ Ȍ ǡ Ǥ ǡ ǦǦ Ǥͻͺͷε ACADMǡ ǡ Ǧ ȏ͵ǡͷȐǡ ȏȂͳͷȐǤ Ǥͻͺͷε ͳͺǦʹͶ ȏ͵ǡǡͳǡͳȐǤ ǡ
ͳͲ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
ǡ ǡ Ǧǡ ȏͷǡͳͷǡͳͺȂʹͲȐǤ ǡ ʹǤ ǡ ǡ ȏʹͳȐǡ Ǧ ȏͶȐǤ Ǧ ǡǦ ǦȋȌΪǦ Ǧ Ǧ ȋ Ȍ ȏʹͳȐȋChapter 2ȌǤ Ǥ 5 Ǧ ȏʹʹȐǤ Ǧ Ǧ ȋȌǡ ȏʹʹȐǤ ǡ Ǥ ǡ Ǥ ǡ ǤǤ Ǥ ǡ Ϊ Ǥ ǡ ǡ Ǥ Ϊ ǡ ǡ Ǥ ǡ Ϊ ǡ Ǥ Ǥ ǡ EǦǦ ȋFigure 1ȌǤ Ǥ Ǧ Ǧ ȋͶǦ ǦȌ Ǥ EǦǦ ȋ ʹͷǦͶͺΨ Ǧȏʹ͵ǡʹͶȐȌǡ ΪǤ Ϊǡ Ǥ ǡ Ǧ Ϊ Ǧ Ϊ ʹ Ǥ Ǥ ǡ ǡ ȏʹͷȐǡ ȏͶǡʹȐǤ ǡ Ǧ Ǥ ǡ Ǧ Ǧ ȋȌ Ǥ ȋ Ȍ Ǧ ȋȌ ȋFigure 1ȌǤ ȏʹȂ͵ͲȐ Ǥ ɘǦ ǡ
ͳͳ Chapter 5
Ǧ Ǥ Ǧ Ǧ Ǥ ǡǦ ǡ Ǧ ȏ͵ͳȐǤ ǡ Ϊ ȏ͵ʹǡ͵͵ȐǤ Ǥǡ Ǥ ǡǡ Ǥ Ǧ Ǥ ǡ Ǥ ǡ ǡǤǡ ǡ Ǥ Ǧ Ǥ Ǧ ȋȌ Ǥ ǡ ǡ Ǥ ǡ Ǥ Ǥ Results Model construction and characterization ȏʹʹȐǤ ǡ ȋȌ ǦȋͳǦ ǦȌȋ ͳȌǤ ȋ ͳȌǤ Ǥ ȏʹʹȐǤǡ ǡ Ǥ ǡ ǤǦ ǦȋȌ ǡ ȏ͵ͶȐǤǡ ͳǡǡ ǡ ǡ ǡ ǦǤ ǡ Ǧ ǡ ȋȌ Ǥ ǡ ǡ ǡ ΪǤ Ǧ
ǡ ǡ ȋ ʹȌ Ǥ Ǧ ǡ ͳǤ Ǧǡ
ͳʹ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
Ǧ Ǧ ȏ͵ͷȐǤ Ǧ ǡ Ͷͳͳ ȏ͵Ȑ Ǥ ͳǤ ʹ Ǧ ǦǤ Ǧ ǡ Ǥ ǡ ͵ͲɊ Ǧ ȋ ʹȌǤ ǡ ȋ ʹȌǤ 5 ǡȏʹʹǡ͵Ȑǡ Ǥ
Cytosol DCA Palmitoyl-CoA (C -Acyl-CoA) чϭϰ DCA ʘ-oxidation Malonyl-CoA Acyl-carnitine FFA C4-C16 Acyl-CoA FFA carnitine CoASH CoASH Microsome carnitine CPT1 ACS C4-C16 CACT C4-C16 CoQ CoQH C4-C16 CPT2 2 Mitochondrion C4-C16 ETFox 2 Acetyl-CoA ACOT FFA ETFQO carnitine C4-C16 ETF CoASH carnitine red ACAT1 Acyl-carnitine CoASH CoASH Acyl-CoA C4-ketoacyl-CoA Acetyl-CoA ETF HMGCS2 MCKAT Acetyl-CoA SCAD MCAD VLCAD ox CoASH C4-C16 C4-C6 C4-C16 C6-C16 ETF CoASH red HMG-CoA
Ketoacyl-CoA Enoyl-CoA Acetyl-CoA HMGCL + NADH + H MTP Acetyl-CoA H2O C4-ketoacyl-CoA NADH + H+ Acetoacetate MSCHAD C4-ketoacyl-CoA CROT NAD+ C8-C16 C4-C16 NAD+ C4-C16 CoASH + NADH + H BDH1 Hydroxyacyl-CoA NAD+ ɴ-OH-butyrate Figure 1. Schematic representation of the extended human model. Ǥ Ǥ ȋȌȋͳ ȌǤ ǦȋȌ ǡ Ǧ ͳͶȋ
dͳͶǡ Ȍ Ǥ Ǧ Ǥ Chapter 2ǡ Ǥ Ǥǡǡ Ǥ Ǥ
ͳ͵ Chapter 5
A B C 14 5000 3.0 )
-1 free CoA Leak * 12 vExAc-carnCn * 4000 Intermediate CoA esters ɇ 10 C4-CoA esters ɇvExFFACn * ;ʅDͿ 2.0 .gProtein vExDCACn * -1 3000 C6-CoA esters ɇ
8 MAT vacsC16 * 6 C8-CoA esters 2000 C10-CoA esters 4 1.0 (μmol.min C12-CoA esters (%) leak Substrate 2 1000
[Metabolite] C14-CoA esters nadhsink J 0 0 C16-CoA esters 0.0 0501000 50 100 0 50 100 [Palmitoyl-CoA] [Palmitoyl-CoA] [Palmitoyl-CoA] CYT ;ʅDͿ CYT ;ʅDͿ CYT ;ʅDͿ Figure 2. The net NADH production flux in the mitochondrionȋǤ Ȁ Ȍ ȋ ǡ ǡȋAȌǢ ǡ ǦǡǦǡǦǦ Ǧǡ Ǧ ȋBȌ ȋ Ǥ ͳȌǤ C Ǯǯ Ǧ Ǧ ZǦǡͳǦ Ǧ Ǥ ǡǤǤͳǦ ǡͳͶǦ ǡ Ǥ ȋSupplementary Figure S2ȌǤǡ Ǧ ȋͳͲͲΨȗȀȋȗ ͳͳȌȌǤ Ǧ ZǦ ȋʹǤΨǦ Ǣȋ ʹǡȌǤ Ǧ ǡ ǤǤ ͳǦ Ǧ ȋʹȌǤ ǡ ȋ Ǥ ʹȌ ͳ ȋ Ȍ ʹͷ Ɋ
Ǧǡ ͳͲͲ Ɋ Ǧ ͳ Ǥ ǡͳ ǡ ͳͲͲ Ɋ ǦǤ ȋͳȌǤ Simulating the impact of ACAD deficiencies on the mitochondrial mFAO flux ǡ ǡ ȏͳͲǡ͵ͺǡ͵ͻȐ ȋ ͵ȌǤ ǣ ȏ͵ͺȐ ȏͶͲȐ ͲǤͷΨ ͶΨ ȏͶͳȐǤ ǡǡ ȋ ͵ȌǤ ǣ ȏȐǡ ȋȌǡ Ǥǡ ȋ ͵ȌǤȋ ʹȌ Ǧ ȋ ͵ǦȌǤ Ǥ
ͳͶ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
A )
-1 14 12 10 WT
.gProtein -1 8 SCAD KO 6 MCAD KO 4
(μmol.min VLCAD KO 2
0 nadhsink J B C D 5000 VLCAD KO MCAD KO SCAD KO free CoA 4000 Intermediate CoA esters
;ʅDͿ C4-CoA esters
MAT 3000 C6-CoA esters 5 C8-CoA esters 2000 C10-CoA esters C12-CoA esters 1000 [Metabolite] C14-CoA esters C16-CoA esters 0 E 40 F 0 G VLCAD KO MCAD KO SCAD KO Leak * 30 0 ɇvExAc-carnCn *
20 0 ɇvExFFACn *
ɇvExDCACn * 10 0 Substrate leak (%) Substrate vacsC16 *
0 0 050100050100050100
[Palmitoyl-CoA]CYT ;ʅDͿ [Palmitoyl-CoA]CYT ;ʅDͿ [Palmitoyl-CoA]CYT ;ʅDͿ Ǥ Figure 3. The net NADH production flux in the mFAOȋAȌǡ ǡ Ǧǡ Ǧǡ ǦǦ Ǧǡ Ǧ ȋȌǦȋB-DȌǤE-G ǡ ǦǡǮǯ Ǧ Ǧ ZǦǡ ͳǦ Ǧ Ǧ Ǥ ǡ Ǥ ǡ ͳǦ ȋ ͵ȌǤ ǡ Ǥ ǡ ǡ Ǥ ͺ ͳͲ ȋ ͵Ȍǡ ͺ ͳͲ Ǧ ȏͶʹȂͶȐǤ ǡ ͶǦȋ ͵Ȍǡ Ǧ Ǧ Ǥǡi.e. Ǧǡ ǡȋ Ǥ ʹǦ ͵ Ǧ ȌǤ ǡ Ǧ Ǥ ǡǡ ȋ ͵ȌǤ ǣ ȏȐǡ ȋȌǡ
ͳͷ Chapter 5
Ǥǡ ȋ ͵ȌǤ ȋ ʹȌ Ǧ ȋ ͵ǦȌǤ Ǥ ǡ Ǥ ǡ ͳǦ ȋ ͵ȌǤ ǡ Ǥ ǡ ǡ Ǥ ͺ ͳͲ ȋ ͵Ȍǡ ͺ ͳͲ Ǧ ȏͶʹȂͶȐǤ ǡ ͶǦȋ ͵Ȍǡ Ǧ ǦǤǡi.e. Ǧǡ ǡȋ Ǥ ʹǦ ͵ Ǧ ȌǤ ǡ Ǧ Ǥ ǡǡ ȋ ͵ȌǤ Impact of individual variations on the mFAO flux Ǥǡ ǡ ΪǤ ȋ ͷȌǤ ΪǦ ȋ Ȍǡ Ǧ ȋ Ǧ Ȍ Ǧ ǡ ȏʹʹǡͶȐǤ ǡ ͳǡǯ
ȋͳαͲȌ
ͳΨ Ǥ ǡ
ͳΨ ȋ ͶȌǤ ǡ ǡ ͶǦ Ǥ Ǥ Ǥ ǡ ǡ ǡ ΪȀ ȏʹǡͶͺȐǤ ͳ ȋ ͶȌ Ǥ ͳ ȋ Ǥ Ͷ ǡ ȌǤ
ͳ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
A B C D ) 14 -1 12
10
.gProtein -1 8 6 4 (μmol.min 2 0 nadhsink J 050100050100050100050100 [Palmitoyl-CoA] [Palmitoyl-CoA] [Palmitoyl-CoA] [Palmitoyl-CoA] CYT ;ʅDͿ CYT ;ʅDͿ CYT ;ʅDͿ CYT ;ʅDͿ A B C ) 14 -1 12 WT 5 10 .gProtein
-1 8 SCAD KO
6 MCAD KO 4
(μmol.min VLCAD KO 2 0 nadhsink J 050100050100050100
[Palmitoyl-CoA]CYT ;ʅDͿ [Palmitoyl-CoA]CYT ;ʅDͿ [Palmitoyl-CoA]CYT ;ʅDͿ Figure 4. Net NADH production fluxȋȌ Ǧ Ǥ ȋʹͷΨ ȌȋAȌǡΪȀ ȋʹͷΨ ȌȋBȌǡ Ǧ ȋʹͷΨ ȌȋCȌǡ Ǧ ȋDȌǡͳȋEȌǡȋͳΨ ȌȋFȌǡȋʹͷΨ ȌȋGȌǤ ȋ ͵Ȍǡ Ǥ ǡǡ Ǧ Ͷ ͳǤ ͺ ȋ ͳȌǡ Ǧ ǦǤǡ Ǧ ȋ ͶȌǤ Ǧ ͳǦǦʹ ȋ ͳȌ Ǧ Ǥ Ǧ ȋ ͶȌǤ ǡ ͳ ǡ Ǥ Impact of acyl-CoA recycling on the mFAO flux ȋȌ ȏʹȂ͵ͲȐǤ Ǥǡ Ǧ
Ǥ ǡͳΨ Ǥ ǡ ǡ Ǥ ǡ ȋ ͷȌǤ ǡ ȋ Ǥ ͳʹȌǤ ȋ ͷǦȌǤ
ͳ Chapter 5
A
) 14 -1 12
10 WT
.gProtein
-1 8 SCAD KO
6 MCAD KO 4
(μmol.min VLCAD KO 2
0 nadhsink J 050100 WT VLCAD KO MCAD KO SCAD KO B C D E 5000 Ϳ 4000 ʅD ; free CoA
MAT 3000 ]
2000 Intermediate
Metabolite 1000 CoA esters [
0 050100050100050100050100 [Palmitoyl-CoA] [Palmitoyl-CoA] [Palmitoyl-CoA] [Palmitoyl-CoA] CYT ;ʅDͿ CYT ;ʅDͿ CYT ;ʅDͿ CYT ;ʅDͿ ͷǤ Ǧ ͳΨ Ǥ ȋȌǡ ȋǦȌ ȋ ͵Ȍǡ Ǥ Ȃ Ǥ ȋ ͵ȌǤ Ǧ ȋ ͳͶǦͶ Ǧ Ȍ Ǧ ͳǤͳͳǦ ǡi.e.
ͳ ͳͶǦͶ ͳͶǦͶ Ǧȋͳ
ȌǤ Ǥ ǡȋ ȌǤ Ǧ ͳȋ ȌǤ ǡͳǦ ͳ ͳͲͲΨ Ǧ ȋ ͵ȌǤ ǡ ͳǦ ͳ ȋ ǦȌǤ ǡ ǡ ȋͶȌǤ ȋ ͶȌǤ ͳǦ ͳ ǣ Ǧ ͳͲΨǡ ǡȋ ǡ ȌǤ ǡ Ǥ
ͳͺ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
A
) 14 -1 12
10 WT
.gProtein
-1 8 SCAD KO
6 MCAD KO 4
(μmol.min VLCAD KO 2 0 nadhsink J 050100 WT VLCAD KO MCAD KO SCAD KO B C D E 5000 4000
;ʅDͿ free CoA 5 MAT 3000
2000
Intermediate 1000 CoA esters [Metabolite] 0 050100050100050100050100 [Palmitoyl-CoA] [Palmitoyl-CoA] [Palmitoyl-CoA] [Palmitoyl-CoA] CYT ;ʅDͿ CYT ;ʅDͿ CYT ;ʅDͿ CYT ;ʅDͿ F G
) 14 -1 12 10 WT
.gProtein
-1 8 SCAD KO
6 MCAD KO 4
(μmol.min VLCAD KO 2 0 nadhsink J 050100050100
[Palmitoyl-CoA]CYT ;ʅDͿ [Palmitoyl-CoA]CYT ;ʅDͿ Figure 6. Simulation results of the extended model with a CPT1 with reduced activity and affinity towards C14-C4 acyl-CoA substrates. ͳǡ ͳǤ ȋAȌ ȋͳǦͶ Ǧ Ȍ ȋB-EȌǤ F-G ȋ Ȍ Ǧ Ǥ ȋͻͲΨ Ȍ ȋFȌ Ǧ ȋͻͲΨ ȌȋGȌǤ ȋ Figure 3Ȍǡ Ǥ Discussion Ǥ Ǥ ǡ ǡ Ǧ Ǥ Ǥ ǡǡ ȏȂͳͷȐǤ Ǥ
ͳͻ Chapter 5
ǡ ǡ ǡ in vivoǤ Ǥ ͳ Ǥ ͳ Ǧ Ǥ ȋȌ ͳ ȏͶͺȐǤ ȋ ȌǤ ǡ Ǧ Ǧ Ǥ ǡ Ǥ Ǥ Ǧ ǡ ǡ Ǥ ǡ Ǧ ǡ ǡ Ǥ ǡ Ǥǡ Ǥ in vitro ǡ Ǧ Ǥ ǡ ͳ ǡ Ǥ ǡ ͶǦͳͶ ǦǤ ǡ in silico ǡ ͳ Ǥ ͳ ͳ Ǥ ͳ ȏͶͻǡͷͲȐ ͳ ǡ ͳ Ǥǡ ͳ Ǥ ǡ Ǥ Ǥ ǡ Ǥ ǡ ȋ Ȍ ǡ Ǧ Ǥ Ǥ ǡ Ǥ ȏʹʹȐǡ
ͳͲ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
ǡ Ǥ Ǥ Ǥ Ǥ Ǧ ǡ Ǧ Ǧ Ǧ Ǥ ǡ 5 Ǥ Ǥ ǡ ǡ Ǥ Materials and Methods Model construction and simulation ȋ ǡ Ǥǡ ǡ ǡ Ȍǡ ͳͳǤ͵ǤͲǤͲǤ ͳǤ Ǧ
Ǧ Ǧ ȋȏǦȐȌͲǤͳ Ɋǡ ȏʹͳȐǤ ǡȏ͵ǡͷͳȐǤ Ǥ ǡ ǡ ΪǦ Ǥǡ Ǧ
ȋ ȌǡȏʹǡͷͳȐǤ Ǥ Flux control analysis ǣ
ௗȀௗ ο ೌೣǡ ܥ௭௬ ൌ ൎ ή ȋͳȌ డ௩Ȁడ οೌೣǡ
p ǤVmax Ǥ ' ͵Ψǡ ͳȏͷʹǡͷ͵ȐǤ References ͳǤ ǡ Ǥ ȾǦǤ ǤʹͲͳͲǢ͵͵ȋͷȌǣͶͻȂǤ ʹǤ ǡ ǡ Ǥ ǦǤ Ǥ ͳͻͻǢ͵ʹͲǣ͵ͶͷȂͷǤ ͵Ǥ ǡ ǡ Ǥǡ Ǥ
ͳͳ Chapter 5
ȾǦ Ǥ Ǥ ʹͲͳǢͺȋͳȌǣʹ͵ȂͶͶǤ ͶǤ ǡǦǡ ǡǡ ǡ ǡ ǡ Ǧǡ ǡ ǡ ǡ ǡ ǡǤ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳȂͳͷǤ ͷǤ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͲʹǢͶȋͳȌǣͶȂͷͲʹǤ Ǥ ǡ ǡ ǡ Ǥ ȾǦ Ǥ Ǥ ʹͲͳͷǢͺǣʹ͵ȂͶͶǤ Ǥ ǡ ǡ ǡ ǡǡ ǡ Ǥ Ǧ ǣ Ǥ ǤʹͲͲǢͳͶͺȋͷȌǤ ͺǤ ǡǡǡǡ ǡ ǡǦǡ ǡ ǡ ǡǡ ǡ Ǥ Ǧ Ǧ ȋȌ ǣ Ǥ ǤʹͲͲͺǢ͵ͳȋͳȌǣͺͺȂͻǤ ͻǤ ǡ ǡǦǡǦǡ ǡǦ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳ͵ǢͺȋͳȌǣͶ͵Ǥ ͳͲǤ ǡ ǡǡ ǡ ǡ ǡ ǡǦ ǡǡǦǡ ǡ ǡǦ ǡ Ǥ Ǧ Ǧ ǣ Ǥ ǤʹͲͳʹǢǣ͵ͲǤ ͳͳǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳͲǢ͵͵ȋͷȌǣͷͷͷȂͳǤ ͳʹǤ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ Ǥ ǤͳͻͻǢͻȋ͵Ȍǣ͵ȂͺǤ ͳ͵Ǥ ǡ ǡǡǡ ǡ ǡ ǡǡ Ǥ Ǧ Ǧ Ǥ ǤͳͻͻͲǢͺȋʹ͵Ȍǣͻʹ͵ȂͶͲǤ ͳͶǤ ǡ ǡ ǡ Ǧǡ Ǥ Ʈ ǯ Ǧ Ǧ Ǥ ǤͳͻͺǢͺȋȌǣͳͲͷʹȂǤ ͳͷǤ ǤǡǤ ǣ Ǥ ǤʹͲͳͲǢ͵͵ȋͷȌǣͷͳ͵ȂʹͲǤ ͳǤ ǡ ǡ ǡ ǡǡ Ǥ Ǥ ǤʹͲͲǢͳȋͳȌǣͷȂͳͳǤ ͳǤ Ǥ ǣ Ǥ ǤʹͲͲͻǢ͵ʹȋʹȌǣʹͳͶȂǤ ͳͺǤ Ǥ Ǥ Ǥ ʹͲͳͲǢ͵͵ȋͷȌǣͷ͵͵ȂǤ ͳͻǤ Ǥ Ǧ ǣ Ǥ Ǥ ʹͲͳǢʹ͵ȋͳȌǣͷͳȂͷǤ ʹͲǤ ǦǤ ǡǤʹͲͳͶǤ ʹͳǤ Ǧ ǡǡǦ ǡǤ Ǧ
ͳʹ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
͵ǦǦ Ǧ Ǧ ǦǤ ǤʹͲͳǢͳ͵ȋͶȌǣͳȂʹʹǤ ʹʹǤ ǡǦǡ ǡǡ ǡ ǡ ǡ Ǧǡ ǡ ǡ ǡ ǡ ǡǤ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳȂͳͷǤ ʹ͵Ǥ ǡ ǡ ǡ ǡ ǡ Ǥ ǤǤʹͲͲ͵ǢͷͻȋͶȌǣ͵ͲȂ͵Ǥ ʹͶǤ ǡ ǡ ǡ ǡ ǡ Ǥ ǣ Ǥ Ǥͳͻͺͳ ǢͳͳȋȌǣͺͳȂͷǤ ʹͷǤ ǡǡǡǡǡǡǡ Ǥ ȾǦ Ǧ Ǧ 5 Ǥ ǤʹͲͳͺǢȋ ʹͲͳȌǣͳȂͳǤ ʹǤ ǡ ǡ ǡǡ ǡǡ ǡ ǡǡ ǡǤ Ǧ ȾǦ ǤǤʹͲͳ͵ǢͻȋͺȌǣʹȂͻǤ ʹǤ ǡǡǡ ǡǡǡ ǡ ǡ ǡ ǡǤ ǦǦʹ Ǥ ǤʹͲͳͶǢͷͷȋͳʹȌǣʹͶͷͺȂͲǤ ʹͺǤ ǡ ǡ Ǥ Ǧ Ǧ ǤǤʹͲͳͷǢͳͲȋ͵ȌǤ ʹͻǤ ǡ ǡ Ǥ ǣ Ǧ Ǧ Ǥ ǤʹͲͳǢʹͺȋȌǣͶ͵ȂͺͶǤ ͵ͲǤ ǡ Ǥ Ǧ ǤǤʹͲͲʹǢͶͳȋʹȌǣͻͻȂͳ͵ͲǤ ͵ͳǤ ǡ ǡǤ Ǧ Ǥ ǤʹͲͳͳǢʹͺȋʹȌǣͳͺʹȂͻͶǤ ͵ʹǤ ǡ ǡǡǡǡ Ǥ Ǧ Ǥ ǤʹͲͲͺǢͻͶȋͳȌǣͶȂͳͷǤ ͵͵Ǥ ǡǡǡǡ Ǥ Ǥ ǤʹͲͳͻ ʹͺǢͶȋͳȌǣͳͶͻȂͷͷǤ ͵ͶǤ ǡ ǡ ǡ Ǧ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳǢͳͷȋͻȌǣ͵ʹͲͶȂͳ͵Ǥ ͵ͷǤ ǡ ǡ Ǥ ǡ Ǧ Ǥ Ǥ ͳͻͻͲǢʹͶȋͳȂ ʹȌǣͳ͵ȂǤ ͵Ǥ ǡǡÞǤ ǦͳͲǦ Ǧ ͳͲǦǦͳǦ Ǧ ǣ Ǧ ǦͳǦ Ǧ ȋǦͳʹȌ ǤǤͳͻͺ͵ǢͳȋͳͲȌǣͺʹͺȂ͵ͶǤ ͵Ǥ ǡ ǡ ǡǡ ǡǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ ǤǤʹͲͳ͵ǢͻȋͺȌǣʹȂͻǤ ͵ͺǤ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ Ǧ
ͳ͵ Chapter 5
ǤǤʹͲͲͻǢͶȋȌǤ ͵ͻǤ ǡǡ ǡ ǡ ǡ ǡ ǡ ǤǦ Ǧ ǣ Ǥ ǤʹͲͲ͵ǢͳͳʹȋͷȌǣͳͳͷʹȂͷǤ ͶͲǤ ǡ ǡǡ ǡ ǡ ǡ ǡǦ ǡǡǦǡ ǡ ǡǦ ǡ Ǥ Ǧ Ǧ ǣ Ǥ ǤʹͲͳʹʹͷǢȋͳȌǣ͵ͲǤ ͶͳǤ ǡǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ ǣ Ǥ ǤʹͲͲ͵ǢͳͳʹȋͷȌǣͳͳͷʹȂͷǤ ͶʹǤ Ǧ ǡ ǡ ǡ Ǥ Ǥ ǤͳͻͺǢͳͲǣͳͷͻȂʹͲͲǤ Ͷ͵Ǥ ǡ Ǥ Ǧ Ǥ Ǥ ͳͻͻʹǢǣͳͶʹȂͷǤ ͶͶǤ ǡǡ ǡ ǡǡ ǡǡ ǡ ǡǡ ǡǡǡǡǡǡǡ ǡǡǡǡ ǡǡ ǡǡ ǡǡ ǡǡ ǡ ǡ ǡǡǡ ǡ ǡǡ ǡǡ Ǧǡ ǡǡ ǡ ǡǡǡǡǡǡǡ ǡǯ ǡ ǡǡǡǡǡǡ ǡ ǡ ǡ ǡ ǡǦ ǡǡ ǡǡǡ ǡ ǡ ǡ ǡ ǡ ǡǦǡ ǡǡǡ ǡ ǡ ǡǤʹʹͳǦ Ǧ Ǧ ǣ Ǥ ǤʹͲͳǢͳͳͻȋͳȂʹȌǣͷȂͺʹǤ ͶͷǤ ǤǦǣ ǫ ǤʹͲͲ͵ǢʹȋʹȂ͵ȌǣͳͺͳȂͺǤ ͶǤ Ǥ ǣ ǤǤʹͲͲʹǢȋͳȌǣ͵ȂͶǤ ͶǤ ǡ ǡ ǡǡ ǡǡ ǡ ǡǡ ǡǤ Ǧ ȾǦ ǤǤʹͲͳ͵ǢͻȋͺȌǣʹȂͻǤ ͶͺǤ ǡǡ ǡǤ Ǧ ͵ǦǦ Ǧ Ǧ ǦǤ ǤʹͲͳǢͳ͵ȋͶȌǣͳȂʹʹǤ ͶͻǤ Ǥ ǦǤʹͲͲʹǢͶͳǣͳͻȂʹ͵ͻǤ ͷͲǤ ǡ ǡ ǡ Ǥ ȝǦ Ǥ ǤͳͻͻǢ͵ʹ͵ǣͳͳͻȂʹʹǤ ͷͳǤ ǡǦǡ ǡǡ ǡ ǡǦ ǡ Ǧ ǡ ǡ ǡ ǡ Ǧ ǡ ǡ Ǥ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳͲǤ ͷʹǤ Ǥ Ǥ ǣ ʹ ǤʹͲͲͳǤǤʹͻͳȂ͵ͲͲǤ ͷ͵Ǥ Ǥ ǣ Ǥ ǤͳͻͻʹǢʹͺȋʹǣ͵ͳ͵Ȃ͵ͲǤ
ͳͶ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
^ƵƉƉůĞŵĞŶƚĂƌLJƚĞdžƚ^dϭ͗DŽĚĞůĚĞƐĐƌŝƉƚŝŽŶ Ǧ ȏͳȐǤ ǡ ȏʹȐǤǡ ǡǤ ǡ ǡ Ǧ Ǥ ͳǤǡ ȏͳȐ Ǥ ǡ 5 Ǥ Ǥ ǡ Ǥ ǡ Ǥ Ǥ Ǥ
KƌĚŝŶĂƌLJĚŝĨĨĞƌĞŶƚŝĂůĞƋƵĂƚŝŽŶƐ;KƐͿ Ǥ ǡ ǡ ǡ Ǥ ǡ ǡ ǡ Ǥ ǡ ǡ ǡ ȋ ͳǡ ǡ ǡ ȌǤ ͳǤ ǡ ǡ Ǧ Ǥ ǡ ͳͳ ͳǦ ǦȋǤǤ ǦȌͳǦ Ǧ ͳǤ ODE’s from metabolites that were already in the rat model. Ǥ ᇱ ି୴ୡୟୡ୲େଵା୴ୡ୮୲ଵେଵି୴୶ୡୡେଵ ሾݐሿ ൌൌ ȋͳȌ ͳ େଢ଼
ᇱ ୴ୡୟୡ୲େଵି୴ୡ୮୲ଶେଵ ሾݐሿ ൌൌ ȋʹȌ ͳ
۱ି୴୴୪ୡୟୢେଵ܌܉܋ܕܞ۱ା୴ୡ୮୲ଶେଵିܜܗ܋܉ܞି ᇱ ሾݐሿ ൌൌ ȋ͵Ȍ ͳ
۱ି୴୫୲୮େଵା୴୴୪ୡୟୢେଵ܌܉܋ܕᇱ ି୴ୡ୰୭୲େଵା୴ ͳ ሾݐሿ ൌൌ ȋͶȌ
ᇱ ୴ୡ୰୭୲େଵି୴୫ୱୡ୦ୟୢେଵ ሾݐሿ ൌൌ ȋͷȌ ͳ
ͳͷ Chapter 5
ᇱ ି୴୫ୡ୩ୟ୲େଵା୴୫ୱୡ୦ୟୢେଵ ሾݐሿ ൌൌ ȋȌ ͳ
େଵସ ۱ି୴୶ܜܘ܋ܞᇱ ି୴ୡୟୡ୲େଵସା ሾݐሿ ൌൌ ȋȌ ͳͶ େଢ଼
ᇱ ୴ୡୟୡ୲େଵସି୴ୡ୮୲ଶେଵସ ሾݐሿ ൌൌ ȋͺȌ ͳͶ
۱ା୴୫ୡ୩ୟ୲େଵା୴୫୲୮େଵି୴୴୪ୡୟୢେଵସ܌܉܋ܕܞ۱ା୴ୡ୮୲ଶେଵସିܜܗ܋܉ܞି ᇱ ሾݐሿ ൌൌ ȋͻȌ ͳͶ
۱ି୴୫୲୮େଵସା୴୴୪ୡୟୢେଵସ܌܉܋ܕܞᇱ ି୴ୡ୰୭୲େଵସା ͳͶ ሾݐሿ ൌൌ ȋͳͲȌ
ᇱ ୴ୡ୰୭୲େଵସି୴୫ୱୡ୦ୟୢେଵସ ሾݐሿ ൌൌ ȋͳͳȌ ͳͶ
ᇱ ି୴୫ୡ୩ୟ୲େଵସା୴୫ୱୡ୦ୟୢେଵସ ሾݐሿ ൌൌ ȋͳʹȌ ͳͶ
େଵଶ ۱ି୴୶ܜܘ܋ܞᇱ ି୴ୡୟୡ୲େଵଶା ሾݐሿ ൌൌ ȋͳ͵Ȍ ͳʹ େଢ଼
۱ܜܘ܋ܞᇱ ୴ୡୟୡ୲େଵଶି ሾݐሿ ൌൌ ȋͳͶȌ ͳʹ
۱ା୴ୡ୮୲ଶେଵଶି୴୫ୡୟୢେଵଶା୴୫ୡ୩ୟ୲େଵସା୴୫୲୮େଵସି୴୴୪ୡୟୢେଵଶܜܗ܋܉ܞି ᇱ ሾݐሿ ൌൌ ȋͳͷȌ ͳʹ
ᇱ ି୴ୡ୰୭୲େଵଶା୴୫ୡୟୢେଵଶି୴୫୲୮େଵଶା୴୴୪ୡୟୢେଵଶ ͳʹ ሾݐሿ ൌൌ ȋͳȌ
ᇱ ୴ୡ୰୭୲େଵଶି୴୫ୱୡ୦ୟୢେଵଶ ሾݐሿ ൌൌ ȋͳȌ ͳʹ
ᇱ ି୴୫ୡ୩ୟ୲େଵଶା୴୫ୱୡ୦ୟୢେଵଶ ሾݐሿ ൌൌ ȋͳͺȌ ͳʹ
ᇱ ି୴ୡୟୡ୲େଵା୴ୡ୮୲ଵେଵି୴୶ େଵ ሾݐሿ ൌൌ ȋͳͻȌ ͳͲ େଢ଼
۱ܜܘ܋ܞᇱ ୴ୡୟୡ୲େଵି ሾݐሿ ൌൌ ȋʹͲȌ ͳͲ
۱܌܉܋ܔܞܞ۱ା୴ୡ୮୲ଶେଵି୴୫ୡୟୢେଵା୴୫ୡ୩ୟ୲େଵଶା୴୫୲୮େଵଶିܜܗ܋܉ܞି ᇱ ሾݐሿ ൌൌ ȋʹͳȌ ͳͲ
۱܌܉܋ܔܞܞᇱ ି୴ୡ୰୭୲େଵା୴୫ୡୟୢେଵି୴୫୲୮େଵା ͳͲ ሾݐሿ ൌൌ ȋʹʹȌ
ᇱ ୴ୡ୰୭୲େଵି୴୫ୱୡ୦ୟୢେଵ ሾݐሿ ൌൌ ȋʹ͵Ȍ ͳͲ
ᇱ ି୴୫ୡ୩ୟ୲େଵା୴୫ୱୡ୦ୟୢେଵ ሾݐሿ ൌൌ ȋʹͶ ͳͲ
େ଼ ۱ૡି୴୶ܜܘ܋ܞᇱ ି୴ୡୟୡ୲େ଼ା ሾݐሿ ൌൌ ȋʹͷȌ ͺ େଢ଼
۱ૡܜܘ܋ܞᇱ ୴ୡୟୡ୲େ଼ି ሾݐሿ ൌൌ ȋʹȌ ͺ
۱ૡ܌܉܋ܔܞܞ۱ૡା୴ୡ୮୲ଶେ଼ି୴୫ୡୟୢେ଼ା୴୫ୡ୩ୟ୲େଵା୴୫୲୮େଵିܜܗ܋܉ܞି ᇱ ሾݐሿ ൌൌ ȋʹȌ ͺ
۱ૡ܌܉܋ܔܞܞᇱ ି୴ୡ୰୭୲େ଼ା୴୫ୡୟୢେ଼ି୴୫୲୮େ଼ା ͺ ሾݐሿ ൌൌ ȋʹͺȌ
ͳ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
ᇱ ୴ୡ୰୭୲େ଼ି୴୫ୱୡ୦ୟୢେ଼ ሾݐሿ ൌൌ ȋʹͻȌ ͺ
ᇱ ି୴୫ୡ୩ୟ୲େ଼ା୴୫ୱୡ୦ୟୢେ଼ ሾݐሿ ൌൌ ȋ͵ͲȌ ͺ
େ ۱ି୴୶ܜܘ܋ܞᇱ ି୴ୡୟୡ୲ୋ ሾݐሿ ൌൌ ȋ͵ͳȌ େଢ଼
ᇱ ୴ୡୟୡ୲େି୴ୡ୮୲ଶେ ሾݐሿ ൌൌ ȋ͵ʹȌ
۱܌܉܋ܔܞܞ۱ା୴ୡ୮୲ଶେି୴୫ୡୟୢୋ୴୫ୡ୩ୟ୲େ଼ା୴୫୲୮େ଼ି୴ୱୡୟୢେିܜܗ܋܉ܞି ᇱ ሾݐሿ ൌൌ ȋ͵͵Ȍ
۱ 5܌܉܋ܔܞܞᇱ ି୴ୡ୰୭୲ୋ୴୫ୡୟୢୋ୴ୱୡୟୢୋ ሾݐሿ ൌൌ ȋ͵ͶȌȌ
ᇱ ୴ୡ୰୭୲େି୴୫ୱୡ୦ୟୢେ ሾݐሿ ൌൌ ȋ͵ͷȌ
ᇱ ି୴୫ୡ୩ୟ୲ୋ୴୫ୱୡ୦ୟୢେ ሾݐሿ ൌൌ ȋ͵Ȍ
ᇱ ି୴ୡୟୡ୲େସା୴ୡ୮୲ଵେସି୴୶ େସ ሾݐሿ ൌൌ ȋ͵Ȍ Ͷ େଢ଼
ᇱ ୴ୡୟୡ୲େସି୴ୡ୮୲ଶେସ ሾݐሿ ൌൌ ȋ͵ͺȌ Ͷ
۱ା୴ୡ୮୲ଶେସି୴୫ୡୟୢେସା୴୫ୡ୩ୟ୲େି୴ୱୡୟୢେସܜܗ܋܉ܞି ᇱ ሾݐሿ ൌൌ ȋ͵ͻȌ Ͷ
ᇱ ି୴ୡ୰୭୲େସା୴୫ୡୟୢେସା୴ୱୡୟୢେସ Ͷ ሾݐሿ ൌൌ ȋͶͲȌ
ᇱ ୴ୡ୰୭୲େସି୴୫ୱୡ୦ୟୢେସ ሾݐሿ ൌൌ ȋͶͳ Ͷ
ᇱ ୴ୟୡୟ୲ଵି୴୦୫ୡୱଶି୴୫ୡ୩ୟ୲େସା୴୫ୱୡ୦ୟୢେସ ሾݐሿ ൌൌ ȋͶʹȌ Ͷ
ODEs from newly introduced metabolites.
ͳ ͳͶ ͳʹ ͳͲ ͺ ͳ ͳͶ ͳʹ ͳͲ ͺ Ͷ Ͷ െ ᇱሾݐሿ ൌൌ ȋͶ͵
ᇱ ୴ୟୡ୭୲େଵି୴୫ୡେଵ ሾݐሿ ൌൌ ȋͶͶȌ ͳ
ᇱ ୴ୟୡ୭୲େଵସି୴୫ୡେଵସ ሾݐሿ ൌൌ ȋͶͷȌ ͳͶ
ᇱ ୴ୟୡ୭୲େଵଶି୴୫ୡେଵଶ ሾݐሿ ൌൌ ȋͶȌ ͳʹ
ᇱ ୴ୟୡ୭୲େଵି୴୫ୡେଵ ሾݐሿ ൌൌ ȋͶȌ ͳͲ
ᇱ ୴ୟୡ୭୲େ଼ି୴୫ୡେ଼ ሾݐሿ ൌൌ ȋͶͺȌ ͺ
ᇱ ୴ୟୡ୭୲େି୴୫ୡେ ሾݐሿ ൌൌ ȋͶͻȌ
ͳ Chapter 5
ᇱ ୴ୟୡ୭୲େସି୴୫ୡେସ ሾݐሿ ൌൌ ȋͷͲȌ Ͷ
ᇱ ି୴୦୫ୡ୪ା୴୦୫ୡୱଶ ሾݐሿ ൌൌ ȋͷͳȌ
ᇱ ି୴ୠୢ୦ଵି୴୶ୡୣ୲୭ୟୡୣ୲ୟ୲ୣା୴୦୫ୡ୪ ሾݐሿ ൌൌ ȋͷʹȌ
ᇱ ୴ୠୢ୦ଵି୴୶ୌ ሾݐሿ ൌൌ ȋͷ͵Ȍ
ᇱ ି୴ୟୡୱେଵି୴ୡ୫୧େଵି୴୶େଵା୴୫ୡେଵ ሾݐሿ ൌൌ ȋͷͶȌ ͳ େଢ଼
ᇱ ି୴ୟୡୱେଵସି୴ୡ୫୧େଵସି୴୶େଵସା୴୫ୡେଵସ ሾݐሿ ൌൌ ȋͷͷȌ ͳͶ େଢ଼
ᇱ ି୴ୟୡୱେଵଶି୴ୡ୫୧େଵଶି୴୶େଵଶା୴୫ୡେଵଶ ሾݐሿ ൌൌ ȋͷȌ ͳʹ େଢ଼
ᇱ ି୴ୟୡୱେଵି୴ୡ୫୧େଵି୴୶େଵା୴୫ୡେଵ ሾݐሿ ൌൌ ȋͷȌ ͳͲ େଢ଼
ᇱ ି୴ୟୡୱେ଼ି୴ୡ୫୧େ଼ି୴୶େ଼ା୴୫ୡେ଼ ሾݐሿ ൌൌ ȋͷͺȌ ͺ େଢ଼
ᇱ ି୴ୟୡୱେି୴ୡ୫୧େି୴୶ୋ୴୫ୡେ ሾݐሿ ൌൌ ȋͷͻȌ େଢ଼
ᇱ ି୴ୟୡୱେସି୴ୡ୫୧େସି୴୶େସା୴୫ୡେସ ሾݐሿ ൌൌ ȋͲȌ Ͷ େଢ଼
ᇱ ୴ୟୡୱେଵସି୴ୡ୮୲ଵେଵସ ሾݐሿ ൌൌ ȋͳȌ ͳͶ େଢ଼
ᇱ ୴ୟୡୱେଵଶି୴ୡ୮୲ଵେଵଶ ሾݐሿ ൌൌ ȋʹȌ ͳʹ େଢ଼
ᇱ ୴ୟୡୱେଵି୴ୡ୮୲ଵେଵ ሾݐሿ ൌൌ ȋ͵Ȍ ͳͲ େଢ଼
ᇱ ୴ୟୡୱେ଼ି୴ୡ୮୲ଵେ଼ ሾݐሿ ൌൌ ȋͶȌ ͺ େଢ଼
ᇱ ୴ୟୡୱେି୴ୡ୮୲ଵେ ሾݐሿ ൌൌ ȋͷȌ େଢ଼
ᇱ ୴ୟୡୱେସି୴ୡ୮୲ଵେସ ሾݐሿ ൌൌ ȋȌ Ͷ େଢ଼
ᇱ ୴ୡ୫୧େଵି୴ன୭୶େଵ ሾݐሿ ൌൌ ȋȌ ͳ ୍ୈ
ᇱ ୴ୡ୫୧େଵସି୴ன୭୶େଵସ ሾݐሿ ൌൌ ȋͺȌ ͳͶ ୍ୈ
ᇱ ୴ୡ୫୧େଵଶି୴ன୭୶େଵଶ ሾݐሿ ൌൌ ȋͻȌ ͳʹ ୍ୈ
ᇱ ୴ୡ୫୧େଵି୴ன୭୶େଵ ሾݐሿ ൌൌ ȋͲȌ ͳͲ ୍ୈ
ᇱ ୴ୡ୫୧େ଼ି୴ன୭୶େ଼ ሾݐሿ ൌൌ ȋͳȌ ͺ ୍ୈ
ᇱ ୴ୡ୫୧େି୴ன୭୶େ ሾݐሿ ൌൌ ȋʹȌ ୍ୈ
ͳͺ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
ᇱ ୴ୡ୫୧େସି୴ன୭୶େସ ሾݐሿ ൌൌ ȋ͵Ȍ Ͷ ୍ୈ
ᇱ ି୴୫୧ୡୈେେଵା୴ன୭୶େଵ ͳ ሾݐሿ ൌൌ ȋͶȌ ୍ୈ
ᇱ ି୴୫୧ୡୈେେଵସା୴ன୭୶େଵସ ͳͶ ሾݐሿ ൌൌ ȋͷȌ ୍ୈ
ᇱ ି୴୫୧ୡୈେେଵଶା୴ன୭୶େଵଶ ͳʹ ሾݐሿ ൌൌ ȋȌ ୍ୈ
ᇱ ି୴୫୧ୡୈେେଵା୴ன୭୶େଵ ͳͲ ሾݐሿ ൌൌ ȋȌ ୍ୈ
ᇱ ି୴୫୧ୡୈେେ଼ା୴ன୭୶େ଼ 5 ͺ ሾݐሿ ൌൌ ȋͺȌ ୍ୈ
ᇱ ି୴୫୧ୡୈେୋ୴ன୭୶େ ሾݐሿ ൌൌ ȋͻȌ ୍ୈ
ᇱ ି୴୫୧ୡୈେେସା୴ன୭୶େସ Ͷ ሾݐሿ ൌൌ ȋͺͲȌ ୍ୈ
ᇱ ି୴୶ୈେେଵା୴୫୧ୡୈେେଵ ሾݐሿ ൌൌ ȋͺͳȌͳ େଢ଼
ᇱ ି୴୶ୈେେଵସା୴୫୧ୡୈେେଵସ ሾݐሿ ൌൌ ȋͺʹȌͳͶ େଢ଼
ᇱ ି୴୶ୈେେଵଶା୴୫୧ୡୈେେଵଶ ሾݐሿ ൌൌ ȋͺ͵Ȍͳʹ େଢ଼
ᇱ ି୴୶ୈେେଵା୴୫୧ୡୈେେଵ ሾݐሿ ൌൌ ȋͺͶȌͳͲ େଢ଼
ᇱ ି୴୶ୈେେ଼ା୴୫୧ୡୈେେ଼ ሾݐሿ ൌൌ ȋͺͷȌͺ େଢ଼
ᇱ ି୴୶ୈେୋ୴୫୧ୡୈେେ ሾݐሿ ൌൌ ȋͺȌ େଢ଼
ᇱ ି୴୶ୈେେସା୴୫୧ୡୈେେସ ሾݐሿ ൌൌ ȋͺȌͶ େଢ଼
ͳͻ Chapter 5
ZĂƚĞĞƋƵĂƚŝŽŶƐ Ǥ Ǥ ǡǡ Ǧ Ǥ
ǦǦ ǡ ȋǤǤ Km ͳͳ ͳ Ǧ ͳ ǡ ȌǤ ʹǦ Ǧ Ǧ Ǥ ɊȉǦͳȉ Ǧͳǡ ɊȉǦͳǤ Ϊ ǡ ǡǡ ʹǡ ǡ Ǧ Ȁ Ǥ et alǤ ʹͲͳ͵ ǡ Ǧ ǡ Ǥ
Ǥ ǡǡ Ǧ
Ǥ ǡ
ǡ Ǥ ǣ ǤVmax of the enzyme ǦǦ ͳ ͳǦ ͳ Ǧͳ Ǧ Ǧ ʹ Ǧʹ Ǧ Ǧ Ǧ Ǧ ǦǦ Ǧ Ȁ ȀǦ Ǧ Ǧ Ǧ
ͳͺͲ ͳͺͳ ǡ Ǧ Ǥ -acid catabolism -acid catabolism Ͷͳͳ
5 ȋͺͺȌ ሻ ቁ ency in human liver fatty Ǥ ిఽౙ౯ౢిఽిౕሾሿ ሻ ేౣౙ౦౪భిఽౙ౯ౢిఽిౕ ା Ǥ ȋͺͻȌ ሿ ȋͻͳȌ ௧ ሻ ሾ ሻ ቁ ȋͻͲȌ ሻ modifiers on MCAD defici modifiers ిఽౙ౯ౢి౨ిౕሾሿ ሻ ቁ ేౣౙ౦౪భిఽౙ౯ౢి౨ిౕ ቀ Ȍ Ǧ Ǧ సభర సర ሻ σ ା ిఽౙ౯ౢి౨ిౕሾሿήిఽిౕ ిు౯ౢిఽఽሾሿ ǡ ǡ ǦǦ ేౣ౬ౢౙౚిు౯ౢిఽఽ ౙ౦౪భ ሻ ା ిఽౙ౯ౢిఽఽሾሿ ା୫ୡୟୡ୲େୟ୰ήେ୬ୡ୷୪େୟ୰େଢ଼ ሿ ే౧ౙ౦౪భήేౣౙ౦౪భిఽౙ౯ౢిఽిౕήేౣౙ౦౪భి౨ిౕ ేౣౙ౦౪మిఽౙ౯ౢిఽఽ ௧ ే౧ౙౙ౪ ି ሾ ା ిు౯ౢిఽఽሾሿήుూ౧ఽሾሿ ౢిఽిౕ ి౨ఽήిభలఽౙ౯ౢిఽఽሾሿ ి౨ిౕήిఽౙ౯ౢి౨ఽሾሿ Simulating the impact of ేౙ౦౪భήౢిఽిౕ ే౧౬ౢౙౚήేౣ౬ౢౙౚిఽౙ౯ౢిఽఽήేౣ౬ౢౙౚుూ౮ ାሺ ି ిఽౙ౯ౢిఽఽሾሿ ేౣ౬ౢౙౚిఽౙ౯ౢిఽఽ ቀ ͳ ǦǦ ే౧ౙ౦౪మήేౣౙ౦౪మిభలఽౙ౯ౢి౨ఽήేౣౙ౦౪మిఽఽ ି ిఽౙ౯ౢి౨ఽሾሿ ͳȋ Ȍ Ǧ Ǧ ేౣౙ౦౪మిఽౙ౯ౢి౨ఽ సభల సల ቀ σ ౙౙ౪ήే౧ౙౙ౪ సభల సర Ǧʹȋ ሻήሺଵା ిఽౙ౯ౢిఽిౕήి౨ిౕ σ ిభలఽౙ౯ౢిఽిౕ ሻήిఽౙ౯ౢి౨ఽሾሿశి౨ిౕήሺేౣౙౙ౪ిఽౙ౯ౢి౨ఽశిఽౙ౯ౢి౨ఽሾሿሻ ሻሺଵା ేౣౙ౦౪భిభలఽౙ౯ౢిఽిౕ ǡǡȀ ǡ ేౣౙ౦౪భిఽౙ౯ౢిఽిౕήేౣౙ౦౪భి౨ిౕ ሻሺଵା ుూ౧ఽሾሿ ేౣ౬ౢౙౚుూ౧ ା ిఽఽ ቁή୫ୡୟୡ୲େ୬ୡ୷୪େୟ୰େଢ଼ାେୟ୰ήେ୬ୡ୷୪େୟ୰େଢ଼ ేౣౙ౦౪మిఽఽ ిఽౙ౯ౢి౨ిౕሾሿ ిఽిౕ ା ిఽఽήిభలఽౙ౯ౢి౨ఽሾሿ ୱୡ୮୲ଵେ୬ήୡ୮୲ଵሺ ేౙౙ౪ήిఽౙ౯ౢి౨ిౕ ేౣ౬ౢౙౚిఽౙ౯ౢిఽఽήేౣ౬ౢౙౚుూ౮ ୱୡୟୡ୲େ୬ήୡୟୡ୲ήሺେୟ୰ήେ୬ୡ୷୪େୟ୰େଢ଼ሾ௧ሿି ేౣౙ౦౪భిఽిౕ ిఽౙ౯ౢిఽఽሾሿήሺుూ౪ఽషుూ౧ఽሾሿሻ ା ేౣౙ౦౪మిభలఽౙ౯ౢి౨ఽήేౣౙ౦౪మిఽఽ ి౨ిౕ ేౙౙ౪ి౨ిౕ Ǧ ి౨ఽ ేౣ౬ౢౙౚుూ౮ ేౣౙ౦౪మి౨ఽ ి౨ిౕ ుూ౪ఽషుూ౧ఽሾሿ ሺଵା ేౣౙౙ౪ి౨ిౕήሺభశ ేౣౙ౦౪భి౨ిౕ ሺଵା ା ୱ୴୪ୡୟୢେ୬ή୴୪ୡୟୢሺ ୱୡ୮୲ଶେ୬ήୡ୮୲ଶሺ ሺଵା େୟ୰ήቀଵା Ǧ ൌ ͳ Ǧ ͳ ൌ ൌ ʹ ͵ǦǦ͵Ǧ ȾǦ ͳɘ ͵ǦǦ͵Ǧ ǦǦȋ Ȍ Ǧ Ǧ Ǧ ɘǦ ʹ ൌ Chapter 5
ిఽౙ౯ౢిఽఽሾሿήሺుూ౪ఽషుూ౧ఽሾሿሻ ిు౯ౢిఽఽሾሿήుూ౧ఽሾሿ ୱ୫ୡୟୢେ୬ή୫ୡୟୢሺ ି ሻ ేౣౣౙౚిఽౙ౯ౢిఽఽήేౣౣౙౚుూ౮ ే౧ౣౙౚήేౣౣౙౚిఽౙ౯ౢిఽఽήేౣౣౙౚుూ౮ ൌ ుూ౪ఽషుూ౧ఽሾሿ ుూ౧ఽሾሿ ిఽౙ౯ౢిఽఽሾሿ ిు౯ౢిఽఽሾሿ ȋͻʹȌ ሺଵା ା ሻήሺଵାσసభలቀ ା ቁሻ ేౣౣౙౚుూ౮ ేౣౣౙౚుూ౧ సర ేౣౣౙౚిఽౙ౯ౢిఽఽ ేౣౣౙౚిు౯ౢిఽఽ
ిఽౙ౯ౢిఽఽሾሿήሺుూ౪ఽషుూ౧ఽሾሿሻ ిు౯ౢిఽఽሾሿήుూ౧ఽሾሿ ୱ୫ୱୡୟୢେ୬ήୱୡୟୢሺ ି ሻ ేౣ౩ౙౚిఽౙ౯ౢిఽఽήేౣ౩ౙౚుూ౮ ే౧౩ౙౚήేౣ౩ౙౚిఽౙ౯ౢిఽఽήేౣ౩ౙౚుూ౮ ൌ ుూ౪ఽషుూ౧ఽሾሿ ుూ౧ఽሾሿ ిఽౙ౯ౢిఽఽሾሿ ిు౯ౢిఽఽሾሿ ȋͻ͵Ȍ ሺଵା ା ሻήሺଵାσసలቀ ା ቁሻ ేౣ౩ౙౚుూ౮ ేౣ౩ౙౚుూ౧ సర ేౣ౩ౙౚిఽౙ౯ౢిఽఽ ేౣ౩ౙౚిు౯ౢిఽఽ
ిు౯ౢిఽఽሾሿ ిౄ౯ౚ౨౮౯ౙ౯ౢిఽఽሾሿ ୱୡ୰୭୲େ୬ήୡ୰୭୲ήሺ ି ሻ ేౣౙ౨౪ిు౯ౢిఽఽ ే౧ౙ౨౪ేౣౙ౨౪ήిు౯ౢిఽఽ ൌ ఽౙ౪ౙ౯ౢిఽఽሾሿ ిు౯ౢిఽఽሾሿ ిౄ౯ౚ౨౮౯ౙ౯ౢిఽఽሾሿ ȋͻͶȌ ଵା ାσసభలቀ ା ቁ ేౙ౨౪ఽౙ౪ౙ౯ౢిఽ సర ేౣౙ౨౪ిు౯ౢిఽఽ ేౣౙ౨౪ిౄ౯ౚ౨౮౯ౙ౯ౢిఽఽ
ሺషొఽీౄఽశొఽీ౪ఽሻήిౄ౯ౚ౨౮౯ౙ౯ౢిఽఽሾሿ ొఽీౄఽήిే౪ౙ౯ౢిఽఽሾሿ ୱ୫ୱୡ୦ୟୢେ୬ή୫ୱୡ୦ୟୢሺ ି ሻ ేౣౣ౩ౙౚిౄ౯ౚ౨౮౯ౙ౯ౢిఽఽήేౣౣ౩ౙౚొఽీఽ ే౧ౣ౩ౙౚήేౣౣ౩ౙౚిౄ౯ౚ౨౮౯ౙ౯ౢిఽఽήేౣౣ౩ౙౚొఽీఽ ൌ ొఽీౄఽ షొఽీౄఽశొఽీ౪ఽ ిౄ౯ౚ౨౮౯ౙ౯ౢిఽఽሾሿ ిే౪ౙ౯ౢిఽఽሾሿ ȋͻͷȌ ሺଵା ା ሻήሺଵାσసభలቀ ା ቁሻ ేౣౣ౩ౙౚొఽీౄఽ ేౣౣ౩ౙౚొఽీఽ సర ేౣౣ౩ౙౚిౄ౯ౚ౨౮౯ౙ౯ౢిఽఽ ేౣౣ౩ౙౚిే౪ౙ౯ౢిఽఽ
ిఽఽήిే౪ౙ౯ౢిఽఽሾሿ ఽౙ౪౯ౢిఽఽిǦʹήఽౙ౯ౢిఽఽሾሿ ୱ୫ୡ୩ୟ୲େ୬ή୫ୡ୩ୟ୲ήሺ ି ሻ ేౣౣౙౡ౪ిే౪ౙ౯ౢిఽఽήేౣౣౙౡ౪ిఽఽి ే౧ౣౙౡ౪ήేౣౣౙౡ౪ిే౪ౙ౯ౢిఽఽήేౣౣౙౡ౪ిఽఽి ൌ ఽౙ౪౯ౢిఽఽ ిఽఽ ఽౙ౪౯ౢిఽఽ ిǦʹ ሾሿ ిే౪ౙ౯ౢిఽఽሾሿ ȋͻȌ ሺଵା ା ሻήሺଵା ାσసభలቀ ା ቁሻ ేౣౣౙౡ౪ఽౙ౪౯ౢిఽఽ ేౣౣౙౡ౪ిఽఽి ేౣౣౙౡ౪ఽౙ౪౯ౢిఽఽ సర ేౣౣౙౡ౪ిǦʹ ేౣౣౙౡ౪ిే౪ౙ౯ౢిఽఽ
ఽౙ౪౯ౢిఽఽήొఽీౄఽήిభరఽౙ౯ౢిఽఽሾሿ ిఽఽήሺషొఽీౄఽశొఽీ౪ఽሻήిభలు౯ౢిఽఽሾሿ ୱ୫୲୮େଵή୫୲୮ሺି ା ሻ ే౧ౣ౪౦ήేౣౣ౪౦ిభలు౯ౢిఽఽήేౣౣ౪౦ిఽఽήేౣౣ౪౦ొఽీఽ ేౣౣ౪౦ిభలు౯ౢిఽఽήేౣౣ౪౦ిఽఽήేౣౣ౪౦ొఽీఽ ൌή ఽౙ౪౯ౢిఽఽ ిఽఽ ొఽీౄఽ షొఽీౄఽశొఽీ౪ఽ ిǦʹ ሾሿ ిు౯ౢిఽఽሾሿ ȋͻȌ ሺଵା ା ሻήሺଵା ା ሻήሺଵାσసభలቀ ା ቁሻ ేౣౣ౪౦ఽౙ౪౯ౢిఽఽ ేౣౣ౪౦ిఽఽ ేౣౣ౪౦ొఽీౄఽ ేౣౣ౪౦ొఽీఽ సఴ ేౣౣ౪౦ిǦʹ ేౣౣ౪౦ిు౯ౢిఽఽ
ి్ౄమሺుూ౪ఽషుూ౧ఽሾሿሻ ୣ୲୯୭ήሺି ାሺେ୭୕୲ିେ୭୕ୌଶሻή୦୯ሾ௧ሿሻ ే౧ు౪౧ ൌ ి్ౄమ ȋͻͺȌ ሺିେ୭୕ୌଶାେ୭୕୲ሻήቀଵା ቁή୫୲୯୭୲୦୯ାሺିେ୭୕ୌଶାେ୭୕୲ሻή୦୯ሾ௧ሿା୫୲୯୭େ୭୕ή୦୯ሾ௧ሿ ేు౪౧ి్ౄమ ుూ౧ఽሾሿ ి్ౄమήሺుూ౪ఽశేౣు౪౧ు౪౮షుూ౧ఽሾሿሻశేౣు౪౧ి్ౄమήሺుూ౪ఽషుూ౧ఽሾሿሻήሺభశ ሻ ା ేు౪౧ు౪౧ ే౧ు౪౧
ిఽౙ౯ౢిఽఽሾሿ ిఽఽήిూూఽఽሾሿ ୱୟୡ୭୲େ୬ήୟୡ୭୲ήሺ ି ሻ ేౣౙ౪ిఽౙ౯ౢిఽఽ ే౧ౙ౪ిఽౙ౯ౢిఽήేౣౙ౪ిఽౙ౯ౢిఽఽ ൌ ిఽఽ ిఽౙ౯ౢిఽఽሾሿ ిూూఽఽሾሿ ȋͻͻȌ ሺଵା ሻሺଵାσసభలቀ ା ቁሻ ేౣౙ౪ిఽఽ సర ేౣౙ౪ిఽౙ౯ౢిఽఽ ేౣౙ౪ిూూఽఽ
ሾݐሿȋͳͲͲȌ ൌ ή
ሾݐሿሻȋͳͲͳȌ ሾݐሿ െ ή ሺ ൌ
ిఽఽήిరఽౙ౪ౙ౯ౢిఽఽሾሿ ఽౙ౪౯ౢిఽఽమ ୟୡୟ୲ଵήሺ ି ሻ ేౣౙ౪భిరఽౙ౪ౙ౯ౢిఽఽήేౣౙ౪భిఽఽ ే౧ౙ౪భήేౣౙ౪భిరఽౙ౪ౙ౯ౢిఽఽήేౣౙ౪భిఽఽ ͳ ൌ െ ఽౙ౪౯ౢిఽఽ ిఽఽ ఽౙ౪౯ౢిఽఽ ిరఽౙ౪ౙ౯ౢిఽఽሾሿ ȋͳͲʹȌ ሺଵା ା ሻήሺଵା ା ሻ ేౣౙ౪భఽౙ౪౯ౢిఽఽ ేౣౙ౪భిఽఽ ేౣౙ౪భఽౙ౪౯ౢిఽఽ ేౣౙ౪భిరఽౙ౪ౙ౯ౢిఽఽ
ͳͺʹ ͳͺ͵ ሿ ݐ ሾ -acid catabolism -acid catabolism ȋͳͲͶȌ ȋͳͲͻȌ ሻሻ ቁ ሻ ሿ ݐ ሾ 5 ిూూఽిౕሾሿ ేౣౙ౩ిూూఽిౕ ቀ ency in human liver fatty సభల సర ఽౙ౪ౙ౪౪ఽሾሿήౄృిఽఽሾሿ ȋͳͲ͵Ȍ σ ሻ ሻήሺ ͵Ǥ ేౣౣౝౙౢఽౙ౪ౙ౪౪ఽήేౣౣౝౙౢౄృిఽఽ ା ͳ ή ͳ ή ͳ ή ͳ ሾݐሿ ή ሾݐሿ ሻ ή ሺെ ή ሻ ሻ ͳ ή ͳ ή ͳ ͳ ή ͳ ሿ ఽౌిౕήిఽిౕ ݐ ሿ ሾ ݐ ሾ ేౣౙ౩ఽౌిౕήేౣౙ౩ిఽిౕ ౄృిఽఽሾሿ ା ేౣౣౝౙౢౄృిఽఽ ା ͳ ή ͳ ౄృిఽఽሾሿ modifiers on MCAD defici modifiers ሻ ή ሾݐሿ ሺെ ేౣౣౝౙ౩మౄృిఽఽ ిఽిౕ ା ేౣౙ౩ిఽిౕ ȋͳͳͳȌ ሻ ା ిఽఽౄృిఽఽሾሿ ే౧ౣౝౙౢήేౣౣౝౙౢౄృిఽఽ ఽౙ౪౯ౢిఽఽήఽౙ౪ౙ౪౪ఽሾሿ ఽౌిౕ ି ͳ ేౣౙ౩ఽౌిౕ ାሺ ిూూఽిሾሿ ేౣ౭౮ిూూఽి ͳ ή ȋͳͲͷȌ సభల సర ͳ ή ిరఽౙ౪ౙ౯ౢిఽఽሾሿ σ ȋͳʹȌ ͳ ή ͳ ǣ ే౧ౣౝౙ౩మేౣౣౝౙ౩మఽౙ౪౯ౢిఽఽేౣౣౝౙ౩మిరఽౙ౪ౙ౯ౢిఽఽ ౄృిఽఽሾሿ ేౣౣౝౙ౩మిరఽౙ౪ౙ౯ౢిఽఽ ି ሿ Simulating the impact of ሻήሺଵା ݐ ሾ ేౣౣౝౙౢౄృిఽఽ ఽౌిౕήిఽిౕ ሻሺଵା ఽౙ౪౯ౢిఽఽήఽౙ౪ౙ౪౪ఽሾሿ Ǧ ేౣౙ౩ఽౌిౕήేౣౙ౩ిఽిౕ ୱୟୡୱେ୬ήୟୡୱήେ୬େଢ଼ሾ௧ሿήେଢ଼ήେ୭େଢ଼ ሾݐሿ ή ሾݐሿ ା ሾݐሿ ͳ ୦୫ୡ୪ήሺ ేౣౣౝౙౢఽౙ౪ౙ౪౪ఽήేౣౣౝౙౢఽౙ౪౯ౢిఽఽ ା െ ొఽీౌౄి ిఽఽ ȋͳͳͲȌ ͳ ή ͳ ή ͳ ή ిఽిౕ ేౣ౭౮ొఽీౌౄి ሻ ేౣౙ౩ిఽిౕ ేౣౣౝౙ౩మిఽఽ ା ͳ ή ͳ ή ͳ ή ሾݐሿ ͳሺെ ͳ ఽౙ౪ౙ౪౪ఽሾሿ ͳ ȋͳͲͺȌ ేౣౣౝౙౢఽౙ౪ౙ౪౪ఽ ୵୭୶ήେ୬୍ୈሾ௧ሿήୈୌ୍ୈήୱ୵୭୶େ୬ ା ఽౙ౪౯ౢిఽఽ െ ሺ ఽౙ౪౯ౢిఽఽిరఽౙ౪ౙ౯ౢిఽఽሾሿ ሾݐሿሻ ሾݐሿ െ ేౣౣౝౙ౩మఽౙ౪౯ౢిఽఽ ሺଵା ేౣౣౝౙ౩మఽౙ౪౯ౢిఽఽేౣౣౝౙ౩మిరఽౙ౪ౙ౯ౢిఽఽ ఽౙ౪౯ౢిఽఽ ͳ ή ͳ ή ͳ ͳ ή ేౣౣౝౙౢఽౙ౪౯ౢిఽఽ ୦୫ୡୱଶሺ ୫୵୭୶େ୬୍ୈή୫୵୭୶ୈୌ୍ୈήሺଵା ଵା ୫ୟୡୱେଢ଼ή୫ୟୡୱେ୬େଢ଼ή୫ୟୡୱେ୭େଢ଼ήሺ ͳ ή ͳ ሻ ή ሾݐሿ ሺെ ൌ ሾݐሿ ͳ ൌെ ൌ ή ൌ ൌ ʹ ȋͳͲȌ ൌ ή ሺ ሾݐሿ ή ൌ ൌ ൌ Ǥ ͳǦ Chapter 5
ሾݐሿ ሾݐሿሻȋͳͳʹȌ ή ሺെ ൌ
ሾݐሿȋͳͳ͵Ȍ ൌ ή
ŽŶƐĞƌǀĞĚŵŽŝĞƚLJĞƋƵĂƚŝŽŶƐ ሼ ൌ Ǧͳ ሾሿǦͳሾሿǦͳ ሾሿǦͳ ሾሿǦͳͶ ሾሿǦͳͶሾሿǦͳͶ ሾሿǦͳͶ ሾሿǦͳʹ ሾሿǦ ͳʹሾሿǦͳʹ ሾሿǦͳʹ ሾሿǦͳͲ ሾሿǦͳͲሾሿǦͳͲ ሾሿǦͳͲ ሾሿǦͺ ሾሿǦͺሾሿǦ ͺ ሾሿǦͺ ሾሿǦ ሾሿǦሾሿǦ ሾሿǦ ሾሿǦͶ ሾሿǦͶሾሿǦͶ ሾሿǦ Ͷ ሾሿǦ Ǧ ሾሿሽ ȋͳͳͶȌ
ͳͺͶ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
DŽĚĞůƉĂƌĂŵĞƚĞƌƐ ͳǤ Ǥ in vitro Ǥet al.ʹͲͳ͵ ȏͳȐǡ Ǥ 5
ͳͺͷ Chapter 5
Parameter Value unit Used references CPT1 sf ͳͳ ͳ ȏ͵Ȑ sf ͳͳͶ ͳǤ͵Ͷ ȏ͵Ȑ sf ͳͳʹ ͳǤͻ͵ ȏ͵Ȑ sf ͳͳͲ ͳǤͷͶ ȏ͵Ȑ sf ͳͺ ͲǤͺ͵ ȏ͵Ȑ sf ͳ ͲǤͷͳ ȏ͵Ȑ sf ͳͶ ͲǤʹͷ ȏ͵ǡͶȐ ρǤǦ V ͳ ͲǤͲʹͺ ȏ͵ǡͷǡȐ ͳǤǦͳ Km ͳͳ ͳʹǤʹ ρ ȏ͵Ȑ
Km ͳͳͶ ͵ͲǤͺ ρ ȏ͵Ȑ
Km ͳͳʹ ͳͳ ρ ȏ͵Ȑ
Km ͳͳͲ ͳǤ ρ ȏ͵Ȑ
Km ͳͺ ʹʹǤͻ ρ ȏ͵Ȑ
Km ͳ ͳͷͳǤͷ ρ ȏ͵Ȑ
Km ͳͶ ͷ͵Ǥͷ ρ ȏ͵ǡͶȐ
Km ͳͳ ͵ͺ ρ ȏ͵Ȑ
Km ͳͳͶ ͷͻ͵ ρ ȏ͵Ȑ
Km ͳͳʹ ͶͲͲ ρ ȏ͵Ȑ
Km ͳͳͲ ͳͷͷͶ ρ
Km ͳͺ ͷͲͳͶ ρ ȏ͵Ȑ
Km ͳ ͳͳͺ͵ ρ ȏ͵Ȑ
Km ͳͶ ͷʹʹ͵ͳ ρ ȏ͵Ȑ
Km ͳͳ ͳʹ͵ ρ ȏ͵Ȑ
Km ͳͳͶ ͵ ρ ȏ͵Ȑ
Km ͳͳʹ ͵ͳ ρ ȏ͵Ȑ
Km ͳͳͲ ͺͺͷ ρ ȏ͵Ȑ
Km ͳͺ ͳͳ͵ͻ ρ ȏ͵Ȑ
Km ͳ ͳ͵ͻ͵ ρ ȏ͵Ȑ
Km ͳͶ ͳͶ ρ ȏ͵Ȑ
Km ͳ ͶͲǤ ρ ȏͳȐ
Ki ͳ ͻǤͳ ρ ȏͳȐ Keq ͳ ͲǤͶͷ ȏͳȐ n ͳ ʹǤͶͻͻ ȏͳȐ
CACT sf ͳ ͳ ȏͳȐ ρǤǦ Vf ͲǤͶʹ ȏͳȐ ͳǤǦͳ Km ͳͷ ρ ȏͳȐ
Km ͳ͵Ͳ ρ ȏͳȐ
Km ͳͷ ρ ȏͳȐ
Km ͳ͵Ͳ ρ ȏͳȐ
Ki ͷ ρ ȏͳȐ
Ki ʹͲͲ ρ ȏͳȐ Keq ͳ ȏͳȐ
ͳͺ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
Parameter Value unit References CPT2 sf ʹͳ ͲǤͺͷ ȏǡͺȐ sf ʹͳͶ ͳǤͲͲ ȏǡͺȐ sf ʹͳʹ ͲǤͻ ȏǡͺȐ sf ʹͳͲ ͳǤͲͲ ȏǡͺȐ sf ʹͺ ͲǤͶʹ ȏǡͺȐ sf ʹ ͲǤʹͷ ȏǡͺȐ sf ʹͶ ͲǤͳͻ ȏǡͺȐ ρǤǦ V ʹ ͲǤ͵ͻʹ ͳǤǦͳ ȏǡͺȐ 5 Km ʹͳ ǤͲͲ ρ ȏǡͺȐ Km ʹͳͶ ͶǤͲ ρ ȏǡͺȐ Km ʹͳʹ ͳͷ ρ ȏǡͺȐ Km ʹͳͲ Ͷ͵ ρ ȏǡͺȐ Km ʹͺ ͳͺǤͶ ρ ȏǡͺȐ Km ʹ ͳʹͷǤͷͶ ρ ȏǡͺȐ Km ʹͶ Ͷ͵Ǥͷ ρ ȏǡͺȐ Km ʹ ͵Ͳ ρ ȏͳȐ Km ʹͳ Ǥ͵ ρ ȏǡͺȐ Km ʹͳͶ Ǥͺ ρ ȏǡͺȐ Km ʹͳʹ ʹʹǤͶ ρ ȏǡͺȐ Km ʹͳͲ ͵ ρ ȏǡͺȐ Km ʹͺ ͷͲǤ͵ ρ ȏǡͺȐ Km ʹ ͷͶǤͷ ρ ȏǡͺȐ Km ʹͶ Ͷ͵Ǥͷ ρ ȏͳȐ
Km ʹ ͵ͷͲ ρ ȏͳȐ Keq ʹ ʹǤʹʹ
VLCAD sf ͳ ͳǤͲͲ ȏǡͻǡͳͲȐ sf ͳͶ ͲǤͶ͵ ȏǡͻǡͳͲȐ sf ͳʹ ͲǤʹ ȏǡͻǡͳͲȐ sf ͳͲ ͲǤͲ ȏǡͻȂͳͳȐ sf ͺ ͲǤͲ͵ ȏǡͻȂͳͳȐ sf ͲǤͲͳ ȏǡͻȂͳͳȐ V ͲǤͳͲ͵ ȏǡͻȂͳͳȐ ρǤǦ Kmͳ ͳǤͷ ȏͳͳǡͳʹȐ ͳǤǦͳ KmͳͶ ͳǤͳͷ ρ ȏͳͳǡͳʹȐ
Kmͳʹ ͲǤͺͲ ρ ȏͳͳǡͳʹȐ
KmͳͲ ͳͲ ρ ȏͳͲȐ
Kmͺ ͺ ρ ȏͳͲȐ
Km ʹͻ ρ ȏͳͲȐ
Km ͲǤͳʹ ρ ȏͳȐ
Km ͳǤͲͺ ρ ȏͳȐ
Km ʹͶǤʹ ρ ȏͳȐ Keq ȏͳȐ
ͳͺ Chapter 5
Parameter Value unit References MCAD sf ͳ ͲǤͲͳ ȏͳͳǡͳ͵Ȑ sf ͳͶ ͲǤʹͳ ȏͳ͵Ȑ sf ͳʹ ͲǤͶͷ ȏͳ͵Ȑ sf ͳͲ ͲǤͷʹ ȏͳ͵Ȑ sf ͺ ͲǤͷ ȏͳ͵Ȑ sf ͳǤͲͲ ȏͳ͵Ȑ sf Ͷ ͲǤͳͶ ȏͳ͵Ȑ V ͲǤͲͶ ȏͻǡͳ͵Ȑ ρǤǦ Kmͳ ʹ͵Ǥͺ ͳǤǦͳ ȏͳ͵Ȑ KmͳͶ ͳͲǤͲ ρ ȏͳ͵Ȑ Kmͳʹ ͻǤ͵ ρ ȏͳ͵Ȑ KmͳͲ ͻǤͳ ρ ȏͳ͵Ȑ Kmͺ ͺ ρ ȏͳ͵Ȑ Km ʹͳǤ ρ ȏͳ͵Ȑ KmͶ ͳǤͶ ρ ȏͳ͵Ȑ Km ͲǤͳʹ ρ ȏͳȐ
Km ͳǤͲͺ ρ ȏͳȐ
Km ʹͶǤʹ ρ ȏͳȐ Keq ȏͳȐ
SCAD sf ͲǤͺͺ ȏͳ͵Ȑ sf Ͷ ͳ ȏͳ͵Ȑ ρǤǦ V ͲǤͲͲ ͳǤǦͳ ȏͻǡͳ͵Ȑ Km ͵͵Ǥͻ ρ ȏͳ͵Ȑ KmͶ ͳʹǤͻ ρ ȏͳ͵Ȑ Km ͲǤͳʹ ρ ȏͳȐ
Km ͳǤͲͺ ρ ȏͳȐ
Km ʹͶǤʹ ρ ȏͳȐ Keq ȏͳȐ CROT ȏͳȐ sf ͳ ͲǤͳ͵ ȏͳȐ sf ͳͶ ͲǤʹ ȏͳȐ sf ͳʹ ͲǤʹͷ ȏͳȐ sf ͳͲ ͲǤ͵͵ ȏͳȐ sf ͺ ͲǤͷͺ ȏͳȐ sf ͲǤͺ ȏͳȐ sf Ͷ ͳ ȏͳȐ ρǤǦ V ͵Ǥ ȏͳȐ ͳǤǦͳ Kmͳ ͳͷͲ ρ ȏͳȐ
KmͳͶ ͳͲͲ ρ ȏͳȐ
Kmͳʹ ʹͷ ρ ȏͳȐ
ͳͺͺ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
Parameter Value unit References
KmͳͲ ʹͷ ρ ȏͳȐ
Kmͺ ʹͷ ρ ȏͳȐ
Km ʹͷ ρ ȏͳȐ
KmͶ ͶͲ ρ ȏͳȐ
Km Ͷͷ ρ ȏͳȐ
Ki ͳǤ ρ ȏͳȐ Keq ͵Ǥͳ͵ ȏͳȐ
MSCHAD sf ͳ ͲǤ ȏͳȐ 5 sf ͳͶ ͲǤͷ ȏͳȐ sf ͳʹ ͲǤͶ͵ ȏͳȐ sf ͳͲ ͲǤͶ ȏͳȐ sf ͺ ͲǤͺͻ ȏͳȐ sf ͳ ȏͳȐ sf Ͷ ͲǤ ȏͳȐ ρǤǦ V ͳ ȏͳȐ ͳǤǦͳ Kmͳ ͳǤͷ ρ ȏͳȐ
KmͳͶ ͳǤͺ ρ ȏͳȐ
Kmͳʹ ͵Ǥ ρ ȏͳȐ
KmͳͲ ͺǤͺ ρ ȏͳȐ
Kmͺ ͳǤ͵ ρ ȏͳȐ
Km ʹͺǤ ρ ȏͳȐ
KmͶ ͻǤͻ ρ ȏͳȐ
Km ͷͺǤͷ ρ ȏͳȐ
Kmͳ ͳǤͶ ρ ȏͳȐ
KmͳͶ ͳǤͶ ρ ȏͳȐ
Kmͳʹ ͳǤ ρ ȏͳȐ
KmͳͲ ʹǤ͵ ρ ȏͳȐ
Kmͺ ͶǤͳ ρ ȏͳȐ
Km ͷǤͺ ρ ȏͳȐ
KmͶ ͳǤͻ ρ ȏͳȐ
Km ͷǤͶ ρ ȏͳȐ Keq ʹǤͳȉͳͲǦͶ ȏͳȐ
MCKAT sf ͳ ͲǤͲͳ Ǧ sf ͳͶ ͲǤʹ ȏͳȐ sf ͳʹ ͲǤ͵ͺ ȏͳȐ sf ͳͲ ͲǤͷ ȏͳȐ sf ͺ ͲǤͺͳ ȏͳȐ sf ͳ ȏͳȐ sf Ͷ ͲǤͶͻ ȏͳȐ ρǤǦ V ͲǤͶ͵ ȏǡͳͶȐ ͳǤǦͳ Km ͳ ͲǤͷ ρ ȏͳͶǡͳͷȐ
ͳͺͻ Chapter 5
Parameter Value unit References
Km ͳͶ ͲǤͷͷ ρ ȏͳͶǡͳͷȐ
Km ͳʹ ͲǤ ρ ȏͳͶǡͳͷȐ
Km ͳͲ ͲǤͻ ρ ȏͳͶǡͳͷȐ
Km ͺ ͳǤʹͻ ρ ȏͳͶǡͳͷȐ
Km ͶǤͶͷ ρ ȏͳͶǡͳͷȐ Km Ͷ ͻǤʹ ρ ȏͳͶȐ Km ͳ ͳͳ͵Ǥͳ ρ ȏͳͷǡͳȐ
Km ͳͶ ͳ͵ʹǤͷ ρ ȏͳͷǡͳȐ
Km ͳʹ ͳͷͳǤͻ ρ ȏͳͷǡͳȐ
Km ͳͲ ͳͶͳǤʹ ρ ȏͳͷǡͳȐ
Km ͺ ͳͶͲǤͶ ρ ȏͳͷǡͳȐ
Km ͶǤ ρ ȏͳͷǡͳȐ
Km Ͷ ͺǤ ρ ȏͳͷȐ
Km ͳ ͷǤ ρ Ǥ ǤǤȀαͳͲ
Km ͳͶ ͷǤ ρ Ǥ ǤǤȀαͳͲ
Km ͳʹ ͺ͵Ǥͺ ρ Ǥ ǤǤȀαͳͲ
Km ͳͲ ͳͲͶ ρ Ǥ ǤǤȀαͳͲ
Km ͺ ͳͷǤʹ ρ Ǥ ǤǤȀαͳͲ
Km ʹͲǤͳ ρ Ǥ ǤǤȀαͳͲ
Km Ͷ ͵ͺͳǤ͵ ρ Ǥ ǤǤȀαͳͲ
Km ͻͳǤ ρ Ǥ ǤǤȀαͳͲ Keq ͳͲͷͳ ȏͳȐ
MTP sfͳ ͳ ȏͳȐ sfͳͶ ͲǤͻ ȏͳȐ sfͳʹ ͲǤͺͳ ȏͳȐ sfͳͲ ͲǤ͵ ȏͳȐ sfͺ ͲǤ͵Ͷ ȏͳȐ ρǤǦ V ʹǤͺͶ ȏͳȐ ͳǤǦͳ Km ʹͷ ρ ȏͳȐ
Km Ͳ ρ ȏͳȐ
Km ͵Ͳ ρ ȏͳȐ
Km ͳ͵Ǥͺ͵ ρ ȏͳȐ
Km ͷͲ ρ ȏͳȐ
Km ͵Ͳ ρ ȏͳȐ Keq ͲǤͳ ȏͳȐ ETFQO ρǤǦ V ͲǤͲ͵ͷ ͳǤǦͳ ȏǡͳǡͳͺȐ Km ͳǤͻ ρ ȏͳȐ Km ʹͲǤ͵ ρ ȏͳǡͳͻȐ Km ͳǤͻ ρ ȏͳǡʹͲȐ Km ʹ ͵ͺǤͳ ρ Ǥ ǤȀαͳ
ͳͻͲ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
Parameter Value unit References
Ki ͳǤͻ ρ Km
Ki ʹ ͵ͺǤͳ ρ Km ʹ Keq ͳͻͻǤͷ ȏʹͳǡʹʹȐ ACAT1 ρǤǦ Vͳ ȏͷǡȐ ͲǤ͵Ͷͻ ͳǤǦͳ Kmͳǡ Ǥʹ ρ ȏʹ͵Ȑ
Kmͳǡ ρ ȏʹͶȐ
Kmͳǡ ʹͳ ρ ȏʹͶȐ 5 Keqͳ ͳͲͷͳ ȏͳȐȋ Ȍ
HMGCS2 ρǤǦ V ʹ ͲǤͲʹͳ ͳǤǦͳ ȏʹͷȐ Km ʹͶ ͲǤ͵ͷ ρ Km ʹ ͷͳ ρ ȏʹȐ
Km ʹ ͵ͷ ρ ȏʹȐ
Km ʹ ͷͲͲ ρ ȏʹȐ Keq ʹ ͵ͲͲͲ ȏʹȐ HMGCL ρǤǦ Vf ͲǤͳ͵͵ ȏʹͷȐ ͳǤǦͳ Km ͺ ρ ȏʹͺȐ Km ͵Ͳ ρ Km ʹͳ ρ ȏʹͻȐ Keq ʹͲͲͲ ρ ȏ͵ͲȐ BDH1 ρǤǦ V ͳ ͳǤͻͻ ȏ͵ͳȐ ͳǤǦͳ Kmͳ ͳͶͻ ρ ȏ͵ͳȐ
Kmͳ ͳͶ ρ ȏ͵ͳȐ Km ͳ ͺ ρ ȏ͵ͳȐ Kmͳ ͳ ρ ȏ͵ͳȐ
Kiͳ ͷͺͶ ρ ȏ͵ͳȐ
Kiͳ ͷ ρ ȏ͵ͳȐ Ki ͳ ͳͲͲͲͲ ρ ȏ͵ͳȐ Kiͳ ͵Ͳͳ ρ ȏ͵ͳȐ ǣ Keq ͳ ͳǤʹͷͷ ȋͳȀʹȌȗȋȋȗȌȀȋȗȌȌ
ACOT ͳ ͲǤͺ͵ ȏ͵ʹȐ ͳͶ ͲǤͺͻ ȏ͵ʹȐ
ͳͻͳ Chapter 5
Parameter Value unit References ͳʹͳȏ͵ʹȐ ͳͲ ͲǤͶ ȏ͵ʹȐ ͺ ͲǤͷͳ ȏ͵ʹȐ ͲǤʹ ȏ͵ʹȐ Ͷ ͲǤͲͶ ȏ͵ʹȐ ρǤǦ ̴ ͲǤͲͶ͵ ȏ͵ʹȂ͵Ȑ ͳǤǦͳ ͳ ʹǤ ρ ȏ͵ʹȐ
ͳͶ ʹǤͶ ρ ȏ͵ʹȐ
ͳͲ Ǥͳ ρ ȏ͵ʹȐ
ͺ ͺǤ͵ ρ ȏ͵ʹȐ
ͳ͵ ρ ȏ͵ʹȐ
Ͷ ͳ ρ ȏ͵ʹȐ
ͳ ʹͶͲͲ ρ ȉ
ͳͶ ͳͺʹͶͲͲ ρ DzDz
ͳʹ ʹͷͲͺͲͲ ρ DzDz
ͳͲ Ͷ͵ͲͲ ρ DzDz
ͺ ͵ͲͺͲͲ ρ DzDz
ͻͺͺͲͲͲ ρ DzDz
Ͷ ͶͺͲͲͲͲͲͲ ρ DzDz
ʹ ͳ͵ͳͳͲͲͲͲ ρ DzDz ̴ ͻ ρ ȏ͵ͷȐ ͳ ʹͶͲͲͲ ȏ͵ͺȐ ͳͶ ͲͲͲ ȏ͵ͺȐ ͳʹ ͲͲͲ ȏ͵ͺȐ ͳͲ ͲͲͲ ȏ͵ͺȐ ͺ ͲͲͲ ȏ͵ͺȐ ͲͲͲ ȏ͵ͺȐ Ͷ ͵ͲͲͲͲͲͲ ȏ͵ͺȐ ʹ ͷͲͲͲͲ ȏ͵ͺȐ Ͷ͵ͲͲͲͲ ȏ͵ͺȐ ͳͲͲͲ ȏ͵ͺȐ ACS sf ͳ ͲǤͻͳ ȏ͵ͻȐ sf ͳͶ ͲǤͻ ȏ͵ͻȐ sf ͳʹ ͳ ȏ͵ͻȐ sf ͳͲ ͲǤͶ ȏ͵ͻȐ sf ͺ ͲǤͲͺ ȏ͵ͻȐ sf ͲǤͲͲ͵ͳ ȏ͵ͻȐ sf Ͷ ͲǤͲͲͲͳͶ
Kmͳʹ ͶǤͷͷ ρ ȏ͵ͻȐ
KmͳͲ Ǥͻ ρ ȏ͵ͻȐ
Kmͺ ͳͳǤͳ ρ ȏ͵ͻȐ
Km ʹͲǤͺ ρ ȏ͵ͻȐ
KmͶ ͷǤͳ ρ
ͳͻʹ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
Parameter Value unit References
Km ͲǤͷ͵ ρ ȏͶͲȐ
Km ͷͲͲ ρ ȏͶͲȐ Omega-oxidation sfͳ ͲǤͲͳ ȏͶͳȐ sfͳͶ ͲǤͲͳ ȏͶͳȐ sfͳʹ ͲǤͲͷ ȏͶͳȐ sfͳͲ ͲǤʹʹ ȏͶͳȐ sfͺ ͲǤ͵ͺ ȏͶͳȐ sf ͺ ȏͶͳȐ 5 sfͶ ͲǤͲͳ ȏͶͳȐ ρǤǦ Vɘ ͳǤͶ ȏͶʹȂͶͷȐ ͳǤǦͳ Kmͳ ʹͲͲͲͲ ρ ȏͶͳȐ
KmͳͶ ʹͲͲͲͲ ρ ȏͶͳȐ
Kmͳʹ ͵Ǥ ρ ȏͶͳȐ
KmͳͲ ͷʹʹ ρ ȏͶͳȐ
Kmͺ Ͷͺͳ ρ ȏͶͳȐ
Km ͺʹͷ ρ ȏͶͳȐ
KmͶ ʹͲͲͲͲ ρ ȏͶͳȐ
Km ͵ ρ ȏͶȐ Transmembranal transport parameters Ǧͳ Ǧͳ k ͵ Ǥ Ǥ Ǧͳ Ǧͳ k ͵ Ǥ Ǥ DzDz Ǧͳ Ǧͳ k ͵ Ǥ Ǥ DzDz Ǧͳ Ǧͳ k ͳǦͲ Ǥ Ǥ DzDz Ǧͳ Ǧͳ k ͳǦͲ Ǥ Ǥ DzDz Ǧͳ Ǧͳ k ͳǦͲ Ǥ Ǥ DzDz Ǧͳ Ǧͳ k ͳǦͲ Ǥ Ǥ DzDz k ͳǦͲ ǤǦͳǤǦͳ DzDz
Boundary metabolites and cofactors ʹͲͲ ρ ȏͳȐ ͳͶͲ ρ ȏͳȐ ͻͷͲ ρ ȏͳȐ Ͳ ρ ȏͳȐ ͲǤ ρ ȏͳȐ ʹͷͲ ρ ȏͳȐ ͳ ρ ȏͳȐ ʹͺͺ ρ ȏͶȐ ʹ ʹͺ ρ ȏͶȐ ͶͻͲͲ ρ ȏͶͺȐ ͵ͷ ρ ȏͶͻȐ
ͳͻ͵ Chapter 5
Parameter Value unit References Conserved moieties ͷͲͲͲ ρ ȏͳȐ Compartment volumes ʹǤʹȉͳͲǦ Ǧͳ ȏͳȐ ͳǤͺȉͳͲǦ Ǧͳ ȏͳȐ ͳǤͲȉͳͲǦ Ǧͳ ȏͷͲȐ CPT1 parameters used for Figure 6. Parameter Value Reference value unit CPT1 sf ͳͳͶ ͲǤͳ͵Ͷ ͳǤ͵Ͷ sf ͳͳʹ ͲǤͳͻ͵ ͳǤͻ͵ sf ͳͳͲ ͲǤͳͷͶ ͳǤͷͶ sf ͳͺ ͲǤͲͺ͵ ͲǤͺ͵ sf ͳ ͲǤͲͷͳ ͲǤͷͳ sf ͳͶ ͲǤͲʹͷ ͲǤʹͷ
Km ͳͳͶ ͵ͲͺͲͲ ͵ͲǤͺ ρ
Km ͳͳʹ ͳͳͲͲͲ ͳͳ ρ
Km ͳͳͲ ͳͲͲ ͳǤ ρ
Km ͳͺ ʹʹͻͲͲ ʹʹǤͻ ρ
Km ͳ ͳͷͳͷͲͲ ͳͷͳǤͷ ρ
Km ͳͶ ͷ͵ͷͲͲ ͷ͵Ǥͷ ρ ͳͶǦͶ ǦǤ ZĞĨĞƌĞŶĐĞƐ ͳǤ ǡ ǡ ǡǡ ǡǡ ǡ ǡǡ ǡǤ Ǧ ȾǦ ǤǤʹͲͳ͵ǢͻȋͺȌǣʹȂͻǤ ʹǤ ǡ ǡ ǡ Ǧ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳǢ ͵Ǥ ǡ ǡ Ǥ ǡ Ǧ Ǥ Ǥ ͳͻͻͲǢʹͶȋͳȂ ʹȌǣͳ͵ȂǤ ͶǤ ǡ ǡ ǡ Ǥ Ǥ Ǥ ͳͻͺ ͳǢʹͶͶȋʹȌǣʹͳȂͺǤ ͷǤ ǡ ǡ ǡ Ǥ Ǥ ǤͳͻͺͳǢʹͷȋͳͶȌǣ͵ͳȂǤ Ǥ ä ǡ ǡ ± ǡ Ǥ Ǧ ʹǤ Ǥ ʹͲͳǢͳ͵ǣʹ͵ͶȂͶǤ Ǥ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ
ͳͻͶ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
ͳͻͻͲǢͳͺͻȋ͵Ȍǣͷ͵ͻȂͶǤ ͺǤ ǡ ǡ ǡ Ǥ Ǥ Ǥ ͳͻͺ͵ǢͻͶȋʹȌǣͷʹͻȂͶʹǤ ͻǤ ǡǡǡǡ ǡ ǡ ǡǡ ǡ Ǥ ǦǦ Ǧ Ǥ ǤͳͻͻͷǢͻͷȋȌǣʹͶͷȂ͵Ǥ ͳͲǤ ǡ ǡ ǡ ǡ ò ǡ ǡ ǡ ǡ Ǥ ǦǦ Ǧ ǣ Ǧ Ǧ Ǧ Ǥ Ǥ ͳͻͻǢ͵ͷȋ͵ͺȌǣͳʹͶͲʹȂͳͳǤ ͳͳǤ ǡǦǡ ǡǡ ǡ ǡ ǡ 5 Ǧǡ ǡ ǡ ǡ ǡ ǡǤ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳȂͳͷǤ ͳʹǤ ǡ ǡǡǡ Ǥ Ǧ Ǥ Ǥ ǦǦ Ǧ Ǥ Ǥͳͻͻʹ ͳͷǢʹȋʹȌǣͳͲʹȂ͵͵Ǥ ͳ͵Ǥ ǡ ǡǤ Ǧ ǦǡǦ Ǧǡ Ǧ Ǥ Ǥ ͳͻͺͺǢͶͺȋͳȌǣʹʹͳȂ͵ͲǤ ͳͶǤ ǡ ǡǡ ǡ ǡǤ ͵Ǧ ǦȋͳȌǣ Ǥ Ǥ ʹͲͳͶǢͲȋͳʹȌǣ͵ʹͳʹȂʹͷǤ ͳͷǤ ǡ ǡ Ǥ Ǥ ǤͳͻͺǢʹͷ͵ȋȌǣͳͺʹȂ͵ͳǤ ͳǤ ǡ ǡǡ ǡǤ͵Ǧ Ǧ Ǥ ǤͳͻͺͳǢͻͲȋʹȌǣͷͳͳȂͻǤ ͳǤ ǡ ǡ Ǥ Ǧ Ǧǣ Ǥ ǤͳͻͺǢʹͶͳǣͺͺ͵ȂͻʹǤ ͳͺǤ ǡ Ǥ Ǧ Ǧ ǣ ǡ ǡ Ǥ Ǥ ͳͻͺͷǢʹͶȋͳͷȌǣ͵ͻͳ͵ȂʹͳǤ ͳͻǤ ǡ ǡǡ Ǥ Ǧ ǣ ǣ Ǥ ǤͳͻͻͳǢ͵ͲȋͷȌǣͳ͵ͳȂʹ͵Ǥ ʹͲǤ Ǥ Ǧ ǤǦǤͳͻͺǢͺͻ͵ȋʹȌǣͳͳȂͻǤ ʹͳǤ ǡ ǡ ǤǦ Ǧ Ǧ ǦǤ ǤͳͻͺͶǢʹͳͻȋ͵ȌǣͳͲͶ͵ȂǤ ʹʹǤ Ǥ ȏ ȐǤ ͷǤͳ Ǣ Ǣ Ǣ ͷ ǤǢ Ǣ ʹͲͲͺǤ ʹͲͲͺǤ ǣ ǣȀȀ ǤǦ ǤǤȀȀ ȀǤ ʹ͵Ǥ ǡ ǡǤǡǤ Ǧ ǣ Ǥ ǤͳͻͶǢͷȋͶȌǣͳͲͻȂǤ
ͳͻͷ Chapter 5
ʹͶǤ Ǥ Ǧ Ǥ Ǥ ͳͻ͵Ǣͳ͵ʹȋͶȌǣͳȂ͵ͲǤ ʹͷǤ ǡ ǡ Ǥ ȋ Ȍ ͵ǦǦ͵Ǧ Ǥ Ǥ ͳͻͷǢʹͷͲȋͺȌǣ͵ͳͳȂʹ͵Ǥ ʹǤ ǡ Ǥ ͵Ǧ Ǧ͵ǦǦ Ǥ ǡ Ǥ ǤͳͻͺͷǢʹʹǣͷͻͳȂͻǤ ʹǤ ʹǤ ʹͺǤ ǡ Ǥ ǦǦ Ǧ Ǥ Ǥ ͳͻͺǢʹͶ͵ȋʹͲȌǣͷʹʹȂͻǤ ʹͻǤ ǡǡ ǡ Ǥ͵Ǧ Ǧ͵ǦǦ ǦͶͳ ǣ Ǧ Ǥ ǤʹͲͲͶǢͶ͵ȋͳͺȌǣͷʹͺȂͻͷǤ ͵ͲǤ Ǥ ͵ͳǤ ǡ Ǥ Ǧ ǤͳͻͻǢͳͻǣͷͻȂͺͳǤ ͵ʹǤ ǡǡǡǦǤǦ ǦǦǤ ǤʹͲͲͻǢͶͺȋʹͶȌǣͷͷͲȂͻǤ ͵͵Ǥ ǡǡǡǡǡǡ ǡǡǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ǤǤʹͲͲͺǢͳ͵ͶȋͳȌǣͳͳʹȂʹ͵Ǥ ͵ͶǤ ǡ ǡ Ǥ Ǧ Ǧ ǤǤʹͲͳͷǢͳͲȋ͵ȌǤ ͵ͷǤ ǡ ǡ ǡ ǡ Ǧ Ǥ Ǧ ʹȋͲͲͷͶ ʹȌ Ǥ ǤʹͲͲͻǢͶͺȋȌǣͳʹͻ͵Ȃ͵ͲͶǤ ͵Ǥ ǡǡǡ ǡǡǡ ǡ ǡ ǡ ǡǤ ǦǦʹ Ǥ ǤʹͲͳͶǢͷͷȋͳʹȌǣʹͶͷͺȂͲǤ ͵Ǥ ǡ Ú ǡ ǡ ǡ ǡ ǡ Ǥ ǦͻȋͻȌ Ǥ ǤʹͲͳͶǢͳȋͷȌǣͻ͵͵ȂͶͺǤ ͵ͺǤ ǡ ǡ Ǧ ǡ Ǥ Ǧ Ǥ ǤʹͲͳʹǢͶͲȋͳȌǣͲȂͷǤ ͵ͻǤ ǡ Ǥ Ǥ ǤͳͻʹǢʹͶȋʹͳȌǣͶͶ͵͵ȂǤ ͶͲǤ ǡ Ǧ ǡ ǡ ǡ Ǥ Ǧ͵Ǥ ǤͳͻͻǢʹͳȋʹͺȌǣͳͶͺȂͷʹǤ ͶͳǤ ǡǡÞǤ ǦͳͲǦ Ǧ ͳͲǦǦͳǦ Ǧ ǣ Ǧ ǦͳǦ Ǧ ȋǦͳʹȌ ǤǤͳͻͺ͵ǢͳȋͳͲȌǣͺʹͺȂ͵ͶǤ ͶʹǤ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ɘǦǡͶͳͳǣ Ǥ ǤʹͲͲͲǢ͵ͺȋʹȌǣ͵͵͵ȂͻǤ Ͷ͵Ǥ ǡǡǡǤ ǦǤ
ͳͻ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
ǤʹͲͲͲǢ͵͵ȋͳȌǣ͵ȂͳǤ ͶͶǤ Ǥǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǯ ǡ ǡ ǡ Ǥ ͶͳͳʹͲǦ Ǥ ǤʹͲͲͷǢͳͳͳȋͳȌǣ͵ȂͻǤ ͶͷǤ ǡ ǡ ǡ Ǥ ͶͷͲͶͳͳȋͶͳͳȌͳ͵ͳ Ǥ ǤͳͻͻͺǢʹ͵ȋ͵Ȍǣʹ͵ͲͷͷȂͳǤ ͶǤ ǡ ǡǤǦȋǦǦͳȌǦ Ǥ Ǥ Ǥ ͳͻͺ ʹʹǢͷ͵ͳȋʹȌǣͳͶͻȂͷǤ ͶǤ Ǥ Ǥ Ǧ ǤʹͲͳ͵ǢͳͲͷȂͶʹǤ 5 ͶͺǤ ǡ ǡ ǡǡ ǡǡ ǡǦǤ Ǧ Ǧ Ȁ ǤʹͲͲͲǢʹʹͲȋͳͻͺͶȌǣ͵ͳȂǤ ͶͻǤ ǡ ǡǡ Ǥ Ǥ Ǥ ͳͻ ǢͳͺͶȋͳȌǣʹʹʹȂ͵Ǥ ͷͲǤ ǡ ǡ ǡǡǡǤǤ ǣ ǤͷǤǣ ǢʹͲͲʹǤ
ͳͻ Chapter 5
Supplementary figures and tables
A B C D 14 ) vmcadC4 -1 vvlcadC6 12 vvlcadC8 vmcadC6 vscadC4 vmcadC8 10 vvlcadC10 vmcadC10 .gProtein
-1 vvlcadC12 8 vmcadC12 vvlcadC14 vscadC6 6 vmcadC14 vvlcadC16 vmcadC16 4 (μmol.min 2 nadhsnk J 0 0501000501000501000 50 100 150 200 250
[Palmitoyl-CoA]CYT ;ʅDͿ Palmitoyl-CoA]CYT ;ʅDͿ Palmitoyl-CoA]CYT ;ʅDͿ Palmitoyl-CoA]CYT ;ʅDͿ Supplementary figure S1, mFAO flux of WT and MCAD KO versions of the published fitted human isolated mFAO dynamic model [Eunen al. 2016] (A) and steady-state fluxes through VLCAD (B), MCAD (C) and SCAD (D). ǣǢǣǤ
Supplementary Table ST1. Flux and concentration control coefficients of the model as described in Supplementary Text ST1. The same model version (healthy, without any deficiencies) was used in Figure 2 in the main text. The control coeffients were calculated over the net NAD production flux (M/SCHAD plus MTP minus ketogenesis) , the consumption flux of palmitoyl-CoA by CPT1 (vCPT1 C16) and the CoASH concentration in the mitochondrial matrix (MAT).
JNAD production JCPT1C16 [CoASH]MAT [palmitoyl-CoA]CYT ʹͷɊ ͳͲͲɊ ʹͷɊ ͳͲͲɊ ʹͷɊ ͳͲͲɊ Vcpt1 0.59 0.00 0.61 0.06 -0.24 -1.11 Vfcact ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vcpt2 ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ǦͲǤͲͺ Vvlcad ͲǤͲͳ ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ǦͲǤͲͶ Vmcad ͲǤͲ͵ ͲǤͲʹ ͲǤͲ͵ ͲǤͲʹ ͲǤͲͳ ͲǤͲͲ Vscad ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ͲǤͲͷ Vcrot ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vmschad ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vmckat ͲǤͲ͵ ͲǤͲͳ ͲǤͲʹ ͲǤͲͳ ͲǤͲʹ ͲǤͲ Vmtp ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vacot ǦͲǤͲͶ ͲǤͲͲ ǦͲǤͲͶ ͲǤͲͲ ͲǤͲʹ ͲǤͲͻ Vacat1 ͲǤͲͳ ͲǤͲͳ ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲ͵ Vhmgcs2 ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vhmgcl ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vbdh1 ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vfetfqo 0.35 0.95 0.33 0.88 0.18 0.98 kmc ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vacs ǦͲǤͲͳ ͲǤͲͲ ǦͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲʹ kcmi ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vwox ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ǦͲǤͲͳ kmic ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ keFFA ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ǦͲǤͲͳ keCn ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ keDCA ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ keAcetoacetateMAT ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͳ keBetahydroxybutyrateMAT ͲǤͲͲ ǦͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ
ͳͻͺ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
14
) 12 -1 10 Leak 8
.gProtein vC16-CoA_cons * -1 6 vnadhsink ɇvExAc-carnCn * 4 ɇvExFFACn * 2 ɇvExDCACn * vacsC16 * J (μmol.min 0 050100 [Palmitoyl-CoA] CYT ;ʅDͿ Supplementary Figure S2. Net NADH production fluxes in the mitochondria (vnadhsink), palmitoyl- CoA consumption flux in nadh production equivalents, leakage of incompletely oxidized intermediate metabolites (“Leak”) expressed in nadh production equivalents and reaction rates which the leakage consists of, namely acyl- ȋȭExAc-carnCn), free fatty acid export 5 ȋȭ Ȍǡ ȋȭȌ -catalyzed return of palmitoyl-CoA to its constant pool (also in nadh production equivalents).
ͳͻͻ Chapter 5
Supplementary Table ST2. Flux control coefficients of model with ACS knockdown to 1% of its reference value JNAD production JCPT1C16 [CoASH]MAT [palmitoyl-CoA]CYT ʹͷɊ ͳͲͲɊ ʹͷɊ ͳͲͲɊ ʹͷɊ ͳͲͲɊ Vcpt1 0.31 ͲǤͲͲ 0.34 ͲǤͲ -0.35 -1.04 Vfcact ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vcpt2 ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ǦͲǤͲͳ ǦͲǤͲͻ Vvlcad ͲǤͲʹ ͲǤͲͳ ͲǤͲͳ ͲǤͲͳ ͲǤͲͲ ǦͲǤͲͻ Vmcad ͲǤͲ͵ ͲǤͲʹ ͲǤͲ͵ ͲǤͲʹ ͲǤͲͳ ͲǤͲʹ Vscad ͲǤͲͲ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲ Vcrot ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vmschad ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͳ Vmckat ͲǤͲʹ ͲǤͲͳ ͲǤͲʹ ͲǤͲͳ ͲǤͲ͵ ͲǤͲͺ Vmtp ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vacot ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲʹ ͲǤͲͳ ͲǤͲͶ Vacat1 ͲǤͲͳ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ͲǤͲͳ ͲǤͲͶ Vhmgcs2 ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vhmgcl ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vbdh1 ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vfetfqo 0.60 0.96 0.56 0.86 0.30 0.95 kmc ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vacs ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ kcmi ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vwox ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ kmic ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Ͳ ͲǤͲͲ keFFA ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ keCn ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ keDCA ͲǤͲͲ ͲǤͲͲ Ͳ Ͳ Ͳ ͲǤͲͲ keAcetoacetateMAT ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͳ keBetahydroxybutyrateMAT ͲǤͲͲ ǦͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ
WT VLCAD KO MCAD KO SCAD KO A 40 B C D Leak *
30 ɇvExAc-carnCn *
ɇvExFFACn * 20 ɇvExDCACn * 10 leak (%) Substrate vacsC16 *
0 050100050100050100050100 [Palmitoyl-CoA]CYT ;ʅDͿ [Palmitoyl-CoA]CYT ;ʅDͿ [Palmitoyl-CoA]CYT ;ʅDͿ [Palmitoyl-CoA]CYT ;ʅDͿ Supplementary Figure S3ǤǦ ͳΨ Ǥ A-D Ǧ ȋAȌǡȋBȌǡȋCȌȋDȌ Ǥ
ʹͲͲ Simulating the impact of modifiers on MCAD deficiency in human liver fatty-acid catabolism
Supplementary Table ST3. Flux control coefficients of WT model with C16-specific CPT1 JNAD production JCPT1C16 [CoASH]MAT [palmitoyl-CoA]CYT ʹͷɊ ͳͲͲɊ ʹͷɊ ͳͲͲɊ ʹͷɊ ͳͲͲɊ Vcpt1 1.02 1.01 1.02 1.00 -0.02 -0.11 Vfcact ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vcpt2 ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vvlcad ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vmcad ͲǤͳ ͲǤͳ ͲǤͳ ͲǤͳ ͲǤͲͲ ǦͲǤͲͳ Vscad ǦͲǤͲʹ ǦͲǤͲͶ ǦͲǤͲʹ ǦͲǤͲͶ ͲǤͲͲ ͲǤͲͳ Vcrot ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vmschad ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vmckat ͲǤͲͺ ͲǤͲͷ ͲǤͲͺ ͲǤͲͷ ͲǤͲͳ ͲǤͲͳ Vmtp ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ 5 Vacot -0.33 -0.36 -0.33 -0.36 ͲǤͲͳ ͲǤͲͶ Vacat1 ͲǤͲͳ ͲǤͲͳ ͲǤͲͳ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ Vhmgcs2 ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vhmgcl ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vbdh1 ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vfetfqo ͲǤͲͶ ͲǤͳ ͲǤͲͶ ͲǤͳ ͲǤͲͳ ͲǤͲ kmc ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vacs ǦͲǤͲͷ ǦͲǤͲͶ ǦͲǤͲͷ ǦͲǤͲͶ ͲǤͲͲ ͲǤͲͲ kcmi ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ Vwox ͲǤͲͶ ͲǤͲ͵ ͲǤͲͶ ͲǤͲ͵ ͲǤͲͲ ͲǤͲͲ kmic ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ keFFA ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ keCn ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ keDCA ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ keAcetoacetateMAT ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͳ ͲǤͲͲ ͲǤͲͲ keBetahydroxybutyrateMAT ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͲǤͲͲ ͶǦͳ Ǧ ǡ ǤͳǦ ͳ ͳǤ
Supplementary table ST4. Total C16-C4 CoA ester concentrations in ACAD KO en WT models with C16-specific CPT1. Reference model Model with C16-specific CPT1 Model ȏǦȐ ȏǦȐ ȏǦȐ ȏǦȐ ͳʹǤͺ ͳͶͻͷ ͳͻ ͳͳǤͷ ͳͳʹ ͳͺͻͻ͵ʹ ͶǤͳ ͳͳͳ ͷ ͶǤͳ ͳͳͳ ͻʹͲ ͺǤͲ ʹ͵ͺ ʹͲ ͶǤͻ Ͷͺ ͺͲͳͳ ͳͳǤ ʹͷͺ ͳʹͻͲ ͳͳǤ ʹͷͲͷ ͻ͵ͷ ͳǦͶ ǡȏǦȐ ȏǦ Ȑ ǤͳǦ ͳ ͳǤ
ʹͲͳ Chapter 5
WT VLCAD KO MCAD KO SCAD KO A B C D 40 Leak *
30 ɇvExAc-carnCn *
ɇvExFFACn * 20 ɇvExDCACn * 10 leak (%) Substrate vacsC16 *
0 050100050100050100050100 [Palmitoyl-CoA]CYT ;ʅDͿ [Palmitoyl-CoA]CYT ;ʅDͿ [Palmitoyl-CoA]CYT ;ʅDͿ [Palmitoyl-CoA]CYT ;ʅDͿ Supplementary Figure S4ǤͳǦ ͳǡi.e. ͳ ͳͶǦͶ ǡǦǤA- D Ǧ ȋAȌǡȋBȌǡȋCȌȋDȌǤ
ʹͲʹ
Chapter 6
Towards identifying in vitro metabolic adaptations that explain symptomatology in MCADD individuals A short report
Anne-Claire M.F. Martines1,#, Emmalie A. Jager1,2,#, Albert Gerding1,3, Justina C. Wolters1,2, ۥBarbara M. Bakkerƌϭ͕ ,ۥDirk-Jan Reijngoud1,2, Terry G.J. Derksϭ͕Ϯ͕ϰ͕
1 Laboratory of Pediatrics, Center of Liver, Digestive and Metabolic Diseases, University of Groningen, Groningen, University Medical Center Groningen, Groningen, The Netherlands, 2 Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands 3 Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, The Netherlands 4 Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center of Groningen, University of Groningen.
.These authors contributed equallyۥη͕
Journal publication in preparation
In vitro metabolic adaptations that explain symptomatology in MCADD individuals
Abstract ȋαͶȌ Ǧ ȋȌ ȋαȌǡ ȋ͵ͲȌ Ǥ ȋαȌ Ǥ ǡ ǦͳͲ Ǧ Ǧ ͺǦ Ǧ Ǥ ǡ Ǧ Ǥ ǡ Ǥ Ǥ Ǥ ǡ 6 Ǥ
ʹͲ Chapter 6
Introduction ȋ ȌȏͳȂȐǤ ͳȀͺ͵ͲͲʹͲͲʹͲͳͷȏȐǤ Ǧ ǤǦ ȋȌ ǡ ǡ ȏͺȂͳͳȐǤ Ǧ ǡ Ǥ ǡ ǦǦ Ǥͻͺͷε Ǧ ACADM ǡ ȏͳͲǡͳʹȂʹͲȐǤ Ǥ Ǥ ͳǡ Ǧ Ǥ ȏʹͳȂʹ͵ȐǤ Ǧ Ǥ ǡ Ǥ ǡ Ǥ ǡ ǡǡ ǡ Ǥͻͺͷε ACADM ȏʹͶȐǤ Ǥ Ǥ ǡǡ Ǥ ǡ Ǥ ǡ ȋ Ǥͳ ȌǤ ȏʹͶȐ Ǧ Ͷ ǡ Ǥ ǡ ǡ Ǥ ǣ Ǧ Ǥ Ǥ ǡ Ǧ
ʹͲͺ In vitro metabolic adaptations that explain symptomatology in MCADD individuals
͵ǦͶ ǡ Ǥ Ǥ
Results Cohort and their characteristics Ǧ Ǧ Ǥͻͺͷε ȋͳȌǤ Table 1: Summary of patient characteristics Patient Gender Gene Manifes- Age of Clinical manifestation ID mutation tation onset/ Diagnosis (years) ͳ Ǥͻͺͷε ʹ Ǧ ǡ 6 ǡ Ǥ ʹ Ǥͻͺͷε ͳ ͳ Ǧ Ǥ ǡʹ Ǧ Ǥ ǡ Ǥ ͵ Ǥͻͺͷε ͳǤͷ ͳǤͷ Ǥ Ǧ Ǥ Ͷ Ǥͻͺͷε ͳͳ ͵Ǥ Ǥ ͷ Ǥͻͺͷε ʹ Ǧ ǡ Ǥ Ǥͻͺͷε Ͳ ͷǤ Ǥ Ǥ Ǥͻͺͷε ʹ ǡ Ǥ ͺ Ǥͻͺͷε ͳ Ǥ ͻ Ǥͻͺͷε Ͳ ͺǤ ǡ Ǧ ʹǤ Ǥ ͳͲ Ǥͻͺͷε ͵Ͳ Ǥ Ǥ ǣ ǡǣ Ǥ ȏͳͲȐ.ǣǡ ǣǤ Ǧ ǣǦ ǤǣǤ Ǥͻͺͷε ACADM ȏʹͷȐ ȏʹǡʹȐ ȏʹͺȐǤ ȋͶ Ȍ
ʹͲͻ Chapter 6
ȋȌ ȏͳͲȐǤ ǡ ȋ ͳȌǤ Ǥ ǡȋȌ ʹȋͳǦʹȌǡ ͳǤʹͷ ȋͲǦ͵ͲȌ Ǥ ǡ Ǥǡ Ǥ ǡͳͲȋͳͲȌ Ǥ ͳͲ Ǥ͵Ͳ Ǥ ͳͲ Ǥ ǡ ͳͲ Ǥ ͳǤ Acyl-carnitines ǡ Ǥ Ǥ Ǧ Ǥ ǦǡͺǦͳͲǣͳǦ Ǧ ǡͳͲǦ Ǧ ǡ ȋ ͳȌǤ Ǧ ǡ Ǧ ǡ Ǥ Ǧ ͺǦ Ǧ Ǥ ǡ ͳͲ ǦͳͲǦ Ǧ ȋ ͳǦȌǤ Ǧ Ǥ Ǧǡ ͺǦ ͳͲǣͳǦ ͳͲǦ Ǧ ȋ ͳǦ ȌǤ ǡ Ǧ ͳͲ ȋ ͳǦ ȌǤ Ǧ ȋȌǤ ͳͲǡ Ǥ Ǧǡ ͺǦǡ ͳͲǣͳǦ Ǧ ȋȌ ȋ ʹǦȌǤ ͳͲǦ Ǧ ȋ ʹȌǤ
ʹͳͲ In vitro metabolic adaptations that explain symptomatology in MCADD individuals
A B 1.5 15 ## ##,*
1.0 10
0.5 5 medium C8 medium C6 mol/g protein) mol/g mol/g protein) mol/g §§ ' ' P P §,¥ ( (
0.0 0 Sympt Asympt (ex. Pt10) Pt10 Ctrl Sympt Asympt (ex. Pt10) Pt10 Ctrl
C D 2.5 2.0 # 2.0 1.5
1.5 1.0 1.0 6 medium C10 mol/g protein) mol/g mol/g protein) mol/g 0.5 medium C10:1 medium ' P
P 0.5 ( ( '
0.0 0.0 Sympt Asympt (ex. Pt10) Pt10 Ctrl Sympt Asympt (ex. Pt10) Pt10 Ctrl
EF 1.5 0.25
0.20 1.0 0.15
0.10 0.5 0.05 intracellular C8 intracellular C6
§§ protein) (nmol/g §§ (nmol/g protein) (nmol/g
0.0 0.00 Sympt Asympt (ex. Pt10) Pt10 Ctrl Sympt Asympt (ex. Pt10) Pt10 Ctrl
GH 1.0 1.0
0.8 0.8
0.6 0.6
0.4 0.4
0.2 0.2 (nmol/g protein) (nmol/g (nmol/g protein) (nmol/g intracellular C10 intracellular C10:1 0.0 0.0 Sympt Asympt (ex. Pt10) Pt10 Ctrl Sympt Asympt (ex. Pt10) Pt10 Ctrl Figure 1Ǥ ǦͳͲǦ Ǧ ȋǦȌ Ǧ ͺǦ Ǧ ȋǦ ȌǤ Ǧ ǡ ǤǤαͶǡͷǡͶǡ ǡ ǡ Ǥ ͳǡ͵ǡͶǡ ͷǤȋͳȌǤȚǣ ȋ ͳͲȌǡ͓ǣ ȋ ͳͲȌǡ͎ǣ ͳͲǡ șǣ ǡ Șǣ ǡƬǣ Ǥ ȗǣ ǤδͲǤͲͷǡ δͲǤͲͳǤ ǡ ǦͳͲǦ Ǧ ȋ ʹǦ ȌǤ ǡ ǦͳͲǦ Ǧ ǡ ȋ͵ ʹǦȌǤ
ʹͳͳ Chapter 6
A B 0.6 6
0.4 4
0.2 ÁÁ 2 0.0 ÁÁ
Sympt Asympt (ex. Pt10) Pt10 Ctrl C8 medium medium C6 mol/g protein) mol/g 0 mol/g protein) mol/g ' ' P
P -0.2
( Sympt Asympt (ex. Pt10) Pt10 Ctrl (
-0.4 -2
C D 0.3 0.3
0.2 0.2
0.1 ÁÁ 0.1 0.0 Sympt Asympt (ex. Pt10) Pt10 Ctrl Á medium C10 mol/g protein) mol/g mol/g protein) mol/g 0.0 medium C10:1 ' P P -0.1
( Sympt Asympt (ex. Pt10) Pt10 Ctrl ( '
-0.2 -0.1
EF 0.5 0.20
0.4 0.15
0.3 0.10 0.2 0.05 ÁÁ 0.1 intracellular C6 intracellular C8 (nmol/g protein) (nmol/g
ÁÁ protein) (nmol/g
0.0 0.00 Sympt Asympt (ex. Pt10) Pt10 Ctrl Sympt Asympt (ex. Pt10) Pt10 Ctrl
GH 0.08 0.04
0.06 0.03
0.04 0.02
0.02 0.01 (nmol/g protein) (nmol/g (nmol/g protein) (nmol/g intracellular C10 intracellular C10:1 0.00 0.00 Sympt Asympt (ex. Pt10) Pt10 Ctrl Sympt Asympt (ex. Pt10) Pt10 Ctrl Figure 2ǤǦͳͲǦ Ǧ ȋǦȌ ǦͳͲǦ Ǧ ȋǦ ȌǤ Ǧ Ǧ ǡ ǤǤαͳ ͓ ͓ͷǡαʹ ͓ͳǦǡͺǦͻ ͓͵ǡͶǡα͵ ͓ͳͲ ͓ǤǤ ͳǤ ǡͳͲ ǦͳͲǦ Ǧ ȋ ͵ ʹǦȌǤ ǡ ǦͺǦǡͳͲǣͳǦͳͲǦ Ǧ ȋ Ͷ ʹǦ ȌǤ Ǧ ͳͲ
ʹͳʹ In vitro metabolic adaptations that explain symptomatology in MCADD individuals
ȋͶ ʹǦ ȌǤǡ ͳͲǡ ǡ ǦͳͲǦ Ǧ Ǥ Targeted proteomics ǡ Ǧ ǡ ȏʹͶȐǤ ǡ ȋ ͵ȌǤ Ǥ A B 1.5 20 §§ && g) P g)
P 15 6 1.0
10
0.5
Superoxide 5 MCAD (fmol/ l.o.d. dismutase (fmol/ dismutase 0.0 0 Sympt Asympt (ex.Pt10) Pt10 Ctrl Sympt Asympt (ex.Pt10) Pt10 Ctrl
C D 0.8 && 0.6 && g) g)
0.6 P P 0.4 0.4 l.o.d. 0.2 0.2 ANT1 (fmol/ ETFQO (fmol/
0.0 0.0 Sympt Asympt (ex.Pt10) Pt10 Ctrl Sympt Asympt (ex.Pt10) Pt10 Ctrl
E && 0.5
g) 0.4 P l.o.d. 0.3
0.2
0.1 SCAD (fmol/
0.0 Sympt Asympt (ex.Pt10) Pt10 Ctrl Figure 3Ǥ Ǥ ͳͲ Ǥ ͳǤ ǡͳͲ ǡȋ ͵ ͵ǦȌǤ ͳͲ ǡ ʹȋ ʹȌǡȀ ͳȋͳǡ ʹͷͶȌ ȋ Ǧ ǡ ǡ Ȍȋ ͵ǦȌǤ ǡͳͲ ȋ ͵ȌǤ
ʹͳ͵ Chapter 6
ȋ Ͷ ͷȌǤ Ǧȋ Ȍȋ Ͷ ͷȌǤ ȏʹͻȐǤ ǡ ͳͲ ǡ ͳͲ ȋ Ͷ ͷȌǤ
A B
§§ g) 20
4 P
g) 15
P 3 §§ 2 10
1 5 MCAD (fmol/ l.o.d. 0 0 Sympt Asympt (ex.Pt10) Pt10 Ctrl (fmol/ Peroxiredoxin-6 Sympt Asympt (ex.Pt10) Pt10 Ctrl
C 0.5
g) 0.4 P 0.3
0.2
0.1 SCAD (fmol/
0.0 Sympt Asympt (ex.Pt10) Pt10 Ctrl Figure 4Ǥ Ǥ αʹ ͓ͳǦͻ ͓͵ǡͶǡǤ Ǥ α͵ ͓ͳͲ ͳǤ Discussion Ǥ Ǧ ǡ ͳͲǡ Ǥ ǡ ͳͲ Ǧ Ǥǡ Ǧ Ǥǡ Ǧ Ǥ Ǧ ͳͲ Ǥǡ Ǧ ͳͲǤ ǡ Ǥ Ǥ Ǧ ȋChapter 3ȏʹͶȐȌǤͳͲǡ
ʹͳͶ In vitro metabolic adaptations that explain symptomatology in MCADD individuals
Ǥǡ ͳͲǤ ǡ ǡ Ǥ ǡ ǡ Ǥ ǡǤͳ ǡ Ǧ Ǥ ǡ ǡ Ǧ Ǥ Materials and Methods Patients and controls Ǥͻͺͷε ACADM 6 ǡ ʹͲͲ Ǥ ȏͳͲȐǤ ǡ Ȁ Ȁ Ǥ ȋͳȌǤ Ǥ ȋ ʹͲͳȀͷͻͲȌǤ ǡ ̵ ǡǤȋ ʹͲͳȀͷͻͲȌǤ Cell culture and harvest
͵ιͷΨʹ ̵ ǦͳͲȋ Ȍǡ ͳͲΨ ȋ ǡ Ȍ ͳΨ Ȁ ȋǡ ȌǤ ǡ ͶͲͲ Ɋ Ǧ ȋȌǤ ǡ ̱ͷΨ ͷ ȋ ȌǤʹͶǡ Ǥ ʹǡ ȋǡ ȌǡͲǤʹͷΨ ȋ ȌǤ ȋͷǯͳǡͲͲͲȌ ͳͲǤ ǡ ȋʹȉͳͲͷǦͳȉͳͲ ȌͳǤͷ ȋȌǡ ȋͷǯ ͳǡͷͲͲ Ȍ ǦͺͲι Ǥʹͷρ Ǧ ǦͶͲȋͲǤͳΨǦͶͲǡͲǤͶ ǡͳͲ ͺǤͲͳ ͺǤͲȌʹͲǡǡ ͶͲͶιͳͷͳͲͳʹǡͲͲͲͶιǤʹͲρ ͷρȋ ̹ ǡ ȌǤ͵Ǧȋ ǦǡͲͷͳͲȌ άͷΨ Ǥ ʹͶ ǡ ͳ Ǥ ǡ ǤǦ Ǧ ǡ ͷͲͲρ ȋǦʹͲιȌǡ ȋͳͲͲͲ ρ Ȍ ǦͺͲι Ǥ ǡ ʹͲͲρ Ǧ ǡǦͺͲιǤ Targeted quantitative proteomics of mitochondrial proteins εͷͲ ǡ ȋ Ȍǡ Ǧ ȾǦǡ ǡ
ʹͳͷ Chapter 6
ȋͳ͵Ǧ Ȍ ȋ Ȍȋ ǡ ǡ Ȍ et al.ȏʹͶȐǤ Acyl-carnitine levels Ǧ et al.ȏͳʹȐǤ Statistical analysis ǡ ȋǦ ǯ Ȍ ȋǦǯ Ȍ ǤδͲǤͲͷ ǤƮ ȋʹʹȌ ȋ ǤǡͷǤͲͲǡʹͲͲȌǤ
References ͳǤ Ǥ ǣ Ǥ ǤʹͲͳͶǢͳͲͳǣͳͶȂͺʹǤ ʹǤ ǡǦǡǤ ǣ Ǥ ǤʹͲͲ ǢȋȌǣͶͶͻȂͲǤ ͵Ǥ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͳͻǢͳͲȋ ȌǣͳͻǤ ͶǤ ǡ ǡ ǡ Ǥ ǤǤʹͲͳǢʹ͵ȋͳȌǣͳ͵ȂʹǤ ͷǤ ǡ ǡ ǡǡǡ ǡ ǡ ǡǤ Ǧ Ǧ ǣ Ǥ ǤʹͲͲǢ͵ͻȋͻͷͷͷȌǣ͵ȂͶʹǤ Ǥ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ ǣǡ ǡ Ǥ ǤʹͲͲͶǢͳͳͳȋȌǣͳ͵ͻͻȂͶͲǤ Ǥ ǡǡ ǡ ǡǦ ǡ ǡǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ ȋȌ Ǥ ǤʹͲͳͻʹ͵Ǣ͵ͳȋͲȌǤ ͺǤ ǡǤ ǣ Ǥ ǤʹͲͳͲǢ͵͵ȋͷȌǣͷͳ͵ȂʹͲǤ ͻǤ ǡǡ ǡ ǡǡ ǡǡ ǡ ǡǡ ǡǡǡǡǡǡǡ ǡǡǡǡ ǡǡ ǡǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡǡ ǡǡ Ǧǡ ǡǡ ǡ ǡǡǡǡǡǡǡ ǡǯ ǡ ǡǡǡǡǡǡ ǡ ǡ ǡ ǡ ǡǦ ǡǡ ǡǡǡ ǡ ǡ ǡ ǡ ǡ ǡǦǡǡ ǡ ǡ ǡ ǡ ǡ Ǥ ʹʹͳ Ǧ Ǧ Ǧ ǣ Ǥ ǤʹͲͳǢͳͳͻȋͳȂʹȌǣͷȂͺʹǤ ͳͲǤ ǡ ǡ ǡ ǡǡ ǡ Ǥ Ǧ ǣ Ǥ ǤʹͲͲǢͳͶͺȋͷȌǤ ͳͳǤ ǡ ǡ ǡ ǡǡ Ǥ Ǥ ǤʹͲͲǢͳȋͳȌǣͷȂͳͳǤ ͳʹǤ ǡǡǡǡ ǡ ǡǦǡ ǡ ǡ ǡǡ ǡ Ǥ Ǧ
ʹͳ In vitro metabolic adaptations that explain symptomatology in MCADD individuals
Ǧ ȋȌ ǣ Ǥ ǤʹͲͲͺǢ͵ͳȋͳȌǣͺͺȂͻǤ ͳ͵Ǥ ǡ ǡǦǡǦǡ ǡǦ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳ͵ǢͺȋͳȌǣͶ͵Ǥ ͳͶǤ ǡ ǡǡ ǡ ǡ ǡ ǡǦ ǡǡǦǡ ǡ ǡǦ ǡ Ǥ Ǧ Ǧ ǣ Ǥ ǤʹͲͳʹǢǣ͵ͲǤ ͳͷǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳͲǢ͵͵ȋͷȌǣͷͷͷȂͳǤ ͳǤ ǡǡ ǡ ǡ ǡǡǤ Ǧ Ǧ Ǥ Ǥ ͳͻͻǢͻȋ͵Ȍǣ͵ȂͺǤ ͳǤ ǡ ǡǡǡ ǡ ǡ ǡǡ 6 Ǥ Ǧ Ǧ Ǥ ǤͳͻͻͲǢͺȋʹ͵Ȍǣͻʹ͵ȂͶͲǤ ͳͺǤ ǡ ǡ ǡ ǦǡǤƮ ǯ Ǧ Ǧ Ǥ ǤͳͻͺǢͺȋȌǣͳͲͷʹȂǤ ͳͻǤ ǤǡǤ ǣ Ǥ ǤʹͲͳͲǢ͵͵ȋͷȌǣͷͳ͵ȂʹͲǤ ʹͲǤ ǡ ǡ Ǥǡ Ǥ ȾǦ Ǥ Ǥ ʹͲͳǢͺȋͳȌǣʹ͵ȂͶͶǤ ʹͳǤ ǡ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǥ ǤʹͲͳͶǢͳͳʹȋͳȌǣ͵ͲȂͻǤ ʹʹǤ ǡ ǡ ǡǡǡǡ ǡǡ Ǥ Ǧ Ǥ ǤʹͲͳͳǢͷȋͳȌǣʹʹͳȂͺǤ ʹ͵Ǥ Ǥǡǡǡǡ ǡ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳͶǢͳͳͳȋ͵Ȍǣ͵ͲȂͺǤ ʹͶǤ ǡ ǡ ǡ Ǧ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳǢ ʹͷǤ ǡ ǡǤ Ǧ Ǧ ȋȌǤͳͻͻͶǢʹͻȋȌǣͶͶͲͳȂͺǤ ʹǤ ǡ ǡ ǡǡ ǡǡǡ ǡ ǡǡ ǡ Ǥ Ǧ ȋȌǦ ǡ ǡ ǤǤʹͲǡ ǤͳͻͻͷǤǤͳͲʹͺͶȂͻͲǤ ʹǤ ǡǡǡ ǡ ǡǡǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ Ǧ Ǧ Ǥ Ǥ ʹͲͳͶǢͻȋͶȌǤ ʹͺǤ ǡ ǡǡ ǡǡǤ Ǧ ǤͳͻͻͷǢʹͲͻȂͳͶǤ ʹͻǤ ǡǡ ǡ ǡǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳͶǢ͵ȋͷȌǣͺ͵ȂͻǤ
ʹͳ Chapter 6
ʹͳͺ In vitro metabolic adaptations that explain symptomatology in MCADD individuals
Supplementary Figures and tables Supplementary table ST1: Characteristics of the individuals from which the control fibroblasts originated. ID Age (years) Indication Outcome C1 Ͷʹ C2 ʹ ǡ C3 ͷ C4 ͳ C5 Ͳ C6.K ʹͲǯ Ǧ C6.W Ͳ Ǯǯ Ǥ Ǯ ǯ Ǥ Ǯ ǯ Ǥ Ǥ 6 A B 0.15 0.8
M) M) 0.6 P P * 0.10
0.4
0.05 Á 0.2 ÁÁ medium C6 ( C6 medium ( C8 medium
0.00 0.0 Sympt Asympt (ex. Pt10) Pt10 Ctrl Sympt Asympt (ex. Pt10) Pt10 Ctrl
CD 0.15 0.08 #,* M) M) P
P 0.06 0.10
0.04
0.05 Á 0.02
medium C10 ( C10 medium ¥ medium C10:1 ( C10:1 medium 0.00 0.00 Sympt Asympt (ex. Pt10) Pt10 Ctrl Sympt Asympt (ex. Pt10) Pt10 Ctrl Supplementary figure S1Ǥ Ǧ Ǥ Ǥ ͳǤ ͳǤ
ʹͳͻ Chapter 6
A B 0.15 1.5 M) M) P P 0.10 1.0
0.05 0.5 medium C8 ( medium medium C6 (
0.00 0.0 Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W
C D 0.08 0.08 M) M) P
0.06 P 0.06
0.04 0.04
0.02 0.02 medium C10 ( C10 medium medium C10:1 ( C10:1 medium 0.00 0.00 Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W
EF 0.15 1.5 M) M) P 0.10 P 1.0
0.05 0.5 Á medium C6 ( C6 medium medium C8 ( medium ÁÁ 0.00 0.0 Sympt Asympt (ex. Pt10) Pt10 Ctrl Sympt Asympt (ex. Pt10) Pt10 Ctrl
GH
0.08 0.08 M) M) P
0.06 P 0.06
0.04 0.04
0.02 Á 0.02 ¥ medium C10 ( medium medium C10:1 ( C10:1 medium 0.00 0.00 Sympt Asympt (ex. Pt10) Pt10 Ctrl Sympt Asympt (ex. Pt10) Pt10 Ctrl
Supplementary figure S2Ǥ Ǧ ǡ ȋǦȌ ǡ ȋǦ ȌǤ Ǥ ʹǤ ͳǤ
ʹʹͲ In vitro metabolic adaptations that explain symptomatology in MCADD individuals
A B 0.6 6
0.4 4 0.2 2 0.0 Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W medium C6 medium C8 medium
mol/g protein) mol/g protein) mol/g 0 ' '
P -0.2 P Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W ( (
-0.4 -2
CD 0.3 0.3
0.2 0.2 0.1 0.1 0.0 Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W medium C10 medium
mol/g protein) mol/g protein) mol/g 6 0.0 medium C10:1 medium ' P -0.1 P Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W ( ( '
-0.2 -0.1 Supplementary figure S3Ǥ Ǧ ǡ Ǥ Ǥ ʹǤ
A B 0.5 0.20
0.4 0.15
0.3 0.10 0.2
intracellular intracellular 0.05 0.1 C6 (nmol/g. protein) C8 (nmol/g. protein) 0.0 0.00 Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W
CD 0.08 0.04
0.06 0.03
0.04 0.02
intracellular 0.02 intracellular 0.01 C10 (nmol/g. protein)
C10:1 (nmol/g. protein) 0.00 0.00 Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W Supplementary figure S4Ǥ Ǧ ǡ Ǥ Ǥ ʹǤ
ʹʹͳ Chapter 6
A B
4 g) 20 P g)
P 3 15
2 10
1 5 MCAD (fmol/ l.o.d. 0 0
Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W Peroxiredoxin-6 (fmol/ Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W
C 0.5
g) 0.4 P 0.3
0.2
0.1 SCAD (fmol/
0.0 Pt1 Pt5 Pt7 Pt8 Pt2 Pt3 Pt4 Pt6 Pt9 Pt10 C3 C4 C5 C6.KC6.W Supplementary figure S5Ǥ ǡ Ǥ ͶǤ ͳǤ
ʹʹʹ
Chapter 7
General discussion
ǡ Ǥ ǡ Ǥ ǡǡ ǡǦ ǡ Ǥ ǡ Ǥ Navigating from computational metabolic model to mice to man
Computational modeling of mFAO and beyond Chapter 2ǡ ǦǦ Ǥ ǡ Ǥ ǡ Ǥ Ǥ 7 Ǧ Ǥ ǡ Ǥ ǡ ǡǯ Ǥ Ǥ Ǧ Ǥ Ǧ Ǥ ǡ ǡ ǦǤǡ ǡ Ǧ Ǧ Ǥ ǡ ͳ Ǧ ȏͳȐǤ ǡ Ǥ ȏʹȐǤ ͳ Ǥ ǡ Ǥ Assumptions ǡ Ǥ ǡ ǡ Ǥ
ʹʹ ͽ
ȟ Ǥ
Ǧ Ǧ Ǥ ǡ ȏ͵ȐǤ ȏͶȐǤ ǡ Ǥ ǡ Ǥ Ǧ Ǧ DzǦǦdz ȏͷȐǤ ȏ͵Ȑ
ிு ିοீᇱ ௬ି మ బ ܸ ܭ ܭ ݁ ோ் ൌܭ ൌ ή ή ܸ ௬ି ܭி ܭ
ǦǤ ǡ ܭ݅ܨܣܦܪʹ ǡܣܥݕ݈Ϋܿܽ݉ܭ ʹܪܦܣܨ݉ܭ ǡ ܣܥݕ݈Ϋܿܽ݅ܭ ǣ
௬ି ிுమ ܸ ܭ ܭ ܭ ൌ ή ή ܸ ௬ି ி ܭ ܭ
Ǥ ǦǤ
ȟ ͲǯȋȌȏȐ
ͳǦ ǦͶǦ Ǧ ͲǤͲ͵͵Ǥǡ Ǥ
ǡǡǯ
Ǧ Ǥǡ
ǯȏͷȐǤ Ǧǡ ǡ
Ͷ ǯ ȏͷȐǤ ǯ ǯ ȋȽȌ ǣ
௬ି ிுమ ͳ ܸ ܭ ܭ ܭ ൌ ή ή ή ߙ ܸ ௬ି ி ܭ ܭ ǡ ǡ ͲǤ͵ͺ ͶǦ Ǧ ೝ ǡ ͳǤͷʹ Ͷ Ǥ ǡ Ǥ ǡ ǡ Ǯ ǯ Ǥ
Dzdz Ǥ
α ȏ͵ǡȐǤ ǡ Ǧ ͳ ͳǦ ȏͺǡͻȐǤ ͳ Ǧ ȏͳȐǤͳǦ ͳ ͳǦ Ǧ
ʹʹͺ
ǡ Ǧ ǡ
ͳȋ ͳȌǤ 14 Published rat model
) 12 Rat model w. sens. CPT1 -1 Rat model w. sens. CPT1, 2x Vcpt1 10
8 .gProtein -1 6
4
2 J (μmol.min
0 0 50 100 [Palmitoyl-CoA] CYT ;ʅDͿ Figure 1. Computational rat dynamic model of isolated mFAO with C16-specific CPT1 (solid lines), with C16-C4 sensitive CPT1 (dashed lines) and with C16-C4 sensitive CPT1 at twice larger Vmax (short dashed lines). ͶǦͳͶ ǦǡͳͶǦͳͶ Ǧ Ǥ ͳ 7 ͶǦͳͶǤ Ǧ ͳ ǡǤ ǡ ȋChapter 5Ȍ Ǧ Ǧ Ǥ Ǧ Ǧ ͳǡ Ǧ ǤChapter 5ǡ Ǧ ͳ ǦǤ Ǥ ǡ Dzdz Ǥ Ǥ ǡ Ǧ
ʹ ǡ ǡ Ǥ ǡ Ǥ ǡ Ǥ ȋChapter 5ȌǤǡChapter 2 ǯ Ǥ Ǧ Chapter 2 Ǧ Ǥ ǡ ȏͳͲȐǤ ǡǡ Ǧ Ǥ Ǥ ǡ Ǧ Ǧ ǡ ȋαͳͲ ȗȏǦ Ǧ
ȐȌǡǦ ȋ ʹȌǤ
ʹʹͻ ͽ
14 Published rat model
) 12 model w. ac-carn export -1
10
8 .gProtein -1 6
4
2 J (μmol.min
0 0 50 100 [Palmitoyl-CoA] CYT ;ʅDͿ Figure 2. Computational rat dynamic model of isolated mFAO with (dashed lines) and without (solid lines) cytosolic acyl-carnitine export.
ǡ Ǧ Ǥ Ǧ ȏͳͳȐǤ Ǧ Ǥ ͳʹ ǡ Ǧ Ǥ ǡChapter 5ǡǦ Ǥ ǡ Ǧ ͳǦ Ǥ ǡ Ǥ ǡ Ǥ Ǧ ǡ Ǧ Ǥ Ǧ ͳǦ Ǥ ͳǤ Ǥ ǡ ͳǤǡ Ǥ Chapter ͷ Ǥ Ǧ ȋȌ Ǥ Ǧ Ǧ Ǥ ȏͳʹȐǡ ǡǡ ǡǡȏͳ͵ǡͳͶȐǤ Ǥ ǡ ȏͳʹǡͳ͵Ȑ ȏͳͷȐǡ Ǧ ȏͳȐǤ Ǥ Ǥ Chapter 1 and 2ǡ Ȁȋ ǡ ʹǡ ǡ Ȍ Ǥ ǡ ͷȀ ǡ
ʹ͵Ͳ
ͳȋ Ȍǡ ȋǤ ǡ ǡ Ȍ ǡ ȏͳȂʹ͵ȐǤ Ǧ Ǧ Ǥ So, what can be done to improve our understanding of the model’s behavior and to improve the accuracy of our dynamic modeling predictions? Ǥ ǡ ǡ Ǥ ǡ Ǧ ǡ ǡ Ǥ ǡ Ǧ ȏʹͶȐǤ 7 Ǥ ǯ Ǥ Ǧ ǡ
ǯǯǤ ǡ Ǧ
ǡȀ ͵ǤͷǤͷȏǡʹͷȐ ǦǦ
ͳͺͲȏǡǡʹͷȐǤ ʹ
ȋȏǡʹȐȌǡǦǯ Ǥ Ǥ ǡ ǡ Ǥǡ ǡ Ǥ ǡ Ȃ Ȃ Ǥ ǡ Ǥ Ǧ Ǥ ǡ ǡ ǦǤ Ǥ Ǥ ǡ Ǧ ȋ Ȍ Ǥ ǡ Ǧ Ǥ Ǧ ǡ ǡ Ǧ ǡ
ʹ͵ͳ ͽ
ȋ ȌǤǡ Ǥ ǡ Ǧ Ǥ
Mouse models as tools to understand symptomatology in MCADD Chapter 3ǡ Ǧ Ǧ Ǧ Ǥ Ǥ ǡ Ͷ ǦȋȌȋ ȌǦ Ǥ ǡ ǦǦ ǡ Ǧ ȋȌȋ ȌǦ Ǥ ȋChapter 2ȌǦ ͳǦ ͳ ȋChapter 5ȌǤ Dzdz Ǥ ȏʹǡʹͺȐǤ ǡ ȋ Ȍ ǡ Ǥ ȏʹǡʹͺȐ ǡ ǡ Ǥ Ǥ ǡ Ǧ Ǥ ǡǦ ȋChapter 4Ȍǡ ǤǦ Ǧ Ǥ ǡ ȏʹͻǡ͵ͲȐǤ Ǧ ǤǦ ͳǦ ȋChapter 3ȌǤ Chapter 4ǡǦ Ǧǡ Ǥ ǡ Ǧ Ǥ ǡ ǡ ǡ Ǥ Ǧ ǡ ǡ Ǥ ǡ Ǧ ǡ Ǧ Ǧ Ǧ Ǥ ǦǦ Ǧ ȏ͵ͳǡ͵ʹȐ Ǧ Ǧ Ǧ Ǥǡ ǡ Ǧ Ǥ Chapter 4ǡ
ʹ͵ʹ
ǡ Ǥǡǡ ǡ Ǥ ȏ͵͵ȐǤ Ǧ Ǥ /ŶǀŝƚƌŽ cell models of human MCADD Chapter 6ǡ ǡ Ǧ Ǥ ǡ ǡ Ǥǡ Ǥ Ǧ 7 ȋȌ ȏ͵ͶȂ͵ͻȐǤ Ǧ Ǥ ǡǡ ǡ Ǥ ǡ Ǧ ȋ Ȍǡ ͻͺͷε ȏͶͲȂͶʹȐǡ ͳͲȋ ͳͲȌ ȏͶ͵ȐǡǦ ȏͶͶȂͶȐ ȏͶͺȂͷʹȐǤ Ǧ ȋ Ȍǡ ȋ ǦǦ Ȍǡ ȋ Ȍǡ ȋ ȌǤ Ǧ Ǧ Ǥ ǡ Ǯ Ǥ Ǧǡ Ǥǡ Ǧ ʹǡ Ȁͻ ȏͷ͵Ȑ ȋǡ ǡ ǡ ȌǤ ʹ ǡ ȋ ͵ȌǤ
ʹ͵͵ ͽ
A HepG2 IHH HUH-7 Hep3B CPT1 liver isoform
CPT1 muscle isoform
CPT2
VLCAD
LCAD
MCAD
SCAD
MTPa
MTPb
CROT
MSCHAD
MCKAT
B
150 * Control 100 100 100 +HoPan
100
50 50 50 *** *** 50
Relative cell number after number cell Relative 72h (% untreated control) 0 0 0 0 HepG2 IHH HUH-7 Hep3B
C KO KO KO KO KO KO KO MCAD
GAPDH Figure 3. Generation of an MCAD-KO hepatocyte cell line. Aǣ ʹǡ ȋ Ȍ Ǧ ͵ȋαͳȌǡ ȏͷͶȐǤ ȏͷͷȐǤ Bǣ ʹ ͷǦ Ǥ ȋ ǡǡ Ǣ ǤǤȌ ȏͷȐǤ Ǥ ǤǤǤ άǡα͵ǦǡȗδͲǤͲͷǡȗȗȗδͲǤͲͲͲͳǦǤC: ʹ Ǥ ͵Ǧ ȋ ȌǤ ʹ ȋͷȌǤ Ǧ ʹ ȋ Ȍ ͷȋ ͵ȌǤ Ǥ Ǧ ʹ ȋͷ ͵ȌǤ ʹ ʹΨǡ ͳͲΨ ȏͷȂͷͻȐǤ ǡ Ǧ ʹ
ʹ͵Ͷ
ʹΨ Ǥ ǡ Ǧ ȋȌǤ Ǧ ȋ ǤȏͲȐȌǤ Ǧ ʹ Ǥ Ǧ ǡ ǡ Ǧ ʹ Ǥ Conclusion Ǥ ǡ ǡ Ǥ ǡ ǡ ȋȌȋ Ȍ Ǥ 7 ȋChapter 5Ȍ ǡǤǤǦ Ǧ ʹ Ǥǡ Ǧ Ǥ ǡ Ǥ References ͳǤ Ǧ ǡǡǦ ǡǤ Ǧ ͵ǦǦ Ǧ Ǧ ǦǤ ǤʹͲͳǢͳ͵ȋͶȌǣͳȂʹʹǤ ʹǤ Ǥ Dz dzǤ ǤʹͲͳǢͳͶȋͳʹͻȌǤ ͵Ǥ Ǥ Ǧ Ǥ Ǥ Ǥ Ǥͳͻ͵ ͺǢȋʹȌǣͳͲͶȂ͵Ǥ ͶǤ ǡ Ǥ ǣ ǤǤʹͲͲǢ͵Ǥ ͷǤ ǡ ǡǤ ǦǤ Ǥ ǤͳͻͻʹͷǢʹͷͶȋͺȌǣʹ͵ͲȂͷǤ Ǥ ǡ ǡ Ǧ ǡ Ǥ Ǧ Ǥ ǤʹͲͳʹǢͶͲȋͳȌǣͲȂͷǤ Ǥ Ǥ Ǥ Ǧ ǤʹͲͳ͵ǢͳͲͷȂͶʹǤ ͺǤ ǡ ǡ ǡǡ ǡǡ ǡ ǡǡ ǡǤ Ǧ ȾǦ ǤǤʹͲͳ͵ǢͻȋͺȌǣʹȂͻǤ ͻǤ ǡǦǡ ǡǡ ǡ ǡ ǡ Ǧǡ ǡ ǡ ǡ ǡ ǡǤ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳȂͳͷǤ ͳͲǤ ǡ ǡ ǡǡ ǡǡ ǡ ǡǡ ǡǤ Ǧ ȾǦ ǤǤʹͲͳ͵ǢͻȋͺȌǣʹȂͻǤ ͳͳǤ ǡ ǡǡ ǡǡǡ ǡ ǡ
ʹ͵ͷ ͽ
ǡ Ǥ Ǧ Ǧ Ǧ ǤǤͳͻͺ͵ǢͳȋͳͳȌǣͺȂͺͶǤ ͳʹǤ ǡ ǡǡǡ ǡò ǡ Ǥǣ Ǥ ͳͲͲͲ ǤʹͲͳͷǢͶȋͲȌǣʹͳǤ ͳ͵Ǥ ǡ ǡǡǡǡǤǣ Ǥ ǤʹͲͳʹͲǢͶͶȋͷȌǣʹͶ͵ȂͷͲǤ ͳͶǤ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǥ Ǥ ʹͲͳͶǢ͵ȋͷȌǣͲͻȂͳͶǤ ͳͷǤ ǡǤǦ ǣ Ǥ ǤʹͲͳǢͳͷǣ͵ͲȂͳͻǤ ͳǤ ǡ ǡ ǡ ǡ ǡ ǡ Ǥǣ Ǧ Ǧ Ǥ Ǥ ʹͲͳͺǢͳȋͶȌǣʹͶͶȂͷͳǤ ͳǤ Ǧ ǡ Ǧ ǡ Ǧ ǡ Ǧ ǡ ǡ ǡ ǦǡǡǡǦ ǡǡǡ ǡ Ǧ ǡ Ǧ ǡ Ǧ ǡ Ǧ ǡ Ǥ Ǥ ȋͺͲǦȌǤʹͲͳ͵Ǣ͵ͶͲȋͳͶͲȌǣͳͷȂͲǤ ͳͺǤ ǡǡ Ǥ ȋǦ ȌǤ Ǥ ʹͲͳǢȋͳȌǣͳȂͳͶǤ ͳͻǤ ǡ ǡ ǡ ǡ Ǧ ǡ Ǧ ǡ ǡ ǡ ǡ Ǥ Ǧ ǤǤʹͲͳǢͷ͵ͻȋ͵ͲȌǣͷͻȂͺʹǤ ʹͲǤ ǡ ǡ ǡ Ǧ ǡ Ǥ ʹ Ǥ Ǥ ʹͲͳͶ ʹǢʹͲȋȌǣͳͲͻȂͷǤ ʹͳǤ ǡǡ ǡǡǡǡ ǡǡ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͳ ͳͲǢ͵ͷʹȋʹͻͳȌǣͲͳͺͻǤ ʹʹǤ ǡ ǡ Ǧ ǡ ǡ ǡ Ǥ ǡ ǡ Ǥ ǤʹͲͳǢȋͳȌǣͲǤ ʹ͵Ǥ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͳǢʹͷȋͶȌǣͷȂǤ ʹͶǤ ǡǡ ǡ Ǥ Ǧ Ǧ ǣ Ǥ ǤʹͲͳǢͻͳȋ͵ȌǣͳͶͲͳȂ ͳʹǤ ʹͷǤ ǡ ǤǦǤ Ǥ ǤǤͳͻͺ͵ǢͳͳȋͷȌǣ͵ͳȂͺͶǤ ʹǤ ǡ Ǥ Ǥ ǤʹͲͲͶǢʹͲȋͳͳȌǣͳͻͷȂǤ ʹǤ ǡ ǡǡǡǡ Ǥ Ǧ Ǥ ǤʹͲͲͺǢͻͶȋͳȌǣͶȂͳͷǤ ʹͺǤ ǡǡǡǡ Ǥ Ǥ ǤʹͲͳͻ ʹͺǢͶȋͳȌǣͳͶͻȂͷͷǤ ʹͻǤ ǡǡǡǡǡǡǡ Ǥ ȾǦ Ǧ Ǧ Ǥ ǤʹͲͳͺǢͺȋͳȌǣͳȂͳǤ ͵ͲǤ ǡǡ ǡ ǡǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳͶǢ͵ȋͷȌǣͺ͵ȂͻǤ ͵ͳǤ ǡ ǡ ǡǡǡǡǡ ǡ ǡ
ʹ͵
ǡ ǡǡǡ ǡ ǡ ǡ ǡ Ǥ Ǧ ǤǤʹͲͳǢʹȋ͵ȌǣͷͲͻȂͷʹʹǤǤ ͵ʹǤ Ǥ ǤǤʹͲͳǢʹȋ͵ȌǣͶͷͶȂͷǤ ͵͵Ǥ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡǡ Ǥ Ǥ ǤʹͲͳǢͷͷͳȋͺȌǣͳͳͷȂͺǤ ͵ͶǤ ǡ ǡ Ǥ ǤǤʹͲͳͺǢͳͲǣͳȂ͵ͺǤ ͵ͷǤ ǡ ǡ ǤǦ͵Ǥ ǤʹͲͳǢʹ͵ȋͷȌǣ͵ͻ͵ȂͶͳͲǤ ͵Ǥ ǡ ǡǡǦǤ Ǥ ǤʹͲͳǢͳͶͶȋȌǣͻ͵ͺȂͶͳǤ ͵Ǥ ǡǡǡǤǦǣ Ǥ ǤʹͲͳͺǢȋͶȌǣʹͶ͵ȂͷǤ ͵ͺǤ ǡǤǦǦǦ ǣ Ǥ ǤʹͲͳͻǢͲͲȋͲͲȌǤ ͵ͻǤ ǡǡǡǡǡ ǡǤǮ Ǥǯ ǤʹͲͳͺǢ͵͵ȋͳȌǣͳͷȂʹͷǤ 7 ͶͲǤ Ǥ Ǧ Ǧ ȋȌ ǤʹͲͳͶǤ ͶͳǤ Ǥ ͻͺͷε ȋ͵ͲͶȌ ȏ ȐǤ ʹͲͳ ȏ ʹͲͳͻ ʹͳȐǤ ǣ ǣȀȀ ǤȀ ʹȀȀȀͲͳͺͺͳͻͺͶ ͶʹǤ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͳǢͷͺȋͷȌǣͻͷͷȂͳǤ Ͷ͵Ǥ ǡǡǡǡ ǡ Ǥ ͳͲ͵ǣ Ǥ ǤʹͲͳͷǢʹͻͲȋͶȌǣʹͶȂ Ǥ ͶͶǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǧ Ǥ ǤʹͲͳ͵Ǣ͵ȋȌǣͻ͵ȂͺͳǤ ͶͷǤ ǡ ǡ Ǥ ʹǤǤʹͲͳͺǢͺȋͳȌǣͳȂͳͲǤ ͶǤ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳͲǢ͵͵ȋͷȌǣͷͷͷȂͳǤ ͶǤ ǤǦǣ ǫ ǤʹͲͲ͵ǢʹȋʹȂ͵ȌǣͳͺͳȂͺǤ ͶͺǤ ǡǡǡǡǡ ǡǡ æǡ ǡ ǡ Ǥ ͶǯǦ ǤǤʹͲͳͷǢͳͳȋȌǣͳȂʹǤ ͶͻǤ ǡǡǡ ǡǡ ǡǡ Ǥ Ǥ Ǥ ʹͲͳͺǢͻȋͳȌǤ ͷͲǤ ǡǡǡǡ ǡ ǡ ǡǡ ǡǡǡ ǡǡǡ ǡ,ǡ ǡ ǡ ǡ ǡǡǤ ǦͶǯǦ Ǥ ǤʹͲͳ ͳʹǢȋͳȌǣͳͳʹͲǤ ͷͳǤ ǡ ǡǡǡǡ Ǥ Ǧ Ǥ ǤʹͲͲͺǢͻͶȋͳȌǣͶȂͳͷǤ ͷʹǤ ǡǡǡǡ Ǥ Ǥ ǤʹͲͳͻǢͶȋͳȌǣͳͶͻȂͷͷǤ ͷ͵Ǥ ǡ ǡ ǡǡ ǡ Ǥ Ǧ
ʹ͵ ͽ
ͻǤ ǤʹͲͳ͵ǢͺȋͳͳȌǣʹʹͺͳȂ͵ͲͺǤ ͷͶǤ ǡ ǡ ǡ Ǧ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳǢͳͷȋͻȌǣ͵ʹͲͶȂͳ͵Ǥ ͷͷǤ ǡ ǡǡǤ᩿ǣ ǤʹͲͲͻǢ͵ȋȌǣͷʹȂͲǤ ͷǤ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ Ǥ Ǥ ʹͲͳʹ ͳͷǢʹͲ͵ȋͳȌǣͻȂǤ ͷǤ ǡ ǡǡ Ǥ ǣ ʹ ǤǤʹͲͳǢͷȋʹͶȌǣͳȂͳʹǤ ͷͺǤ ǡǡ ǡǡǡǡǡ ǡ ǡ ǡ Ǥ Ǥ ǤʹͲͳͺ͵ǢͺȋͳȌǣͳͳͺͷǤ ͷͻǤ ǡǡ ¡ ǡǡǤ ʹ Ǥ ǦǤʹͲͳǢͳͺͳȋͳȌǣͷͳȂͻǤ ͲǤ ǡǡǡ ǡ ǡ ǡ ǡǡǤ ǣ ǡ Ǥ ǤʹͲͳʹǢͳͳͺȋ ȌǣͳͲʹȂͳͳǤ
ʹ͵ͺ
Appendices
Summary
Summary
Ǧ ǦȋȌ ȋ ʹͲͳͶͷͲȌǡ ȋ Ȍǡ ȋ ȌǤ Ǥ ͳȀͺ͵ͲͲ ʹͲͲʹͲͳͷȋͳȌǤ ǦǤ ǡ de novo Ǥ ǤǦ ȋȌ Ǧ ȋ ȌǤǡ ͳͺǦʹͶǤ ǡ ǡ ǡ Ǥ ǦǦ Ǥͻͺͷε Ǧ ACADM ǡ Ǥ Ǥ Ǥ Ǥ Ǥ Ǥ ǡ ȋi.e. in silicoȌǡ in vivo in vitroǤ ȋʹȌǡ Ǥ Ǥ ǡi.e. ǡ Ǥ ǡ Ǧ Ǧ ȋȌ ǡ Ǥ ǡ Ǥ ǡ ǯ Ǧ Ǥ ǡ ǡ Ǧǡȋ ȌǤ Ǧ ǡ Ǥ ǡ ǡ Ǯ ǯ ǡ Ǥ ǡ Ǥ Ǥ
ʹͶͷ Appendices
͵ǡ Ǧ ǡ Ǥ Ǧ Ǧ Ǥ ǦǦ Ǧ Ǥ ǡȋȌΪȋȌ ǡ Ǥ Ǧ Ǥ ʹǤ Ͷǡ ǦǡǦ Ǥ Ǧ ǡ Ǥ ǡǦ ǡ ǡ Ǧ Ǧ Ǧ Ǥ Ǧ ǡ ǡ Ǧ ͵Ǥ ǤǦ ǡ ǡ ǡ Ǧ Ǧ Ǥ ͷǡ ǡ ǡ Ǧ Ǥ Ǥ ʹ Ǥ ǡ ǦǤ ʹǤ ǡ ǡ Ǥ Ǧ ǡ ͳǡ Ǥ Ǥ ǡ Ǥ Ǥ ǦǤ ǡ ǡ ͵Ͳ ǡ Ǥ Ǧ Ǥ ǡ Ǥ ǡǤǤ Ǥ
ʹͶ Summary
Ǥ Ǧ ǡ ǡ ȋȌȋ Ȍ Ǥ ȋͷȌ Ǥ Ǧ Ǥ ǡ ǡ Ǥ
ʹͶ
^ĂŵĞŶǀĂƚƚŝŶŐ
Samenvatting
Ǧ Ǧ ȋȌ ´ ȋ ʹͲͳͶͷͲȌ ´ Ǥ Ǧ ´ Ǥ Ǥ ͳȀͺ͵ͲͲʹͲͲʹͲͳͷȋ ͳȌǤ ´ ǡ Ǥ Ǥ Ǥ Ǧ ´ȋȌǡ Ǥ Ǥ Ǧ´ ͳͺ ʹͶ Ǥ ǡ Ǧ ǡ Ǧ´Ǥ ´Ǥ´ ͻͺͷε ǡ ǡ ´ Ǥ ´Ǥ ´ ǡ Ǥ Ǯǯ Ǥ ´ ǡ Ǥ ǡ ǡ Ǥ Ǧ ´ Ǥ Ã ȋ ʹȌǤ ͷ Ǥ Ǥ ǡ Ǥ ÃǤ ǡ ǡ Ǥ ǦȋȌǡ Ǥ Ã Ǥ ǤǦ Ǧ ǡ ǡ Ǥ
ʹͷͳ Appendices
ǡ Ǧ Ǥ ǡ Ǥ Ǧ Ǥ Ǧ Ǥ´ Ǥ Ǥ Ǥ Ǥ Ǥ ͵ ǡ Ǥ Ǥ Ǧ Ǧ Ǥ ǦǦ ǦǦ Ǧ ǡ Ǥ ǡȋȌΪȋȌ ǡ Ǥ Ǥ ʹ Ǥ Ͷ ǡ Ǥ Ǧ Ǥ Ǥ ȋ Ǧ Ȍǡ Ǧ Ǧ Ǥ ǡǤ ͵ Ǥ Ǥ ǡ ǤǦ ´ Ǧ ǡ Ǥ ͷ ǡ Ǥ
ʹͷʹ Samenvatting
Ǥ ´Ǥ ʹ Ǥ ǦǤ ʹ Ǥ ǦǡǦǦ ´ǤǦ Ǧ ͳ ǡ Ǥ ÃǦ´Ǥ Ǧ´Ǥ Ǧ´Ǥ ´ Ǥ ´ Ǥ ± Ǧ´ ͵ͲǦ ǡ Ǥ Ǧ Ǥ Ǥ ǡ Ǥ Ǥ ´ǡ ǡ ȋȌ Ǥ ȋ ͷȌ ͵Ǥ ǡ Ǥ ǡ Ǧ´Ǥ
ʹͷ͵
Acknowledgements
Acknowledgements
ǡǡǡǡ ǡǡ Ǥǡ ǡ Ǥ Ǥ Ǧ ǡ ǡ ǡ Ǥ ǡ Ǥǡ ǡ ǡ ǡ ǡ ȋ ȌǤ ǤǤ Ǥ ʹͲͳͶǡǡ ǡ ǡ Ǥ Ǥ Ǥ ǡ Ǥ Ǧ ǡ ǡ Ǥ Ǥǡ ǡ ǡ ǡ Ǥ ǤǤ ǡǤ ǡǤ Ǥ ǡǤ ǡ ǡ Ǥǡǡ Ǥ ǡ Ǥ ǤǤ ǯǤǡ Ǥ Ǥ Ǥ ǡ ǯ Ǥ ǡǡ
ʹ ǡ ǡ Ǩ Ǩ ǡ ǡǡ Ǥǡ ǤǤ Ǥ ǡȀ
ʹͷ Appendices
Ǥ ǡ ǡ Ǥ ǡ ȋ Ȍǡ Ǥ ǡ Ǥ ʹͲͳ͵Ǥ ǡ Ǥ ǡǡ Ǥǡ Ǥǡǡ Ǥǡ ʹ Ǩǡ ǯ Ǥ Ǥ ǡ Ǥ Ǥ ǯ Ǩǡ Ǥ Ǥǡ Ǥ Ǥ Ǥǡǡ ǡ Ǥ Ǥ Ǥ ȀǡǤ Ǥ ǡ ǡ ǡǡǡǡ ǡ ǡ ȋǣǦȌ Ǥ ǡ Ǥǡ Ǥ ǡ Ǥ ǡ ǡ Ǥ ǡǡǡ Ǥ Dz dz -Ǥ ǡ ʹͲͳͷ ǣǦǤ Ǧ ǤǦ ǡ ǡ ǡǡ ǡ ȋǨȌǡ ǡ ȋ Ȍ Ǥ ǡ Ǩ
ʹͷͺ Acknowledgements
ǡ ǡ ǡ Ǥǡ ǡ Ǧ ǡ ǡ Ǥ ǡ ǡǤǡ ǡ ʹͲͳͷǤ Ǧ Ǧ Ǥ Ǥǡ ǡǡ Ǥ Ǧ ǡǤ Ǩ ǡ Ǧ Ǥ ǡ ǡ Ǥ ǤǤǡ Ǥ Ǥǡ ǦǤǡ Ǧ Ǥǡ Ǥ Ǧ Ǥ ǡ ǡ Ǥ Ǧ Ǧ ǡǤǡ ǡ Ǥ Ǥǡ ǡ Ǥ ȋ Ǥ Ȍ Ǥǡ ǦǤ Ǥ Ǥ ǡ Ǥ Ǥ ǡ ǡ Ǥ ǡ Ǧ ʹ ǡ Ǥǡ Ǥǡ Ǥ ǤǤǡ ǡ ǡ Ǧ ǦǤ ǡ ǡ
ʹͷͻ Appendices
ǡ Ǥǡ Ǥǡ Ǧ ʹ ǡ Ǥ ǡ ǡǤ Ǥǡ Ǥ ǡ ǡ Ǥ ǤǡǡȋȌǡǡǡ ǡ Ǥǡ ǡǡ Ǥ ǡǡ ǡǡǡ Ǥ Ǥ ǡǦ Ǧ Ǥ ǡ Ǥ ǡ Ǧ ǦǤ ȋȌ Ǥ Ǥ ǡ ǡ Ǥ ǡ Ǧ Ǧ ǡ Ǩ -Ǥ Ǥ Ǥǡ ǤǤǦǤǡ Ͷ Ǥǡ Ǩ Ǥ Ǥ ǦǡǦǤ ǡǦ ǤǤ ǡ Ǥ ǡ ǡǡ ǡ ǤǡǡǤǡǡǡǡǤ Ǥ Ǥ ǡ Ǥ ǡ Ǥ
ʹͲ Acknowledgements
ǤǤǦ ǤǡǤǡ Ǩ ǯǡ ǡ ǡǡ ǡ ǡ ǯǤ Ǥ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡ ǡǡǡǤ ǡ Ǥǡ ǡ ǤǤ ǡ Ǥ ǡ ǡ ǡ Ǥ Ǥ ǨǨ ǡ ǯǤ Ǥ ǡ ǡ ǡ ǡ ǡ ǤǤ ǡ ǡ ǡ ǡ ǡ ǤǡǡǤǡǡǡǡǡǡǡǡ Ǥ ǤǤ ǯ ǡ Ǩ ǯ Ǩ ǤǤ ǡ ǡ ǡ ǤǤ Ǥ Ǥ Ǥȋ Ȍ ǡ Ǧ Ǥ ǡ ǡ ǡ ȋi.e. Ȍ Ǥ ǡ Ǥ Ǥ ǡ ǡ ǡ Ǧ Ǧ Ǥ Ǥ Ǥ Ǥ
ʹͳ Appendices
ǦǤǨ Ǥ ȀǤ Ǩ ǡǤǨ ǡǤ ǡǡǡ ǡ ǡǤǡǤ Ǥǡǡ ǡ ǡ ǡ ǡ Ǥ Ǥ ǡ Ǩȋ ǡǡ ǡ ǡ ǡ °ǡǡ ǡ ǡ Öǡǡ ǡǡ ǡǡ ǡ ǡǡǡǡ ǡǡ ǡ ǡǡǡǡ ǡ ǡ ǡǡǡǡ ǡǡǡǡǡǡǡǡǡǡǡ ǡ ǡǡ Ȍǡȋǡǡ ǡ ǡǡǡǡǡ ǡǡ ǡȌǡ Ǧȋ ǡ ǡ ǡǡǤǡǡ ǡǡ ȌǨ ǡ ǡ ǡ ǡ ǡ ǡ ǡǡǡ-Ǥǡ ǡ ǡǡ Ǥ Ǥ ǡ ǡ Ǥǡ ǯǤ ǡ ǡ ǡ ǡ ǡ ǡ Ǥ ǤᇡǡǨ
ʹʹ
ŝŽŐƌĂƉŚLJ
Ǧ ͳͲͳͻͺͳǡǡ ǡ Ǥ ͳͻͻͻǡ ȋȌǤ ǡ ǡ Ǥ ǡ ǡ Ǥ Ǥ Ǧ ȋ ǡ Ȍ Ǥ ǡǡ ǡ ǡ Ǥ Ǥ ǡ ͶǦ ǡǡ ǡ ǡǤ Ǥǡ Ǧ Ǥ ǡȋ ȌǦǦ ǡ ǡ ǡ ǡǤ ǡ Ǥ Ǥ Ǥ Ǧ Ǧ Ǥ ǡ ǤǡͳǦ ǡ Ǥ Ǥǡ ͳ Ǧ Ǧ ǤǦ ǯ ǡ ǦǤǡ Ǥ ǡ Ǧ Ǧ Ǧ ǡ Ǥ ǡ Ǥ ȋȌ ǡ ǯǤǡ ǡ ǡ ǤǤǤǡǤ ǡ Ǥ Ǥ Ǥ Ǧ ǡ ǯ Ǥ ǡ ǡ Ǥ ǡǡǦǦ ǡ Ǥ ǡ Ǧ ǡ ǯ Ǥ
ʹ
WŽƌƚĨŽůŝŽ
ȋȌ ʹͲͳ ʹͲͳ ͲǤͷ ʹͲͳ ͳǤͶ ȋǦȌ ʹͲͳ ͶǤͲ ʹͲͳ Ǧ ʹͲͳ ͺǤͲ ʹͲͳ ǡ ǡ ʹͲͳ ͲǤͷ Ǧ ʹͲͳ ͲǤ͵ ʹͲͳ ͷǤͲ ʹͲͳ ʹͲͳ ͲǤͷ ʹͲͳ ͲǤͷ ǡǡ ʹͲͳ ͳǤͲ ǣǦ ʹͲͳ ͲǤͻ ʹͲͳ Ǧ ʹͲͳ ͶǤͲ ʹͲͳ ʹͲͳ ͲǤͷ ʹͲͳ ʹͲͳ ͳǤͲ ʹͲͳ ʹǤͲ ȋǦȌ ʹͲͳ ͶǤͲ ʹͲͳͷ ͲǤͻ ȋ ʹͳͷͳȌ ʹͲͳͷ ʹǤͲ ʹͲͳͷȋ Ȍ ʹͲͳͷ ͳǤͲ ʹͲͳͷ ͳǤͶ ǣǦ ʹͲͳͷ ͲǤͻ ʹͲͳͷ ͲǤͷ ʹͲͳͷ ʹͲͳͷ ʹǤͲ ʹͲͳͷ ʹͲͳͷ ͲǤͷ ǣ ʹͲͳͷ ͲǤ͵ ʹͲͳͷ ʹͲͳͷ ͲǤͷ ǣ ʹͲͳͷ ͵ǤͲ ̷ʹͲͳͶ ʹͲͳͶ ͲǤͷ ʹͲͳͶ ͳǤͲ ʹͲͳͶ ǡǡ ʹͲͳͶ ͲǤͷ ʹͲͳͶ ǡǡ ʹͲͳͶ ͲǤͷ ʹͲͳͶ ʹͲͳͶ ͲǤͷ ȋʹͲͳͶȌǡ ǡ ʹͲͳͶ ʹǤͲ ̷ʹͲͳ͵ ʹͲͳ͵ ͲǤͷ ʹͲͳ͵ ͲǤͷ Ǧ ʹͲͳ͵ ͲǤ ʹͲͳ͵ ʹǤͲ ʹͲͳ͵ ͵ǤͲ ʹͲͳ͵ȋ ʹͲͳ͵Ȍǡǡ ʹͲͳ͵ ͲǤͷ Ǧ ʹͲͳ͵ ͲǤ͵
ʹͳ
>ŝƐƚŽĨƉƵďůŝĐĂƚŝŽŶƐ
ǡ ǡ Ǥ Ǥ ǡ ʹǡʹͲͳʹ ǡ ǡ ǡ ǡ ǡ Ǥ Ǧ Ǥ Ǥ ʹͲͳ͵ ǢͻȋȌǣ͵ͺͷȂͻͺ ǡǦǡ ǡǡ ǡ ǡ ǡ Ǧǡ ǡ ǡ ǡ ǡ ǡǤ ǣ Ǧ ǤǤʹͲͳǢͳͶȋͳȌǣͳȂͳͷ Ǧ ǡǡǦ ǡǤ Ǧ ͵ǦǦ Ǧ Ǧ ǦǤ ǤʹͲͳǢͳ͵ȋͶȌǣͳȂʹʹǤ
ʹͷ